Skip to main content
Erschienen in: BMC Psychiatry 1/2014

Open Access 01.07.2014 | Review

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

verfasst von: Martin A Katzman, Pierre Bleau, Pierre Blier, Pratap Chokka, Kevin Kjernisted, Michael Van Ameringen, the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University

Erschienen in: BMC Psychiatry | Sonderheft 1/2014

insite
INHALT
download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background

Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.

Methods

These guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE, PsycINFO, and manual searches (1980–2012). Treatment strategies were rated on strength of evidence, and a clinical recommendation for each intervention was made, based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines.

Results

These guidelines are presented in 10 sections, including an introduction, principles of diagnosis and management, six sections (Sections 3 through 8) on the specific anxiety-related disorders (panic disorder, agoraphobia, specific phobia, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), and two additional sections on special populations (children/adolescents, pregnant/lactating women, and the elderly) and clinical issues in patients with comorbid conditions.

Conclusions

Anxiety and related disorders are very common in clinical practice, and frequently comorbid with other psychiatric and medical conditions. Optimal management requires a good understanding of the efficacy and side effect profiles of pharmacological and psychological treatments.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1471-244X-14-S1-S1) contains supplementary material, which is available to authorized users.

Competing interests

Unrestricted educational grants for the development of these guidelines were provided by Astra Zeneca Canada, Eli-Lilly Canada, Janssen Inc., Lundbeck Canada, Pfizer Canada, Purdue Canada, Servier Canada Inc., Shire Canada, and Valeant Canada. None of the members received payment for participating in the development of these guidelines.
The following authors do not have any competing interests to declare: AB, GA, JRW, KO, MMA, MF, LK, MR, SM.
Advisory board/speaker's bureau: Astra Zeneca (KK, KR, MK, P. Bleau, P. Blier, RWL, RSM), Biovail (RWL), Boehringer Ingelheim (MK), BMS (KK, KR, MK, P. Bleau, P. Blier, PC, RWL, RSM), Canadian Institutes of Health Research (CIHR) (RWL), Canadian Network for Mood and Anxiety Treatments (CANMAT) (RWL), Canadian Psychiatric Association (CPA) Foundation (RWL), Eli Lilly Canada (MK, P. Bleau, P. Blier, PC, SG, RWL, RSM, IS), France Foundation (RSM), GlaxoSmithKline (MK, P. Blier, RSM, SG), Janssen Ortho (KK, MK, P. Blier, PC, RSM), Labopharm (P. Blier), Litebook Company (RWL), Lundbeck (KK, KR, MK, P. Bleau, P. Blier, PC, RWL, RSM, SG), Lundbeck Institute (RWL), Organon (MK, RSM), Merck (P. Blier, RSM), Mochida (RWL), Otsuka (KK), Pfizer (P. Bleau, P. Blier, PC, RWL, RSM, SG), Pierre Fabre (P. Blier), Purdue (IS), Servier (P. Blier, RWL, SG), Shire (MK, RSM, IS), Solvay (MK), St. Jude's Medical (RWL), Sunovion (KK, P. Blier), Takeda (P. Blier, RWL), UBC Institute of Mental Health/Coast Capital Savings (RWL), Valeant (P. Blier, IS), Wyeth (P. Bleau, MK, SG)
Consultation fees: AstraZeneca (MK), BMS (MK), Boehringer Ingelheim (MK), Clinique et Développement In Virtuo Inc. (SB), Eli Lilly Canada (MK, SG), GlaxoSmithKline (MK, SG), Janssen Ortho (MK), Lundbeck (MK, PR, SG), Organon (MK), Pfizer (SG), Servier (SG), Shire (MK), Solvay (MK), Wyeth (MK, SG)
Educational support: Astra Zeneca (RSM), BMS (RSM), CME Outfitters (RSM), Eli Lilly Canada (RSM, IS), France Foundation (RSM), I3CME (RSM), Merck (RSM), Optum Health (RSM), Pfizer (RSM), Physicians' Postgraduate Press (RSM), Shire (IS)
Research grants/clinical trial funding: AstraZeneca (KK, MK, P. Bleau, RSM, RWL), Biovail (RWL), BMS (KK, P. Bleau, RWL), Canadian Foundation for Innovation (MK), Canadian Institutes of Health Research (CIHR) (MK, RWL, SG), Canadian Network for Mood and Anxiety Treatments (CANMAT) (RWL), Canadian Psychiatric Association (CPA) Foundation (MK, RWL), Centre for Addiction and Mental Health Foundation (MK), CR Younger Foundation (SG), Eli Lilly Canada (MK, P. Bleau, PR, RSM, RWL), Genuine Health (MK), GlaxoSmithKline (MK), Janssen Ortho (MK, RSM), Litebook Company (RWL), Lundbeck (KK, MK, P. Bleau, RSM, RWL), Lundbeck Institute (RWL), Mochida (RWL), National Alliance for Research on Schizophrenia and Depression (NARSAD) (RSM), National Institutes of Mental Health (NIMH) (RSM), Ontario Ministry of Health (SG), Ontario Mental Health Foundation (SG), Organon (MK), Pfizer (P. Bleau, RSM, RWL), Roche (PR), Servier (RWL), Sick Kids Foundation (MK), Solvay (MK), St. Jude's Medical (RWL), Shire (MK, RSM), Stanley Medical Research Institute (RSM), Takeda (RWL), UBC Institute of Mental Health/Coast Capital Savings (RWL), Wyeth (MK, P. Bleau)
Unrestricted grants: Astra Zeneca Canada (MK), Eli Lilly Canada (MK), Janssen Inc. (MK), Lundbeck Canada (MK), Pfizer (MK), Purdue Pharma (MK), Servier Canada (MK), Shire Canada (MK), Valeant Canada (MK)
Reimbursements, fees, funding, or salary: In the past five years, MVA received reimbursements, fees, funding, or salary from: Astra Zeneca, Biovail, Canadian Foundation for Innovation (CFI), Cephalon, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Hamilton Academic Health Sciences Organization (HAHSO) Innovation Grant (AFP Innovation Grant), Janssen Ortho, Labo Pharm, Lundbeck, National Institutes of Health (NIH), Novartis, Pfizer Inc., Servier, Shire, Sunovion, Valeant, Wyeth-Ayerst
Stock/share ownership: Clinique et Développement In Virtuo Inc. (SB)

Authors’ contributions

We thank all co-authors for their considerable expertise in generating these guidelines. Authors who were members of the executive committee (MK, PB, PB, PC, KK, MVA) took part in teleconferences and a meeting in December 2012 to reach consensus on the strength of evidence and treatment recommendations. Draft guidelines were then developed by the core committee and revised by all co-authors. The entire content was subsequently circulated to all members of the Canadian Anxiety Guidelines Initiative Group for additional comments and approval during 2013. GA, LJK, RWL, RSM, and IS provided additional reviews of the comorbidity section. The final manuscript was then circulated to external reviewers (MP, DS, LDM) and revisions were made based on input from the core committee.
Abkürzungen
AACAP
American Academy of Child and Adolescent Psychiatry
ABM
attention bias modification
ACOG
American Congress of Obstetricians and Gynecologists
ADHD
attention-deficit/hyperactivity disorder
APA
American Psychiatric Association
ASD
acute stress disorder
B-I-I
blood-injection-injury
BPD
borderline personality disorder
CBT
cognitive behavioral therapy
CBWT
cognitive behavioral writing therapy
CCHS
Canadian Community Health Survey
CHD
coronary heart disease
CPT
cognitive processing therapy
CR
controlled release
DBT
dialectical behavioral therapy
DDI
drug-drug interactions
DIRT
danger ideation reduction therapy
DSM-5
Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
EMDR
eye movement desensitization and reprocessing
ERP
exposure with response prevention
FDA
Food and Drug Administration
GAD
generalized anxiety disorder
HARS
Hamilton Anxiety Rating Scale
HDL
high-density lipoprotein
ICBT
internet-based CBT
IPT
interpersonal therapy
IV
intravenous
LDL
low-density lipoprotein
MAOI
monoamine oxidase inhibitor
MBCT
mindfulness-based cognitive therapy
MBT
mindfulness-based therapy
MDD
major depressive disorder
Mini-SPIN
Mini-Social Phobia Inventory
MRI
magnetic resonance imaging
N/A
not available
NaSSA
noradrenergic and specific serotonergic antidepressant
NCS-A
National Comorbidity Survey – Adolescent supplement
NCS-R
National Comorbidity Survey – Replication
NMDA
N-methyl-D-aspartate
NNT
number needed to treat
NPPO-REAC
neuro psycho physical optimization-radio electric asymmetric conveyor
NSAID
nonsteroidal anti-inflammatory drug
OCD
obsessive-compulsive disorder
ODT
orally disintegrating tablet
PNAS
poor neonatal adaptation syndrome
PTSD
posttraumatic stress disorder
QoL
quality of life
RCT
randomized controlled trial
REAC
radioelectric asymmetric conveyor
RIMA
reversible inhibitors of monoamine oxidase A
RR
relative risk
rTMS
repetitive transcranial magnetic stimulation
SAD
social anxiety disorder
SET
social effectiveness therapy
SHAT
spiritual-hypnosis assisted therapy
SNRI
serotonin–norepinephrine reuptake inhibitor
SR
sustained release
SSRI
selective serotonin reuptake inhibitor
SUD
substance use disorder
TC
total cholesterol
TCA
tricyclic antidepressant
TF-CBT
trauma-focused-CBT
TG
triglycerides
vLDL
very-low-density lipoprotein
VRE
virtual reality exposure
XL
extended release
XR
extended release
Y-BOCS
Yale-Brown Obsessive Compulsive Scale.

Introduction

Anxiety and related disorders are among the most common of mental disorders. Lifetime prevalence of anxiety disorders is reportedly as high as 31%; higher than the lifetime prevalence of mood disorders and substance use disorders (SUDs) [15]. Unfortunately, anxiety disorders are under-diagnosed [6] and under-treated [5, 7, 8].
These guidelines were developed to assist clinicians, including primary care physicians and psychiatrists, as well as psychologists, social workers, occupational therapists, and nurses with the diagnosis and treatment of anxiety and related disorders by providing practical, evidence-based recommendations. This guideline document is not focused on any individual type of clinician but rather on assessing the data and making recommendations. Subsequent “user friendly” tools and other initiatives are planned.
The guidelines include panic disorder, agoraphobia, specific phobia, social anxiety disorder (SAD), generalized anxiety disorder (GAD), as well as obsessive-compulsive disorder (OCD), and posttraumatic stress disorder (PTSD). Also included are brief discussions of clinically relevant issues in the management of anxiety and related disorders in children and adolescents, women who are pregnant or lactating, and elderly patients, and patients with comorbid conditions.

Methods

These guidelines are based on a thorough review of the current literature and were developed by a panel of Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE searches of English language citations (1980–2012), using search terms encompassing the specific treatments and specific anxiety and related disorders. These searches were supplemented with data from PsycINFO and manual searches of the bibliographies of efficacy studies, meta-analyses, and review articles. Treatment strategies were rated on strength of evidence for the intervention (Table 1). A clinical recommendation for each intervention was then made, based on global impression of efficacy in clinical trials, effectiveness in clinical practice, and side effects, using a modified version of the periodic health examination guidelines (Table 2).
Table 1
Levels of evidence
1
Meta-analysis or at least 2 randomized controlled trials (RCTs) that included a placebo condition
2
At least 1 RCT with placebo or active comparison condition
3
Uncontrolled trial with at least 10 subjects
4
Anecdotal reports or expert opinion
Levels of evidence do not assume positive or negative or equivocal results, they merely represent the quality and nature of the studies that have been conducted.
Level 1 and Level 2 evidence refer to treatment studies in which randomized comparisons are available. Recommendations involving epidemiological or risk factors primarily arise from observational studies, hence the highest level of evidence for these is usually Level 3. Recommendations, such as principles of care, reflect consensus opinion based on evidence from various data sources, and therefore are primarily Level 4 evidence.
Table 2
Treatment recommendation summary
First-line
Level 1 or Level 2 evidence plus clinical support for efficacy and safety
Second-line
Level 3 evidence or higher plus clinical support for efficacy and safety
Third-line
Level 4 evidence or higher plus clinical support for efficacy and safety
Not recommended
Level 1 or Level 2 evidence for lack of efficacy
The guidelines were initiated prior to the introduction of the American Psychiatric Association’s (APA) fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the committee was sensitive to potential changes to the nosology of anxiety and related disorders and its impact on the guidelines. However, it was agreed that, since the evidence for treatment is based on studies using DSM-IV criteria (or earlier), the introduction of the DSM-5 would not fundamentally alter the evidence and recommendations at this time. Whether using DSM-5 diagnostic criteria for the inclusion patients in clinical trials in the future will have an impact on outcomes, remains to be seen.
The panel of Canadian experts in anxiety and related disorders responsible for the development of these guidelines via consensus process included 10 psychiatrists and seven psychologists who were organized into subpanels based on their expertise in particular anxiety or related disorders as well as in treating specific patient populations. Preliminary treatment recommendations and the evidence upon which they had been based were reviewed at a meeting of the panel in December 2012; subsequently, draft guidelines were prepared by the subpanels which were then circulated to the entire group for consensus ratification during 2013. Preliminary recommendations were also presented to the Canadian psychiatric community for input in September 2012 at the Canadian Psychiatric Association annual conference.
These guidelines are presented in 10 sections, the first of which is this introduction. In the following section, the principles of diagnosis and management of anxiety and related disorders are covered. That section provides an overview of the differential diagnoses associated with anxiety and related disorders in general, discusses issues that affect all anxiety disorders, and presents the general advantages and disadvantages of psychological treatment and pharmacotherapy options. In the subsequent six sections (Sections 3 through 8), the specific diagnosis and management of the individual anxiety and related disorders (panic disorder, specific phobia, SAD, OCD, GAD, and PTSD) are reviewed and recommendations are made for psychological and pharmacological treatments. Section 9 discusses issues that may warrant special attention pertaining to anxiety and related disorders in children and adolescents, pregnant or lactating women, and the elderly. The last section of these guidelines addresses clinical issues that may arise when treating patients with anxiety and related disorders who are also diagnosed with comorbid psychiatric conditions such as major depressive disorder (MDD), bipolar disorder, or other psychoses, and attention deficit/hyperactivity disorder (ADHD), or medical comorbidities, such as pain syndromes, cardiovascular disease, and diabetes/metabolic syndrome.

Principles of diagnosis and management of anxiety and related disorders

Epidemiology

Prevalence and impact

Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence rates as high as 31% [15] and 12-month prevalence rates of about 18% [3, 4]. Rates for individual disorders vary widely. Women generally have higher prevalence rates for most anxiety disorders, compared with men [4, 5, 9]. Anxiety and related disorders are associated with an increased risk of developing a comorbid major depressive disorder [1012].
Anxiety and related disorders put a significant burden on patients and their family members [13]. They are associated with substantial functional impairment, which increases as the severity of anxiety [14] or the number of comorbid anxiety disorders increases [7, 15]. In addition, studies have demonstrated quality of life impairments in patients with various anxiety and related disorders [16, 17]. Anxiety has a considerable economic impact on society as well, being associated with greater use of health care services [5, 18] and decreased work productivity [18, 19].
Importantly, studies report that about 40% of patients diagnosed with anxiety and related disorder are untreated [5, 7].

Suicide risk

In large surveys, anxiety and related disorders were independently associated with a significant 1.7-2.5 times increased risk of suicide attempts [2023]; however, data are conflicting as to whether the risk is moderated by gender [20, 23]. Increased risk of suicide attempts or completed suicide has been reported for patients with panic disorder, PTSD [20, 24], and GAD [24], even in the absence of a comorbid mood disorder. These data indicate that patients with an anxiety disorder warrant explicit evaluation for suicide risk. The presence of a comorbid mood disorder significantly increases the risk of suicidal behavior [22, 25].

Initial assessment of patients with anxiety

The management of patients presenting with anxiety symptoms should initially follow the flow of the five main components outlined in Table 3.
Table 3
Overview of the management of anxiety and related disorders
• Screen for anxiety and related symptoms
• Conduct differential diagnosis (consider severity, impairment, and comorbidity)
• Identify specific anxiety or related disorder
• Psychological and/or pharmacological treatment
• Perform follow-up
Anxiety and related disorders are generally characterized by the features of excessive anxiety, fear, worry, and avoidance. While anxiety can be a normal part of everyday life, anxiety disorders are associated with functional impairment; as part of the key diagnostic criteria for anxiety disorders is the requirement that the symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning [26].
Asking patients if they are feeling nervous, anxious or on edge, or whether they have uncontrollable worry, can be useful to detect anxiety in patients in whom the clinician suspects an anxiety or related disorder [7]. The DSM-5 suggests the questions shown in Table 4 for the identification of anxiety-related symptoms; items scored as mild or greater may warrant further assessment [26]. If anxiety symptoms are endorsed, they should be explored in more detail by including questions about the onset of the anxiety symptoms, associations with life events or trauma, the nature of the anxiety (i.e., worry, avoidance, or obsession), and the impact they have had on the patient’s current functioning.
Table 4
General screening questions
• During the past two weeks how much have you been bothered by the following problems?
    ○ Feeling nervous, anxious, frightened, worried, or on edge
    ○ Feeling panic or being frightened
    ○ Avoiding situations that make you anxious
Adapted from reference [26].
Table 5 presents suggested screening questions for individual anxiety and related disorders, from various validated screening tools [2730], some of which are freely available online (e.g., http://​www.​macanxiety.​com/​online-anxiety-screening-test).
Table 5
Screening questions for specific anxiety and related disorders
Panic disorder – MACSCREEN [29, 30]
• Do you have sudden episodes/spells/attacks of intense fear or discomfort that are unexpected or out of the blue?
If you answered "YES" then continue
• Have you had more than one of these attacks?
• Does the worst part of these attacks usually peak within several minutes?
• Have you ever had one of these attacks and spent the next month or more living in fear of having another attack or worrying about the consequences of the attack?
SAD (Based on Mini-SPIN [28])
• Does fear of embarrassment cause you to avoid doing things or speaking to people?
• Do you avoid activities in which you are the center of attention?
• Is being embarrassed or looking stupid among your worst fears?
GAD [31]
• During the past 4 weeks, have you been bothered by feeling worried, tense, or anxious most of the time?
• Are you frequently tense, irritable, and having trouble sleeping?
OCD – MACSCREEN [29, 30]
Obsessions:
• Are you bothered by repeated and unwanted thoughts of any of the following types:
    ○ Thoughts of hurting someone else
    ○ Sexual thoughts
    ○ Excessive concern about contamination/germs/disease
    ○ Preoccupation with doubts (“what if” questions) or an inability to make decisions
    ○ Mental rituals (e.g., counting, praying, repeating)
    ○ Other unwanted intrusive thoughts
• If you answered "YES" to any of the above… Do you have trouble resisting these thoughts, images, or impulses when they come into your mind?
Compulsions:
• Do you feel driven to perform certain actions or habits over and over again, or in a certain way, or until it feels just right? Such as:
    ○ Washing, cleaning
    ○ Checking (e.g., doors, locks, appliances)
    ○ Ordering/arranging
    ○ Repeating (e.g., counting, touching, praying)
    ○ Hoarding/collecting/saving
• If you answered "YES" to any of the above… Do you have trouble resisting the urge to do these things?
PTSD – MACSCREEN [29, 30]
• Have you experienced or seen a life-threatening or traumatic event such as a rape, accident, someone badly hurt or killed, assault, natural or man-made disaster, war, or torture?
If you answered "YES" then continue
• Do you re-experience the event in disturbing (upsetting) ways such as dreams, intrusive memories, flashbacks, or physical reactions to situations that remind you of the event?

Conduct differential diagnosis

The differential diagnosis of anxiety and related disorders should consider whether the anxiety is due to another medical or psychiatric condition, is comorbid with another medical or psychiatric condition, or is medication-induced or drug-related [32].
When a patient presents with excessive or uncontrollable anxiety it is important to identify other potential causes of the symptoms, including direct effects of a substance (e.g., drug abuse or medication) or medical condition (e.g., hyperthyroidism, cardiopulmonary disorders, traumatic brain injury), or another mental disorder [26]. However, since comorbid conditions are common, the presence of some of these other conditions may not preclude the diagnosis of an anxiety or related disorder.
Certain risk factors have been associated with anxiety and related disorders and should increase the clinician’s index of suspicion (Table 6) [4, 9, 3337]. A family [33] or personal history of mood or anxiety disorders [34, 35] is an important predictor of anxiety symptoms. In addition, family history is associated with a more recurrent course, greater impairment, and greater service use [33]. A personal history of stressful life events is also associated the development of anxiety and related disorders [36, 37], in particular, childhood abuse [37].
Table 6
Common risk factors in patients with anxiety and related disorders
• Family history of anxiety [33]
• Personal history of anxiety or mood disorder [34, 35]
• Childhood stressful life events or trauma [36, 37]
• Being female [4, 9]
• Chronic medical illness [34, 40]
• Behavioral inhibition [41, 42]
Women generally have higher prevalence rates across all anxiety and related disorders, compared with men [4, 5, 9]. The median of age of onset is very early for some phobias and for separation anxiety disorder (seven to 14 years), but later for GAD, panic disorder, and PTSD (24-50 years) [1, 2].
Loneliness [38], low education [38], and adverse parenting [39], as well as chronic somatic illnesses, such as cardiovascular disease, diabetes, asthma, and obesity may increase the risk for a lifetime diagnosis of anxiety [34, 40].
Comorbid medical and psychiatric disorders
Anxiety and related disorders frequently co-occur with other psychiatric disorders [3]. More than half of patients with an anxiety disorder have multiple anxiety disorders [3, 15], and almost 30% will have three or more comorbid anxiety or related disorders [3]. Anxiety is often comorbid with substance use and mood disorders [3, 40]. An estimated 52% of patients with bipolar disorder [43], 60% of patients with MDD [44], and 47% of those with ADHD [45] will have a comorbid anxiety or related disorder. Therefore, anxiety disorders should be considered in these patients.
The high frequency of comorbidity must be considered when diagnosing anxiety and related disorders since this can have important implications for diagnosis and treatment [32]. Anxiety disorders comorbid with other anxiety or depressive disorders are associated with poorer treatment outcomes, greater severity and chronicity [4649], more impaired functioning [46], increased health service use [50], and higher treatment costs [51]. The impact tends to increase with an increasing number of comorbid conditions [46].
Patients with anxiety disorders have a higher prevalence of hypertension and other cardiovascular conditions, gastrointestinal disease, arthritis, thyroid disease, respiratory disease, migraine headaches, and allergic conditions compared to those without anxiety disorders [16, 52]. Comorbid anxiety and related disorders have a significant impact on quality of life (QoL) in patients with medical conditions [52].
Baseline assessment
Baseline assessment should include a review of systems, prescribed medications, over-the-counter agents, alcohol use, caffeine intake, and illicit drug use, in addition to evaluation of the anxiety symptoms and functioning [32]. Table 7 lists potential investigations that can be considered based on an individual patient’s presentation and specific symptoms (e.g., dizziness or tachycardia). Ideally, a physical examination and baseline laboratory investigations should be performed before pharmacotherapy is initiated, with repeat assessments according to best practice guidelines [32]. Patients with anxiety and related disorders should be monitored initially every one to two weeks and then every four weeks for weight changes and adverse effects of medications, as this is a major factor contributing to discontinuation of medication.
Table 7
Considerations for baseline laboratory investigations (as needed based on patient’s presenting symptoms)
Basic lab tests
 
• Complete blood count
• Fasting glucose
• Fasting lipid profile (TC, vLDL, LDL, HDL, TG)
• Thyroid-stimulating hormone
• Electrolytes
• Liver enzymes
If warranted
 
• Urine toxicology for substance use
 
Adapted from references [32, 53]. HDL = high density lipoprotein; LDL = low density lipoprotein; TC = total cholesterol; TG = triglyceride; vLDL = very low density lipoprotein.
Closer monitoring may be required in children younger than 10 years of age, older or medically ill patients, patients on medications associated with metabolic changes, and those on multiple medications [32].

Identify specific anxiety or related disorder

The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) has been finalized by the American Psychiatric Association (APA) [26]. The new DSM-5 provides diagnostic criteria for psychiatric disorders based on scientific reviews of the literature, field trial data, internal evaluations, public comments, and a final review by APA’s Board of Trustees.
The “anxiety disorders” chapter now includes panic disorder, agoraphobia, GAD, selective mutism, separation anxiety disorder, SAD (social phobia), specific phobia, substance/medication-induced anxiety disorder, as well as anxiety disorder due to another medical condition or not elsewhere classified. OCD and PTSD have been moved to separate chapters on obsessive-compulsive and related disorders and trauma- and stressor-related disorders, respectively [26].
Table 8 provides a brief summary of the key DSM-5 diagnostic features of the anxiety and related disorders that are included in these guidelines [26]. While the DSM-5 is the most up-to-date diagnostic criteria, it is important to note that the evidence for treatment is based on studies using DSM-IV criteria (or earlier) for inclusion of patients. However, most of the diagnostic criteria have not changed substantially (see Sections 3–9 for more information on diagnosis); the exception being agoraphobia, which is now designated as a separate diagnosis.
Table 8
Key features of specific anxiety and related disorders
Disorder
Key features
Panic disorder
• Recurrent unexpected panic attacks, in the absence of triggers
• Persistent concern about additional panic attacks and/or maladaptive change in behavior related to the attacks
Agoraphobia
• Marked, unreasonable fear or anxiety about a situation
• Active avoidance of feared situation due to thoughts that escape might be difficult or help unavailable if panic-like symptoms occur
Specific phobia
• Marked, unreasonable fear or anxiety about a specific object or situation, which is actively avoided (e.g., flying, heights, animals, receiving an injection, seeing blood)
Social anxiety disorder (SAD)
• Marked, excessive or unrealistic fear or anxiety about social situations in which there is possible exposure to scrutiny by others
• Active avoidance of feared situation
Generalized anxiety disorder (GAD)
• Excessive, difficult to control anxiety and worry (apprehensive expectation) about multiple events or activities (e.g., school/work difficulties)
• Accompanied by symptoms such as restlessness/feeling on edge or muscle tension
Obsessive–compulsive disorder (OCD)
• Obsessions: recurrent and persistent thoughts, urges, or images that are experienced as intrusive and unwanted and that cause marked anxiety or distress
• Compulsions: repetitive behaviors (e.g., hand washing) or mental acts (e.g., counting) that the individual feels driven to perform to reduce the anxiety generated by the obsessions
Posttraumatic stress disorder (PTSD)
• Exposure to actual or threatened death, serious injury, or sexual violation
• Intrusion symptoms (e.g., distressing memories or dreams, flashbacks, intense distress) and avoidance of stimuli associated with the event
• Negative alterations in cognitions and mood (e.g., negative beliefs and emotions, detachment), as well as marked alterations in arousal and reactivity (e.g., irritable behavior, hypervigilance)
Adapted from reference [26].
Specific individual anxiety and related disorders should be diagnosed with the DSM-5 criteria in the sections devoted to each anxiety disorder. An accurate diagnosis is important to help guide treatment.

Psychological and pharmacological treatment

Treatment options for anxiety and related disorders include psychological and pharmacological treatments. All patients should receive education about their disorder, efficacy (including expected time to onset of therapeutic effects) and tolerability of treatment choices, aggravating factors, and signs of relapse [32]. Information on self-help materials such as books or websites may also be helpful.
The choice of psychological or pharmacological treatment depends on factors such as patient preference and motivation, ability of the patient to engage in the treatment, severity of illness, clinicians’ skills and experience, availability of psychological treatments, patient’s prior response to treatment, and the presence of comorbid medical or psychiatric disorders [32].
A brief overview of psychological and pharmacological treatments is provided below, with more specific recommendations in the individual sections for each anxiety and related disorder.
Overview of psychological treatment
Psychological treatments play an important role in the management of anxiety and related disorders. Regardless of whether formal psychological treatment is undertaken, patients should receive education and be encouraged to face their fears. Meta-analyses have demonstrated the efficacy of psychological treatments in group and individual formats in patients with panic disorder [5456], specific phobia [57], SAD [58, 59], OCD [6063], GAD [55, 64, 65], or PTSD [6669], particularly exposure-based and other cognitive behavioral therapy (CBT) protocols [70, 71], as well as mindfulness-based cognitive therapy (MBCT) [72]. When choosing psychological treatments for individual patients, the forms of therapy that have been most thoroughly evaluated in the particular anxiety or related disorder should be used first.
CBT is not a single approach to treatment, but rather a process that focuses on addressing the factors that caused and maintain the individual patient’s anxiety symptoms [73]. Some of the core components of CBT are shown in Table 9 [73].
Table 9
Components of cognitive behavioral interventions
Exposure
• Encourage patients to face fears
• Patients learn corrective information through experience
• Extinction of fear occurs through repeated exposure
• Successful coping enhances self-efficacy
Safety response inhibition
• Patients restrict their usual anxiety-reducing behaviors (e.g., escape, need for reassurance)
• Decreases negative reinforcement
• Coping with anxiety without using anxiety-reducing behavior enhances self-efficacy
Cognitive strategies
• Cognitive restructuring, behavioral experiments, and related strategies target patients’ exaggerated perception of danger (e.g., fear of negative evaluation in SAD)
• Provides corrective information regarding the level of threat
• Can also target self-efficacy beliefs
Arousal management
• Relaxation and breathing control skills can help patient control increased anxiety levels
Surrender of safety signals
• Patient relinquishes safety signals (e.g., presence of a companion, knowledge of the location of the nearest toilet)
• Patients learn adaptive self-efficacy beliefs
Adapted from reference [73].
CBT can be effectively delivered as individual or group therapy for most anxiety and related disorders. In addition, a variety of self-directed or minimal intervention formats (e.g., bibliotherapy/self-help books, or internet/computer-based programs with or without minimal therapist contact) have demonstrated significant improvements in anxiety symptoms [7479]. Meta-analyses have also shown that exposure therapy can be effectively administered in a virtual reality format [80, 81]. These strategies may be particularly useful in cases where real-life exposure is difficult due to inconvenience, expense, or patient reluctance.
Psychotherapy and pharmacotherapy generally demonstrate about equivalent efficacy for the treatment of most anxiety and related disorders [71, 82]. Results with combination therapy vary for the different anxiety disorders, and results have been conflicting [82, 83] (see Sections 3–9 for evidence and references regarding combination therapy). Therefore, current evidence does not support the routine combination of CBT and pharmacotherapy as initial treatment. However, when patients do not benefit from CBT or have a limited response, a trial of pharmacotherapy is advisable. Similarly, patients who show limited benefit from pharmacotherapy may benefit from CBT. All patients being treated with pharmacotherapy should be instructed to gradually face their fears (exposure to decrease avoidance).
Overview of pharmacological treatment
This section provides a general overview of some of the commonly recommended pharmacological agents. Evidence and recommendations for specific medications are described in the individual sections for each of the anxiety and related disorders.
Table 10 shows medications that have Health Canada approved indications for use in different anxiety and related disorders [84], and dosing suggestions are shown in Additional file 1. Various antidepressants including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), noradrenergic and specific serotonergic antidepressants (NaSSAs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and reversible inhibitors of monoamine oxidase A (RIMAs) have demonstrated some efficacy in the treatment of anxiety and related disorders (see Sections 3–9 for evidence and references). SSRIs and SNRIs are usually preferred as initial treatments, since they are generally safer and better tolerated than TCAs or MAOIs [32].
Table 10
Medications with Health Canada–approved indications for anxiety and related disorders
 
Anxiety disorders
Panic disorder
Social anxiety disorder
Obsessive–compulsive disorder
Generalized anxiety disorder
Posttraumatic stress disorder
ANTIDEPRESSANTS
      
SSRIs
      
Escitalopram (Cipralex®)
   
X
X
 
Fluoxetine (Prozac®)
   
X
  
Fluvoxamine (Luvox®)
   
X
  
Paroxetine (Paxil®)
 
X
X
X
X
X
Paroxetine CR (Paxil® CR)
 
X
X
   
Sertraline (Zoloft®)
 
X
 
X
  
TCAs
      
Clomipramine
   
X
  
Other antidepressants
      
Venlafaxine XR (Effexor® XR)
 
X
X
 
X
 
Duloxetine (Cymbalta®)
    
X
 
AZAPIRONES
      
Buspirone (BuSpar®, Buspirex®)
    
X
 
BENZODIAZEPINES*
X
     
Data from respective Canadian product monographs [84].
*Multiple generic and brand name products, consult product monographs: alprazolam, bromazepam, chlordiazepoxide, clorazepate, diazepam, lorazepam, and oxazepam are indicated for anxiety disorders; alprazolam is also indicated for panic disorder.
CR = controlled release; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; XR = extended release.
Benzodiazepines may be useful as adjunctive therapy early in treatment, particularly for acute anxiety or agitation, to help patients in times of acute crises, or while waiting for onset of adequate efficacy of SSRIs or other antidepressants [32]. Due to concerns about possible dependency, sedation, cognitive impairment, and other side effects, benzodiazepines should usually be restricted to short-term use, and generally dosed regularly rather than as-needed [32].
Several anticonvulsants and atypical antipsychotics have demonstrated efficacy in some anxiety and related disorders, but for various reasons, including side effects, as well as limited randomized controlled trial (RCT) data and clinical experience, these agents are generally recommended as second-line, third-line, or adjunctive therapies (see Sections 3–9 for evidence and references).
The choice of medication should take into consideration the evidence for its efficacy and safety/tolerability for the treatment of the specific anxiety and related disorder, as well as for any comorbid conditions the patient might have, in both acute and long-term use.
Safety and side effects
Antidepressants: The most common side effects seen with SSRIs and SNRIs include headache, irritability, gastrointestinal complaints, insomnia, sexual dysfunction, weight gain, increased anxiety, drowsiness, and tremor [8588]. Patients report that the most common bothersome side effects are sexual dysfunction, drowsiness, fatigue, and weight gain [87, 88]. Most side effects occur early and transiently during the first two weeks of treatment, but others, such as sexual dysfunction and weight gain, may persist for the duration of treatment [85, 87, 89].
Use of SSRIs or SNRIs has been associated with an increased risk of upper gastrointestinal bleeding, particularly when used in combination with nonsteroidal anti-inflammatory drugs (NSAIDs) [90, 91]. SSRI use has also been associated with low bone mineral density [92, 93], as well as an increased risk of fractures [94] and hyponatremia [95].
Abrupt discontinuation of SSRIs or SNRIs can lead to a discontinuation syndrome with gastrointestinal, psychiatric, vasomotor, and other symptoms [85, 96].
Health Canada and the US Food and Drug Administration (FDA) require antidepressants to include a warning regarding an increased risk of suicidal ideation and behavior in children and adolescents [97, 98]. The increased risk of suicidal behavior reported in pediatric patients [99] does not appear to be seen in adults, and may in fact be decreased [99, 100]. Careful monitoring for evidence of self-harming or suicidal thoughts or behaviors is important in both adult and pediatric patients.
SSRIs and SNRIs are generally better tolerated and safer than TCAs and MAOIs, having less anticholinergic effects, toxicity, lethality, and psychomotor or cognitive impairment [85, 101]. MAOIs are generally reserved for second- or third-line treatment because of side effects, drug interactions, and dietary restrictions [32].
Anxiolytics: The most common side effects associated with benzodiazepines include primarily sedation, fatigue, ataxia, slurred speech, memory impairment, and weakness [85]. Benzodiazepines are associated with withdrawal reactions, rebound, and dependence, with the risk being greater with short- and intermediate-acting compared to long-acting agents [102]. These agents should be used with caution in patients with SUDs [85, 103]. Older patients (generally over 65 years of age) may be at high risk for falls and fractures due to psychomotor impairment associated with benzodiazepines [104, 105]. Cognitive impairment has been reported [106], some of which may persist after cessation of therapy [107]. In particular, memory impairment has been associated with high-dose or high-potency benzodiazepines, particularly in older people [102, 107].
Reported side effects of azapirones (buspirone) include dizziness, drowsiness, and nausea [32, 108].
Atypical antipsychotics: Atypical antipsychotics are associated to varying degrees with weight gain, diabetes, and other metabolic side effects, including alterations in glucose and lipid levels [109116]. Metabolic disturbances generally appear to be higher with olanzapine, intermediate with risperidone and quetiapine, and lower with aripiprazole, asenapine, lurasidone, and ziprasidone [109114].
Atypical antipsychotics have varying sedative effects, with quetiapine, clozapine, asenapine, and olanzapine generally causing more sedation than ziprasidone, risperidone, lurasidone, or aripiprazole [111, 115]. Data on cognitive effects are conflicting, with some studies suggesting improvements [111], while other data suggest greater cognitive dysfunction in patients using, versus those not using, antipsychotics [117].
Because of the risks of diabetes and weight gain, and the fact that there is limited RCT evidence of the efficacy of these agents in anxiety and related disorders, atypical antipsychotics are generally recommended as second-line, third-line, or adjunctive therapies (see Sections 3–9 for evidence and references).
Anticonvulsants: Anticonvulsants are associated with gastrointestinal side effects, somnolence, weight gain, tremor, as well as dermatologic and hematologic side effects [111, 118]. In addition, several anticonvulsants have a potential risk of serious rash, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis [111]. Regular monitoring of serum medication levels and liver function is required for patients on divalproex [84, 111].

Follow-up

Anxiety and related disorders are often chronic and a systematic approach to treatment should include patient education, assessment of comorbidities, and evidence-based pharmacological and psychological interventions with adequate monitoring and duration. Pharmacological treatment is often associated with a delay of about two to eight weeks in onset of symptom relief, with full response taking up to 12 weeks or more. Longer-term therapy has been associated with continued symptomatic improvement and the prevention of relapse, and therapy should be continued for at least 12-24 months for most patients [32].
Medication should be initiated at low doses and titrated to the recommended dosage range at one- to two-week intervals over four to six weeks. Once the therapeutic range has been achieved, improvement is usually seen over the next four to eight weeks. Follow-up should occur at two-week intervals for the first six weeks and monthly thereafter [32].
For a patient undergoing psychotherapy, the treatment schedule is structured around weekly contact with a therapist for about 12-20 weeks, although shorter protocols and minimal intervention programs have also proven effective (see Sections 3–9 for evidence and references). A follow-up appointment four weeks later and then every two to three months is usually sufficient [32].
Assessing response to treatment
Therapy should seek to improve symptoms and distress. The optimal goal is full remission of symptoms and return to a premorbid level of functioning [32, 85]. However, goals may need to be individualized for some patients with disorders that have been present since childhood as they may never have had adequate premorbid functioning. A response to therapy is often defined as a percentage reduction in symptoms (usually 25-50%) on an appropriate scale. Remission is often defined as loss of diagnostic status, a pre-specified low score on an appropriate disorder-specific scale, and no functional impairment in fully recovered patients as measured by a scale such as the Sheehan Disability Scale or SF-36 [32, 119, 120].
Objective scales can be used to help assess a patient’s progress. The Clinical Global Impression (CGI) scale is brief, comprehensive, and can easily be used at each appointment to assess improvement. The clinician-rated Hamilton Anxiety Rating Scale (HARS) can assess anxiety symptoms in general and is often used in clinical trials but is less practical in clinical practice. A variety of self-report and clinician-rated scales are available to assess the specific anxiety or related disorder.

Panic disorder and agoraphobia

Epidemiology

The lifetime and 12-month prevalence of panic disorder have been estimated at 4.7-5.1% and 2.1-2.8%, respectively [121, 122]. The estimated prevalence of panic attacks is considerably greater at 28.3% (lifetime) and 6.4-11.2% (12-month) [121, 123]. Youth with panic attacks (which often do not meet diagnostic criteria for panic disorder) will frequently have or develop other psychiatric disorders including mood disorders (bipolar disorder and MDD), other anxiety or related disorders, SUDs, eating disorders, psychotic disorders, and personality disorders [122, 124, 125]. Annually, 8-10% of the general public will have a panic attack without ever developing any identifiable psychopathology [126]. About 40-70% of patients with panic disorder experience nocturnal panic (waking from sleep in a state of panic) [127]. Rates of 12-month and lifetime agoraphobia (without panic) are quite low, at 0.8% and 1.4%, respectively [2, 3].
The risk of panic disorder and agoraphobia is higher in women than men, and patients who are middle-aged, widowed/divorced, and those of low income [122]. In the Canadian Community Health Survey 1.2 (CCHS 1.2) there were no differences in the rates of panic disorder or agoraphobia in urban versus rural settings [128].
Panic disorder has a negative impact on both psychological and physical functioning, and puts a substantial burden on the patient’s family [13]. Patients with panic disorder have more QoL impairment and dissatisfaction [16, 17], greater likelihood of suicide attempts [20], and increased cognitive and emotional dysfunction [129133] compared to healthy controls. Panic disorder is also associated with substantial societal costs [134], both in terms of health care utilization [135] and loss of workplace productivity [136]. In a 2012 survey, panic disorder conferred a substantial rate of work absenteeism (mean: 36.0 days/year) [136].

Comorbidity

Patients with panic disorder, or those experiencing panic attacks, have significantly increased odds of being diagnosed with a comorbid disorder, including another anxiety or related disorder, mood disorder, impulse-control disorder, or SUD [121, 137]. MDD is very common, occurring in an estimated 35-40% of patients with panic disorder [121]. Panic disorder also frequently co-occurs with agoraphobia [138].
Panic disorder is more prevalent in patients with medical conditions, including thyroid disease, cancer, chronic pain, cardiac disease, irritable bowel syndrome, migraine, as well as allergic and respiratory diseases compared with the general population [85, 139141]. The presence of medical comorbidity is associated with greater severity of panic disorder symptoms and disability [140, 142].

Diagnosis

For a diagnosis of panic disorder, a patient must have had recurrent, unexpected panic attacks (Table 11), followed by at least one month of persistent concern or worry about further attacks or their consequences, or a significant maladaptive behavioral change related to attacks (Table 12) [26].
Table 11
DSM-5 criteria for panic attacks
• An abrupt surge of intense fear or intense discomfort that reaches a peak within minutes, and includes ≥4 of the following symptoms:
(1) Palpitations, pounding heart, or accelerated heart rate
(2) Sweating
(3) Trembling or shaking
(4) Sensations of shortness of breath or smothering
(5) Feelings of choking
(6) Chest pain or discomfort
(7) Nausea or abdominal distress
(8) Feeling dizzy, unsteady, light-headed, or faint
(9) Chills or heat sensations
(10) Paresthesias (numbness or tingling sensations)
(11) Derealization (feelings of unreality) or depersonalization (being detached from oneself)
(12) Fear of losing control or going crazy
(13) Fear of dying
Adapted from reference [26].
Table 12
DSM-5 diagnosis of panic disorder
• The person has experienced both of the following:
    ○ Recurrent unexpected panic attacks
    ○ ≥1 of the attacks followed by ≥1 month of 1 or both of the following:
        • Persistent concern or worry about additional panic attacks or their consequences
        • Significant maladaptive change in behavior related to the attacks
Adapted from DSM-5 [26].
A panic attack continues to be considered a noncodable event in the DSM-5, with only minor revisions, including removal of the “10-minute” window, changing “hot flushes” to “heat sensations,” and the re-ordering of the list of symptoms to increase clinical utility [26, 143].
Compared to the DSM-IV-TR [144], changes to the diagnostic criteria for panic disorder largely consisted of minor phrasing changes to improve clinical utility, with the most substantial change being the title of the disorder [26, 143]. The DSM-5 now lists agoraphobia (anxiety about having a panic attack in certain situations, which are avoided or endured with marked distress) as a separate codable disorder, whereas previously panic disorder could be diagnosed as “panic disorder with agoraphobia” or “panic disorder without agoraphobia” [26, 145].
For a diagnosis of agoraphobia, a patient must have intense fear about at least two different types of situations, with the fear resulting from thoughts that escape may be difficult or help may be unavailable if panic-like symptoms occur (Table 13) [26, 145]. The situations provoke anxiety and are avoided or endured with intense fear or anxiety, or may require that a companion be present. The resultant fear or anxiety is out of proportion to any actual danger from the situation, causes substantial functional impairment, and usually lasts for six months or longer [26].
Table 13
DSM-5 diagnosis of agoraphobia
• Marked fear or anxiety about ≥2 of the following 5 groups of situations:
(1) Public transportation (e.g., traveling in automobiles, buses, trains, ships, or planes)
(2) Open spaces (e.g., parking lots, market places, or bridges)
(3) Being in shops, theatres, or cinemas
(4) Standing in line or being in a crowd
(5) Being outside of the home alone in other situations
• The individual fears or avoids these situations due to thoughts that escape might be difficult or help might not be available in the event of panic-like symptoms
• The agoraphobic situations almost always provoke fear or anxiety
• The situations are actively avoided, require presence of a companion, or endured with marked fear or anxiety
• The fear or anxiety is out of proportion to actual danger posed by agoraphobic situation
• The fear, anxiety, or avoidance is persistent, typically lasting ≥6 months
• The fear, anxiety, and avoidance cause clinically significant distress or functional impairment
Adapted from DSM-5 [26].
While the most up-to-date DSM-5 diagnostic criteria are presented here, the treatment data described within this section are based on studies involving patients meeting DSM-IV panic criteria (or older).
Establishing the context in which panic attacks occur, and whether there is any prior history of recurrent, unexpected panic attacks, is important for accurate diagnosis. Panic attacks frequently occur in other psychiatric disorders (e.g., MDD, PTSD), and medical conditions (e.g., cardiac, respiratory), and the DSM-5 has identified panic attacks as a specifier to be used in the absence of a diagnosable panic disorder [85]. Another disorder may better account for the panic attacks; for example, panic attacks in social situations may be SAD, those related to defined phobic objects or situations may be specific phobia, those related to reminders of traumatic events may be PTSD [26, 85], and those related to being kidnapped by extraterrestrials may be schizophrenia [26]. Some medical conditions that can be associated with panic symptoms include hyper- or hypothyroidism, hypoglycemia, seizure disorders, and cardiac conditions [26, 85]. Panic attacks may also be associated with intoxication or withdrawal from drugs of abuse, medications such as decongestants, stimulants, or beta-adrenergic agonist inhalers, or caffeine [85].

Psychological treatment

CBT has been extensively studied, and is an efficacious psychological treatment for panic disorder (Level 1) [56, 70, 146, 147]. In fact, CBT was significantly favored over medications for the treatment of panic disorder in a meta-analysis [71]. In a meta-analysis of 42 studies, exposure and combinations of exposure, cognitive restructuring and other CBT techniques had the most consistent evidence of efficacy for the treatment of panic disorder [56]. Strategies that included exposure were the most effective for panic measures. For measures of agoraphobia, combined strategies were more effective than single techniques, which did not result in significant improvements. Factors that improved the effectiveness of treatments were the inclusion of homework and a follow-up program [56]. Another meta-analysis also found that CBT that included interoceptive exposure was superior to relaxation therapy for panic symptoms [55]. CBT can be effectively delivered in both individual and group settings [56, 148, 149]. Conducting exposure in virtual reality appears to be effective when used as part of a CBT protocol [150154].
Minimal intervention formats, such as self-help books (bibliotherapy) [75, 76, 155158], treatment via telephone/videoconferencing [75, 159161], and internet-based CBT (ICBT) [75, 79, 162169] have been shown to be more effective than wait-list or relaxation controls, as effective as face-to-face CBT, and may be cost-effective options particularly for agoraphobic patients who are unwilling or unable to attend a clinic. When using bibliotherapy, providing information all at one time was as effective as pacing [157], and therapist support does not appear to be essential [75, 158]. Most ICBT programs have some therapist contact by either telephone or email, and once weekly contact appeared to be as effective as more frequent contact [168].
CBT panic disorder protocols usually involve 12-14 weekly sessions, but briefer strategies of six to seven sessions have been shown to be as effective [148, 149, 170]. In addition, compressing the duration of therapy by administering 13 sessions over three weeks has also been shown to be as effective as traditional weekly CBT [171]. Patients with higher baseline severity, disability, or comorbidity may have better outcomes with standard CBT [172]. CBT programs sometimes include one or more follow-up or “booster” sessions [170, 173].
Predictors of decreased response to CBT were severity of panic disorder, strength of blood/injury fears, earlier age of initial onset of panic symptoms, comorbid social anxieties, and degree of agoraphobic avoidance [174, 175]. Changes in symptoms are preceded by changes in beliefs during therapy [176], and change in beliefs and avoidance behaviors are considered key process variables [170, 176].
Eye movement desensitization and reprocessing (EMDR) does not appear to offer advantages over the same strategy without the eye movement component for the treatment of panic disorder [177, 178].

Combined psychological and pharmacological treatment

A meta-analysis of 21 trials found that combination psychotherapy and pharmacotherapy with antidepressants was superior to CBT or pharmacotherapy alone during the acute treatment phase and while medication was continued [179, 180]. After termination of treatment, combined therapy was more effective than pharmacotherapy alone and was as effective as psychotherapy [179, 180]. Prior meta-analyses have reported similar findings [54, 146, 181], suggesting that CBT alone or CBT combined with pharmacotherapy should be considered as first-line treatment.
A meta-analysis of the combination of psychotherapy and benzodiazepines included only three trials, and found no benefit to combination therapy compared with psychotherapy or medication alone [182]. The follow-up data suggested that the combination might be inferior to behavior therapy alone [182].
Adding self-administered CBT to SSRI therapy did not result in significant improvements overall, but patients did report a significantly greater rate of decline in fear of bodily sensations compared to medication alone [183]. Early results suggest a benefit of MBCT as an adjunct to pharmacotherapy in relieving anxiety and depressive symptoms in patients with panic disorder [184, 185].
Providing CBT sessions around the time of medication discontinuation was associated with a lower relapse rate during follow-up among patients treated with antidepressants [186]. In addition, CBT has been shown to be helpful in facilitating benzodiazepine discontinuation [187, 188].
A cost-effectiveness study found that combined CBT and pharmacotherapy was associated with a robust clinical improvement compared to usual care, with only a moderate increase in costs [189].
In a RCT, buspirone enhanced the effects of CBT in the short-term, but had no significant benefit over CBT alone during long-term follow-up [190].
Data on the efficacy of d-cycloserine as an adjunct to CBT are conflicting, with one study suggesting significant benefits at posttreatment and one-month follow-up [191], while another found an acceleration of symptom reduction in severely ill patients but no significant improvement in outcomes overall [192] compared to CBT plus placebo. Another compound acting at the N-methyl-D-aspartate (NMDA) receptor, Org 25935, demonstrated no benefit over placebo in augmenting CBT for panic disorder [193].

Long-term effects of psychological treatment

In naturalistic long-term follow-up studies, the benefits of CBT were maintained for up to three years [148, 169, 170, 188]. At two-year follow-up, individual, group, and brief CBT were associated with lower relapse rates compared to the wait-list control [148]. A long-term follow-up study of patients who had become panic-free with exposure therapy found that 93% remained in remission after two years and 62% after 10 years [194].
A meta-analysis found that at six to 24 months follow-up, remission/response rates with the combination of psychotherapy and antidepressants continued to be superior to antidepressants alone, or to psychotherapy as long as therapy was continued [179, 180].

Pharmacological treatment

The management of patients with panic disorder should follow the principles discussed in Section 2. Pharmacological interventions that have good evidence for efficacy in treating panic disorder include SSRIs, TCAs, and other antidepressants, as well as benzodiazepines. Treatments that have been investigated for use in panic disorder have been assessed according to the criteria for strength of evidence (Tables 1 and 2) and are summarized in Tables 14 and 15.
Table 14
Strength of evidence for pharmacotherapy for panic disorder
Agent
Level of evidence
Agent
Level of evidence
Antidepressants
SSRIs
 
TCAs
 
Citalopram [198200]
1
Clomipramine [199, 211, 213, 232, 233]
1
Fluoxetine [201204]
1
Imipramine [207, 224, 233240]
1
Fluvoxamine [195, 205210]
1
MAOIs and RIMAs
 
Paroxetine [211219]
1
Phenelzine [240]
2
Sertraline [183, 220224]
1
Moclobemide [204, 232, 241, 242]
1*
Escitalopram [198]
2
Tranylcypromine [243]
3
Paroxetine CR [225]
2
Other antidepressants
 
SNRIs
 
Reboxetine [200, 219, 244]
1
Venlafaxine XR [215, 216, 227229]
1
Mirtazapine [203, 245, 246]
2
Duloxetine [230]
3
Bupropion SR [247, 248]
3*
Milnacipran [231]
3
  
Other therapies
Anxiolytics
 
Atypical antipsychotics
 
    Benzodiazepines
 
Risperidone [217, 267]
2
      Alprazolam [234, 249254]
1
Olanzapine [268]
3
      Clonazepam [218, 250, 255258]
1
Quetiapine [267]
3
      Lorazepam [251, 259, 260]
1
Adjunctive aripiprazole [269]
3
      Diazepam [261263]
1
Adjunctive olanzapine [270]
3
      Adjunctive clonazepam [264, 265]
1
Adjunctive risperidone [271]
3
      Adjunctive alprazolam ODT [266]
3
Anticonvulsants
 
Other treatments
 
Divalproex [272275]
3
Buspirone [254, 282]
1 (-ve)
Levetiracetam [276]
3
Trazodone [283]
2 (-ve)
Gabapentin [277]
2 (-ve)
Propranolol [262, 284, 285]
2 (-ve)
Tiagabine [278, 279]
2 (-ve)
Adjunctive pindolol [286]
2
Carbamazepine [280]
3 (-ve)
  
Adjunctive divalproex [281]
3
*Conflicting data. No significant superiority over placebo in overall population, but significant benefits in subgroup of more severely ill patients. CR = controlled release; MAOI = monoamine oxidase inhibitor; ODT = orally disintegrating tablets; RIMA = reversible inhibitor of monoamine oxidase A; SNRI = serotonin–norepinephrine reuptake inhibitor; SR = sustained release; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; XR = extended release; (-ve) = negative.
Table 15
Recommendations for pharmacotherapy for panic disorder
First-line
Citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, paroxetine CR, sertraline, venlafaxine XR
Second-line
Alprazolam, clomipramine, clonazepam, diazepam, imipramine, lorazepam, mirtazapine, reboxetine
Third-line
Bupropion SR, divalproex, duloxetine, gabapentin, levetiracetam, milnacipran, moclobemide, olanzapine, phenelzine, quetiapine, risperidone, tranylcypromine
Adjunctive therapy
Second-line: alprazolam ODT, clonazepam
Third-line: aripiprazole, divalproex, olanzapine, pindolol, risperidone
Not recommended
Buspirone, propranolol, tiagabine, trazodone
CR = controlled release; ODT = orally disintegrating tablets; SR = sustained release; XR = extended release.

First-line agents

SSRIs: Evidence from meta-analyses [195197] and RCTs supports the use of the SSRIs citalopram [198200], fluoxetine [201204], fluvoxamine [195, 205210], paroxetine [211219], and sertraline [183, 220, 221, 223, 224] (all Level 1), as well as escitalopram [198] and paroxetine controlled-release (CR) [225] (both Level 2) for the treatment of panic disorder. In meta-analyses, SSRIs demonstrated significant improvements in panic symptoms, agoraphobic avoidance, depressive symptomatology, and general anxiety [195197, 226]. Effect sizes for SSRIs and TCAs are similar [195, 196], although dropout rates may be lower with SSRIs [195].
SNRIs: Venlafaxine extended-release (XR) has been shown to be useful in reducing the severity of panic disorder symptoms in RCTs (Level 1) [215, 216, 227229]. Two studies found significantly greater rates of panic-free patients compared with placebo [215, 216] while two did not [228, 229].

Second-line agents

TCAs: There is good evidence from RCTs to support the use of the TCAs clomipramine [199, 211, 213, 232, 233] and imipramine [207, 224, 233240] in panic disorder (Level 1). In meta-analyses, TCAs have demonstrated efficacy for the treatment of panic symptoms and agoraphobia [195197, 226]. Efficacy is generally equivalent to SSRIs, however, since TCAs tend to be less well tolerated and have higher discontinuation rates than SSRIs [195], they are recommended as second-line options.
Other antidepressants: Although there is level 1 evidence to support the use of reboxetine [200, 219, 244], limited experience with this agent in Canada, and its side effect profile, which includes dry mouth, constipation, and insomnia [244], led to its recommendation as a second-line option. Mirtazapine has demonstrated efficacy for the treatment of panic disorder in several open trials [245, 246] and one small RCT [203] (Level 2). It appears to be as effective as fluoxetine [203] and may be a useful second-line choice.
Benzodiazepines: Alprazolam [234, 249254], clonazepam [218, 250, 255258], lorazepam [251, 259, 260], and diazepam [261263] have demonstrated efficacy for the treatment of panic disorder (Level 1). While it has been suggested that alprazolam may be more effective, a meta-analysis found no evidence that it was superior to other benzodiazepines for the treatment of panic disorder [252]. Although benzodiazepines are second-line options, they may be useful at any time during therapy for the short-term management of acute or severe agitation or anxiety. They may also be useful at the initiation of SSRI treatment to hasten response (Level 1) [264266].

Third-line agents

MAOIs and RIMAs: Results with moclobemide for the management of panic disorder have been conflicting (Level 1). In clinical trials, moclobemide demonstrated efficacy similar to that of clomipramine and fluoxetine [204, 232], but was not superior to placebo [241, 242]. However, significant efficacy in more severely ill patients [241], suggests it may be useful in treatment-resistant patients. In a RCT, phenelzine was more effective than placebo and as effective as imipramine (Level 2) [240]. In a small randomized, uncontrolled trial, tranylcypromine demonstrated efficacy for patients with comorbid panic and social anxiety disorders (Level 3) [243].
Atypical antipsychotics: There is some evidence that atypical antipsychotics may have some benefits in the treatment of patients with refractory panic disorder [217, 267, 268]. In a RCT, risperidone monotherapy was as effective as paroxetine (Level 2) [217]. Open-label data also support the use of risperidone [267], olanzapine [268], and quetiapine [267]. There are also open-label data supporting the use of some atypical antipsychotics as adjunctive therapy (see below).
Other therapies: The antidepressants duloxetine [230], milnacipran [231], and bupropion sustained release (SR) [247, 248] have shown some efficacy in open trials, as have the anticonvulsants divalproex [272275] and levetiracetam [276] (all Level 3). In a RCT, gabapentin was superior to placebo in patients who were more severely ill, but not in the overall group (Level 2, negative) [277]. These agents are recommended only as third-line options in patients with refractory panic disorder.

Adjunctive therapy

There is good evidence that adjunctive clonazepam [264, 265] (Level 1), and open-label evidence that adjunctive alprazolam orally-disintegrating tablet (ODT) [266] (Level 3), used short-term (<8 weeks including taper) at the initiation of SSRI treatment, can lead to a more rapid response [264266].
In a RCT, pindolol added to fluoxetine therapy in patients with treatment-resistant panic disorder was associated with significant improvement in panic disorder symptoms compared with fluoxetine plus placebo (Level 2) [286]. Open-label data also support the use of the atypical antipsychotics aripiprazole [269], olanzapine [270], and risperidone [271] (all Level 3), as well as the anticonvulsant divalproex [281], as adjunctive strategies for patients with treatment-resistant panic disorder.
Buspirone (Level 1, negative) [254, 282], propranolol (Level 2, negative) [262, 284, 285], tiagabine [278, 279] (Level 2, negative), and trazodone (Level 2, negative) [283] have not demonstrated efficacy and are not recommended for the treatment of panic disorder. Carbamazepine (Level 3, negative) [280] also does not appear to be effective in this disorder.

Maintenance pharmacological treatment

In long-term, open, follow-up studies, citalopram [287, 288], fluoxetine [204, 288], fluvoxamine [288], paroxetine [288290], and moclobemide [204], as well as clomipramine [287, 289] and imipramine [291, 292] demonstrated maintenance of benefits and continued improvements over six months to three years of ongoing treatment. In a RCT, sertraline and imipramine were equally effective over a six month period [224]. However, in another RCT, imipramine was not superior to placebo in the proportion of panic-free patients after eight months of therapy [293].
Venlafaxine XR [294] and imipramine [295] have been shown to prevent relapse in randomized, placebo-controlled, discontinuation studies. After three months of acute treatment, relapse rates were significantly lower with ongoing venlafaxine XR [294] or imipramine [295] therapy compared with switching to placebo during six to 12 months of follow-up.
Benzodiazepines are generally recommended for short-term use only. However, several trials have demonstrated the benefits of up to two years of alprazolam maintenance therapy [291, 293]. There was no evidence of tolerance, but up to one-third of patients were unable to discontinue therapy [293]. The efficacy of clonazepam was maintained over a three-year course of treatment [290], and patients who had been asymptomatic for at least one year were able to successfully discontinue the medication, using a slow tapering strategy over four to seven months, and improvement in panic disorder was maintained [296].

Biological and alternative therapies

Biological therapies: In open-label case series, noninvasive brain stimulation using a radioelectric asymmetric conveyor (REAC) demonstrated efficacy for panic symptoms and agoraphobia (Level 3) [297, 298]. A small case series suggested repetitive transcranial magnetic stimulation (rTMS) could improve panic and anxiety in patients with panic disorder with comorbid MDD (Level 4) [299]. However, a small RCT found no additional benefit of rTMS compared to sham rTMS as an add-on to SSRI therapy in patients with panic disorder (Level 2, negative) [300].
Alternative therapies: In a RCT, capnometry-assisted respiratory training was as effective as cognitive training in reducing panic symptom severity and panic-related cognitions and improving perceived control (Level 2) [301]. However, breathing training did not significantly improve reactivity or recovery after a respiratory challenge in another small trial (Level 2, negative) [302]. In a RCT, patients with panic disorder randomized to the exercise groups (plus paroxetine or placebo) had a trend toward better improvement compared to relaxation training, but this was not significant (Level 2, negative) [303]. However, in an open cross-over study, acute aerobic exercise was found to reduce anxiety as well as panic attack frequency and intensity in patients with panic disorder compared to a quiet rest condition (Level 3) [304]. These therapies may be useful for some patients; however, more data are needed.

Summary

As much as 40% of the general population has experienced a panic attack at some point in their lifetime. However, patients with actual panic disorder experience recurrent, unexpected panic attacks as well as persistent concern or behavioral change around further attacks.
Data support pharmacotherapy, CBT alone, and CBT combined with pharmacotherapy as initial treatments for panic disorder. CBT alone may be insufficient in patients with comorbid moderate-to-severe major depression, or in those with severe, frequent panic attacks, or rapid worsening of agoraphobia, and/or suicidal ideation, as well as in situations where one might consider initial rescue treatment with a benzodiazepine to minimize or stop the panic attacks while waiting the 4-12 weeks for the first-line pharmacotherapy to become effective. Also there are patients who are not motivated to participate in CBT (preferring medication as initial treatment) or are too fearful to engage in any kind of exposure before being treated with a first-line pharmacotherapeutic agent. At the very least, if agoraphobic distress or avoidance persists, these patients need instruction and support to engage in exposure exercises. For panic symptoms, strategies should include exposure; and combined strategies should be considered for patients with agoraphobia. CBT can be effectively delivered in both individual and group settings, as well as via self-help books, virtual reality, and internet-based programs. The benefits of CBT are maintained during follow-up. In addition, data suggest that combination of psychotherapy and pharmacotherapy may be superior to pharmacotherapy alone during follow-up.
Pharmacotherapeutic approaches should begin with a first-line agent. If response to optimal dosing is inadequate or the agent is not tolerated, treatment should be switched to another first-line agent before considering second-line medications. First-line options for the treatment of panic disorder include citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine XR, escitalopram, or paroxetine CR. Second-line choices include the TCAs (clomipramine and imipramine), mirtazapine, reboxetine, or benzodiazepines (alprazolam, clonazepam, lorazepam, and diazepam).
Patients who do not respond to first- or second-line agents are considered to have treatment-refractory illness. In such patients it is important to reassess the diagnosis and consider comorbid medical (e.g., ischemic heart disease) and psychiatric conditions (e.g., SUDs) that may be affecting response to therapy. Third-line agents, adjunctive therapies, as well as biological and alternative therapies may be useful when patients fail to respond to an optimal treatment trial of first- and second-line therapies used alone and in combination.

Specific phobia

Epidemiology

A specific phobia is an intense fear of a specific object or situation and is usually associated with avoidance of the feared object. The most prevalent phobia types include animal (e.g., insects, snakes), natural environment (e.g., heights, storms, water), situational (e.g., flying, enclosed spaces), and blood-injection-injury (B-I-I) (e.g., blood, dentists, hospitals) [305, 306]. Large US and European epidemiologic surveys report lifetime prevalence estimates of 10-13% and 12-month prevalence rates of 7-9% [2, 3, 305, 307]. Rates among adolescents may be particularly high with lifetime prevalence estimates of 36.5% and 12-month prevalence rates of 27.3% being reported [308]. Specific phobias are more common in women than men [306]. Age of onset is usually in the range of five to 12 years (median: seven years) [2]; however, this varies by type of phobia. Animal and B-I-I phobias generally begin in childhood, whereas situational phobias (e.g., driving phobia, claustrophobia) have a later onset, typically during late adolescence or early adulthood [306].
Specific phobias are associated with significant distress, regardless of the number of feared stimuli reported [305]. Specific phobias have a negative impact on social/occupational functioning and lead to restriction of usual daily activities, which increases with an increasing number of fears [305].

Comorbidities

Specific phobias tend to co-occur with other specific phobias, with less than 10% of patients having only one fear [305]. The mean number of fears, in one survey, was three [305]. In addition, specific phobias are frequently comorbid with other psychiatric disorders, including SUDs, mood disorders, and other anxiety or related disorders (particularly panic disorder, SAD, and GAD), as well as personality disorders [305, 309, 310].

Diagnosis

To receive a DSM-5 diagnosis of specific phobia a patient must experience marked (intense) fear or anxiety about a specific object or situation, which is associated with significant distress or functional impairment (Table 16) [26]. The object or situation will be actively avoided or endured with intense anxiety. Compared to the DSM-IV-TR criteria for specific phobia [144], few changes were made in the DSM-5 [26, 306]. Of note, recognition that the fear is excessive or unreasonable has been removed and a new criterion stating “the fear or anxiety is out of proportion to danger posed” has been added. Avoidance has been clarified as “actively avoided” to distinguish the avoidance seen in specific phobias from passive avoidance that may occur for other reasons [26, 306].
Table 16
DSM-5 diagnosis of specific phobia
• Marked fear or anxiety about a specific object or situation (e.g., flying, seeing blood)
• The phobic object or situation almost always provokes immediate fear or anxiety and is actively avoided or endured with marked fear or anxiety
• The fear or anxiety is out of proportion to the actual danger posed by the specific object or situation
• The fear, anxiety, or avoidance is persistent, typically ≥6 months
• There is marked distress or functional impairment
Adapted from DSM-5 [26].
While the most up-to-date DSM-5 diagnostic criteria are presented here, it is important to note that most of the treatment data described within this section are based on patients meeting DSM-IV criteria (or older).
Specific phobias are delineated into five types: animal type, natural environment type, B-I-I type, situational type, or other type (Table 17) [26]. The fear of contracting an illness has been removed because of high relatedness to OCD and anxiety disorder related to medical condition [26].
Table 17
Specific phobia specifiers in DSM-5
Specifier
Examples
Animal
Spiders, insects, dogs
Natural environment
Heights, storms, water
Blood-injection-injury
Needles, invasive medical procedures
Situational
Airplanes, elevators, enclosed spaces
Other
Choking or vomiting. In children, loud sounds or costumed characters
Adapted from DSM-5 [26].
Specific phobias can be difficult to distinguish from panic disorder [311]. It is important to consider the focus of apprehension (e.g., fear of crashing while on an airplane versus fear of having a panic attack on an airplane), the types of panic attacks experienced (e.g., expected versus unexpected), and the range of situations associated with fear and avoidance [311].

Psychological treatment

Psychosocial interventions, particularly exposure-based treatments, are the treatments of choice and are associated with a high degree of success in providing remission of specific phobias [311]. Both in vivo exposure and virtual reality exposure (VRE) can be effective [57, 311, 312], with in vivo exposure being shown to be superior to alternative types (e.g., imaginal, virtual reality, etc.) at posttreatment but not at follow-up [57].
In general, exposure-based therapy has been shown to be more effective if: sessions are grouped closely together; exposure is prolonged, real (not imagined), and provided in multiple different settings; and there is some degree of therapist involvement (not entirely self-directed) [32, 311]. While one-session treatments have demonstrated efficacy [313], a meta-analysis found that a greater number of sessions predicted more favorable outcomes [57].
There is no evidence that either flooding or gradual exposure is more effective [314], however, progressive exposures are generally more tolerable to patients [311]. An example of graded exposure in a patient with arachnophobia would be to look at pictures of spiders, hold a rubber spider, look at a live spider in a jar, touch the jar containing the spider, stand two feet from a live spider, and finally touch a live spider. This approach can be used to guide exposure depending on the patient’s symptom severity and tolerance to each level of exposure.
While a meta-analysis of 33 RCTs of psychological approaches found that treatment outcomes were not moderated by type of specific phobia [57], studies have suggested that certain subtypes may respond more favorably to specific types of treatment (Table 18).
Table 18
Psychological treatments with demonstrated efficacy in specific phobias
Psychological treatment
Phobia
Exposure-based treatments
All specific phobias [57, 311, 312]
Virtual reality exposure
Heights [327329], flying [319, 321324], spiders [331, 332], claustrophobia [330]
Computer-based self-help programs
Spiders [334, 335], flying [323], small animals [336, 337]
Applied muscle tension (exposure combined with muscle tension exercises)
Blood-injection-injury type [311, 315, 316]
Cognitive therapy and exposure
Dental [318], flying [319, 320]
For patients with B-I-I phobias, exposure therapy combined with muscle tension exercises (applied tension) designed to prevent fainting [311] has been shown to be effective [315, 316]. Use of stress-reducing medical devices, such as decorated butterfly needles and syringes, has been shown to significantly reduce needle phobia and stress in both pediatric and adult patients [317]. CBT reduced avoidance of oral injections and decreased anxiety in patients with dental phobias [318].
Fear of flying has been effectively treated with group CBT [319, 320]. In addition, computer-generated VRE has demonstrated efficacy [319, 321324], which was comparable to standard exposure therapy in several studies [322, 324], and can have long-term benefits [325, 326]. Bibliotherapy was found to be less effective than VRE or CBT for patients with fear of flying [319]. VRE has also been shown to be effective for patients with a fear of heights [327329], and those with claustrophobia [330]. This approach may also be useful for treating fears for which in vivo exposure may not be practical (e.g., fear of storms) [32].
Arachnophobia has been successfully treated with in vivo[331] and VR [331, 332] exposure, with little difference between the two modalities [331]. A spiderless form of VRE, which presented images that were not spiders, but had some of the characteristics of spiders, was shown to be useful in patients with severe arachnophobia who were reluctant to undergo direct exposure or VRE [333]. An internet-based self-help program was associated with improvement, but was not as effective as one session of in vivo exposure at the post-treatment assessment, although results were similar at follow-up [334]. However, even one session of VRE was associated with greater fear reduction compared to a control group, and may be a useful self-help intervention to reduce fear of spiders [335]. Computer-based self-help has also shown promise for other small-animal phobias (e.g., cockroaches, mice) [336, 337].

Combined psychological and pharmacological treatment

It has been speculated that d-cycloserine, a partial agonist at the NMDA receptor, may improve extinction of fear in patients with phobias undergoing behavioral exposure therapy [338]. In a RCT (n=28), d-cycloserine as an adjunct to VRE resulted in significantly larger reductions of acrophobia symptoms compared with VRE alone [338]. In another study (n=100), adjunctive d-cycloserine did not improve the reduction of spider fears compared to exposure-based therapy alone, however, patients had heightened, but subclinical, spider fears [339].
In two RCTs, use of adjunctive cortisol, a glucocorticoid, significantly enhanced the benefits of exposure therapy compared with placebo in patients with acrophobia (n=40) [340] and arachnophobia (n=20) [341], with evidence suggesting that cortisol may facilitate the extinction of phobic fear at follow-up.
Enhanced emotional memory may be stimulated through elevated noradrenaline levels, and data suggest that yohimbine hydrochloride, a noradrenaline agonist, can facilitate fear extinction. In RCTs, there were no significant VRE-enhancing effects with adjunctive yohimbine compared with placebo in patients with fear of flying (n=48) [342] or claustrophobia (n=24) [343]. However, in the claustrophobia study, patients treated with yohimbine showed greater improvements in outcomes at the one-week follow-up [343].
In contrast, naltrexone was found to render one-session exposure therapy less effective compared with placebo or no treatment in 15 patients with specific phobias (animals) [344].

Long-term effects of psychological treatment

Long-term treatment of specific phobia is rare. As discussed above, CBT and exposure therapies have demonstrated sustained benefits at long-term follow-up assessments [325, 326].

Pharmacological treatment

There is a minimal role for pharmacotherapy in the treatment of specific phobias, largely due to the lack of research on medications in this condition, and the success of exposure-based therapies [32, 311].
Antidepressants have been investigated in two small RCTs [345, 346]. In a small RCT, paroxetine was significantly more effective than placebo in resolving anxiety in patients with specific phobias (n=11) [345]. Similarly, escitalopram was associated with a strong treatment effect in a small RCT (n=12); however, the trial was under-powered to show statistically significant superiority over placebo on the primary outcome [346]. In addition, cases of successful treatment of flying phobias with fluoxetine [347], and storm phobia with fluvoxamine [348], have been reported.
Benzodiazepines have usually been assessed as adjuncts to exposure therapy, and these studies have found no additional benefit with medication [349351]. Benzodiazepines are often used in clinical practice to provide acute symptom relief when it is necessary for a patient with a specific phobia to face a feared situation (e.g., dental procedure, magnetic resonance imaging [MRI], unexpected flight) [32]. Nasal midazolam has proven useful in facilitating MRI in claustrophobic patients [352, 353].

Summary

Specific phobia is quite common, particularly among adolescents. Patients with specific phobia exhibit an intense fear or anxiety about a specific object or situation which is associated with significant distress or functional impairment. The most prevalent phobia types include animal, natural environment, situational, and B-I-I.
Exposure-based techniques, including virtual exposure, are highly effective, and are the foundation of treatment for specific phobias. Pharmacotherapy is generally unproven, and thus not a recommended treatment for most cases.

Social anxiety disorder

Epidemiology

SAD is one of the most common anxiety disorders, with lifetime prevalence estimates ranging from 8-12% among the international general population [2, 354356]. It is more common in women than men [355, 357360], and higher rates have been reported in developed (6.1%) versus developing (2.1%) countries [361]. SAD has an early age of onset, typically during adolescence (mean 12 years), and tends to have a chronic and unremitting course [2, 362, 363]. Factors such as low educational achievement, low socioeconomic status, being single or separated, and having comorbid MDD have been associated with a higher prevalence of SAD in epidemiological studies [359, 360, 364].
SAD is associated with significant impairments including problems with educational and occupational performance, family functioning, and an overall reduced QoL [14, 15, 17, 354, 363, 365369]. SAD also confers a substantial economic burden upon afflicted individuals and society in terms of work days missed and health care costs [370, 371]. Canadians with SAD were twice as likely to report at least one disability day in the past two weeks, compared to those without SAD [356].

Psychiatric comorbidity

SAD is associated with significant comorbidity, with up to 72% of patients reporting criteria for another psychiatric disorder [372]. The highest rates of comorbidity have been found with MDD and other anxiety or related disorders [355, 356, 360]. Avoidant personality disorder [373], body dysmorphic disorder [374, 375], SUD [356, 376], ADHD [377, 378], and schizophrenia [379] also commonly occur with SAD.

Diagnosis

SAD is characterized by a persistent fear that in social and performance situations the individual will say or do something that will lead to humiliation, embarrassment, or negative evaluation by others (Table 19) [26]. Social situations are actively avoided or endured with distress, and the individual recognizes the fears as excessive or unreasonable. The avoidance or anxiety induced by these fears incurs significant functional impairment and distress [144]. Compared to the DSM-IV-TR [144], changes to the diagnostic criteria for SAD in the DSM-5 have been minimal, largely consisting of minor phrasing changes to improve clinical utility [26]. The criterion that the “person recognizes that the fear is excessive or unreasonable” has been changed to “out of proportion to the actual threat posed by the social situation.” Since patients with SAD are often unable to recognize that their fear may be excessive the clinician may be in a better position to judge this.
Table 19
DSM-5 diagnosis of SAD (social phobia)
• Marked fear or anxiety about social situations in which the person may be exposed to scrutiny by others
• Fear that actions or showing anxiety symptoms will cause negative evaluation (e.g., embarrassment, humiliation) or offend others
• The social situation:
    ○ Almost always provokes fear or anxiety
    ○ Is actively avoided or endured with marked fear or anxiety
• The fear, anxiety, or avoidance:
    ○ Is out of proportion to the actual threat posed by the social situation
    ○ Is persistent, typically ≥6 months
    ○ Causes significant distress or functional impairment
• If another medical condition is present (e.g., stuttering, obesity), the disturbance is unrelated or out of proportion to it
• Specify “performance only” if the fear is restricted to speaking or performing in public
Adapted from DSM-5 [26].
The DSM-IV-TR criteria excluded social fears/avoidance associated with and secondary to medical conditions, however, the DSM-5 recognizes that SAD may be secondary to a medical condition. Some patients experience excessive social anxiety about their medical symptoms (e.g., stuttering, tremulousness from Parkinson’s disease, obesity, disfigurement from burns or injury), and may experience disability due to their social anxiety [26].
In addition, the “generalized” subtype specifier included in DSM-IV-TR has been removed, while the “performance only” specifier has been added [26, 380] for DSM-5. This change was made because there was little supporting evidence for the generalized specifier, and the evidence that SAD symptoms fall along a continuum of severity characterized by the number of fears [380]. The “performance only” specifier appears to represent a subset of SAD patients typically experiencing impairment from performance fears primarily related to their professional lives [26].
While the most up-to-date DSM-5 diagnostic criteria are presented here, it is important to note that all of the treatment data described within this section are based on patients meeting DSM-IV criteria (or older).

Psychological treatment

Psychological treatment, in the form of CBT, is considered to be the gold-standard nonpharmacological treatment in SAD. Cognitive techniques involved in CBT for SAD include restructuring and challenging of maladaptive thoughts, while the behavioral component is typically in the form of exposure therapy. The efficacy of CBT compared with placebo, treatment-as-usual, or wait-list conditions, is supported by many RCTs as well as meta-analytic evidence [58, 59, 70, 71, 381]. Although results vary, several studies of acute SAD treatment have also found a similar efficacy between CBT and pharmacotherapy [382387]. Some reports suggest that after treatment discontinuation, gains achieved with CBT may persist longer than those achieved with pharmacotherapy [388, 389]. CBT for SAD can be administered in group or individual formats. Although some studies have reported that individual CBT is superior to group CBT [390, 391], meta-analyses have failed to find significant differences in efficacy between the two modalities [58, 59, 381].
The treatment literature has also examined the efficacy of the individual components of CBT. There is evidence to support the effectiveness of exposure therapy alone [389, 392], however the efficacy of exposure alone compared with CBT is equivocal in the current treatment literature [392395].
There are several variants of CBT that have been examined in the literature. For example, videotaped feedback was not shown to enhance the effects of exposure-based treatment [396]. However, CBT with VRE was found to be more effective than wait-list control and as effective as CBT with imaginal or in vivo exposure according to two meta-analyses [80, 150].
A form of CBT focused on interpersonal behavior found similar improvements in social anxiety compared to standard CBT but also increased relationship satisfaction and social approach behaviors [397]. Evidence to support interpersonal therapy (IPT) in SAD is conflicting [398400]; while some results have been negative [398], it is likely that IPT is more effective than wait-list control [399], but less effective than traditional CBT [399, 400].
Similarly, while less effective than traditional CBT, mindfulness-based therapy (MBT) has been associated with improvements in symptoms of SAD [401]. In addition, small studies of attentional bias training suggest there may be some benefit associated with training patients to disengage from negative social cues, but data are conflicting [402, 403].
ICBT is a newer treatment that may increase the availability of CBT for anxiety and mood disorders in the future. Studies have evaluated this treatment in comparison to individual and group CBT. ICBT has demonstrated efficacy in RCTs of SAD, significantly improving social anxiety symptoms compared to wait-list control conditions [404410]. Most ICBT programs include minimal therapist contact via email [404410] or telephone [405, 409]. Many programs involve a component of interaction with other participants through the use of internet discussion groups [411]. However, it remains unclear whether the therapist component is necessary, and studies comparing guided with unguided ICBT have yielded conflicting results. In one RCT, clinician-assisted ICBT was more effective than a self-guided ICBT, and the self-guided ICBT was not significantly better than the wait-list condition [406]. Similarly, a self-help program augmented with minimal therapist contact was more useful than a pure self-help strategy [412]. However, several other RCTs have found that unguided ICBT self-help was as effective as ICBT with therapist involvement [410, 411]. A few ICBT programs included face-to-face in vivo exposure sessions [409, 413], but one RCT found that adding this component did not significantly improve outcomes versus ICBT with self-directed exposure [413]. In addition, several RCTs have shown ICBT (with minimal therapist contact) to be as effective as face-to-face CBT [414, 415], while being more cost-effective [416]. As with other RCTs, research on ICBT has involved pre-screening of participants in-person or by telephone, with posttreatment and follow-up assessments by telephone or through self-report measures. Little is known about the effectiveness of self-administered treatments (ICBT or self-help books) used with no pre-screening or planned follow-up contacts.

Combined psychological and pharmacological treatments

When used in combination, pharmacotherapy has not been shown to add to the benefits of CBT in some studies [387, 417], while one study found the combination of phenelzine and CBT superior to either modality alone [418]. D-cycloserine has also been found to enhance treatment outcomes when used during exposure exercises as an adjunct to exposure alone [419, 420]. In addition, a study of psychodynamic group therapy with or without the addition of clonazepam also found combination treatment to be superior to clonazepam treatment alone [421].

Long-term effects of psychological treatment

The benefits of CBT have been found to be maintained at six to 12 month follow-up visits [58, 382, 390, 393, 409, 413, 422, 423], with sustained improvement being reported at five years posttreatment [424, 425]. Long-term assessments post-ICBT have shown sustained improvement at one to five years follow-up [409, 413, 423, 424]. Long-term benefits with psychotherapy appear to be more enduring than those of pharmacotherapy after treatment discontinuation [388, 389].

Pharmacological treatment

The management of patients with SAD should follow the principles discussed in Section 2. Pharmacological interventions that have good evidence for efficacy in treating SAD include SSRIs, SNRIs, anticonvulsants, and benzodiazepines. Treatments that have been investigated for use in SAD have been assessed according to the criteria for strength of evidence (Tables 1 and 2) and are summarized in Tables 20 and 21.
Table 20
Strength of evidence of pharmacotherapy for SAD
Agent
Level of evidence
Agent
Level of evidence
Antidepressants
SSRIs [58, 426429]
1
TCAs
 
Escitalopram [430432]
1
Clomipramine [458, 459]
3
Fluvoxamine [433435]
1
Imipramine [460]
3 (-ve)
Fluvoxamine CR [436, 437]
1
MAOIs and RIMAs
 
Paroxetine [431, 438444]
1
Phenelzine [384, 386, 418, 461, 462]
1
Sertraline [445448]
1
Moclobemide [417, 462466]
1*
Fluoxetine [382, 387, 449]
1*
Other antidepressants
 
Citalopram [450, 451]
2
Mirtazapine [467, 468]
1*
Paroxetine CR [452]
2
Bupropion SR [469]
3
Adjunctive paroxetine [453]
3
  
SNRIs
   
Venlafaxine XR [439, 441, 454, 255, 456]
1
  
Duloxetine [457]
2
  
Other therapies
Anxiolytics
 
Anticonvulsants
 
    Benzodiazepines
 
Pregabalin [474, 475]
1
      Clonazepam [385, 470, 471]
1
Gabapentin [476, 477]
2
      Alprazolam [386]
2
Levetiracetam [478480]
2 (-ve)
      Bromazepam [472]
2
Divalproex [481]
3
      Adjunctive clonazepam [473]
2 (-ve)
Tiagabine [477, 482]
3
  
Topiramate [483]
3
Other treatments
 
Atypical antipsychotics
 
Atenolol [461, 484]
1 (-ve)
Olanzapine [493]
2
Buspirone [383, 485]
1 (-ve)
Quetiapine [494, 495]
2 (-ve)
Atomoxetine [486, 487]
1*
Adjunctive aripiprazole [496]
3
Propranolol [488]
2 (-ve)
Adjunctive risperidone [271]
3
Selegiline [489]
3
  
Pergolide [490]
3 (-ve)
  
Adjunctive buspirone [491]
3
  
Adjunctive pindolol [492]
2 (-ve)
  
*Conflicting data. CR = controlled release; MAOI = monoamine oxidase inhibitor; RIMA = reversible inhibitor of monoamine oxidase A; SNRI = serotonin–norepinephrine reuptake inhibitor; SR = sustained release; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; XR = extended release; (-ve) = negative.
Table 21
Recommendations for pharmacotherapy for SAD
First-line
Escitalopram, fluvoxamine, fluvoxamine CR, paroxetine, paroxetine CR, pregabalin, sertraline, venlafaxine XR
Second-line
Alprazolam, bromazepam, citalopram, clonazepam, gabapentin, phenelzine
Third-line
Atomoxetine, bupropion SR, clomipramine, divalproex, duloxetine, fluoxetine, mirtazapine, moclobemide, olanzapine, selegiline, tiagabine, topiramate
Adjunctive therapy
Third-line: aripiprazole, buspirone, paroxetine, risperidone
Not recommended: clonazepam, pindolol
Not recommended
Atenolol*, buspirone, imipramine, levetiracetam, propranolol*, quetiapine
CR = controlled release; SR = sustained release; XR = extended release.
*Beta-blockers have been successfully used in clinical practice for performance situations such as public speaking.
Note: although there is limited evidence for citalopram in SAD, it is likely as effective as the other SSRIs, in contrast there are negative trials of fluoxetine in SAD suggesting it may be less effective than other SSRIs [382, 449].

First-line agents

Antidepressants: Meta-analyses demonstrate that SSRIs and SNRIs are significantly more effective than placebo [58, 426429] and RIMAs [426, 428] for the treatment of SAD. There is level 1, RCT evidence supporting the use of the SSRIs escitalopram [430, 431], fluvoxamine [433435], fluvoxamine CR [436, 437], paroxetine [431, 438444], and sertraline [445448], as well as the SNRI venlafaxine XR [439, 441, 454456], for the first-line treatment of SAD. There is also good evidence for the efficacy of paroxetine CR (Level 2) [452].
Pregabalin: Pregabalin has also demonstrated efficacy versus placebo for the treatment of SAD in RCTs at higher (600 mg/day) but not lower dose levels (150-300 mg/day) (Level 1) [474, 475]. Although there is Level 1 evidence for pregabalin, it is not clear how its efficacy compares to that of SSRIs. In addition, SSRIs may have a broader spectrum of efficacy for common comorbid conditions.

Second-line agents

Benzodiazepines: In RCTs, the benzodiazepines clonazepam (Level 1) [470][385, 471], alprazolam [386], and bromazepam [472] (both Level 2) have demonstrated efficacy in the treatment of SAD.
Although, a meta-analysis found benzodiazepines to be as effective as SSRIs [58], these agents are recommended as second-line options because of the lack of effect on common comorbidities and the potential for abuse/dependence in individuals with a history of SUDs.
Antidepressants: In RCTs, citalopram was found to be significantly more effective than placebo [451], and as effective as moclobemide [450] (Level 2). Although there is limited evidence for citalopram in SAD, it is likely as effective as the other SSRIs.
The efficacy of phenelzine has been established in multiple RCTs (Level 1) [384, 386, 418, 461, 462]; however, this agent is recommended as a second-line option because of concerns regarding dietary restrictions, drug interactions, and the potential for hypertensive crisis.
Anticonvulsants: Gabapentin was significantly more effective than placebo in a RCT [476], and as effective as tiagabine in a small cross-over study (Level 2) [477].

Third-line agents

Antidepressants: Results with fluoxetine have been mixed (Level 1, conflicting) [382, 387, 449]. A large RCT found that fluoxetine was more effective than placebo and as effective as CBT [387]. However, in two other small RCTs, fluoxetine alone or when added to self-exposure showed no benefit over placebo, with or without self-exposure [382, 449]. These negative trials with fluoxetine suggest it may be less effective than other SSRIs [382, 449].
Similarly, results with moclobemide have also been mixed (Level 1, conflicting) [417, 462466], with some RCTs demonstrating significantly higher response rates with moclobemide compared with placebo (Level 1) [462464], while others have not [465, 466]. Moclobemide was found to be superior to CBT early in treatment; however, after six months CBT was found to be superior.
Data from two small RCTs assessing mirtazapine were also mixed (Level 1, conflicting), with one showing significant improvements over placebo [468] and the other showing no differences [467].
In a dose-finding study in which patients treated with open-label duloxetine 60 mg/day were randomized to continue or double their dose, both doses improved symptoms, but there was no significant advantage to the higher dose (Level 2) [457].
Small open-label trials have also suggested that bupropion SR [469] and clomipramine [458, 459] (both Level 3) may be effective in patients with SAD.
Anticonvulsants: Open-label studies have demonstrated some efficacy with divalproex [481], topiramate [483], and tiagabine [482] (all Level 3). In addition, tiagabine was comparable to gabapentin in a small RCT, crossover study in eight adults [477].
Other treatments: Olanzapine was effective in a small RCT (Level 2) [493], and selegiline demonstrated efficacy in a small, open-label trial (Level 3) [489]. In a RCT, atomoxetine significantly improved SAD symptoms compared with placebo [487]; however, in a another small RCT, atomoxetine showed no significant difference in outcomes compared with placebo (Level 1, conflicting) [486].
All of these agents are recommended as third-line options, and may be useful in refractory patients after first- and second-line monotherapies and adjuncts have been unsuccessful.

Adjunctive therapy

Adjunctive strategies have generally been studied in patients who have had an inadequate response to antidepressant therapy and can be considered for patients with treatment-resistant SAD.
Third-line adjunctive therapies: Open-label studies and case series have suggested that patients with refractory SAD may benefit from adjunctive therapy with aripiprazole [496], risperidone [271], buspirone [491], or paroxetine [453] (all Level 3).
Not recommended adjunctive or combination therapies: In RCTs, clonazepam [473] combined with paroxetine and pindolol augmentation of paroxetine [492] (both Level 2, negative) were not significantly superior to placebo in augmenting the effects of SSRI treatment for SAD.
In RCTs there was no evidence of benefits with the beta-blockers atenolol (Level 1, negative) [461, 484] or propranolol (Level 2, negative) [488], or for the following treatments: buspirone [383, 485], levetiracetam [478480] (both Level 1, negative), or quetiapine (Level 2, negative) [494, 495]. These agents are not recommended for SAD. Imipramine [460] and pergolide (both Level 3, negative) [490] also do not appear to be effective in this disorder.

Maintenance pharmacological treatment

Long-term therapy has been evaluated in relapse prevention and naturalistic follow-up studies. Relapse-prevention studies are those in which responders to medication are randomized to continued active treatment or placebo. A meta-analysis of four relapse prevention studies included 760 patients with SAD and found a highly significant reduction in relapse rates with continued SSRI treatment compared with placebo over three to six months. The relative risk (RR) for relapse was 0.39 (95% CI 0.30–0.49) and number needed to treat (NNT) was 3.57 (95% CI 2.94–4.76) [497]. The anticonvulsant pregabalin has also demonstrated reductions in relapse rates over six months [498].
In RCTs, escitalopram [431], fluvoxamine CR [499], and venlafaxine XR [456] have demonstrated continued improvement compared with placebo over approximately six months. Additional open follow-up data support the long-term efficacy of moclobemide over six to 24 months [464, 500].

Biological and alternative therapies

Biological therapies: In an open-label study, neuro psycho physical optimization-radio electric asymmetric conveyor (NPPO-REAC) (a brain stimulation technique) was as effective as sertraline for the treatment of SAD (Level 3) [501].
Alternative therapies: St John’s wort failed to demonstrate superiority over placebo, and is not recommended for the treatment of SAD (Level 2, negative) [502].

Summary

SAD is one of the most common anxiety disorders, occurring more often in women than men. SAD has a negative impact on QoL, functional and occupational outcomes, and is often associated with other comorbid disorders, including MDD and other anxiety and related disorders. SAD is characterized by intense fear or anxiety relating to social or performance situations where the individual is exposed to scrutiny by others. These situations are often actively avoided.
CBT and exposure therapy alone are effective first-line options for the treatment of SAD, although limited data suggest that CBT may be more effective in maintaining benefits during follow-up. VRE and internet-based programs have also demonstrated efficacy. The benefits of CBT are maintained over one to five years of follow-up. CBT and pharmacotherapy appear to have similar efficacy for the acute treatment of SAD, but after treatment discontinuation, gains achieved with CBT appear to persist longer than those achieved with pharmacotherapy. In most studies, adding pharmacotherapy has not been shown to increase the benefits of CBT.
Pharmacotherapeutic approaches should begin with a first-line antidepressant such as escitalopram, fluvoxamine, fluvoxamine CR, paroxetine, paroxetine CR, sertraline, or venlafaxine XR, or the anticonvulsant pregabalin. If response to optimal doses is inadequate or the agent is not tolerated, therapy should be switched to another first-line agent before considering a second-line medication. Second-line choices include the benzodiazepines alprazolam, bromazepam, and clonazepam, as well as citalopram, gabapentin, and phenelzine. Pregabalin has also been shown to maintain benefits and prevent relapse in a six-month study.
Patients who do not respond to several medication trials and/or CBT are considered to have treatment-refractory illness. In such patients it is important to reassess the diagnosis and consider comorbid medical and psychiatric conditions that may be affecting response to therapy. Third-line agents and adjunctive therapies may be useful when patients fail to respond to optimal treatment trials of first- and second-line therapies used alone and in combination.

Generalized anxiety disorder

Epidemiology

The estimated 12-month prevalence of GAD ranges from 1-4%, and the lifetime prevalence is approximately 6% [2, 3, 16, 503]. GAD is more frequent in Caucasians compared to other groups [504]. The usual age of onset varies and may be bimodal with the median age of onset being approximately 31 years [2] and mean age of onset being 32.7 years [505]. The prevalence of GAD is estimated to be 3% in children and 10.8% in adolescents [506], with the age of onset for children and adolescents being between ages 10 and 14 [507]. Some data suggest that women may be two to three times more likely to suffer from GAD than men [16, 508], and GAD may be more common in older adults [509, 510]. This disorder is reportedly frequently under-recognized with less than one-third of patients being adequately treated [511, 512]. This is further complicated in children because of the previous designation of Overanxious Disorder of Childhood and its possible differentiation of childhood GAD from GAD in adults.
GAD is associated with functional [15, 511, 513], occupational [511], and QoL impairments [16, 511], as well as substantial economic costs [511, 514]. In addition, in primary care 60-94% of patients with GAD report painful physical symptoms [515, 516], and these were the main reason for initial presentation to a physician in 72% of cases [516].

Comorbidity

GAD is associated with high rates of comorbid psychiatric conditions including other anxiety or related disorders and MDD [16]. The risk of medical conditions is also elevated [16], including pain syndromes [16, 517], hypertension [16], as well as cardiovascular and gastric conditions [16, 518]. The presence of comorbid depression increases the severity of illness, functional impairment [519], and economic costs [514].

Diagnosis

GAD is characterized by excessive anxiety and worry about multiple events or activities such as school or work difficulties, which is apparent on a majority of days over the previous six months (Table 22) [26]. In addition, GAD is associated with restlessness, muscle tension, fatigue, concentration difficulties, irritability, and sleep issues [26].
Table 22
DSM-5 diagnosis of GAD
• Excessive anxiety and worry (apprehensive expectation) about a number of events or activities (e.g., school/work performance)
• The individual finds it difficult to control the worry
• Excessive anxiety and worry are associated with ≥3 of the following symptoms (with at least some occurring more days than not for ≥6 months):
    ○ Restlessness or feeling keyed-up or on edge, being easily fatigued, difficulty concentrating, irritability, muscle tension, or sleep disturbance
• The disturbance causes clinically significant distress or functional impairment
Adapted from DSM-5 [26].
The diagnostic criteria for GAD underwent one minor revision in the DSM-5 [26] compared to the DSM-IV-TR [144], the requirement that the disturbance not occur exclusively during a mood, psychotic, or pervasive developmental disorder was removed. However, it remains important to note that most of the treatment data described within this section are based on patients meeting DSM-IV criteria (or older).

Psychological treatment

Meta-analyses clearly demonstrate that CBT significantly reduces GAD symptoms and is markedly more effective than placebo or wait-list control conditions for GAD (Level 1) [55, 64, 65, 70, 520]. Few studies have compared CBT and pharmacotherapy alone in the same trial, but the magnitude of benefits appear to be comparable for both groups [521523]. Individual and group therapy appear to be equally effective in terms of anxiety symptom reduction, but individual therapy may lead to earlier improvement in worry and depression symptoms [65, 520].
The intensity of therapy was assessed in a meta-analysis of 25 studies [65]. Regimens including fewer than eight sessions were as effective as those of eight or more for anxiety symptoms, but the more intense regimens were more effective in improving symptoms of worry and depression compared with fewer sessions [65].
Several studies have demonstrated the utility of internet-based or computer-based CBT programs [79, 524526]. ICBT has been shown to be significantly more effective than wait-list control [79, 524, 525], with benefits being maintained at long-term follow-up [525]. In addition, a peer-to-peer cognitive self-therapy program was as effective as treatment-as-usual, with a decreased need for therapist contact [527].
A meta-analysis of five trials found no significant differences between CBT and relaxation therapy [55]. However, more recent studies suggest that applied relaxation has limited efficacy [528530]. One RCT found little evidence that patients with GAD can learn to relax in therapy or that a decrease in activation is associated with a reduction in anxiety [529]. Balneotherapy, a relaxation therapy involving spa-related treatments, demonstrated potential advantages over SSRI pharmacotherapy in improving anxiety scores and response rates in patients with GAD in a large RCT [531]; however, while this study may be interesting, concerns pertaining to blinding and potential bias indicate further study is needed [531].
Several research-based variables have been specifically identified among individuals with GAD in order to generate evidence-based CBT protocols for GAD, including: intolerance of uncertainty, poor problem-solving confidence, as well as positive and negative metacognitive beliefs about the function or utility of worry [532]. Specific psychotherapeutic protocols based upon models of the disorder that target variables underlying GAD have been developed to individualize therapy. Acceptance-based behavior therapy [533], meta-cognitive therapy [528, 534], CBT targeting intolerance of uncertainty [530], and adjunctive MBCT [184] have demonstrated efficacy for the treatment of GAD. Targeting worry and relaxation [535], as well as looming vulnerability (the tendency to generate and maintain internal scenarios of increasing risk and danger) [536], may also be beneficial.
Psychodynamic therapy may also be of benefit, however the research findings to date are unclear. A RCT found that short-term psychodynamic psychotherapy was as effective as CBT in improving anxiety scores, but CBT was superior on measures of worry and depression [537]. Another study found no significant differences between brief psychodynamic therapy, pharmacotherapy, or the combination [523].
No significant benefits were found with the addition of interpersonal and emotional processing therapy to CBT when compared with CBT plus supportive listening [538]. However, pretreatment motivational interviewing as an adjunct to CBT was shown to help reduce resistance to therapy, improve homework compliance, and improve worry outcomes — this strategy may be particularly useful in more severe cases [539, 540].
In clinical practice, the approach may need to be individualized to the problems experienced by the patient.

Psychological and pharmacological treatment

Few data are available on the use of combined psychological and pharmacological treatment. A meta-analysis concluded that combination pharmacotherapy and CBT was more effective than CBT alone at posttreatment but not at six-month follow-up [83]. While large effect sizes were found for GAD, data were available from only two studies, and these compared CBT plus diazepam or buspirone with CBT alone [83]. Compared to pharmacotherapy alone, the few studies that have assessed the benefits of adjunctive psychotherapy have been conflicting [184, 523, 541, 542]. One study suggested benefits of the combination [184], while two other studies did not [523, 541]. However, adjunctive CBT was shown to facilitate benzodiazepine tapering in patients with GAD [542].
There is no current evidence to support the routine combination of CBT and pharmacotherapy. However, as in other anxiety and related disorders, when patients do not benefit from CBT or have a limited response, a trial of pharmacotherapy is advisable. Similarly, patients who show limited benefit from pharmacotherapy may benefit from CBT.

Long-term effects of psychological treatment

Long-term follow-up data from a meta-analysis [520] and RCTs [523, 525, 535, 543] suggest that benefits of psychological treatments are maintained at one to three years follow-up after treatment.

Pharmacological treatment

The management of patients with GAD should follow the principles discussed in Section 2. Pharmacological interventions that have good evidence for efficacy in treating GAD include SSRIs, SNRIs, TCAs, benzodiazepines, pregabalin, quetiapine XR, and other therapies. Treatments that have been investigated for use in GAD have been assessed according to the criteria for strength of evidence (Tables 1 and 2) and are summarized in Tables 23 and 24.
Table 23
Strength of evidence for pharmacotherapy for GAD
Agent
Level of evidence
Agent
Level of evidence
Antidepressants
SSRIs
 
TCAs
 
Escitalopram [544552]
1
Imipramine [553, 581583]
1
Paroxetine [546, 547, 553558]
1
Other antidepressants
 
Sertraline [556, 559561]
1
Agomelatine [584, 585]
1
Citalopram [562]
3
Vortioxetine [586, 587]
1*
Fluoxetine [563]
3
Bupropion XL [549]
2
Paroxetine CR [564, 565]
3
Trazodone [583]
2
SNRIs
 
Mirtazapine [588]
3
Duloxetine [566571]
1
  
Venlafaxine XR [548, 553, 570580]
1
  
Other therapies
Anxiolytics
 
Atypical antipsychotics
 
    Benzodiazepines
 
Quetiapine XR [551, 557, 602, 603]
1
      Alprazolam [589593]
1
Adjunctive quetiapine [565, 604, 605]
1*
      Bromazepam [589, 594]
1
Adjunctive risperidone [606, 607]
1*
      Diazepam [583, 589, 595, 596]
1
Adjunctive olanzapine [608]
2
      Lorazepam [589, 593, 597601]
1
Adjunctive aripiprazole [269, 609]
3
  
Adjunctive quetiapine XR [610]
3
  
Adjunctive or monotx ziprasidone [611, 612]
2 (-ve)
Anticonvulsants
 
Other treatments
 
Pregabalin [576, 577, 592, 593, 597, 613]
1
Buspirone [108, 561, 572, 589, 598, 618, 619]
1
Divalproex chrono [614]
2
Hydroxyzine [594, 619, 620]
1
Tiagabine [615, 616]
1 (-ve)
Pexacerfont [552]
2 (-ve)
Adjunctive pregabalin [617]
2
Propranolol [621]
2 (-ve)
  
Memantine [622]
4 (-ve)
*Conflicting data. SNRI = serotonin–norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; XL = extended release; XR=extended release; (-ve) = negative.
Table 24
Recommendations for pharmacotherapy for GAD
First-line
Agomelatine, duloxetine, escitalopram, paroxetine, paroxetine CR, pregabalin, sertraline, venlafaxine XR
Second-line
Alprazolam*, bromazepam*, bupropion XL*, buspirone, diazepam*, hydroxyzine, imipramine, lorazepam*, quetiapine XR*, vortioxetine
Third-line
Citalopram, divalproex chrono, fluoxetine, mirtazapine, trazodone
Adjunctive therapy
Second-line: pregabalin
Third-line: aripiprazole, olanzapine, quetiapine, quetiapine XR, risperidone
Not recommended: ziprasidone
Not recommended
Beta blockers (propranolol), pexacerfont, tiagabine
CR = controlled release; XL = extended release; XR=extended release.
*Note: These have distinct mechanisms, efficacy and safety profiles. Within these second-line agents, benzodiazepines would be considered first in most cases, except where there is a risk of substance abuse, while bupropion XL would likely be reserved for later. Quetiapine XR remains a good choice in terms of efficacy, but given the metabolic concerns associated with atypical antipsychotic, it should be reserved for patients who cannot be provided antidepressants or benzodiazepines. Please refer to text for further rationale for the recommendations.

First-line agents

Antidepressants (SSRIs & SNRIs): Evidence from RCTs supports the use of SSRIs including escitalopram [544552] and sertraline [556, 559561], as well as the SNRIs duloxetine [566571] and venlafaxine XR [548, 553, 570580] (all Level 1) for the first-line treatment of GAD. Similar evidence exists for paroxetine [546, 547, 553558] supporting its use as a first-line option. Paroxetine CR has a similar active ingredient, and although there are less data supporting its use, it is likely interchangeable with paroxetine as a first-line agent (Level 3) [564, 565]. In head-to-head comparisons, the efficacy of SSRIs and SNRIs appear to be similar [546, 547, 549, 556, 558, 570, 571]. Some data suggest that escitalopram may be less effective than venlafaxine XR [548] or quetiapine XR [551]. Efficacy of venlafaxine was similar to pregabalin in one RCT [576], but less effective in another [577].
Other antidepressants: In two 12-week, double-blind RCTs, agomelatine was found to be more effective than placebo (Level 1) [584, 585], and as effective as escitalopram [585].
Pregabalin: The anticonvulsant pregabalin was more effective than placebo in RCTs [576, 577, 592, 593, 597, 613] and as effective as benzodiazepines [592, 593, 597] in patients with GAD (Level 1). Pregabalin was more effective than venlafaxine XR in one RCT [577], but equivalent in another [576].

Second-line agents

Benzodiazepines: Alprazolam [589593], bromazepam [589, 594], diazepam [583, 589, 595, 596], and lorazepam [589, 593, 597601] all have demonstrated efficacy for the treatment of GAD (all Level 1). While these agents have level 1 evidence for efficacy, they are recommended as second-line therapy, and usually only for short-term use, because of side effects, dependence, and withdrawal issues.
TCAs and other antidepressants: In RCTs, imipramine was superior to placebo and as effective as benzodiazepines for the treatment of GAD (Level 1) [553, 581583]. However, because of side effects and potential toxicity in overdose, imipramine is recommended as a second-line option. While there are little data on bupropion XL (Level 2), in a 12-week RCT in patients with GAD it was as effective as escitalopram (a first-line option), supporting its use as a second-line option [549].
Vortioxetine is a so-called "serotonin modulator" because of its activity in a variety of serotonin receptors. Results from two similar, eight-week, placebo-controlled RCTs with vortioxetine were conflicting, with one trial being positive [587] and the other negative (Level 1, conflicting) [586]. The differences in outcomes may be related to differences in recruitment between the two studies [623], and data suggest that vortioxetine may be useful in GAD.
Quetiapine XR: There is good evidence for the efficacy of quetiapine XR for the management of GAD (Level 1) [551, 557, 602, 603]. Two meta-analyses [115, 116] concluded that quetiapine was significantly superior to placebo and equivalent to antidepressants [115] for the treatment of GAD. However, quetiapine was associated with more weight gain and sedation, and higher dropout rates due to adverse events compared with placebo or antidepressants [115, 116]. Due to tolerability and long-term safety concerns with atypical antipsychotics, this treatment is recommended as a second-line option for patients who cannot be provided antidepressants or benzodiazepines.
Other treatments: Buspirone was more effective than placebo and as effective as benzodiazepines in several RCTs (Level 1) [108, 561, 572, 589, 598, 618, 619]. There are limited data comparing buspirone to antidepressants, with it being less effective than venlafaxine XR in one study [572], but as effective as sertraline in another [561]. Limited effectiveness in clinical practice relegates buspirone to a second-line agent.
Hydroxyzine has demonstrated efficacy superior to placebo and similar to benzodiazepines and buspirone in RCTs (Level 1) [594, 619, 620]; however, clinical experience with this agent in the treatment of GAD remains limited.

Third-line agents

The following agents are recommended as third-line options because of limited data, side effects, or lack of clinical experience as a primary therapy for the treatment of GAD.
Antidepressants: In open-label studies or case series, the antidepressants citalopram [562], fluoxetine [563], paroxetine CR [564, 565], and mirtazapine [588] have demonstrated efficacy in patients with GAD (all Level 3). In a RCT, trazodone was as effective as diazepam (Level 2) [583].
Other treatments: Divalproex chrono was superior to placebo for the treatment of GAD (Level 2) [614], however this formulation is not widely available.

Adjunctive therapy

Adjunctive strategies have generally been studied in patients who have had an inadequate response to SSRI therapy, and can be considered for patients with treatment-resistant GAD.
Second-line adjunctive therapies: Adjunctive pregabalin demonstrated good efficacy in a large RCT in patients with GAD who had an inadequate response to prior treatments (Level 2) [617].
Third-line adjunctive therapies: A meta-analysis of five RCTs of adjunctive atypical antipsychotics found no significant improvement in response rates but higher discontinuation rates versus placebo in patients with refractory GAD [116].
Two RCTs suggest that adjunctive risperidone (Level 1, conflicting) [606, 607] may be useful in some patients, but in the larger RCT it demonstrated superiority over placebo only in patients with moderate to severe residual symptoms at baseline [607]. Similarly, data on adjunctive quetiapine have been inconsistent (Level 1, conflicting) [565, 604, 605], with one RCT being negative [565], while another, unblinded RCT showed some, but limited benefits [605]. Adjunctive olanzapine demonstrated efficacy in a small RCT in patients who remained symptomatic after six weeks of SSRI therapy [608]. Adjunctive treatment with quetiapine XR [610] or aripiprazole [269, 609] (both Level 3) also had some benefit in open trials.
Because of the limited evidence for efficacy and their potential for weight gain and metabolic side effects, atypical antipsychotics should be reserved for highly treatment-refractory cases of GAD, and other than quetiapine XR, used only as an adjunctive treatment.
Not recommended adjunctive therapies: Ziprasidone does not appear to be effective as adjunctive therapy (Level 2, negative) [611].
Propranolol [621] and pexacerfont [552] (both Level 2, negative) have not demonstrated efficacy and are not recommended in the treatment of GAD. While a small randomized, open-label trial suggested that tiagabine was as effective as paroxetine, the results of three placebo-controlled RCTs do not support the efficacy of tiagabine in patients with GAD (Level 1, negative) [615, 616]. Memantine also does not appear to be effective in this disorder (Level 4, negative) [622].

Maintenance pharmacological treatment

Long-term therapy has been evaluated in relapse prevention and naturalistic follow-up studies. Relapse-prevention studies are those in which responders to SSRI therapy are randomized to continued active treatment or placebo. A meta-analysis of three relapse prevention studies included 1342 patients with GAD and found a highly significant reduction in relapse rates with continued SSRI treatment compared with placebo over six to 12 months (odds ratio for relapse was 0.20) [497].
In RCT discontinuation studies, duloxetine [624], escitalopram [625], paroxetine [626], and venlafaxine XR [627] have demonstrated significantly lower relapse rates over six to 18 months in the range of 10-20% with active treatment compared to 40-56% with placebo. Pregabalin [628] and quetiapine XR [629] have also demonstrated significantly lower relapse rates over six to 12 months of continued treatment in discontinuation trials.
In long-term RCT studies, escitalopram [546], paroxetine [546], and venlafaxine XR [578, 579] have demonstrated continued improvement compared with placebo over approximately six months.

Biological and alternative therapies

In general, these therapies may be useful for some patients; however, more data are needed.
Biological therapies: In a small open trial, rTMS was effective as monotherapy or as an adjunct to SSRIs in patients with GAD (Level 3) [630], and improvements were largely maintained six months after treatment [631].
Alternative therapies: Several herbal preparations have demonstrated efficacy comparable to lorazepam for the treatment of GAD including silexan (lavender oil) (Level 1) [600, 632] and Galphimia glauca extract (Level 2) [601]. Cochrane meta-analyses found two studies of passiflora (passion flower) indicating it was as effective as benzodiazepines (Level 2) [633], and one study of valerian which found no significant differences between placebo, valerian, or diazepam (Level 2, negative) [634, 635]. Unfortunately, because these preparations are poorly standardized and have substantial variation in proportion of the active ingredient in different products, they cannot be widely recommended.
A RCT of adjunctive resistance training (weightlifting) or aerobic exercise found significant symptomatic improvements compared to a wait-list condition (Level 2) [636]. A systematic review included four studies of acupuncture in GAD or anxiety neurosis, and while all trials reported positive findings, methodological details were lacking and the authors concluded that there was insufficient evidence to determine efficacy (Level 2) [637]. Open-label studies suggest that adjunctive meditation and yoga-based treatments may be useful in patients with GAD (Level 3) [638, 639].
Not recommended alternative therapy: In a RCT, there were no significant improvements with bright light therapy compared with placebo (Level 2, negative) [640], and this treatment is not recommended.

Summary

The lifetime prevalence of GAD is approximately 6%, it is more frequent in women than in men, with age of onset reflecting a bimodal distribution (onset in late-teens to early-twenties, and again in the 30s and 40s). GAD is associated with substantial functional impairment and a high prevalence of comorbid psychiatric and medical disorders. According to DSM-5 criteria, GAD is characterized by excessive anxiety and worry about multiple situations and is associated with restlessness, muscle tension, and behavioral changes.
CBT is an effective first-line option for the treatment of GAD and is as effective as pharmacotherapy. Internet-based and computer-based CBT have also demonstrated efficacy. Evidence does not support the routine combination of CBT and pharmacotherapy, but when patients do not benefit from CBT, a trial of pharmacotherapy is advisable, and vice versa.
Pharmacotherapeutic approaches should begin with one of the first-line options including an SSRI such as escitalopram, paroxetine, or sertraline, an SNRI such as duloxetine or venlafaxine XR, or other antidepressant such as agomelatine. The anticonvulsant pregabalin is also a recommended first-line therapy.
If response to optimal doses is inadequate or the agent is not tolerated, therapy should be switched to another first-line agent before considering second-line medications. Second-line choices include bupropion XL, buspirone, hydroxyzine, imipramine, quetiapine XR, vortioxetine, as well as the benzodiazepines, alprazolam, bromazepam, diazepam, and lorazepam.
Patients who do not respond to multiple courses of therapy are considered to have treatment-refractory illness. In such patients it is important to reassess the diagnosis and consider comorbid medical and psychiatric conditions that may be affecting response to therapy. Third-line agents, adjunctive therapies, as well as biological and alternative therapies may be useful when patients fail to respond to an optimal treatment trial of first- and second-line therapies used alone and in combination.

Obsessive-compulsive disorder

Epidemiology

OCD is a relatively uncommon, yet severe, mental disorder, with an estimated lifetime and 12-month prevalence of 1.0-2.3% and 0.7%-1.2% in adults, respectively [2, 3, 641, 642]. Mean age of onset of OCD is ~20 years of age, but symptoms can occur below the age of 10, with few new cases after the early 30s [2, 641, 643]. Rates of treatment-seeking have been estimated to be only about 14-56% of patients, suggesting that OCD may be under-recognized and under-treated [644, 645]. Social isolation, history of physical abuse, and negative emotionality are risk factors for the development of OCD [646].
OCD is associated with a substantial negative impact on QoL for both patients [647, 648] and their caregivers [649]. Patients experience cognitive, social, and occupational impairments [642, 645, 650, 651]. In addition, up to one-quarter of patients with OCD have attempted suicide [645, 652]. OCD symptoms are associated with increased rates of health care utilization compared to those without OCD symptoms [642], with health care costs estimated at $10.6 billion/year (2005) in the US [653].

Comorbidity

About 60-90% of patients with OCD also have a comorbid disorder [641, 645]. Patients with OCD or OCD symptoms have a three-times higher rate of comorbidity compared to those without OCD symptoms [642]. Common comorbidities include mood, anxiety, and somatoform disorders, as well as SUDs, psychotic disorders, and bipolar disorders [641, 642, 645].

Diagnosis

A diagnosis of OCD requires the presence of obsessions and/or compulsions (Table 25) [26]. Obsessions are defined as recurrent, persistent, and intrusive thoughts, images, or urges that cause marked anxiety, and compulsions are defined as repetitive behaviors or mental acts that the patient feels compelled to perform to reduce the obsession-related anxiety [26]. The obsessions or compulsions are time consuming and cause significant impairment in social or occupational functioning.
Table 25
DSM-5 diagnosis of OCD
• Presence of either obsessions, compulsions, or both
    ○ Obsessions are defined by the following:
        • Recurrent and persistent thoughts, urges, or images that are experienced as intrusive and unwanted and that cause marked anxiety or distress
        • The individual attempts to ignore or suppress such thoughts, urges, or images, or to neutralize them with other thoughts or actions
    ○ Compulsions are defined by the following:
        • Repetitive behaviors (e.g., hand washing, ordering, checking) or mental acts (e.g., praying, counting, repeating words silently) that the individual feels driven to perform in response to an obsession or according to rigid rules
        • Compulsions are aimed preventing or reducing anxiety or preventing some dreaded situation or event; however, they are not connected in a realistic way with what they are designed to neutralize or are clearly excessive
• The obsessions or compulsions are time-consuming (e.g., take >1 h/day) or cause clinically significant distress or functional impairment
• Specify patient’s degree of insight as to reality of OCD beliefs:
    ○ Good or fair insight (i.e., definitely or probably not true)
    ○ Poor insight (i.e., probably true)
    ○ Absent insight (i.e., completely convinced beliefs are true)
• Specify if "tic-related" OCD
Adapted from DSM-5 [26].
In the DSM-5, OCD has been moved from the “anxiety disorders” [144] to a new diagnostic category called “obsessive-compulsive and related disorders.” In addition to OCD, this new category also includes diagnostic criteria for body dysmorphic disorder, hoarding disorder, hair-pulling disorder (trichotillomania), and skin picking disorder [26].
Most of the other modifications to the OCD diagnostic criteria in the DSM-5 were minor wording changes designed to enhance clarity or further operationalize concepts that were considered too vague [26]. In particular, the definitions of obsessions and compulsions were clarified and simplified [26, 654]. The requirement that the patient recognizes that the obsessions or compulsions are “excessive or unreasonable” has been deleted, since these terms are subject to interpretation and patients can have varying levels of insight. As a result, the previous DSM-IV-TR specifier of “poor insight” has been expanded to include: good or fair, poor, and absent insight [26]. Finally, a specifier of "tic-related" OCD has been added [26].
While the most up-to-date DSM-5 diagnostic criteria are presented here, it is important to note that most of the treatment data described within this section are based on patients meeting DSM-IV criteria (or older).

Psychological treatment

Meta-analyses support the beneficial effects of psychological treatment for OCD, mainly CBT, generally including exposure with response prevention (ERP) [6063, 70, 71, 655657]. CBT is equivalent or superior to pharmacotherapy [71, 658660]. Results with CBT were generally similar in comparisons of interventions with an emphasis on ERP and those with an emphasis on cognitive elements [60, 63, 655]. A treatment specifically designed to address fear of contamination with infectious substances, using a cognitive intervention that includes no direct exposure (“danger ideation reduction therapy, DIRT”), was found to be more efficacious than ERP [661, 662]. Cognitive interventions may be important in patients who do not have overt compulsions, which can make ERP more difficult. One meta-analysis found that exposure in vivo combined with imaginal exposure was better than exposure in vivo alone [60].
Several meta-analyses have demonstrated no significant differences in efficacy between group and individual CBT [60, 62, 663]. However, results of head-to-head trials are conflicting, with some RCTs finding no significant differences in efficacy between group and individual therapy [663, 664], and others showing individual therapy to be superior [665667]. Differences in results may be explained by the fact that in individual therapy the therapist may have the advantage of being more aware of the patient’s dysfunctional beliefs, however, the group therapy setting may offer the advantages of group encouragement, reciprocal support, imitation, and interpersonal learning which may result in an increased motivation and reduced discontinuation of treatment [62].
An important practical question concerns the intensity and duration of treatment. The intensive ERP program described by Foa’s group involves 15 two-hour sessions scheduled five days a week over three weeks [658, 668]. A similar program administered twice-weekly (a more practical approach for many patients and therapists) was as effective at the end of follow-up as the intensive five-days/week strategy [669]. A step-care approach in which patients received six weeks of low-intensity counseling with ERP bibliotherapy followed by standard ERP for non-responders only was found to be as effective as initial therapy with standard ERP (17 sessions twice weekly), but was significantly less costly [670].
Other techniques that may be useful include acceptance and commitment therapy (ACT) [671], modular cognitive therapy (CT) addressing OCD beliefs [672, 673], CT addressing obsessional doubt [674], organizational training [675, 676], and mindfulness training [677]. RCTs on the benefits of adding motivational interviewing to CBT have been conflicting, with one showing no additional benefits [678], while another demonstrated improved symptom reduction and remission rates compared with CBT alone [679]. While EMDR was more effective than an SSRI in a RCT [680], data are limited and this technique is not generally recommended for patients with OCD.
Data suggest that therapist-guided exposure is better than self-exposure [60]. While both treatment conditions showed significant symptom reduction, therapist-administered ERP was superior to self-administered ERP in improving OCD symptoms and self-reported functional impairment [681]. Other data suggest that ERP delivered by telephone is equivalent to face-to-face ERP [682]. Bibliotherapy in the form of self-help manuals delivered to patients via email has demonstrated significantly greater improvements in OCD symptoms compared with wait-list control groups in two RCTs [683, 684].
ICBT is an easily accessible treatment that has the potential to reach untreated patients and motivate them for face-to-face psychotherapy if necessary [684, 685]. Several RCTs have demonstrated that ICBT programs are significantly more effective than supportive therapy or relaxation control strategies [685687]. ICBT was as effective as therapist-led CBT only when patients completed at least one self-exposure session [687]. ICBT was associated with significantly better outcomes when it included brief, scheduled, therapist-initiated telephone support compared with on-demand phone support [688].
Family accommodation (i.e., family members taking part in the performance of rituals, avoidance of anxiety-provoking situations, or modification of daily routines to assist a relative with OCD) has been associated with poorer response to both behavioral and pharmacological treatments [689]. Clinicians may want to consider targeting family accommodation in order to improve treatment outcomes for some patients.
Although hoarding disorder is now a separate diagnosis [690], the limited data available on the treatment of hoarding will be mentioned in this section on OCD. One RCT found that group CBT significantly reduced hoarding and depression symptoms while bibliotherapy alone was associated with very limited improvements [691]. The addition of posttreatment, nonclinician, home assistance did not significantly improve outcomes.

Combined psychological and pharmacological treatment

The combination of psychological and pharmacological treatment has been shown to be superior to medication alone [657, 658, 692694], but not to CBT alone [83, 658, 692, 694, 695]. These findings suggest that if pharmacotherapy is required or preferred, adding CBT to pharmacological treatment of OCD may enhance response rates and reduce relapse rates. Unlike in some anxiety and related disorders, there does not appear to be any contraindication to combining CBT with medications in patients with OCD [696], and combined treatment may improve relapse prevention [697].
Adding d-cycloserine may hasten the onset of improvements with ERP, with significant benefits over placebo during the first four or five ERP sessions [698700], but this effect has not been seen in all studies [701].

Long-term effects of psychological treatment

Follow-up studies suggest that the benefits of CBT are maintained at one to five years of follow-up [664, 695, 702704].

Pharmacological treatment

The management of patients with OCD should follow the principles discussed in Section 2. SSRIs are recommended first-line pharmacological interventions for OCD, while SNRIs, clomipramine, and other antidepressants are recommended second- and third-line treatments. Treatments that have been investigated for use in OCD have been assessed according to the criteria for strength of evidence (Tables 1 and 2) and are summarized in Tables 26 and 27.
Table 26
Strength of evidence of pharmacotherapy for OCD
Agent
Level of evidence
Agent
Level of evidence
Antidepressants
SSRIs
 
MAOIs
 
Escitalopram [705709]
1
Phenelzine [737, 738]
2*
Fluoxetine [660, 710716]
1
Tranylcypromine [739]
4
Fluvoxamine [711, 713, 714, 717719]
1
TCAs
 
Paroxetine [705, 720722]
1
Clomipramine [658, 711, 713, 714, 716718, 720, 724, 740, 741]
1
Sertraline [659, 710, 711, 713, 714, 723725]
1
IV clomipramine [742744]
2
Citalopram [680, 726728]
2
Desipramine [723, 745]
2 (-ve)
IV citalopram [729]
3
Adjunctive clomipramine [746, 747]
2 (-ve)
Adjunctive citalopram [730]
3
Other antidepressants
 
SNRIs
 
Mirtazapine [748]
2
Venlafaxine XR [721, 731733]
2
Bupropion [749]
3 (-ve)
Duloxetine [734736]
4
Adjunctive mirtazapine [727]
3
Other therapies
Antipsychotics
 
Anxiolytics
 
Adjunctive aripiprazole [750755]
1
    Benzodiazepines
 
Adjunctive risperidone [755761]
1*
      Clonazepam [771]
2 (-ve)
Adjunctive olanzapine [760, 762, 763]
1*
      Adjunctive clonazepam [772]
2 (-ve)
Adjunctive quetiapine [728, 746, 747, 764768]
1*
Other treatments
 
Adjunctive haloperidol [758, 769]
2
Clonidine [773]
2 (-ve)
Adjunctive amisulpride [770]
3
Adjunctive pindolol [774776]
1*
Adjunctive ziprasidone [767]
4
Adjunctive celecoxib [777]
2
Anticonvulsants
 
Adjunctive granisetron [778]
2
Adjunctive topiramate [795798]
1*
Adjunctive IV ketamine [779, 780]
2
Adjunctive lamotrigine [799, 800]
2
Adjunctive memantine [622, 781783]
2
Adjunctive pregabalin [801, 802]
3
Adjunctive ondansetron [784, 785]
2
Adjunctive gabapentin [803, 804]
3 (-ve)
Adjunctive N-acetylcysteine [786, 787]
2
Opioids
 
Adjunctive riluzole [788, 789]
3
Tramadol [805, 806]
4
Adjunctive lithium [790, 791]
1 (-ve)
Naltrexone [807]
3 (-ve)
Adjunctive buspirone [792, 793]
2 (-ve)
Adjunctive morphine [808]
2
Adjunctive minocycline [794]
4 (-ve)
*Conflicting data. IV = intravenous; MAOI = monoamine oxidase inhibitor; SNRI = serotonin–norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; XR = extended release; (-ve) = negative.
Table 27
Recommendations for pharmacotherapy for OCD
First-line
Escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline
Second-line
Citalopram, clomipramine, mirtazapine, venlafaxine XR
Third-line
IV citalopram, IV clomipramine, duloxetine, phenelzine, tramadol, tranylcypromine
Adjunctive therapy
First-line: aripiprazole, risperidone
Second-line: memantine, quetiapine, topiramate
Third-line: amisulpride, celecoxib, citalopram, granisetron, haloperidol, IV ketamine, mirtazapine, N-acetylcysteine, olanzapine, ondansetron, pindolol, pregabalin, riluzole, ziprasidone
Not recommended: buspirone, clonazepam, lithium, morphine
Not recommended
Clonazepam, clonidine, desipramine
IV = intravenous; XR = extended release.

First-line agents

SSRIs: Evidence from RCTs and meta-analyses support the use of SSRIs, including escitalopram [705709], fluoxetine [660, 710716], fluvoxamine [711, 713, 714, 717719], paroxetine [705, 720722], and sertraline [659, 710, 711, 713, 714, 723725] (all Level 1), in the treatment of OCD. In meta-analyses, response rates with SSRIs are generally twice those of placebo [809], at 40-60% with treatment versus <20% with placebo [711, 713, 714, 740, 741]. Pooled response rates are not significantly different between SSRIs [809]. In meta-analyses and head-to-head trials, compared with clomipramine, the SSRIs fluoxetine, fluvoxamine, paroxetine, and sertraline had similar efficacy but better tolerability [711, 713, 714, 716718, 720, 724].
Dimensional analyses have suggested that symmetry/hoarding symptoms may be associated with a poorer response to SSRI therapy [810, 811], while aggressive/religious/sexual symptoms may predict better outcomes [810, 812]. It has been hypothesized that the symmetry/hoarding symptom dimension may be mediated by the dopamine system and aggressive behaviors by the serotonin system [810, 812].

Second-line agents

Clomipramine: There is good evidence to support the use of clomipramine in the treatment of OCD (Level 1) [658, 711, 713, 714, 716718, 720, 724, 740, 741]. Clomipramine has efficacy similar to SSRIs, but SSRIs are generally better tolerated [711, 713, 714, 716718, 720, 724]. Side effects and safety are issues with clomipramine and therefore it is recommended as a second-line choice. Common adverse effects include anticholinergic effects such as dry mouth, constipation, and blurred vision, as well as urinary retention, orthostatic hypotension, weight gain, and sedation [813, 814]. The major safety concerns are cardiac arrhythmias, seizures, drug interactions, and toxicity in overdose [813, 814].
Antidepressants: In RCTs, citalopram was more effective than placebo but less effective than psychotherapy (Level 2) [680, 726]. Additional data from augmentation studies support the efficacy of citalopram for the treatment of OCD [727, 728]. However, given that other SSRIs have much stronger evidence, citalopram was designated a second-line option. The only RCT data on the use of mirtazapine in OCD are from a discontinuation study in which continued mirtazapine was associated with continued improvement (Level 2) [748]. There is some evidence to support the use of venlafaxine XR for the treatment of OCD (Level 2) [721, 731733]. In RCTs, venlafaxine XR was more effective than placebo [732], and as effective as paroxetine [721] and clomipramine [731]. In a double-blind extension of a RCT [721], paroxetine was more efficacious than venlafaxine in the treatment of non-responders to previous treatment with the alternate antidepressant [733].

Third-line agents

Intravenous clomipramine: In a RCT, intravenous (IV) clomipramine was more effective than placebo in patients with OCD (Level 2) [742]. Initiating therapy with IV then switching to oral therapy does not appear to be associated with greater benefit compared with oral therapy alone [743, 744].
Other agents: IV citalopram [729] (Level 3), as well as duloxetine [734736], tramadol [805, 806], and tranylcypromine [739] (all Level 4) have demonstrated some efficacy in open trials or case reports. Results with phenelzine have been inconsistent. In one RCT, phenelzine was not significantly better than placebo [738], but in another it was as effective as clomipramine (Level 2) [737]. In the placebo-controlled trial, post-hoc analysis suggested that phenelzine may be beneficial in patients with symmetry or other atypical obsessions [738].
These agents are recommended as third-line options, and may be useful in refractory patients after first- and second-line monotherapies and adjuncts have been unsuccessful.

Adjunctive therapy

Adjunctive strategies have generally been studied in patients who have had an inadequate response to SSRI therapy, and can be considered for patients with treatment-resistant OCD. A meta-analysis demonstrated that response rates with adjunctive medication were twice those of placebo, however these were still quite low (31.8% versus 13.6%) [815]. Meta-analyses of RCTs found that adding risperidone (and possibly quetiapine) to antidepressants increased efficacy but decreased tolerability, while adjunctive olanzapine did not improve response rates [816, 817].
First-line adjunctive therapies: In RCTs, adjunctive aripiprazole was significantly more effective than placebo (Level 1) [750, 754], and may be as effective as risperidone [755]. Additional open-label data also support the beneficial effects of adjunctive aripiprazole [751753].
As adjunctive therapy for treatment-resistant OCD, risperidone was more effective than placebo (Level 1) [756759] and as effective as olanzapine [760] and aripiprazole overall [755]. Compared with aripiprazole, risperidone may provide greater improvement in obsessions [755]. Risperidone was also as effective as haloperidol for obsessions, but less so for compulsions, however it was better tolerated [758]. More recently an open, randomized study found that while augmentation with ERP was superior to risperidone or pill placebo, risperidone was not significantly more effective than placebo [761]. However, patients in this study had some response to SSRI therapy and may have been less refractory compared to those in other studies. Considering the tolerability concerns of atypical antipsychotics, these data reinforce that this augmentation strategy should be reserved for patients with treatment-resistant OCD.
Second-line adjunctive therapies: RCT evidence demonstrated that adjunctive memantine was superior to placebo (Level 2) [783]. Additional open-label data also support this therapy [622, 781, 782]. Another option which may be useful as an adjunctive therapy in those with refractory OCD is the atypical antipsychotic quetiapine (Level 1, conflicting) [728, 746, 747, 764766, 768].
Data from small RCTs suggest that topiramate may be a useful adjunctive therapy, but data are conflicting (Level 1) [796, 797]. In one RCT, adjunctive topiramate significantly improved Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores compared with placebo [797], while in another trial, adjunctive topiramate significantly improved compulsions but not obsessions [796]. Additional open-label data support the use of adjunctive topiramate [795, 798].
Third-line adjunctive therapies: The agents discussed below are recommended as third-line adjunctive options, since some data are available to suggest they may be useful but there is conflicting or inadequate evidence to warrant stronger recommendations. These agents may be useful for some patients, but more data are needed.
Other atypical antipsychotics have been assessed as adjunctive therapies in patients with refractory OCD, including olanzapine (Level 1, conflicting) [760, 762, 763], amisulpride (Level 3) [770], and ziprasidone (Level 4) [767].
There is level 2 evidence to support the use of adjunctive haloperidol in patients with refractory OCD [758, 769], and although it may be as effective as adjunctive risperidone, it is a third-line choice because it was less well tolerated [758].
Adjunctive mirtazapine was associated with an earlier onset of response of OCD symptoms compared with citalopram alone, but there was no advantage of the combination over time (Level 2) [727]. Some data also support the efficacy of adjunctive citalopram for treatment-resistant OCD (Level 3) [730].
Adjunctive anticonvulsants may be useful for some patients with refractory illness [799802]. In a small RCT, adjunctive lamotrigine improved both obsessions and compulsions compared to SSRI therapy (Level 2) [799]. Open-label data also suggest that adjunctive pregabalin may be useful (Level 3) [801, 802].
Other agents that have been studied as adjunctive therapy for treatment-resistant OCD include celecoxib [777], granisetron [778], IV ketamine [779, 780], ondansetron [784, 785], N-acetylcysteine [786, 787] (all Level 2), and riluzole (Level 3) [788, 789]. There is little clinical experience with these agents for refractory OCD, therefore they are recommended as third-line adjunctive options only.
Results with pindolol augmentation have been inconsistent, with significant improvements in one small RCT [774], but not in other randomized or open trials (Level 1, conflicting) [775, 776].
In two randomized, quetiapine-controlled trials, adjunctive clomipramine was not superior to SSRI therapy (Level 2, negative) [746, 747]. Clinical experience suggests that some patients may benefit from adjunctive clomipramine; however, plasma levels should be monitored because of the risk of drug interactions with SSRIs [747, 813].
Clonazepam [771], clonidine [773], and desipramine (all Level 2, negative) [723, 745] have not demonstrated efficacy and are not recommended in the treatment of OCD. Bupropion [749] and naltrexone (both Level 3, negative) [807] also do not appear to be effective in this disorder.
Adjunctive buspirone [792, 793], clonazepam [772] (Level 2, negative), or lithium [790, 791] (Level 1, negative) have not demonstrated efficacy for the treatment of OCD. There is currently no evidence for the efficacy of adjunctive gabapentin (Level 3, negative) [803, 804] or minocycline (Level 4, negative) [794], but there are insufficient data to make recommendations at this time. In a RCT, adjunctive once-weekly oral morphine was effective in patients who had failed six SSRI trials (Level 2) [808], however, morphine is not generally recommended because of its potential for abuse.

Maintenance pharmacological treatment

Long-term therapy has been evaluated in relapse prevention and naturalistic follow-up studies. Relapse-prevention studies are those in which responders to SSRI therapy are randomized to continued active treatment or placebo. A meta-analysis of six relapse prevention studies included 951 patients with OCD and found a highly significant reduction in relapse rates with continued SSRI treatment compared with placebo over six to 12 months (odds ratio for relapse was 0.38) [497]. In RCTs, escitalopram [818], paroxetine [722], sertraline [819], and high-dose fluoxetine [820] have demonstrated reductions in relapse rates. In RCT discontinuation studies, mirtazapine [748] and clomipramine [821] have demonstrated continued improvement compared with placebo over approximately six to 12 months. Additional data support the long-term efficacy of fluoxetine, fluvoxamine XR, and sertraline over six to 24 months [710, 822824].

Biological and alternative therapies

Biological therapies: Biological therapies may be useful in patients with OCD who have not responded to CBT and multiple medication trials. Open trials have suggested that rTMS may be a promising adjunctive therapy in patients with treatment-refractory OCD [825, 826]. However, results of sham-controlled trials are conflicting, with some trials finding significant improvements [827, 828] and others concluding that rTMS was ineffective for treatment-resistant OCD (Level 1, conflicting) [829831]. Some data suggest that rTMS may improve comorbid depressive symptoms in patients with OCD [829, 830].
Several very small studies have suggested that deep brain stimulation may improve symptoms and functionality in up to two-thirds of patients with highly treatment-refractory OCD (Level 4) [832834].
Open trials suggest that capsulotomy (Level 3) [835839] or cingulotomy (Level 3) [840842] may be effective in reducing symptoms in patients with severe, treatment-refractory OCD, however these treatments are usually considered last resorts.
Alternative therapies: A meta-analysis of meditation therapies found only two small studies and showed that transcendental meditation and Kundalini yoga were likely no more effective than other kinds of relaxation therapies in treating OCD (Level 3, negative) [843]. Open studies suggest that adjunctive moderate-intensity aerobic exercise may help improve OCD symptoms (Level 3) [844, 845].
Small RCTs and open trials have suggested that herbal therapies such as milk thistle (Silybum marianum L. Gaertn.) (Level 2) [715], valerian root (Valeriana officinalis L.) (Level 2) [846], and St John’s wort (Hypericum perforatum) (Level 3) [847] may be useful in patients with OCD. Unfortunately, because these preparations are poorly standardized and have substantial variation in the proportion of the active ingredient in different products, they cannot be widely recommended. These therapies may be useful for some patients; however, more data are needed.

Summary

OCD is a relatively rare, yet severe, mental disorder, with an onset in the 20s or earlier. It is characterized by the presence of obsessions (persistent, intrusive thoughts) and/or compulsions (repetitive behaviors the individual feels compelled to perform). OCD is associated with substantial functional impairment and a high prevalence of comorbid disorders.
CBT, and notably ERP, are effective first-line options for the treatment of OCD, being equivalent or superior to pharmacotherapy. CBT can be effectively delivered in both individual and group settings, as well as via self-exposure, self-help books, telephone, and internet-based programs. The benefits of CBT are maintained over one to five years of follow-up. The combination of psychotherapy and pharmacotherapy appears to be superior to pharmacotherapy alone, but not to CBT alone, and data suggest that adding CBT to pharmacological treatment may yield better long-term outcomes.
Pharmacotherapeutic approaches should begin with a first-line SSRI such as escitalopram, fluoxetine, fluvoxamine, paroxetine, or sertraline. If response to optimal doses is inadequate or the agent is not tolerated, therapy should be switched to another first-line agent before considering second-line medications. Second-line choices include citalopram, clomipramine, mirtazapine, and venlafaxine XR. OCD can be difficult to treat; therefore, in order to preserve any benefits of a therapy, adjunctive strategies may be important early in treatment.
Patients who do not respond to multiple courses of therapy are considered to have treatment-refractory illness. In such patients it is important to reassess the diagnosis and consider comorbid medical and psychiatric conditions that may be affecting response to therapy. Third-line agents, adjunctive therapies, as well as biological and alternative therapies may be useful when patients fail to respond to optimal treatment trials of first- and second-line therapies used alone and in combination.

Posttraumatic stress disorder

Epidemiology

The lifetime prevalence of PTSD in Canada was estimated to be 9.2%, and current (1-month) rates were 2.4% [848]. Over 76% of Canadians reported exposure to a significantly traumatic event [848]. US and European community studies report lifetime prevalence rates of 6.4-6.8% and 12-month rates of 1.1-3.5% [2, 849, 850]. The most common forms of trauma resulting in PTSD included unexpected death of someone close, sexual assault, serious illness or injury to someone close, having a child with serious illness, and being beaten by a partner or caregiver [848850]. Onset is generally in the mid to late 20s [2], and the prevalence is about twice as high among women versus men [849, 851].
PTSD was associated with significant QoL [852] and functional impairments [848, 853855], which increase with increasing severity of symptoms [855]. In addition, PTSD is associated with high rates of chronic pain [856859], sleep problems [860], and sexual dysfunction [861], as well as cognitive dysfunction [862, 863] and alexithymia [864]. The risk of suicide attempts is increased two- to three-fold by the presence of PTSD [20, 849, 865].
In primary care, PTSD was associated with more and longer hospitalizations as well as a greater use of mental health care [866]. Among Canadian military personnel, greater use of mental health care was associated with cumulative lifetime trauma exposure, index trauma type, PTSD symptom interference, suicidal ideation, female gender, and comorbid MDD [867, 868].

Comorbidity

An estimated 75% of patients with PTSD have another comorbid psychiatric disorder [3, 848]; and rates are particularly high for other anxiety and related disorders [3, 849, 859, 869, 870], MDD [3, 849, 859, 871, 872], oppositional defiant disorder [3], ADHD [3], SUD [849], alcohol dependence [3, 873], and borderline personality disorder (BPD) [874]. Comorbid panic or mood disorders have been associated with greater functional impairment than PTSD alone [870, 871]. Patients with comorbid PTSD and BPD had a poorer QoL, more comorbidity with other psychiatric conditions, and increased odds of a lifetime suicide attempt versus patients with either condition alone [20, 874].

Diagnosis

By definition PTSD requires exposure to trauma, including actual or threatened death, serious injury, or sexual violation [26]. It is characterized by intrusive and distressing memories or dreams, dissociative reactions, and substantial psychological or physiological distress related to the event (Table 28) [26]. A diagnosis of PTSD requires the disturbances to be present for longer than one month; symptoms of >3 days but less than one month may be diagnosed as acute stress disorder (ASD), if the required ASD criteria are met [26].
Table 28
DSM-5 diagnosis of PTSD
• The person has been exposed to actual or threatened death, serious injury, or sexual violation in ≥1 of the following ways:
    ○ Directly experienced or witnessed the traumatic event, learned that trauma occurred to close family member or friend (actual or threatened death must have been violent or accidental), experienced repeated exposure to aversive details of trauma
• Presence of ≥1 of the following intrusion symptoms associated with the trauma:
    ○ Recurrent, involuntary, and intrusive distressing memories, distressing dreams, dissociative reactions (e.g., flashbacks), psychological or physiological distress at reminders of trauma
• Persistent avoidance of stimuli associated with the trauma, including ≥1 of the following:
    ○ Avoidance of distressing memories or feelings and external reminders (e.g., people, places) of the trauma
• Negative alterations in cognitions and mood associated with the trauma, including ≥2 of the following:
    ○ Inability to recall important aspect of the trauma, diminished interest or participation in activities, feeling of detachment or estrangement from others, persistent negative beliefs, distorted blame, and negative emotional state
• Marked alterations in arousal and reactivity associated with the trauma, including ≥2 of the following:
    ○ Irritable or aggressive behavior, reckless or self-destructive behavior, hypervigilance, exaggerated startle response, problems with concentration, sleep disturbance
• Duration of disturbance >1 month
• Symptoms cause clinically significant distress or impaired functioning
• Specify whether with dissociative symptoms (depersonalization or derealization) or with delayed expression (full criteria not met until at least 6 months after the event)
Adapted from DSM-5 [26].
Compared to the DSM-IV-TR [144], changes to the diagnostic criteria for PTSD in the DSM-5 include adjusting the symptom clusters, adding some new symptoms, and re-classifying PTSD as a ‘‘trauma- and stressor-related disorder’’ instead of an anxiety disorder [26, 875]. In addition to PTSD, this new category also includes diagnostic criteria for reactive attachment disorder, disinhibited social engagement disorder, ASD, and adjustment disorders [26]. The DSM-5 diagnostic criteria for PTSD sharpens the definition of “traumatic event,” and there are now four symptom clusters rather than three with the “avoidance” and “numbing of responsiveness” being separated (Table 28). The DSM-5 also eliminated the acute and chronic PTSD specifiers. The PTSD diagnostic criteria apply to adults, adolescents, and children >6 years of age. A subtype has been added for children ≤6 years of age, as well as a dissociative symptoms specifier for patients of all ages [26].
While the most up-to-date DSM-5 diagnostic criteria are being presented here, it is important to note that the treatment data described within this section are based on patients meeting DSM-IV criteria (or older).
PTSD is frequently comorbid with other psychiatric disorders, including other anxiety and related disorders, MDD, and SUDs, which may complicate diagnosis and management [849, 859]. In addition, patients with PTSD frequently present with somatic symptoms and pain [859]. It is important to ask patients with psychological or somatic symptoms about trauma [32, 859].

Prevention and early intervention

A number of studies have assessed early intervention with psychological and pharmacological strategies for the prevention of PTSD. Meta-analyses do not support the efficacy of wide spread use of single-session [876, 877] or multiple-session [878] psychological debriefing after trauma in preventing or reducing the intensity of PTSD in individuals who have been exposed to a traumatic event but have not been identified as suffering from any specific psychological difficulties. In fact, these interventions may have an adverse effect on some individuals [876, 878]. These findings pertain to individual debriefings only; there is insufficient evidence to comment on the utility of group debriefings.
Conversely, meta-analyses have demonstrated the benefit of multisession trauma-focused-CBT (TF-CBT) in patients with ASD or PTSD [879, 880]. Therefore, debriefing of all trauma victims is not recommended, rather, screening and treating appropriate individuals is preferred [876]. For the prevention of chronic PTSD in patients with ASD or acute PTSD, brief TF-CBT was more effective than both wait-list and supportive counseling interventions, but there was no evidence of the effectiveness of structured writing compared to minimal intervention [880].
There are few data on the use of pharmacotherapy for the prevention of PTSD. In a cohort study and a RCT, the early use of benzodiazepines following trauma was not beneficial, and may increase the risk of developing PTSD [881, 882]. Similarly, retrospective data suggested that gabapentin or pregabalin had no effect on PTSD development [883]. Data from cohort studies on the use of the beta-blocker propranolol have been conflicting [884888], but one small RCT did show a significant decrease in the severity of PTSD symptoms and lower likelihood of developing subsequent PTSD [889]. SSRI therapy was significantly more effective than placebo in preventing PTSD symptoms according to parent reports but not child reports in a RCT in children [890]. Cohort studies suggest that the early use of morphine during trauma care may reduce the risk of the subsequent development of PTSD in children and adults [891894].

Psychological treatment

Psychological therapies for PTSD generally include education about the disorder and its treatment, as well as exposure to cues relating to the traumatic event. Psychotherapy has demonstrated significant efficacy, although a meta-analysis suggested it may be less effective than pharmacotherapy in improving PTSD and comorbid depression symptoms [895].
Meta-analyses of over 30 RCTs of psychological interventions provide evidence of the efficacy of several CBT approaches for the management of chronic PTSD compared with wait-list or usual care control groups [66, 67]. There was evidence that individual TF-CBT, EMDR, stress management, and group TF-CBT were effective, while other nontrauma focused psychological treatments (supportive therapy, nondirective counseling, psychodynamic therapy, and hypnotherapy) did not reduce PTSD symptoms as significantly [66, 67]. Individual TF-CBT and EMDR appeared to be equally effective, but superior to stress management in the treatment of PTSD [66]. Another meta-analysis also found EMDR and TF-CBT were equally effective [68]. However, in a head-to-head RCT, EMDR resulted in faster recovery compared with the more gradual improvement with brief TF-CBT [896]. Cognitive therapy approaches have been used effectively in treating PTSD following sexual or interpersonal violence [897901], civilian trauma [902908], and military trauma [909914].
Cognitive processing therapy (CPT) is an effective protocol that combines cognitive therapy and written accounts [899901, 910913]; however, an analysis of the components found no differences in outcomes with either component alone or the combined protocol [899].
Prolonged exposure (PE) is a widely studied CBT approach. A meta-analysis of 13 RCTs concluded that PE therapy was more effective than wait-list or psychological placebo control conditions, and as effective as other active treatments (e.g., CBT, CPT, EMDR) [69]. One study found that 30-minute imaginal exposure sessions were as effective as 60-minute sessions [915]. Imaginal appears to be as effective as in vivo exposure [69, 916].
Data are conflicting as to the benefits of adding cognitive restructuring to exposure therapy; several studies suggest that exposure alone is superior to the combination [917919], however, another large RCT found the combination to be significantly better than imaginal or in vivo exposure alone [916]. When used as an adjunct to exposure therapy, cognitive restructuring may improve non-fear problems like anger and guilt, and may be a useful adjunct in patients in which these emotions predominate [920, 921]. Similarly, the addition of social emotional rehabilitation to exposure therapy did not improve PTSD symptoms but did improve social functioning in male combat veterans with chronic PTSD [922].
Meta-analyses and systematic reviews reveal two current limitations of CBT for PTSD. The first is that about one-third to one-half of patients experience substantial residual symptoms and functional impairments posttreatment, still report symptoms meeting diagnostic criteria at follow-up, or relapse and require booster sessions [923925]. The second issue pertains to external validity. While CBT for PTSD has been shown to be efficacious in RCTs, there is a dearth of effectiveness studies to suggest that CBT can be generalized to many patients commonly found in clinical practice. Many RCTs have excluded patients with complex clinical profiles including childhood abuse histories, current SUDs, personality disorders, suicidality or self-injurious behavior, homelessness, refugees, intimate partner violence, and significant dissociative symptoms among others [926, 927]. In this regard, Bradley et al. [923] found a positive association between the number of exclusion criteria and the strength of effect sizes, such that studies with stricter inclusion criteria tended to report larger treatment effects. Additionally, numerous studies fail to report whether patients experience any adverse effects from psychological treatments [66], or whether dropout rates (ranging between 0-50%) result from treatment demands.
Dialectical behavior therapy (DBT), which was developed to reduce self-harm behavior in patients with BPD, was shown to be useful in patients with PTSD [928930]. When used as a pretreatment, DBT reduced self-harm behaviors allowing over half of patients to become suitable candidates for PTSD treatment [929].
Another study [931] demonstrated some success with PE treatment of PTSD and comorbid substance abuse. Results of a recent expert clinician survey on best practices suggests that CBT is useful for fear-based PTSD, while this treatment approach may require an additional treatment module targeting affective regulation for patients presenting with a diagnosis of Disorders of Extreme Stress (DESNOS) or complex PTSD [932].
Internet-based treatments are being increasingly investigated, in part because they can be administered remotely and anonymously to under-served or disaster-stricken areas at a relatively low-cost [933]. RCTs have shown that therapist-assisted ICBT is more effective than wait-list or supportive care control strategies in improving PTSD symptoms, depression, anxiety, and disability [934940]. In addition, a strong therapeutic relationship can be established through the internet, which improved the treatment process [936]. VRE therapy has also demonstrated some utility in improving PTSD symptoms [941943]. Compared to face-to-face CBT, video-conference CBT was equally effective [944] but telehealth CBT was less effective [914]; however, both were effective compared with pre-treatment.

Combined psychological and pharmacological treatment

Research evaluating combined treatment in PTSD is limited; a meta-analysis found only four small trials [945]. Combination SSRI plus psychotherapy was not superior to psychotherapy alone in two RCTs [946, 947], but was superior to pharmacotherapy alone in the other two trials [948, 949]. In contrast, a more recent RCT found that combination therapy was superior to psychotherapy alone [950]. The role of combining psychotherapy and medication requires further study.
Adjunctive propranolol with trauma reactivation therapy was found to help prevent reconsolidation of the traumatic memory and thus decreased physiological responses and PTSD symptoms during subsequent follow-up in randomized and open trials [951, 952]. Two RCTs have found that use of d-cycloserine did not enhance the overall treatment effects of exposure therapy [953, 954], and may in fact decrease response to psychotherapy [954].

Long-term effects of psychological treatment

Open follow-up data of psychological treatments suggest that benefits are maintained at six- to 18-month assessments after treatment [923, 955958]. Longer-term follow-up of patients treated with EMDR showed that benefits were maintained at three years, with the majority of patients who had initially remitted being at full working capacity [959]. Very long-term follow-up showed that improvements in PTSD and related symptoms achieved with CPT and PE were maintained over an extended five to 10 year period [901].

Pharmacological treatment

The management of patients with PTSD should follow the principles discussed in Section 2. Pharmacological interventions that have good evidence for efficacy in treating PTSD include fluoxetine, paroxetine, sertraline, and venlafaxine XR. Treatments that have been investigated for use in PTSD have been assessed according to the criteria for strength of evidence (Tables 1 and 2) and are summarized in Tables 29 and 30.
Table 29
Strength of evidence of pharmacotherapy for core symptoms of PTSD
Agent
Level of evidence
Agent
Level of evidence
Antidepressants
SSRIs
 
TCAs
 
Fluoxetine [960965]
1*
Imipramine [992, 993]
1
Paroxetine [966970]
1
Amitriptyline [994]
2
Sertraline [971978]
1*
Desipramine [970, 995]
2*
Fluvoxamine [979984]
2
MAOIs and RIMAs
 
Escitalopram [985]
3
Phenelzine [992, 993, 996]
1*
Citalopram [974, 986, 787, 988]
2 (-ve)
Moclobemide [997, 998]
3
SNRIs
 
Other antidepressants
 
Venlafaxine XR [975, 989]
1
Mirtazapine [9991002]
2
Duloxetine [990, 991]
3
Reboxetine [984]
2
  
Bupropion SR 1003
3
  
Tianeptine [997, 1004]
3
  
Adjunctive bupropion SR 1005
2 (-ve)
Other therapies
Anxiolytics
 
Anticonvulsants
 
    Benzodiazepines
 
Topiramate [1009, 1010]
1*
      Alprazolam 1006
2 (-ve)
Lamotrigine 1011
2
      Clonazepam [881, 1007, 1008]
3 (-ve)
Carbamazepine [1012, 1013]
3
Atypical antipsychotics
 
Divalproex [10141017]
1 (-ve)
Risperidone 1030
2
Tiagabine 1018
2 (-ve)
Aripiprazole [10311033]
3
Adjunctive gabapentin [1019, 1020]
4
Quetiapine [1034, 1035]
3
Adjunctive levetiracetam 1021
4
Olanzapine [10361038]
2 (-ve)
Adjunctive pregabalin 1022
4
Adjunctive risperidone [10391044]
1*
Adjunctive tiagabine [10231025]
4
Adjunctive olanzapine 1045
2
Adjunctive topiramate [10261029]
2 (-ve)
Adjunctive aripiprazole [1033, 1046, 1047]
3
Other treatments
 
Adjunctive quetiapine [10481050]
3
Buspirone [1051, 1052]
4
  
Trazodone 1053
4
  
Memantine 1054
4
  
Adjunctive eszopiclone 1055
2
  
Adjunctive clonidine 1056
3
  
Adjunctive guanfacine [1057, 1058]
1 (-ve)
  
Adjunctive zolpidem 1059
2 (-ve)
*Conflicting data. MAOI = monoamine oxidase inhibitor; RIMA = reversible inhibitor of monoamine oxidase A; SNRI = serotonin–norepinephrine reuptake inhibitor; SR = sustained release; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; XR=extended release; (-ve) = negative.
Table 30
Recommendations for pharmacotherapy for core symptoms of PTSD
First-line
Fluoxetine, paroxetine, sertraline, venlafaxine XR
Second-line
Fluvoxamine, mirtazapine, phenelzine
Third-line
Amitriptyline, aripiprazole, bupropion SR, buspirone, carbamazepine, desipramine, duloxetine, escitalopram, imipramine, lamotrigine, memantine, moclobemide, quetiapine, reboxetine, risperidone, tianeptine, topiramate, trazodone
Adjunctive therapy
Second-line: eszopiclone, olanzapine, risperidone
Third-line: aripiprazole, clonidine, gabapentin, levetiracetam, pregabalin, quetiapine, reboxetine, tiagabine
Not recommended: bupropion SR, guanfacine, topiramate, zolpidem
Not recommended
Alprazolam, citalopram, clonazepam, desipramine, divalproex, olanzapine, tiagabine
SR = sustained release; XR = extended release.

First-line agents

Antidepressants (SSRIs & SNRIs): Evidence from meta-analyses [895, 1060] and RCTs supports the use of the SSRI paroxetine [966970] and the SNRI venlafaxine XR [975, 989] (both Level 1) for the first-line treatment of PTSD. Data with fluoxetine are mixed, with both positive [960962] and negative [963965] RCTs (Level 1, conflicting). Similarly, RCTs with sertraline have yielded both positive [971, 972, 975, 976, 978] and negative [973, 974, 977] results (Level 1, conflicting). However, there appear to be sufficient data from the larger RCTs to suggest that these agents can be effective first-line options. Conflicting results may be related to the types of traumas, symptom clusters, and comorbidities included in the various studies.

Second-line agents

Antidepressants: The efficacy of mirtazapine was demonstrated in one small RCT (Level 2) 1000 and three open trials [999, 1001, 1002]. In a randomized, open-label trial, response rates were significantly higher with mirtazapine than sertraline 1001.
Fluvoxamine demonstrated efficacy for PTSD in open trials [979983], and in a RCT was as effective as reboxetine (Level 2) [984].
Phenelzine was more effective than placebo in two RCTs [992, 993], but not significantly different from placebo in a RCT crossover study (Level 1, conflicting) [996]. Caution is needed when using MAOIs because of the dietary restrictions and potential for drug interactions.

Third-line agents

The following agents are recommended as third-line options because of limited data, side effects, or lack of clinical experience as a primary therapy for the treatment of PTSD.
Antidepressants: In small RCTs, imipramine (Level 1) [992, 993] and amitriptyline (Level 2) [994] demonstrated some efficacy in patients with PTSD. Data with desipramine are mixed, with one RCT showing significant benefit, which were comparable to paroxetine [970], and the other showing improvements in depression only [995]. While RCTs with the TCAs suggest some benefit with these agents, it appears to be limited.
Reboxetine and fluvoxamine were equally effective in a small RCT (both Level 2) [984], and open-label studies suggest that bupropion SR 1003, duloxetine [990, 991], escitalopram [985], moclobemide [997, 998], and tianeptine [997, 1004] (all Level 3) may be useful in PTSD.
Anticonvulsants: Data on topiramate are mixed, with one RCT finding significant benefits over placebo 1010, while the other did not 1009 (Level 1, conflicting). There are also limited data suggesting efficacy of other anticonvulsants, including lamotrigine (Level 2) 1011 and carbamazepine (Level 3) [1012, 1013].
Atypical antipsychotics: Some data suggest that the atypical antipsychotics, risperidone (Level 2) 1030, aripiprazole (Level 3) [1031, 1032], and quetiapine (Level 3) [1034, 1035] may be a useful alternative to SSRIs for some patients with PTSD. A meta-analysis of seven RCTs using atypical antipsychotics, either as monotherapy or adjunctively, concluded that these agents may be beneficial in the treatment of PTSD, particularly for the symptom of “intrusion” 1061.
Other therapies: Small, open case series have suggested benefits with trazodone 1053, buspirone [1051, 1052], and memantine 1054 (all Level 4).

Adjunctive therapies

Adjunctive strategies have generally been studied in patients who have had an inadequate response to adequate antidepressant therapy, and can be considered for patients with treatment-resistant PTSD.
Second-line adjunctive therapies: In a RCT, adjunctive eszopiclone was significantly more effective than placebo in improving PTSD and sleep symptoms (Level 2) 1055. There is RCT evidence for the use of adjunctive atypical antipsychotics, including risperidone (Level 1, conflicting) [10391044] and olanzapine (Level 2) 1045, for patients with treatment-resistant PTSD. While a number of small RCTs demonstrated benefits with adjunctive risperidone [10391042], a large, six-month trial in approximately 250 patients failed to show improvements in PTSD symptoms compared with placebo 1043.
Third-line adjunctive therapies: Open-label trials and case series suggest that adjunctive quetiapine [10481050] or aripiprazole [1033, 1046, 1047] (both Level 3) are useful in patients with refractory PTSD.
Similarly, there are some data suggesting adjunctive anticonvulsants including: gabapentin [1019, 1020], levetiracetam 1021, pregabalin 1022, or tiagabine [10231025] (all Level 4), as well as the alpha-adrenergic agonist clonidine (Level 3) 1056, can improve symptoms in patients with treatment-resistant PTSD.
Not recommended adjunctive therapies: Small RCTs failed to show the superiority of adjunctive therapy with guanfacine (Level 1, negative) [1057, 1058], bupropion SR 1005 (Level 2, negative), or zolpidem 1059 (Level 2, negative). While case series suggested that adjunctive topiramate [1026, 1027, 1029] may be effective in treatment-resistant PTSD, a RCT failed to show superiority over placebo 1028 (Level 2, negative).

Treatments for specific PTSD-associated symptoms

Several agents have been used to target particular symptoms associated with PTSD. Prazosin has demonstrated significant efficacy for reducing trauma nightmares and improving sleep quality in patients with PTSD compared with placebo (Level 1) [1035, 10621066]. Some open-label data suggest that naltrexone may help reduce flashbacks (Level 3) [10671070], and fluphenazine may improve trauma re-experiencing symptoms (Level 3) 1037.
Cyproheptadine was not effective for nightmares or sleep problems in patients with PTSD and may actually exacerbate sleep disturbance (Level 2, negative) 1071.
In general, data do not currently support the use of divalproex [10141017] (Level 1, negative), alprazolam 1006, citalopram [974, 986988], olanzapine [10361038], tiagabine 1018 (all Level 2, negative), or clonazepam (Level 3, negative) [881, 1007, 1008].

Maintenance pharmacological treatment

Long-term therapy has been evaluated in relapse-prevention and naturalistic follow-up studies. Relapse-prevention studies are those in which responders to SSRI therapy are randomized to continued active treatment or placebo. A meta-analysis of three relapse-prevention studies included 272 patients with PTSD, and found a highly significant reduction in relapse rates with continued SSRI treatment compared with placebo over approximately six months (odds ratio for relapse was 0.25) [497].
In RCT discontinuation studies, fluoxetine [1072, 1073] and sertraline 1074 have demonstrated significantly lower relapse rates over six months in the range of 5-22% with active treatment compared to 16-50% with placebo [10721074]. However, in a small discontinuation RCT, tiagabine was not superior to placebo in preventing relapse 1075.
Open follow-up studies with paroxetine 1076 and sertraline 1077 have demonstrated sustained and continued improvement over six to 12 months of continued SSRI therapy.

Biological and alternative therapies

In general, these therapies may be useful for some patients; however, more data are needed.
Biological therapies: In RCTs, rTMS was effective as monotherapy or as an adjunct to SSRIs in patients with PTSD (Level 1) [10781080], and at least some improvements were maintained at two to three months after treatment [1078, 1079]. Open prospective and retrospective data suggest that adjunctive electroconvulsive therapy may be helpful in patients with refractory PTSD (Level 3) [1081, 1082].
Alternative therapies: In a RCT, acupuncture was more effective than a wait-list control and as effective as group CBT (Level 2) 1083. Adjunctive use of symptom-oriented hypnotherapy 1059 or mantra repetition 1084 (both Level 2) improved PTSD symptoms in small trials; and in a small case series, patients with PTSD benefited from transcendental meditation (Level 4) 1085.

Summary

The lifetime prevalence of PTSD is around 6-9%; it is more frequent in women than in men, with an onset generally in the mid to late 20s. PTSD is associated with high rates of functional impairment, somatic complaints, suicide risk, and comorbid psychiatric disorders. A diagnosis of PTSD requires evidence of exposure to trauma, and is characterized by intrusive and dissociative symptoms.
Evidence does not support the wide spread use of early intervention with psychological strategies for the prevention of PTSD. Debriefing of all trauma victims is not recommended, rather, screening and treating appropriate individuals is preferred. In general, there is little evidence supporting the use of pharmacotherapy for the prevention of PTSD, with most studies suggesting no preventive benefits.
CBT is an effective first-line option for the treatment of PTSD. Effective approaches include TF-CBT, EMDR, PE, and stress management therapy. ICBT and VRE have also demonstrated efficacy. Benefits are maintained during long-term follow-up of up to one to 10 years after treatment. Research evaluating combined psychological and pharmacological treatments in PTSD is limited, and this requires further study.
Pharmacotherapeutic approaches should begin with one of the first-line options which include SSRIs such as fluoxetine, paroxetine, or sertraline, or the SNRI venlafaxine XR. If response to optimal doses is inadequate or the agent is not tolerated, therapy should be switched to another first- or second-line agent, or a second-line agent should be added. Patients with PTSD may make few gains during treatment, and it is important to preserve even small gains achieved with initial therapy. Therefore, augmentation with second- or third-line agents may be important early in treatment.
Patients who do not respond to multiple courses of therapy are considered to have treatment-refractory illness. In such patients it is important to reassess the diagnosis and consider comorbid medical and psychiatric conditions that may be affecting response to therapy. Third-line agents, adjunctive therapies, as well as biological and alternative therapies may be useful when patients fail to respond to an optimal treatment trial of first- and second-line therapies used alone and in combination.

Special populations

Women during pregnancy and the postpartum period

Epidemiology

Women have been found to be at higher risk for anxiety and related disorders than men [2]. Anxiety disorders during the perinatal period are increasingly gaining research attention. Although further investigation is needed, data from a large national survey suggest the overall prevalence of anxiety and related disorders is unchanged in women during pregnancy 1086; however, other data have found an increased risk for individual disorders, such as GAD [1087, 1088]. Similarly, some data suggest that anxiety disorders are also not more prevalent during the postpartum period 1086, but other studies suggest higher rates of OCD and GAD during this period [1089, 1090]. In addition, PTSD can develop as a result of pregnancy complications that are experienced as traumatic [1091, 1092].
Anxiety and related disorders during pregnancy or postpartum may have a negative impact on the pregnancy, the child, or the mother. While studies report that maternal anxiety disorders are associated with adverse pregnancy outcomes such as a shorter gestational age, premature delivery, or elective cesarean delivery [10931095], a meta-analysis found no relationship between anxiety symptoms per se and adverse perinatal outcomes 1096. Anxiety symptoms during pregnancy have been associated with depressive symptoms, substance use, and anemia, as well as decreased use of prenatal vitamins [1093, 10971099].
Parenting may also be affected by maternal anxiety and related disorders. Mothers with anxiety disorders have been found to be less promoting of psychological autonomy than those mothers without anxiety 1100. Maternal anxiety has been found to be predictive of child cognitive development 1101, associated with behavioral/emotional problems in childhood [1101, 1102], and maternal anxiety and related disorders have been found to be related to subsequent development of an anxiety disorder in the child 1103.

Treatment issues

Psychosocial treatments, with CBT specifically, have strong empirical support for the treatment of anxiety and related disorders [63, 70, 71, 1104], but evidence of their efficacy in perinatal women with anxiety disorders is lacking. Cohort studies have shown beneficial effects of group CBT in pregnant women with B-I-I phobia 1105, and individual CBT in women with OCD in the postnatal period 1106. Arch et al. argued that although exposure-based CBT or behavioral therapy may have been avoided in the past because of concerns of potential harm, they likely can be viable, safe alternatives in pregnancy 1107. The lack of data on the use of structured psychosocial interventions for anxiety and related disorders during the perinatal period is a significant gap in the literature.
It is important to consider the risks and benefits of pharmacotherapy during pregnancy and while breastfeeding during the postpartum period. Risks to the fetus and newborn should be weighed against that of the potential harm of untreated anxiety and related disorders, an area that is gaining increasingly more research attention. Treatment decisions should attempt to optimize outcomes for both mother and baby.
Detailed recommendations on the use of psychiatric medications during pregnancy and lactation are available from the American Congress of Obstetricians and Gynecologists (ACOG) Practice Bulletin 1108. Although it is over five years old, risks associated with various psychotropic medications are summarized 1108. The FDA pregnancy risk category system has been criticized as being insufficient 1109 and is currently under the process of revision. The Canadian Hospital for Sick Children Motherisk website (http://​www.​Motherisk.​org) is also a useful resource.
Antidepressants: There appears to be little evidence of an association between maternal antidepressant use and increased risks of congenital malformations in general, and major congenital malformations in infants [11101113]. The exception is a statistically increased risk of cardiac defects with antidepressants, and with paroxetine specifically, although the clinical significance of this has been questioned [1108, 11131117]. There have been reports of increased rates of spontaneous abortion following antidepressant use during pregnancy; in the most recent meta-analysis, this was not supported using data from studies with higher study quality but found by others who included all studies [11181120]. In terms of delivery outcomes, a recent meta-analysis found a statistically increased risk for preterm birth, lower gestational age, birth weight, and APGAR scores – but the effects were small, generally in the normal range, and of questionable clinical significance 1118. However, data support an increased risk for poor neonatal adaptation syndrome (PNAS) [11211123], while findings of increased risk for persistent pulmonary hypertension in the antenatally exposed infant have not been consistent [11241127]. Systematic reviews suggest that overall prenatal exposure to antidepressants does not appear to be associated with changes in long-term neurocognitive or behavioral development in children [11281130] and that illness itself appears to play a role in negative outcomes (although this study examined the effects of maternal depression) 1131. Two reports link prenatal antidepressant use to childhood autism spectrum disorders [1132, 1133] and two others link bupropion exposure to childhood ADHD [1134, 1135]. These studies have limitations and further research is required.
In terms of breastfeeding, potential risks of antidepressant use during lactation must be weighed against the recognized benefits for the infant. Antidepressants are excreted into breast milk and although data are limited, the majority are found in very low amounts with few isolated instances of adverse signs 1108. If antidepressant treatment is indicated, sertraline or paroxetine is preferred 1136. Long-term data on potential neurobehavioral effects are lacking. Clinicians can consult LactMed at http://​toxnet.​nlm.​nih.​gov/​cgi-bin/​sis/​htmlgen?​LACT for the latest information available.
Benzodiazepines: The data on benzodiazepines remain more limited. A recent meta-analysis did not find an increased risk of major malformations or cardiac defects following prenatal benzodiazepine exposure, but concluded the significant increase in risk of oral cleft remains based on data derived from case-control studies 1137, although another meta-analysis reported the absolute risk is small (<1%) 1138. A case-control study published in 2002 examining exposure to five benzodiazepines (including clonazepam) and not included in the above meta-analyses, with over 60,000 infants, did not find an association with various congenital malformations or oral clefts 1139. Although there are a lack of meta-analytic data, neonatal withdrawal or toxicity syndrome has been described with antenatal benzodiazepine exposure and close monitoring of the infant has been recommended 1108. The neurobehavioral effects on the child over the long-term due to antenatal exposure have been topics of debate and remain uncertain 1108. Benzodiazepines are excreted into breast milk at low levels generally. A recent study with 124 mothers documented low levels of adverse effects (sedation in particular) and supported the initiation of breastfeeding 1140. Caution may be advised regardless however in infants who poorly metabolize benzodiazepines 1108.
Atypical antipsychotics: Data on the use of antipsychotics during pregnancy continue to be limited 1141. Thus far, there does not appear to be an increased risk for malformations although inconsistent data have been reported with some suggesting the data are inconclusive [11411143]. These drugs have been found to be associated with both increased and decreased birth weight as well as increased risk for preterm birth [11441149]. The second-generation antipsychotics can increase the risk of complications given the risk of metabolic syndrome, and thus diabetes, in the mother. Monitoring has been recommended 1150. Both the FDA and Health Canada have issued safety alerts advising of the potential risk for abnormal muscle movements and withdrawal symptoms in infants exposed to antipsychotic medications during the 3rd trimester of pregnancy [11511153]. Data on breastfeeding are more limited, but levels in breast milk have typically been shown to be low although adverse effects have been reported 1154.

Summary

The management of anxiety and related disorders in women who are pregnant or lactating requires careful consideration of both the potential risks of any treatment option as well as risks of an untreated anxiety disorder. Antidepressants are generally associated with low teratogenic risk and adverse delivery outcomes. Patients should be counseled about PNAS and its management. Less is known about the risk of benzodiazepine and atypical antipsychotic exposure during pregnancy as the data are more limited. Treatment must be individualized and decisions should be made with the most up-to-date information with the best course of action decided upon with the patient. Poorly or untreated psychiatric illness carries its own risks, both in the short- and long-term.

Children and adolescents

Epidemiology

Anxiety and related disorders were the most common psychiatric disorders noted in the National Comorbidity Survey-Adolescent supplement (NCS-A) (age 13-18 years), with a lifetime and 12-month prevalence of 31.9% and 24.9%, respectively [1155, 1156]. Prevalence rates for individual anxiety and related disorders are shown in Table 31[1155, 1156].
Table 31
Prevalence estimates of anxiety and related disorders among youths in the NCS-A (age 13-18 years)
Anxiety and related disorder
Estimated prevalence (%)
 
12-month
Lifetime
Any anxiety disorder
24.9
31.9
Separation anxiety disorder
1.6
7.6
Specific phobia
15.8
19.3
Social anxiety disorder
8.2
9.1
Posttraumatic stress disorder
3.9
5.0
Panic disorder
1.9
2.3
Generalized anxiety disorder
1.1
2.2
Adapted from references [1155, 1156]. NCS-A = National Comorbidity Survey-Adolescent supplement
Specific phobias are very common in children. However, although most adolescents reported at least one fear (77%), lifetime prevalence rates are in the range of 10-35% [308, 1156]. A study including children as young as five years of age found lower rates of diagnosed specific phobias (1%) 1157. B-I-I and animal fears are the most common types reported in pediatric populations [308, 1157]. The prevalence of OCD is only 0.25% in children 1158, but is 1-2% in adolescents, which is comparable to the rate seen in adults [2, 1159, 1160].
In the adolescent population, anxiety and related disorders were found to have the earliest median age of onset (six years), compared to other psychiatric disorders (11-15 years) 1156. Similarly, in the adult population, the median age of onset was earliest for anxiety and related disorders (11 years) compared to other psychiatric disorders (20-30 years) [2]. Separation anxiety disorder and the phobias (seven to 14 years) have much earlier median ages of onset compared to OCD, GAD, panic disorder, or PTSD (20-30 years) [1, 2, 1161].
Anxiety and related disorders can have a substantial long-term impact, putting children at elevated risk for MDD, other anxiety disorders, and SUD in adulthood [11, 12]. Anxiety and related disorders among younger patients are associated with high rates of comorbid psychiatric conditions [11621165], SUD [11661169], sleep problems [11701173], somatic symptoms 1174, and suicidality 1175, as well as problems with cognition/attention [1164, 1176, 1177], academic performance [1178, 1179], and peer relationships 1180.

Diagnostic issues

Diagnostic evaluation of pediatric patients should be based on DSM-5 criteria, but use developmentally appropriate language, and consider collateral information from parents and teachers. Children may express anxiety through crying, tantrums, freezing, or clinging, as well as through play. The DSM-5 provides some modifications to adult criteria to assist in the diagnosis of anxiety and related disorders in children (Table 32) [26]. In particular, a separate subtype for patients ≤6 years of age has been added to the criteria for PTSD to make it more developmentally sensitive to young children [26].
Table 32
DSM-5 diagnostic criteria for anxiety and related disorders specific to children
Anxiety or related disorder
DSM-5 diagnoses specific to children
Separation anxiety disorder
• Developmentally inappropriate and excessive fear or anxiety concerning separation from those to whom the individual is attached, as evidenced by ≥3 of the following:
    ○ Distress when separation occurs, worry about loss or separation, reluctance to leave home, be alone, or go to sleep because of fear of separation, nightmares involving separation, or complaints of physical symptoms (e.g., headaches, upset stomach) when separation occurs
• Duration of at least 4 weeks
• Onset before 18 years of age
• The disturbance causes clinically significant distress or impairment in social, academic (occupational), or other important areas of functioning
Selective mutism
• Consistent failure to speak in specific social situations in which there is an expectation for speaking (e.g., at school) despite speaking in other situations
Anxiety or related disorder
Changes to adult DSM-5 diagnostic criteria specific to children
Specific phobia
• The fear or anxiety may be expressed by crying, tantrums, freezing, or clinging
• Other specifiers: loud sounds or costumed characters
SAD (social phobia)
• The anxiety must occur in peer settings, not just during interactions with adults
• The fear or anxiety may be expressed by crying, tantrums, freezing, clinging, shrinking, or failure to speak in social situations
OCD, panic disorder
• No pediatric specific criteria
PTSD
• Qualifiers in children
    ○ Intrusion symptoms: repetitive play may occur in which themes or aspects of the traumatic event(s) are expressed; there may be frightening dreams without recognizable content; trauma-specific re-enactment may occur in play
• Specific subtype for children ≤6 years of age
GAD
• Less stringent criteria for symptoms than in adults
Adapted from DSM-5 [26].

Prevention strategies

Psychoeducational programs for children and adolescents aimed at preventing the development of an anxiety or related disorder have shown small, but significant effects 1181. Both universal (administered to all children within target population) 1182 and indicated prevention programs (administered to children demonstrating highly anxious symptoms) [1183, 1184] demonstrate benefits, but indicated programs are associated with larger effect sizes than universal programs 1181.
Both psychological and pharmacological strategies have been assessed for the prevention of PTSD. An early psychological intervention with children involved in road traffic accidents failed to result in any significant benefits over a control group 1185.
In a RCT in burn victims, sertraline was more effective in preventing PTSD symptoms than placebo according to parent report but not child report [890]. Data do not support the use of propranolol in preventing PTSD 1186 or ASD [886] in pediatric injury patients.

Treatment issues

Psychological treatment
Psychological therapies for children often need to be adapted to suit the chronological and developmental ages of young patients and to include parental involvement. Meta-analyses support the efficacy of CBT for the treatment of anxiety and related disorders in children and adolescents [11871191]. A meta-analysis of 24 clinical trials showed that almost 70% of youths who received CBT no longer met diagnostic criteria for their anxiety disorder compared to only 13% of wait-list controls 1189. Meta-analyses and RCTs have confirmed the efficacy of CBT in children with SAD [11921197], panic disorder 1198, OCD [11991204], PTSD [946, 12051211], school refusal [12121215], and separation anxiety disorder 1216.
CBT has demonstrated efficacy in both group and individual formats [1189, 1190, 1194, 1217, 1218], as well as in computer- or internet-based formats [1219, 1220].
One commonly used pediatric CBT protocol is the “Coping Cat” program [1221, 1222], which has demonstrated efficacy in RCTs [1221, 1223, 1224] and in long-term follow-up studies [1222, 1225]. In a RCT, Coping Cat CBT was as effective as pharmacotherapy with an SSRI, but less effective than combination therapy [1223, 1224].
Additional specific psychological approaches that have demonstrated efficacy in treating anxiety in children and adolescents include: attention bias modification (ABM) 1226, MBCT 1195, and social effectiveness therapy (SET) [1227, 1228] for SAD; ERP [1229, 1230], family-based CBT [1231, 1232], and meta-cognitive therapy 1229 for OCD; cognitive behavioral writing therapy (CBWT) 1233, spiritual-hypnosis assisted therapy (SHAT) 1234, emotion regulation therapy 1235, exposure therapy 1236, and EMDR [905, 1237, 1238] for PTSD; and exposure therapy for specific phobias [313].
Approaches that include parental or family involvement may have some additional benefit over strategies that include children only [12391245], especially when parents suffer from an anxiety or related disorder themselves 1246. Parental training only has also demonstrated beneficial effects on children with an anxiety disorder [1247, 1248].
The presence of comorbidities may have a negative impact on the efficacy of CBT in pediatric patients 1249. However, integrated CBT protocols designed to target both conditions have demonstrated efficacy in youths with anxiety and related disorders and comorbid ADHD 1250, aggression 1251, or comorbid SUD 1252.
Long-term follow-up studies have shown sustained benefits of CBT over two to seven years posttreatment [1218, 1225, 1228, 1253, 1254].
Pharmacological treatment
Complete treatment recommendations for the management of anxiety and related disorders in youths are beyond the scope of these guidelines and the reader is referred to specific guidelines for the assessment and treatment of children and adolescents with anxiety disorders, such as those developed by the American Academy of Child and Adolescent Psychiatry (AACAP) [12551258].
For children and adolescents, psychological treatments are generally preferred over pharmacotherapy, or if warranted combination therapy may be an option. RCTs comparing combined pharmacological and psychological treatments in younger patients with anxiety have demonstrated efficacy equal or superior to either treatment alone [1199, 1223, 1224, 1259]. In the pediatric population, safety concerns associated with antidepressants (see “Safety Issues”) should be weighed against the potential benefits of therapy. Medication may be warranted in children and adolescents with severe impairment or those who are unlikely to respond to CBT due to cognitive or other issues. A “start low and go slow” approach is advised when using medications in this patient population.
The strength of evidence for pharmacotherapeutic agents in the treatment of pediatric patients is shown in Table 33. When pharmacotherapy is felt to be warranted, SSRIs are generally preferred for children and adolescents with anxiety and related disorders.
Table 33
Strength of evidence of treatments for anxiety and related disorders in children and adolescents
Disorder
Antidepressants
Benzodiazepines and other treatments
OCD
Fluoxetine (Level 1) [12641269]
Antipsychotics
 
Clomipramine (Level 1) [12741276]
Adjunctive aripiprazole (Level 3) 1293
 
Citalopram (Level 2) [1264, 1270]
Other
 
Fluvoxamine (Level 2) 1271
Riluzole (Level 4) 1294
 
Paroxetine (Level 2) 1272
 
 
Sertraline (Level 2) 1273
 
Panic disorder
 
Anxiolytics
  
Clonazepam (Level 4) [1287, 1288]
  
Alprazolam (Level 4) 1289
SAD
Fluoxetine (Level 1) [1227, 1277]
Anxiolytics
 
Fluvoxamine (Level 2) 1278
Alprazolam (Level 2, -ve) 1290
 
Paroxetine (Level 2) 1279
 
 
Venlafaxine XR (Level 2) 1282
 
 
Escitalopram (Level 3) 1280
 
 
Sertraline (Level 3) 1281
 
 
Mirtazapine (Level 3) 1283
 
Separation anxiety disorder
Fluoxetine (Level 2) 1277
Anxiolytics
 
Fluvoxamine (Level 2) 1278
Clonazepam (Level 2, -ve) 1292
GAD
Fluoxetine (Level 2) 1277
Anxiolytics
 
Fluvoxamine (Level 2) 1278
Alprazolam (Level 2, -ve) 1290
 
Sertraline (Level 2) 1284
 
School-refusal
Citalopram (Level 4) 1285
Anxiolytics
 
Adjunctive imipramine (Level 2) 1259
Alprazolam (Level 2, -ve) 1291
PTSD
Sertraline (Level 2, -ve) 1286
 
 
Adjunctive sertraline (Level 2, -ve) [946]
 
XR = extended release; (-ve) = negative.
Antidepressants: SSRIs and TCAs have been well studied in pediatric patients with anxiety and related disorders (Table 33) [12601262], although these agents should be used with caution in youths as discussed in the section on safety issues below. Most of the data in pediatric patients are in those with OCD [1204, 1261, 1263] or SAD 1197.
There is good evidence for the efficacy of SSRIs in children and adolescents with OCD, including fluoxetine (Level 1) [12641269], citalopram (Level 2) [1264, 1270], fluvoxamine (Level 2) 1271, paroxetine (Level 2) 1272, and sertraline (Level 2) 1273, as well as for the TCA clomipramine (Level 1) [12741276].
Similarly, there is good evidence for the efficacy of SSRIs in SAD, including fluoxetine (Level 1) [1227, 1277], fluvoxamine (Level 2) 1278, paroxetine (Level 2) 1279, escitalopram (Level 3) 1280, and sertraline (Level 3) 1281, as well as for the SNRI venlafaxine XR (Level 2) 1282, and some evidence for mirtazapine (Level 3) 1283.
There is level 2 evidence for the efficacy of fluoxetine 1277 and fluvoxamine 1278 in separation anxiety disorder, and for fluoxetine 1277, fluvoxamine 1278, and sertraline 1284 in GAD. In school-refusing children and adolescents, a small case-series suggested benefit with citalopram (Level 4) 1285, and a RCT demonstrated that imipramine as an adjunct to CBT was more effective than CBT alone (Level 2) 1259.
In pediatric PTSD, sertraline alone 1286 or as an adjunct to CBT [946] was not more effective than placebo or CBT (both Level 2, negative) and cannot be recommended at this time.
Benzodiazepines: There are little data demonstrating the efficacy of benzodiazepines in children and adolescents with anxiety and related disorders (Table 33) [12871292]. In fact, the few RCTs have demonstrated no significant improvements in anxiety symptoms with alprazolam over placebo in overanxious or avoidant disorders (Level 2, negative) 1290 or school-refusal (Level 2, negative) 1291, or with clonazepam in separation anxiety disorder (Level 2, negative) 1292. Benzodiazepines have limited utility in youths, although they may be useful for short-term therapy in specific situations where there is a need to achieve rapid reduction in severe anxiety symptoms to allow exposure-related psychotherapy (e.g., panic disorder, school refusal behavior).
Other treatments: In open trials in pediatric patients with treatment-resistant OCD, the atypical antipsychotic aripiprazole (Level 3) 1293 and the glutamate antagonist riluzole (Level 4) 1294 have demonstrated some efficacy.
Combination psychological and pharmacological therapies
The combination of sertraline and CBT was significantly superior to both monotherapies in a large RCT in pediatric patients with separation anxiety disorder, GAD, or SAD 1223. In pediatric patients with OCD, the addition of CBT in those with a partial response to SSRIs resulted in significantly greater response rates compared with the SSRI alone 1199, while the addition of d-cycloserine to CBT was not superior to placebo 1295.
Alternative therapies
There is currently little evidence supporting the efficacy of exercise in reducing anxiety symptoms in pediatric populations 1296, although some open data suggest it may have a small beneficial effect in pediatric PTSD [1297, 1298].
Safety issues
An important consideration when using antidepressant medications in children and adolescents is the potential for an increased risk of suicidality. Clinicians should be aware of the potential activating side effects of SSRIs (insomnia, agitation, tremor, and anxiety), especially in young children [12991301]. Regulatory bodies in many countries have issued black-box warnings about suicidal ideation/suicide attempts with the use of antidepressants in patients younger than 19 years. However, in a comprehensive analysis, the pooled absolute risk difference for suicidal thinking or behavior between SSRI- and placebo-treated youth with anxiety and related disorders was non-significant (0.5-0.7%), and lower than the risk for youth treated for MDD (0.9%) 1302. Anxiety and related disorders also increase the risk of suicidality — nearly eight times for suicidal ideation and six times for suicide attempts compared with not having an anxiety disorder 1175. Therefore, risks and benefits of treatment should be discussed with both children and their parents.
The most common antidepressant adverse events are generally activation and vomiting in children, and somnolence in adolescents 1303. More conservative dosing strategies may be needed especially in younger children or those with low body weight 1301.

Summary

The management of anxiety and related disorders in children and adolescents can be challenging. Diagnostic evaluation of pediatric patients should use developmentally appropriate language and consider collateral information from parents and teachers. Children may express anxiety through crying, tantrums, freezing, or clinging, as well as through play. For children and adolescents, psychological therapies are generally preferred over pharmacotherapy, or if warranted combination therapy may be an option. Psychological therapies often need to be adapted to suit the chronological and developmental ages of young patients and to include parental involvement. When pharmacotherapy is warranted, SSRIs are generally preferred, although antidepressants should be used with caution in pediatric patients.

Elderly

Epidemiology

The lifetime and 12-month prevalence of any anxiety or related disorder among those age 65 or older is estimated to be 13.6% and 7.0%, respectively, compared with 27.8% and 17.8% in the overall adult population 1304. Including subthreshold anxiety increases the 12-month prevalence from about 6% to over 26% in older adults 1305. The prevalence rates of anxiety and related disorders have generally been shown to decline with age, and as in younger age groups, the prevalence is higher in women than in men [509, 1304, 1306, 1307]. The decline in prevalence may be related to age biases in the assessment of anxiety and the masking effect of other risk factors that increase with aging 1308. Under-diagnosis is common, with one study finding that only 34% of older patients with GAD had previously had anxiety symptoms documented 1309.
Among older adults (≥55 years) with mood or anxiety and related disorders, 60-70% do not use mental health care services [1310, 1311], although use is higher among those with comorbid disorders 1312. Older adults with anxiety and related disorders have higher rates of sleep disturbances [13131315] and greater impairment in cognitive functioning [13161319] compared to those without anxiety disorder. In addition, anxiety negatively impacts physical functioning and mobility [1320, 1321], and health related QoL [1321, 1322].
Comorbidities
Depression is among the most common comorbid disorders among older adults with anxiety and related disorders [13231325], and is associated with poorer outcomes of both disorders 1326. Approximately 80% of adults ≥65 years of age have at least one chronic medical condition, and this may be even higher among those with anxiety disorders 1327. Older patients with anxiety and related disorders report higher rates of diabetes, gastrointestinal conditions, and dementia [1325, 1327, 1328].
Chronic urinary incontinence, hearing impairment, hypertension, respiratory disease, and poor sleep were associated with elevated rates of anxiety symptoms or disorders [1315, 1329]. Comorbid anxiety in patients with medical illnesses, particularly cardiovascular disease, has been associated with an increased risk of mortality [1330, 1331]. Furthermore, the relationship between anxiety and related disorders in the elderly and cognitive impairment remains largely neglected 1332.

Diagnostic issues

The recognition and accurate diagnosis of anxiety and related disorders in older patients can be challenging 1333. Modifications to the DSM-5 diagnostic criteria may assist clinicians in more accurately recognizing and diagnosing anxiety and related disorders in the elderly 1333.
Older patients with anxiety often present differently than younger patients [1327, 1334]. Avoidance and excessive anxiety may be difficult to detect in older patients 1333. Older adults may describe symptoms differently; for example, they may discuss concerns rather than worries [1327, 1333]. They are less likely to attribute symptoms to anxiety and related disorders, but rather may attribute them to physical illness and they may have difficulty remembering symptoms [1327, 1335]. Obtaining information from collateral sources may be useful. Assessing impact on work or social functioning may also be complicated by changes in responsibilities associated with aging (e.g., retirement) 1333. It may be helpful to ask about activities relevant to older adults, such as visiting grandchildren. Similarly, avoidance may be harder to detect because of limitations in physical mobility or visual problems, leading to a decline in activities outside the home 1336.
Chronic medical illness or the use of medications can also complicate the diagnosis of anxiety and related disorders 1333. Determining which came first, the physical illness or the anxiety symptoms can be helpful. However, when a medical illness is chronic, this precludes the likelihood that the anxiety would resolve when the medical condition resolves.
Late-onset anxiety and related disorders are relatively unusual [2], therefore older patients with new onset anxiety should be investigated for potential causative factors (e.g., physical illness, medication side effects).

Psychological treatment

Relaxation training, CBT, supportive therapy, and CT have support for the treatment of anxiety symptoms and disorders in older patients 1337. Meta-analyses suggest the efficacy of psychological treatment is similar to that of pharmacotherapy for the treatment of anxiety and related disorders in older patients [1338, 1339].
In meta-analyses, CBT was an effective option in reducing anxiety symptoms among older patients compared to wait-list or active controls [13401342]. Some data suggest that CBT may be less effective for anxiety and related disorders in older patients than in working-age adults [1337, 1342]. Older patients may benefit from the inclusion of learning- and memory-aids with standard CBT [1343, 1344]. In RCTs in older patients, CBT demonstrated efficacy for the treatment of GAD [1337, 1343, 13451347] and panic disorder [1348, 1349]. Exposure therapy, with or without CBT, demonstrated efficacy in case-controlled studies in patients with PTSD 1350 or specific phobias 1351. CBT may also be effectively delivered via telephone, although improvements may not be long lasting 1352.
In a case-control study, regular physical exercise reduced the risk of developing anxiety disorders among older adults 1353.

Pharmacological treatment

Data suggest that pharmacotherapy including antidepressants or anticonvulsants is likely as effective in older adults as it is in younger patients [575]. Most of the studies in older patients include those ≥60 or 65 years and have been conducted in patients with GAD or panic disorder.
The most robust data in elderly patients with GAD are from a large RCT (n=273), which demonstrated significant improvements and good tolerability with pregabalin compared with placebo 1354. Pregabalin was also effective as adjunctive therapy in an open trial in older patients with comorbid GAD and depression 1355.
Pooled analyses of subsets of older patients from multiple RCTs demonstrate that duloxetine 1356 and venlafaxine [575] were effective for the treatment of GAD. Citalopram was effective in an eight-week RCT 1357 and in an open study over six months of treatment 1358. Some data suggest that escitalopram may be useful in older patients with GAD [550, 1359]; although in one RCT, response rates were not significantly different than placebo in the intention-to-treat analysis [550]. Sertraline was more effective than CBT 1349, particularly at a one-year follow-up assessment 1360, and was as effective as buspirone [561] in older adults with GAD.
In older patients with panic disorder, paroxetine was as effective as CBT and more effective than a wait-list control, and results were sustained at a six-month follow-up 1348. Escitalopram 1361 and citalopram 1361 were equally effective in a small, open trial. A small, open trial also showed fluvoxamine to be effective in older patients with GAD, panic disorder, or OCD 1362. Data in patients with MDD, suggest that mirtazapine may have beneficial anxiolytic effects in the elderly [1363, 1364].
Data show that 45-60% of older patients (>55 years) with anxiety and related disorders are prescribed a benzodiazepine, which is higher than the rate of antidepressant use [13651367]. The very high use of these agents is a cause for concern since they are not a preferred long-term treatment strategy and elderly patients may be more sensitive to their negative effects [1365, 1366].
Safety issues
The elderly maybe more susceptible to adverse drug events and drug-drug interactions (DDIs) due to gradual age-related physiologic changes that affect the pharmacokinetic and pharmacodynamic properties of many medications [1368, 1369]. Factors which may alter drug metabolism and plasma concentrations among elderly patients include frailty, reduced homoeostatic mechanisms, and psychosocial issues 1368. Age-related changes in body composition can result in increases or decreases of drug volume distribution, and hepatic or renal dysfunction can impair drug metabolism and drug clearance [1369, 1370]. All of these changes are highly variable in elderly patients, further complicating use of medications in this population [1368, 1369]. A review of the literature found that almost half of available antidepressants are associated with age-related clearance changes and identified at least 45 medications that could interact with specific antidepressants 1371.
DDIs may be more common in older adults because of the greater number of concomitant medication they may be taking to treat multiple comorbid conditions. In one study of US community-dwelling older adults, almost 30% used at least five prescription medications, 80% used at least one prescription medication, and almost half used over-the-counter and dietary supplements 1372.
Psychotropic medications have been associated with an increased risk of fractures [1369, 1373, 1374]. In a meta-analysis, the RR of fractures was 1.34 for benzodiazepines, 1.60 for antidepressants, 1.54 for anticonvulsants, and 1.59 for antipsychotics 1373. In a prospective cohort study (The Rotterdam Study) of subjects over 55 years of age, the risk of non-vertebral fractures was 2.35 for current SSRI use versus non-use 1375. The increased risk for hip fracture associated with benzodiazepines was further increased with increasing dose and the use of concomitant interacting drugs [1369, 1374]. There does not appear to be any difference between atypical antipsychotic agents in the increased risk of falls or fractures 1376.
An increased mortality risk has been associated with the use antipsychotics in older patients with dementia [13771379], which appears to be greater with conventional compared to atypical antipsychotics [13781380].
Antidepressants are frequently used to treat symptoms of anxiety in older adults who suffer from comorbid medical conditions such as heart disease. In a meta-analysis of SSRIs versus placebo or no antidepressant therapy in patients with coronary heart disease (CHD) and depression, SSRIs were associated with lower rates of all-cause mortality and readmissions for CHD, indicating that treatment may improve CHD prognosis 1381. Clinicians should weigh the risks associated with antidepressants against the potential benefits when making prescribing decisions.

Summary

While onset of anxiety and related disorders in late-life is uncommon, they do persist into older age and can have substantial impact on QoL and functionality. Older patients can present differently compared to younger patients, and diagnosis can be complicated by communication barriers, changes in role functioning, memory difficulties, and comorbid medical conditions.
Few treatment studies are conducted in older patients; however, data suggest that psychological treatment and pharmacotherapy appear to be similarly effective in older patients. Using pharmacotherapy in elderly patients can be challenging, and should consider patient factors such as body mass, hepatic and renal function, comorbid conditions, and use of concomitant medications.

Anxiety with comorbid conditions

Overview

Anxiety and related disorders often present together with other psychiatric or medical conditions [3, 16, 43, 1382, 1383]. About 60-80% of patients with an anxiety disorder have at least one other comorbid psychiatric condition, which most commonly include another anxiety or related disorder, MDD, bipolar disorder, ADHD, and SUD [3]. The presence of comorbid disorders has a negative impact on most aspects of care. Patients with psychiatric comorbidities have more severe symptoms [46, 1384], poorer treatment outcomes for both disorders [47, 13851387], greater functional impairment [46, 871, 1384], poorer QoL [1388, 1389], and an increased risk of suicide [652].
Medical conditions and pain disorders are also common comorbidities in patients with anxiety and related disorders. Medical conditions frequently reported in patients with anxiety and related disorders include cardiovascular disease, gastrointestinal disease, arthritis, respiratory disease, thyroid disease, migraine, and allergic conditions [16, 52]. Patients with both anxiety disorders and medical conditions experience elevated disability, including more psychiatric comorbidity and depressive symptoms, as well as poorer interpersonal and physical functioning [52, 142]. Patients with chronically painful conditions such as arthritis, back pain, or migraine are at a two- to four-fold higher risk of having an anxiety or related disorder, particularly panic disorder or PTSD 1390.
The high probability of comorbid disorders should be considered when diagnosing and treating patients with anxiety and related disorders. In patients with comorbid psychiatric conditions, such as another anxiety disorder or mood disorder, consider therapies that are effective for both disorders [32]. Benzodiazepines should be prescribed with additional caution in patients with comorbid SUDs. In patients with comorbid medical conditions, the clinician must weigh the benefits and risks of medication for the anxiety or related disorder, but should also consider the impact of untreated anxiety [32].

Major depressive disorder (MDD)

Q. What is the prevalence and impact of comorbid MDD and anxiety/related disorders?

MDD is very common in patients with anxiety, being reported in 20-36% of patients [121, 310, 360, 1382]; and conversely, about 60% of patients with MDD will have a comorbid anxiety or related disorder [44]. In patients with anxiety, comorbid depression has been associated with more severe symptoms [46, 1384], lower likelihood of remission [47], greater functional impairment [46, 871, 1384], an increased risk of suicide [652], and a greater risk of having another comorbid anxiety disorder [360]. Similarly, in patients with MDD, comorbid anxiety and related disorders were associated with poorer treatment outcomes including higher recurrence rates [13851387], poorer QoL 1391, and an increased risk of suicide [24, 1387, 1392, 1393].

Q. What pharmacological treatment may be useful for patients with an anxiety/related disorder and comorbid MDD?

Guidelines generally recommend antidepressants (most commonly SSRIs and SNRIs) as first-line treatments in patients with both anxiety and depressive symptoms [32, 1394]. SSRIs and SNRIs in patients with anxiety and related disorders, including panic disorder, GAD, OCD, or PTSD, with comorbid MDD have been shown to be effective in improving both disorders [224, 723, 1359, 1395]. Among the atypical antipsychotics, quetiapine has been found to have efficacy as monotherapy in both MDD 1396 and GAD 1397, as well as MDD with anxiety 1398, while case series suggest that aripiprazole augmentation of antidepressants [496], and risperidone monotherapy [267] may also reduce comorbid depressive and anxiety symptoms.

Bipolar disorder or psychoses

Q. What is the prevalence and impact of comorbid bipolar disorder or psychoses with anxiety/related disorders?

Among patients with anxiety and related disorders, almost 14% also met criteria for bipolar I or II disorder [121]. However, among patients with bipolar disorder the rates of comorbid anxiety disorders are very high compared to the general population, and the DSM-5 notes anxiety disorders as the most common comorbidities in patients with bipolar disorder [26]. In epidemiological surveys, the lifetime comorbidity rates for any anxiety or related disorder among patients with bipolar disorder was 52% in Canada [43] and 60-75% in the US [1389, 1399]. In a clinic population, the rate of anxiety and related disorders was 22% in patients with bipolar disorder, compared to 17% in patients with schizophrenia, and 30% in those with schizoaffective disorder 1400. A meta-analysis of prevalence studies found that the rates of various anxiety disorders in patients with schizophrenia and related psychotic disorders ranged from 10-15% 1401.
Comorbid anxiety and related disorders in patients with bipolar disorder were associated with a greater risk of MDD and drug use disorders, a poorer bipolar course, lower QoL, and lower psychosocial functioning [1388, 1389]. Data are conflicting on the impact of anxiety and related disorders on suicidal tendencies in patients with bipolar disorder, with some analyses finding an increased risk [1389, 1402], but not all 1403. Similar findings have been reported in patients with schizophrenia, where comorbid anxiety and related disorders have been associated with more past SUDs, lower social adjustment and overall QoL, and greater suicidality [1404, 1405].

Q. What pharmacological treatment may be useful for patients with an anxiety/related disorder and comorbid bipolar disorder or psychoses?

The management of patients with anxiety and related disorders and comorbid bipolar disorder, schizophrenia, or other psychosis should consider therapies that are effective for both disorders [32]. Atypical antipsychotics are recommended treatments for bipolar disorder and schizophrenia [111, 1406], while the long-term use of antidepressants may destabilize patients with bipolar I disorder [111, 1394].
Data in patients with a diagnosed anxiety or related disorder and comorbid bipolar disorder or psychosis are limited. In a RCT, risperidone monotherapy was shown to be no more effective than placebo for patients with bipolar and comorbid panic disorder or GAD 1407. However, in a single-blind trial, olanzapine or lamotrigine when added to lithium demonstrated improvements in anxiety disorder symptoms in patients with remitted bipolar disorder 1408; and in an open trial, switching to aripiprazole significantly improved social anxiety and psychosis in patients with SAD and schizophrenia [379]. In addition, atypical antipsychotics have demonstrated efficacy in RCTs in patients with anxiety and related disorders (see specific disorder sections for evidence), and data show that these agents can significantly reduce anxiety symptoms in patients with bipolar disorder [14091413]. Taken together, these data suggest these agents may be useful in comorbid patients.
Anticonvulsants have also demonstrated efficacy in the treatment of some anxiety and related disorders (see specific disorder sections for evidence) and are often used for the treatment of bipolar disorder [111]. In patients with bipolar disorder, adjunctive valproate and gabapentin have demonstrated efficacy for the treatment of panic disorder [281, 1414] and resulted in reductions in anxiety symptoms [1415, 1416].

ADHD

Q. What is the prevalence of comorbid ADHD and anxiety/related disorders?

It is estimated that the lifetime rate of ADHD in children is 6-9%, with 70% persistence into adolescence and 50-60% into adulthood [45, 1417, 1418]. In a community-based survey, the estimated prevalence of current self-reported adult ADHD was 4.4% [45]. While ADHD has long been known to persist into adulthood [1419, 1420], it has only recently become the focus of widespread clinical attention [14211423].
Of adults identified with ADHD in the National Comorbidity Survey-Replication (NCS-R), only one in 10 had received treatment within the previous year [45]. Of these individuals, it is estimated that approximately 47% meet criteria for an anxiety or related disorder within 12 months of assessment, with the most common being SAD (29.3%), followed by specific phobia (22.7%), PTSD (11.9%), panic disorder (8.9%), and GAD (8.0%) [45]. Patients with an anxiety or related disorder were reportedly four times more likely to meet criteria for ADHD than the general population [45]. Similar results were found in a Canadian survey of patients in an anxiety disorders clinic, where the rate of adult ADHD was 28% [378].

Q. What factors should be considered when treating patients with an anxiety/related disorder and comorbid ADHD?

When managing a patient with ADHD, it may be important to differentiate ADHD with anxious symptoms from comorbid ADHD and anxiety/related disorders. This can be challenging, as anxiety symptoms are frequently related to a sense of being overwhelmed or to compensatory skills in patients with ADHD. Stimulants may play a larger role in managing ADHD in patients with anxiety symptoms [1424, 1425]; however, in an open trial, atomoxetine improved ADHD and comorbid symptoms of depression and anxiety 1426.
Treatment of patients with comorbid ADHD and an anxiety or related disorder may be more complicated. Generally, in patients with comorbid anxiety disorders and ADHD the diagnostic and treatment priority should be determined by the relative severity of symptoms and risks of each disorder 1427. There are limited data on the role of stimulants in patients with ADHD and an anxiety disorder. In a RCT, atomoxetine significantly improved ADHD and SAD symptoms compared with placebo [487]. In separate open trials, adjunctive atomoxetine 1428 and adjunctive extended release mixed amphetamine salts 1429 significantly improved anxiety symptoms in patients with ADHD and GAD refractory to antidepressants alone.

Medical comorbidities

Q. What is the prevalence and impact of comorbid medical conditions and anxiety/related disorders?

Medical conditions are also common comorbidities that must be considered when prescribing medication for patients with anxiety and related disorders. Medical conditions are reported in over 60% of patients with anxiety and related disorders including cardiovascular diseases, gastrointestinal diseases, arthritis, respiratory diseases such as asthma, thyroid disease, migraine headaches, back pain, and allergic conditions [16, 52, 14301432]. Comorbidities are particularly common among patients with GAD, panic disorder, and PTSD [16, 140, 515, 517, 1390, 1433].
Patients with anxiety and related disorders and medical conditions experience more psychiatric comorbidity, depressive symptoms, and more severe anxiety disorder symptoms, as well as poorer interpersonal and physical functioning [52, 140, 142, 515].

Q. What factors should be considered when treating patients with an anxiety/related disorder and comorbid chronic pain?

Chronically painful conditions (i.e., arthritis, back pain, and migraine) are commonly associated with anxiety [515, 1390, 1430, 1434]. Patients with anxiety and related disorders are twice as likely to have painful physical symptoms compared to of those without, 45-60% versus 28% [515, 1433]. About 60-70% of patients with anxiety disorders report migraine headaches [140, 141].
For the management of anxiety and related disorders in patients with pain it may be helpful to consider treatments that have demonstrated efficacy in both anxiety disorders as well as pain. While there are few data available, duloxetine has demonstrated efficacy for both GAD and pain symptoms in RCTs [14351437]. TCAs, and to a lesser extent SSRIs, have been shown to reduce headache attacks in patients with migraine 1438, and provide moderate relief of neuropathic pain 1439.

Q. What factors should be considered when treating patients with an anxiety/related disorder and comorbid cardiovascular disease?

Although panic attacks can sometimes be mistaken for cardiovascular symptoms, it is important to be aware that patients with anxiety and related disorders do have a two- to three-times greater risk of cardiovascular disease compared to the general population [1431, 1432]. In addition, anxiety disorders have been associated with increased risk of cardiovascular hospitalization rates and mortality risk [14401442]. In patients with cardiovascular or cerebrovascular comorbidity, it is important to consider the impact of treatments used for anxiety on heart rate, blood pressure, and lipid measures [14431445].

Q. What factors should be considered when treating patients with an anxiety/related disorder and comorbid diabetes and metabolic syndrome?

Patients with anxiety symptoms have an elevated risk of type 2 diabetes 1446. While glycemic measures do not appear to be affected by anxiety symptoms 1447, some treatments, particularly some atypical antipsychotics, alter glucose parameters, lipid levels, and cause weight gain [109116, 1443]. Some antidepressants, including amitriptyline, mirtazapine, and paroxetine have also been associated with weight gain 1448.

Canadian Anxiety Guidelines Initiative Group

Additional authors

Martin M. Antony1, Stéphane Bouchard2, Alain Brunet3, Martine Flament4, Sophie Grigoriadis5, Sandra Mendlowitz6, Kieron O’Connor7, Kiran Rabheru4, Peggy M.A. Richter5, Melisa Robichaud8, John R. Walker9
1Department of Psychology, Ryerson University, Toronto, M5B 2K3, Canada; 2Department of Psychoeducation and Psychology, University of Québec in Outaouais, Gatineau, J9A 1L8, Canada; 3Department of Psychiatry, McGill University, Montreal, H3A 1A1, Canada; 4Department of Psychiatry, University of Ottawa, Ottawa, K1Z 7K4, Canada; 5Department of Psychiatry, University of Toronto, Toronto, M5S 1A1, Canada; 6Department of Child Psychiatry, University of Toronto, Toronto, M5S 1A1, Canada; 7Department of Psychiatry, University of Montreal, Montreal, H3C 3J7, Canada; 8Departments of Psychiatry and Psychology, University of British Columbia, Vancouver, V6T 2A1, Canada; 9Department of Clinical Health Psychology, University of Manitoba, Winnipeg, R3E 3N4, Canada
Email: Martin M. Antony - mantony@psych.ryerson.ca; Stéphane Bouchard - stephane.bouchard@uqo.ca; Alain Brunet - alain.brunet@mcgill.ca; Martine Flament - martine.flament@theroyal.ca; Sophie Grigoriadis - sophie.grigoriaidis@sunnybrook.ca; Sandra Mendlowitz - sandra.mendlowitz@sickkids.on.ca; Kieron O’Connor - kieron.oconnor@umontreal.ca; Kiran Rabheru - kiranrabheru@hotmail.com; Peggy M.A. Richter - peggy.richter@sunnybrook.ca; Melisa Robichaud - robichau@mail.ubc.ca; John R. Walker - jwalker@cc.umanitoba.ca

Additional contributors to the comorbidity section

Gordon Asmundson10, Larry J. Klassen11, Raymond W. Lam12, Roger S. McIntyre13, Isaac Szpindel14
10Department of Psychology, University of Regina, Regina, S4S 0A2, Canada; 11Department of Psychiatry, Faculty of Medicine, University of Manitoba, Winnipeg, R3T 2N2, Canada; 12Department of Psychiatry, University of British Columbia, Vancouver, V6T 2A1, Canada; 13Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, M5S 1A1, Canada; 14Attention and Learning Related Disorders, START Clinic, Toronto, M4W 2N4, Canada
Email: Gordon Asmundson - gordon.asmundson@uregina.ca; Larry J. Klassen - larryjklassen@hotmail.com; Raymond W. Lam - r.lam@ubc.ca; Roger S. McIntyre - roger.mcintyre@uhn.ca; Isaac Szpindel - iszpindel@startclinic.ca

Acknowledgements

The consensus group would like to thank Astra Zeneca Canada, Eli-Lilly Canada, Janssen Inc., Lundbeck Canada, Pfizer Canada, Purdue Canada, Servier Canada Inc., Shire Canada, and Valeant Canada for their generous support of the guideline process with unrestricted educational grants. Funds were used for editorial assistance and meeting logistics; none of the members received payment for participating in the guideline development process. The consensus group would also like to thank Pauline Lavigne and Steven Portelance who provided medical writing services on their behalf.
Declarations
The development and publication of these guidelines was supported by unrestricted educational grants provided by Astra Zeneca Canada, Eli-Lilly Canada, Janssen Inc., Lundbeck Canada, Pfizer Canada, Purdue Canada, Servier Canada Inc., Shire Canada, and Valeant Canada. None of the members received payment for participating in the development of these guidelines.
This article has been published as part of BMC Psychiatry Volume 14 Supplement 1, 2014: Canadian Anxiety Disorders Guidelines Initiative: Clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. The full contents of the supplement are available online at http://​www.​biomedcentral.​com/​bmcpsychiatry/​supplements/​14/​S1.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Competing interests

Unrestricted educational grants for the development of these guidelines were provided by Astra Zeneca Canada, Eli-Lilly Canada, Janssen Inc., Lundbeck Canada, Pfizer Canada, Purdue Canada, Servier Canada Inc., Shire Canada, and Valeant Canada. None of the members received payment for participating in the development of these guidelines.
The following authors do not have any competing interests to declare: AB, GA, JRW, KO, MMA, MF, LK, MR, SM.
Advisory board/speaker's bureau: Astra Zeneca (KK, KR, MK, P. Bleau, P. Blier, RWL, RSM), Biovail (RWL), Boehringer Ingelheim (MK), BMS (KK, KR, MK, P. Bleau, P. Blier, PC, RWL, RSM), Canadian Institutes of Health Research (CIHR) (RWL), Canadian Network for Mood and Anxiety Treatments (CANMAT) (RWL), Canadian Psychiatric Association (CPA) Foundation (RWL), Eli Lilly Canada (MK, P. Bleau, P. Blier, PC, SG, RWL, RSM, IS), France Foundation (RSM), GlaxoSmithKline (MK, P. Blier, RSM, SG), Janssen Ortho (KK, MK, P. Blier, PC, RSM), Labopharm (P. Blier), Litebook Company (RWL), Lundbeck (KK, KR, MK, P. Bleau, P. Blier, PC, RWL, RSM, SG), Lundbeck Institute (RWL), Organon (MK, RSM), Merck (P. Blier, RSM), Mochida (RWL), Otsuka (KK), Pfizer (P. Bleau, P. Blier, PC, RWL, RSM, SG), Pierre Fabre (P. Blier), Purdue (IS), Servier (P. Blier, RWL, SG), Shire (MK, RSM, IS), Solvay (MK), St. Jude's Medical (RWL), Sunovion (KK, P. Blier), Takeda (P. Blier, RWL), UBC Institute of Mental Health/Coast Capital Savings (RWL), Valeant (P. Blier, IS), Wyeth (P. Bleau, MK, SG)
Consultation fees: AstraZeneca (MK), BMS (MK), Boehringer Ingelheim (MK), Clinique et Développement In Virtuo Inc. (SB), Eli Lilly Canada (MK, SG), GlaxoSmithKline (MK, SG), Janssen Ortho (MK), Lundbeck (MK, PR, SG), Organon (MK), Pfizer (SG), Servier (SG), Shire (MK), Solvay (MK), Wyeth (MK, SG)
Educational support: Astra Zeneca (RSM), BMS (RSM), CME Outfitters (RSM), Eli Lilly Canada (RSM, IS), France Foundation (RSM), I3CME (RSM), Merck (RSM), Optum Health (RSM), Pfizer (RSM), Physicians' Postgraduate Press (RSM), Shire (IS)
Research grants/clinical trial funding: AstraZeneca (KK, MK, P. Bleau, RSM, RWL), Biovail (RWL), BMS (KK, P. Bleau, RWL), Canadian Foundation for Innovation (MK), Canadian Institutes of Health Research (CIHR) (MK, RWL, SG), Canadian Network for Mood and Anxiety Treatments (CANMAT) (RWL), Canadian Psychiatric Association (CPA) Foundation (MK, RWL), Centre for Addiction and Mental Health Foundation (MK), CR Younger Foundation (SG), Eli Lilly Canada (MK, P. Bleau, PR, RSM, RWL), Genuine Health (MK), GlaxoSmithKline (MK), Janssen Ortho (MK, RSM), Litebook Company (RWL), Lundbeck (KK, MK, P. Bleau, RSM, RWL), Lundbeck Institute (RWL), Mochida (RWL), National Alliance for Research on Schizophrenia and Depression (NARSAD) (RSM), National Institutes of Mental Health (NIMH) (RSM), Ontario Ministry of Health (SG), Ontario Mental Health Foundation (SG), Organon (MK), Pfizer (P. Bleau, RSM, RWL), Roche (PR), Servier (RWL), Sick Kids Foundation (MK), Solvay (MK), St. Jude's Medical (RWL), Shire (MK, RSM), Stanley Medical Research Institute (RSM), Takeda (RWL), UBC Institute of Mental Health/Coast Capital Savings (RWL), Wyeth (MK, P. Bleau)
Unrestricted grants: Astra Zeneca Canada (MK), Eli Lilly Canada (MK), Janssen Inc. (MK), Lundbeck Canada (MK), Pfizer (MK), Purdue Pharma (MK), Servier Canada (MK), Shire Canada (MK), Valeant Canada (MK)
Reimbursements, fees, funding, or salary: In the past five years, MVA received reimbursements, fees, funding, or salary from: Astra Zeneca, Biovail, Canadian Foundation for Innovation (CFI), Cephalon, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Hamilton Academic Health Sciences Organization (HAHSO) Innovation Grant (AFP Innovation Grant), Janssen Ortho, Labo Pharm, Lundbeck, National Institutes of Health (NIH), Novartis, Pfizer Inc., Servier, Shire, Sunovion, Valeant, Wyeth-Ayerst
Stock/share ownership: Clinique et Développement In Virtuo Inc. (SB)

Authors’ contributions

We thank all co-authors for their considerable expertise in generating these guidelines. Authors who were members of the executive committee (MK, PB, PB, PC, KK, MVA) took part in teleconferences and a meeting in December 2012 to reach consensus on the strength of evidence and treatment recommendations. Draft guidelines were then developed by the core committee and revised by all co-authors. The entire content was subsequently circulated to all members of the Canadian Anxiety Guidelines Initiative Group for additional comments and approval during 2013. GA, LJK, RWL, RSM, and IS provided additional reviews of the comorbidity section. The final manuscript was then circulated to external reviewers (MP, DS, LDM) and revisions were made based on input from the core committee.
insite
INHALT
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Kessler RC, Angermeyer M, Anthony JC, R DG, Demyttenaere K, Gasquet I, G DG, Gluzman S, Gureje O, Haro JM, et al: Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry. 2007, 6: 168-176.PubMedCentralPubMed Kessler RC, Angermeyer M, Anthony JC, R DG, Demyttenaere K, Gasquet I, G DG, Gluzman S, Gureje O, Haro JM, et al: Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry. 2007, 6: 168-176.PubMedCentralPubMed
2.
Zurück zum Zitat Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005, 62: 593-602.PubMed Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005, 62: 593-602.PubMed
3.
Zurück zum Zitat Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005, 62: 617-627.PubMedCentralPubMed Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005, 62: 617-627.PubMedCentralPubMed
4.
Zurück zum Zitat Somers JM, Goldner EM, Waraich P, Hsu L: Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry. 2006, 51: 100-113.PubMed Somers JM, Goldner EM, Waraich P, Hsu L: Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry. 2006, 51: 100-113.PubMed
5.
Zurück zum Zitat Martin-Merino E, Ruigomez A, Wallander MA, Johansson S, Garcia-Rodriguez LA: Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care. Fam Pract. 2010, 27: 9-16.PubMed Martin-Merino E, Ruigomez A, Wallander MA, Johansson S, Garcia-Rodriguez LA: Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care. Fam Pract. 2010, 27: 9-16.PubMed
6.
Zurück zum Zitat Vermani M, Marcus M, Katzman MA: Rates of detection of mood and anxiety disorders in primary care: a descriptive, cross-sectional study. Prim Care Companion CNS Disord. 2011, 13: doi 10.4088/PCC.4010m01013 Vermani M, Marcus M, Katzman MA: Rates of detection of mood and anxiety disorders in primary care: a descriptive, cross-sectional study. Prim Care Companion CNS Disord. 2011, 13: doi 10.4088/PCC.4010m01013
7.
Zurück zum Zitat Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B: Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007, 146: 317-325.PubMed Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B: Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007, 146: 317-325.PubMed
8.
Zurück zum Zitat Weisberg RB, Dyck I, Culpepper L, Keller MB: Psychiatric treatment in primary care patients with anxiety disorders: a comparison of care received from primary care providers and psychiatrists. Am J Psychiatry. 2007, 164: 276-282.PubMed Weisberg RB, Dyck I, Culpepper L, Keller MB: Psychiatric treatment in primary care patients with anxiety disorders: a comparison of care received from primary care providers and psychiatrists. Am J Psychiatry. 2007, 164: 276-282.PubMed
9.
Zurück zum Zitat McLean CP, Asnaani A, Litz BT, Hofmann SG: Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res. 2011, 45: 1027-1035.PubMedCentralPubMed McLean CP, Asnaani A, Litz BT, Hofmann SG: Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res. 2011, 45: 1027-1035.PubMedCentralPubMed
10.
Zurück zum Zitat Stein M, Fuetsch M, Muller N, Hofler M, Lieb R, Wittchen H: Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults. Arch Gen Psychiatry. 2001, 58: 251-256.PubMed Stein M, Fuetsch M, Muller N, Hofler M, Lieb R, Wittchen H: Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults. Arch Gen Psychiatry. 2001, 58: 251-256.PubMed
11.
Zurück zum Zitat Pine DS, Cohen P, Gurley D, Brook J, Ma Y: The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry. 1998, 55: 56-64.PubMed Pine DS, Cohen P, Gurley D, Brook J, Ma Y: The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry. 1998, 55: 56-64.PubMed
12.
Zurück zum Zitat Wittchen HU, Kessler RC, Pfister H, Lieb M: Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. Acta Psychiatr Scand Suppl. 2000, 14-23. Wittchen HU, Kessler RC, Pfister H, Lieb M: Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. Acta Psychiatr Scand Suppl. 2000, 14-23.
13.
Zurück zum Zitat Senaratne R, Van Ameringen M, Mancini C, Patterson B: The burden of anxiety disorders on the family. J Nerv Ment Dis. 2010, 198: 876-880.PubMed Senaratne R, Van Ameringen M, Mancini C, Patterson B: The burden of anxiety disorders on the family. J Nerv Ment Dis. 2010, 198: 876-880.PubMed
14.
Zurück zum Zitat Erickson SR, Guthrie S, Vanetten-Lee M, Himle J, Hoffman J, Santos SF, Janeck AS, Zivin K, Abelson JL: Severity of anxiety and work-related outcomes of patients with anxiety disorders. Depress Anxiety. 2009, 26: 1165-1171.PubMed Erickson SR, Guthrie S, Vanetten-Lee M, Himle J, Hoffman J, Santos SF, Janeck AS, Zivin K, Abelson JL: Severity of anxiety and work-related outcomes of patients with anxiety disorders. Depress Anxiety. 2009, 26: 1165-1171.PubMed
15.
Zurück zum Zitat Sherbourne CD, Sullivan G, Craske MG, Roy-Byrne P, Golinelli D, Rose RD, Chavira DA, Bystritsky A, Stein MB: Functioning and disability levels in primary care out-patients with one or more anxiety disorders. Psychol Med. 2010, 40: 2059-2068.PubMedCentralPubMed Sherbourne CD, Sullivan G, Craske MG, Roy-Byrne P, Golinelli D, Rose RD, Chavira DA, Bystritsky A, Stein MB: Functioning and disability levels in primary care out-patients with one or more anxiety disorders. Psychol Med. 2010, 40: 2059-2068.PubMedCentralPubMed
16.
Zurück zum Zitat Comer JS, Blanco C, Hasin DS, Liu SM, Grant BF, Turner JB, Olfson M: Health-related quality of life across the anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions (NESARC). J Clin Psychiatry. 2011, 72: 43-50.PubMedCentralPubMed Comer JS, Blanco C, Hasin DS, Liu SM, Grant BF, Turner JB, Olfson M: Health-related quality of life across the anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions (NESARC). J Clin Psychiatry. 2011, 72: 43-50.PubMedCentralPubMed
17.
Zurück zum Zitat Barrera TL, Norton PJ: Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorder. J Anxiety Disord. 2009, 23: 1086-1090.PubMedCentralPubMed Barrera TL, Norton PJ: Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorder. J Anxiety Disord. 2009, 23: 1086-1090.PubMedCentralPubMed
18.
Zurück zum Zitat Wittchen HU: Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002, 16: 162-171.PubMed Wittchen HU: Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002, 16: 162-171.PubMed
19.
Zurück zum Zitat Waghorn G, Chant D, White P, Whiteford H: Disability, employment and work performance among people with ICD-10 anxiety disorders. Aust N Z J Psychiatry. 2005, 39: 55-66.PubMed Waghorn G, Chant D, White P, Whiteford H: Disability, employment and work performance among people with ICD-10 anxiety disorders. Aust N Z J Psychiatry. 2005, 39: 55-66.PubMed
20.
Zurück zum Zitat Nepon J, Belik SL, Bolton J, Sareen J: The relationship between anxiety disorders and suicide attempts: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Depress Anxiety. 2010, 27: 791-798.PubMedCentralPubMed Nepon J, Belik SL, Bolton J, Sareen J: The relationship between anxiety disorders and suicide attempts: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Depress Anxiety. 2010, 27: 791-798.PubMedCentralPubMed
21.
Zurück zum Zitat Bolton JM, Cox BJ, Afifi TO, Enns MW, Bienvenu OJ, Sareen J: Anxiety disorders and risk for suicide attempts: findings from the Baltimore Epidemiologic Catchment area follow-up study. Depress Anxiety. 2008, 25: 477-481.PubMed Bolton JM, Cox BJ, Afifi TO, Enns MW, Bienvenu OJ, Sareen J: Anxiety disorders and risk for suicide attempts: findings from the Baltimore Epidemiologic Catchment area follow-up study. Depress Anxiety. 2008, 25: 477-481.PubMed
22.
Zurück zum Zitat Sareen J, Cox BJ, Afifi TO, de Graaf R, Asmundson GJ, ten Have M, Stein MB: Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry. 2005, 62: 1249-1257.PubMed Sareen J, Cox BJ, Afifi TO, de Graaf R, Asmundson GJ, ten Have M, Stein MB: Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry. 2005, 62: 1249-1257.PubMed
23.
Zurück zum Zitat Cougle JR, Keough ME, Riccardi CJ, Sachs-Ericsson N: Anxiety disorders and suicidality in the National Comorbidity Survey-Replication. J Psychiatr Res. 2009, 43: 825-829.PubMed Cougle JR, Keough ME, Riccardi CJ, Sachs-Ericsson N: Anxiety disorders and suicidality in the National Comorbidity Survey-Replication. J Psychiatr Res. 2009, 43: 825-829.PubMed
24.
Zurück zum Zitat Pfeiffer PN, Ganoczy D, Ilgen M, Zivin K, Valenstein M: Comorbid anxiety as a suicide risk factor among depressed veterans. Depress Anxiety. 2009, 26: 752-757.PubMedCentralPubMed Pfeiffer PN, Ganoczy D, Ilgen M, Zivin K, Valenstein M: Comorbid anxiety as a suicide risk factor among depressed veterans. Depress Anxiety. 2009, 26: 752-757.PubMedCentralPubMed
25.
Zurück zum Zitat Schaffer A, Levitt A, Bagby R, Kennedy S, Levitan R, Joffe R: Suicidal ideation in major depression: sex differences and impact of comorbid anxiety. Can J Psychiatry. 2000, 45: 822-826.PubMed Schaffer A, Levitt A, Bagby R, Kennedy S, Levitan R, Joffe R: Suicidal ideation in major depression: sex differences and impact of comorbid anxiety. Can J Psychiatry. 2000, 45: 822-826.PubMed
26.
Zurück zum Zitat American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 2013, Washington, DC: American Psychiatric Association, Fifth American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 2013, Washington, DC: American Psychiatric Association, Fifth
27.
Zurück zum Zitat Van Ameringen M, Pollack M: Generalized Anxiety Disorder (Oxford Psychiatry Library). 2010, New York, NY: Oxford University Press Van Ameringen M, Pollack M: Generalized Anxiety Disorder (Oxford Psychiatry Library). 2010, New York, NY: Oxford University Press
28.
Zurück zum Zitat Connor K, Kobak K, Churchill L, Katzelnick D, Davidson J: Mini-SPIN: A brief screening assessment for generalized social anxiety disorder. Depress Anxiety. 2001, 14: 137-140.PubMed Connor K, Kobak K, Churchill L, Katzelnick D, Davidson J: Mini-SPIN: A brief screening assessment for generalized social anxiety disorder. Depress Anxiety. 2001, 14: 137-140.PubMed
29.
Zurück zum Zitat Mancini C, Van Ameringen M, Pipe B, Oakman J: Development and validation of self-report psychiatric screening tool: MACSCREEN [poster]. Anxiety Disorders Association of America 23rd Annual Conference; March 27-30; Toronto, Canada. 2003 Mancini C, Van Ameringen M, Pipe B, Oakman J: Development and validation of self-report psychiatric screening tool: MACSCREEN [poster]. Anxiety Disorders Association of America 23rd Annual Conference; March 27-30; Toronto, Canada. 2003
30.
Zurück zum Zitat Van Ameringen M, Mancini C, Simpson W, Patterson B: Potential use of Internet-based screening for anxiety disorders: a pilot study. Depress Anxiety. 2010, 27: 1006-1010.PubMed Van Ameringen M, Mancini C, Simpson W, Patterson B: Potential use of Internet-based screening for anxiety disorders: a pilot study. Depress Anxiety. 2010, 27: 1006-1010.PubMed
31.
Zurück zum Zitat Ballenger J, Davidson J, Lecrubier Y, Nutt D, Borkovec T, Rickels K, Stein D, Wittchen H: Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001, 62 (Suppl 11): 53-58.PubMed Ballenger J, Davidson J, Lecrubier Y, Nutt D, Borkovec T, Rickels K, Stein D, Wittchen H: Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001, 62 (Suppl 11): 53-58.PubMed
32.
Zurück zum Zitat Swinson R, Antony M, Bleau P, Chokka P, Craven M, Fallu A, Kjernisted K, Lanius R, Manassis K, McIntosh D, et al: Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry. 2006, 51: 9S-91S. Swinson R, Antony M, Bleau P, Chokka P, Craven M, Fallu A, Kjernisted K, Lanius R, Manassis K, McIntosh D, et al: Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry. 2006, 51: 9S-91S.
33.
Zurück zum Zitat Milne BJ, Caspi A, Harrington H, Poulton R, Rutter M, Moffitt TE: Predictive value of family history on severity of illness: the case for depression, anxiety, alcohol dependence, and drug dependence. Arch Gen Psychiatry. 2009, 66: 738-747.PubMedCentralPubMed Milne BJ, Caspi A, Harrington H, Poulton R, Rutter M, Moffitt TE: Predictive value of family history on severity of illness: the case for depression, anxiety, alcohol dependence, and drug dependence. Arch Gen Psychiatry. 2009, 66: 738-747.PubMedCentralPubMed
34.
Zurück zum Zitat Batelaan NM, Smit F, de Graaf R, van Balkom AJ, Vollebergh WA, Beekman AT: Identifying target groups for the prevention of anxiety disorders in the general population. Acta Psychiatr Scand. 2010, 122: 56-65.PubMed Batelaan NM, Smit F, de Graaf R, van Balkom AJ, Vollebergh WA, Beekman AT: Identifying target groups for the prevention of anxiety disorders in the general population. Acta Psychiatr Scand. 2010, 122: 56-65.PubMed
35.
Zurück zum Zitat Karsten J, Hartman CA, Smit JH, Zitman FG, Beekman AT, Cuijpers P, van der Does AJ, Ormel J, Nolen WA, Penninx BW: Psychiatric history and subthreshold symptoms as predictors of the occurrence of depressive or anxiety disorder within 2 years. Br J Psychiatry. 2011, 198: 206-212.PubMed Karsten J, Hartman CA, Smit JH, Zitman FG, Beekman AT, Cuijpers P, van der Does AJ, Ormel J, Nolen WA, Penninx BW: Psychiatric history and subthreshold symptoms as predictors of the occurrence of depressive or anxiety disorder within 2 years. Br J Psychiatry. 2011, 198: 206-212.PubMed
36.
Zurück zum Zitat McLaughlin KA, Hatzenbuehler ML: Stressful life events, anxiety sensitivity, and internalizing symptoms in adolescents. J Abnorm Psychol. 2009, 118: 659-669.PubMedCentralPubMed McLaughlin KA, Hatzenbuehler ML: Stressful life events, anxiety sensitivity, and internalizing symptoms in adolescents. J Abnorm Psychol. 2009, 118: 659-669.PubMedCentralPubMed
37.
Zurück zum Zitat Chu DA, Williams LM, Harris AW, Bryant RA, Gatt JM: Early life trauma predicts self-reported levels of depressive and anxiety symptoms in nonclinical community adults: Relative contributions of early life stressor types and adult trauma exposure. J Psychiatr Res. 2013, 47: 23-32.PubMed Chu DA, Williams LM, Harris AW, Bryant RA, Gatt JM: Early life trauma predicts self-reported levels of depressive and anxiety symptoms in nonclinical community adults: Relative contributions of early life stressor types and adult trauma exposure. J Psychiatr Res. 2013, 47: 23-32.PubMed
38.
Zurück zum Zitat Flensborg-Madsen T, Tolstrup J, Sorensen HJ, Mortensen EL: Social and psychological predictors of onset of anxiety disorders: results from a large prospective cohort study. Soc Psychiatry Psychiatr Epidemiol. 2012, 47: 711-721.PubMed Flensborg-Madsen T, Tolstrup J, Sorensen HJ, Mortensen EL: Social and psychological predictors of onset of anxiety disorders: results from a large prospective cohort study. Soc Psychiatry Psychiatr Epidemiol. 2012, 47: 711-721.PubMed
39.
Zurück zum Zitat Heider D, Matschinger H, Bernert S, Alonso J, Brugha TS, Bruffaerts R, de Girolamo G, Dietrich S, Angermeyer MC: Adverse parenting as a risk factor in the occurrence of anxiety disorders : a study in six European countries. Soc Psychiatry Psychiatr Epidemiol. 2008, 43: 266-272.PubMed Heider D, Matschinger H, Bernert S, Alonso J, Brugha TS, Bruffaerts R, de Girolamo G, Dietrich S, Angermeyer MC: Adverse parenting as a risk factor in the occurrence of anxiety disorders : a study in six European countries. Soc Psychiatry Psychiatr Epidemiol. 2008, 43: 266-272.PubMed
40.
Zurück zum Zitat Strine TW, Mokdad AH, Balluz LS, Gonzalez O, Crider R, Berry JT, Kroenke K: Depression and anxiety in the United States: findings from the 2006 Behavioral Risk Factor Surveillance System. Psychiatr Serv. 2008, 59: 1383-1390.PubMed Strine TW, Mokdad AH, Balluz LS, Gonzalez O, Crider R, Berry JT, Kroenke K: Depression and anxiety in the United States: findings from the 2006 Behavioral Risk Factor Surveillance System. Psychiatr Serv. 2008, 59: 1383-1390.PubMed
41.
Zurück zum Zitat Kagan J, Snidman N: Early childhood predictors of adult anxiety disorders. Biol Psychiatry. 1999, 46: 1536-1541.PubMed Kagan J, Snidman N: Early childhood predictors of adult anxiety disorders. Biol Psychiatry. 1999, 46: 1536-1541.PubMed
42.
Zurück zum Zitat Muris P, van Brakel AM, Arntz A, Schouten E: Behavioral inhibition as a risk factor for the development of childhood anxiety disorders: A longitudinal study. J Child Fam Stud. 2011, 20: 157-170.PubMedCentralPubMed Muris P, van Brakel AM, Arntz A, Schouten E: Behavioral inhibition as a risk factor for the development of childhood anxiety disorders: A longitudinal study. J Child Fam Stud. 2011, 20: 157-170.PubMedCentralPubMed
43.
Zurück zum Zitat Schaffer A, Cairney J, Cheung A, Veldhuizen S, Levitt A: Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics. Can J Psychiatry. 2006, 51: 9-16.PubMed Schaffer A, Cairney J, Cheung A, Veldhuizen S, Levitt A: Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics. Can J Psychiatry. 2006, 51: 9-16.PubMed
44.
Zurück zum Zitat Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003, 289: 3095-3105.PubMed Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003, 289: 3095-3105.PubMed
45.
Zurück zum Zitat Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, et al: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006, 163: 716-723.PubMedCentralPubMed Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, et al: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006, 163: 716-723.PubMedCentralPubMed
46.
Zurück zum Zitat Klein Hofmeijer-Sevink M, Batelaan NM, van Megen HJ, Penninx BW, Cath DC, van den Hout MA, van Balkom AJ: Clinical relevance of comorbidity in anxiety disorders: a report from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord. 2012, 137: 106-112. Klein Hofmeijer-Sevink M, Batelaan NM, van Megen HJ, Penninx BW, Cath DC, van den Hout MA, van Balkom AJ: Clinical relevance of comorbidity in anxiety disorders: a report from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord. 2012, 137: 106-112.
47.
Zurück zum Zitat Bruce S, Machan J, Dyck I, Keller M: Infrequency of "pure" GAD: impact of psychiatric comorbidity on clinical course. Depress Anxiety. 2001, 14: 219-225.PubMed Bruce S, Machan J, Dyck I, Keller M: Infrequency of "pure" GAD: impact of psychiatric comorbidity on clinical course. Depress Anxiety. 2001, 14: 219-225.PubMed
48.
Zurück zum Zitat Shankman S, Klein D: The impact of comorbid anxiety disorders on the course of dysthymic disorder: a 5-year prospective longitudinal study. J Affect Disord. 2002, 70: 211-217.PubMed Shankman S, Klein D: The impact of comorbid anxiety disorders on the course of dysthymic disorder: a 5-year prospective longitudinal study. J Affect Disord. 2002, 70: 211-217.PubMed
49.
Zurück zum Zitat Boylan K, Bieling P, Marriott M, Begin H, Young L, MacQueen G: Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry. 2004, 65: 1106-1113.PubMed Boylan K, Bieling P, Marriott M, Begin H, Young L, MacQueen G: Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry. 2004, 65: 1106-1113.PubMed
50.
Zurück zum Zitat Mackenzie CS, Reynolds K, Cairney J, Streiner DL, Sareen J: Disorder-specific mental health service use for mood and anxiety disorders: associations with age, sex, and psychiatric comorbidity. Depress Anxiety. 2012, 29: 234-242.PubMedCentralPubMed Mackenzie CS, Reynolds K, Cairney J, Streiner DL, Sareen J: Disorder-specific mental health service use for mood and anxiety disorders: associations with age, sex, and psychiatric comorbidity. Depress Anxiety. 2012, 29: 234-242.PubMedCentralPubMed
51.
Zurück zum Zitat McLaughlin T, Geissler E, Wan G: Comorbidities and associated treatment charges in patients with anxiety disorders. Pharmacotherapy. 2003, 23: 1251-1256.PubMed McLaughlin T, Geissler E, Wan G: Comorbidities and associated treatment charges in patients with anxiety disorders. Pharmacotherapy. 2003, 23: 1251-1256.PubMed
52.
Zurück zum Zitat Sareen J, Jacobi F, Cox BJ, Belik SL, Clara I, Stein MB: Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med. 2006, 166: 2109-2116.PubMed Sareen J, Jacobi F, Cox BJ, Belik SL, Clara I, Stein MB: Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med. 2006, 166: 2109-2116.PubMed
53.
Zurück zum Zitat Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009, 11: 225-255.PubMed Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009, 11: 225-255.PubMed
54.
Zurück zum Zitat van Balkom AJ, Bakker A, Spinhoven P, Blaauw BM, Smeenk S, Ruesink B: A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis. 1997, 185: 510-516.PubMed van Balkom AJ, Bakker A, Spinhoven P, Blaauw BM, Smeenk S, Ruesink B: A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis. 1997, 185: 510-516.PubMed
55.
Zurück zum Zitat Siev J, Chambless DL: Specificity of treatment effects: cognitive therapy and relaxation for generalized anxiety and panic disorders. J Consult Clin Psychol. 2007, 75: 513-522.PubMed Siev J, Chambless DL: Specificity of treatment effects: cognitive therapy and relaxation for generalized anxiety and panic disorders. J Consult Clin Psychol. 2007, 75: 513-522.PubMed
56.
Zurück zum Zitat Sanchez-Meca J, Rosa-Alcazar AI, Marin-Martinez F, Gomez-Conesa A: Psychological treatment of panic disorder with or without agoraphobia: a meta-analysis. Clin Psychol Rev. 2010, 30: 37-50.PubMed Sanchez-Meca J, Rosa-Alcazar AI, Marin-Martinez F, Gomez-Conesa A: Psychological treatment of panic disorder with or without agoraphobia: a meta-analysis. Clin Psychol Rev. 2010, 30: 37-50.PubMed
57.
Zurück zum Zitat Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ: Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev. 2008, 28: 1021-1037.PubMed Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ: Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev. 2008, 28: 1021-1037.PubMed
58.
Zurück zum Zitat Fedoroff I, Taylor S: Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol. 2001, 21: 311-324.PubMed Fedoroff I, Taylor S: Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol. 2001, 21: 311-324.PubMed
59.
Zurück zum Zitat Acarturk C, Cuijpers P, van Straten A, de Graaf R: Psychological treatment of social anxiety disorder: a meta-analysis. Psychol Med. 2009, 39: 241-254.PubMed Acarturk C, Cuijpers P, van Straten A, de Graaf R: Psychological treatment of social anxiety disorder: a meta-analysis. Psychol Med. 2009, 39: 241-254.PubMed
60.
Zurück zum Zitat Rosa-Alcazar AI, Sanchez-Meca J, Gomez-Conesa A, Marin-Martinez F: Psychological treatment of obsessive-compulsive disorder: a meta-analysis. Clin Psychol Rev. 2008, 28: 1310-1325.PubMed Rosa-Alcazar AI, Sanchez-Meca J, Gomez-Conesa A, Marin-Martinez F: Psychological treatment of obsessive-compulsive disorder: a meta-analysis. Clin Psychol Rev. 2008, 28: 1310-1325.PubMed
61.
Zurück zum Zitat Jonsson H, Hougaard E: Group cognitive behavioural therapy for obsessive-compulsive disorder: a systematic review and meta-analysis. Acta Psychiatr Scand. 2009, 119: 98-106.PubMed Jonsson H, Hougaard E: Group cognitive behavioural therapy for obsessive-compulsive disorder: a systematic review and meta-analysis. Acta Psychiatr Scand. 2009, 119: 98-106.PubMed
62.
Zurück zum Zitat Gava I, Barbui C, Aguglia E, Carlino D, Churchill R, De Vanna M, McGuire HF: Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2007, CD005333- Gava I, Barbui C, Aguglia E, Carlino D, Churchill R, De Vanna M, McGuire HF: Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2007, CD005333-
63.
Zurück zum Zitat Ougrin D: Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis. BMC Psychiatry. 2011, 11: 200-PubMedCentralPubMed Ougrin D: Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis. BMC Psychiatry. 2011, 11: 200-PubMedCentralPubMed
64.
Zurück zum Zitat Borkovec T, Ruscio A: Psychotherapy for generalized anxiety disorder. J Clin Psychiatry. 2001, 62 (Suppl 11): 37-42. discussion 43-35PubMed Borkovec T, Ruscio A: Psychotherapy for generalized anxiety disorder. J Clin Psychiatry. 2001, 62 (Suppl 11): 37-42. discussion 43-35PubMed
65.
Zurück zum Zitat Hunot V, Churchill R, Silva de Lima M, Teixeira V: Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev. 2007, CD001848- Hunot V, Churchill R, Silva de Lima M, Teixeira V: Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev. 2007, CD001848-
66.
Zurück zum Zitat Bisson J, Andrew M: Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2007, CD003388- Bisson J, Andrew M: Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2007, CD003388-
67.
Zurück zum Zitat Bisson JI, Ehlers A, Matthews R, Pilling S, Richards D, Turner S: Psychological treatments for chronic post-traumatic stress disorder. Systematic review and meta-analysis. Br J Psychiatry. 2007, 190: 97-104.PubMed Bisson JI, Ehlers A, Matthews R, Pilling S, Richards D, Turner S: Psychological treatments for chronic post-traumatic stress disorder. Systematic review and meta-analysis. Br J Psychiatry. 2007, 190: 97-104.PubMed
68.
Zurück zum Zitat Seidler GH, Wagner FE: Comparing the efficacy of EMDR and trauma-focused cognitive-behavioral therapy in the treatment of PTSD: a meta-analytic study. Psychol Med. 2006, 36: 1515-1522.PubMed Seidler GH, Wagner FE: Comparing the efficacy of EMDR and trauma-focused cognitive-behavioral therapy in the treatment of PTSD: a meta-analytic study. Psychol Med. 2006, 36: 1515-1522.PubMed
69.
Zurück zum Zitat Powers MB, Halpern JM, Ferenschak MP, Gillihan SJ, Foa EB: A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clin Psychol Rev. 2010, 30: 635-641.PubMed Powers MB, Halpern JM, Ferenschak MP, Gillihan SJ, Foa EB: A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clin Psychol Rev. 2010, 30: 635-641.PubMed
70.
Zurück zum Zitat Hofmann SG, Smits JA: Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008, 69: 621-632.PubMedCentralPubMed Hofmann SG, Smits JA: Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008, 69: 621-632.PubMedCentralPubMed
71.
Zurück zum Zitat Roshanaei-Moghaddam B, Pauly MC, Atkins DC, Baldwin SA, Stein MB, Roy-Byrne P: Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety?. Depress Anxiety. 2011, 28: 560-567.PubMed Roshanaei-Moghaddam B, Pauly MC, Atkins DC, Baldwin SA, Stein MB, Roy-Byrne P: Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety?. Depress Anxiety. 2011, 28: 560-567.PubMed
72.
Zurück zum Zitat Hofmann SG, Sawyer AT, Witt AA, Oh D: The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. J Consult Clin Psychol. 2010, 78: 169-183.PubMedCentralPubMed Hofmann SG, Sawyer AT, Witt AA, Oh D: The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. J Consult Clin Psychol. 2010, 78: 169-183.PubMedCentralPubMed
73.
Zurück zum Zitat Boschen MJ, Oei TP: A cognitive behavioral case formulation framework for treatment planning in anxiety disorders. Depress Anxiety. 2008, 25: 811-823.PubMed Boschen MJ, Oei TP: A cognitive behavioral case formulation framework for treatment planning in anxiety disorders. Depress Anxiety. 2008, 25: 811-823.PubMed
74.
Zurück zum Zitat Coull G, Morris PG: The clinical effectiveness of CBT-based guided self-help interventions for anxiety and depressive disorders: a systematic review. Psychol Med. 2011, 41: 2239-2252.PubMed Coull G, Morris PG: The clinical effectiveness of CBT-based guided self-help interventions for anxiety and depressive disorders: a systematic review. Psychol Med. 2011, 41: 2239-2252.PubMed
75.
Zurück zum Zitat Lewis C, Pearce J, Bisson JI: Efficacy, cost-effectiveness and acceptability of self-help interventions for anxiety disorders: systematic review. Br J Psychiatry. 2012, 200: 15-21.PubMed Lewis C, Pearce J, Bisson JI: Efficacy, cost-effectiveness and acceptability of self-help interventions for anxiety disorders: systematic review. Br J Psychiatry. 2012, 200: 15-21.PubMed
76.
Zurück zum Zitat Lucock M, Padgett K, Noble R, Westley A, Atha C, Horsefield C, Leach C: Controlled clinical trial of a self-help for anxiety intervention for patients waiting for psychological therapy. Behav Cog Psychother. 2008, 36: 541-551. Lucock M, Padgett K, Noble R, Westley A, Atha C, Horsefield C, Leach C: Controlled clinical trial of a self-help for anxiety intervention for patients waiting for psychological therapy. Behav Cog Psychother. 2008, 36: 541-551.
77.
Zurück zum Zitat Craske MG, Rose RD, Lang A, Welch SS, Campbell-Sills L, Sullivan G, Sherbourne C, Bystritsky A, Stein MB, Roy-Byrne PP: Computer-assisted delivery of cognitive behavioral therapy for anxiety disorders in primary-care settings. Depress Anxiety. 2009, 26: 235-242.PubMedCentralPubMed Craske MG, Rose RD, Lang A, Welch SS, Campbell-Sills L, Sullivan G, Sherbourne C, Bystritsky A, Stein MB, Roy-Byrne PP: Computer-assisted delivery of cognitive behavioral therapy for anxiety disorders in primary-care settings. Depress Anxiety. 2009, 26: 235-242.PubMedCentralPubMed
78.
Zurück zum Zitat Cavanagh K, Seccombe N, Lidbetter N: The implementation of computerized cognitive behavioural therapies in a service user-led, third sector self help clinic. Behav Cogn Psychother. 2011, 39: 427-442.PubMed Cavanagh K, Seccombe N, Lidbetter N: The implementation of computerized cognitive behavioural therapies in a service user-led, third sector self help clinic. Behav Cogn Psychother. 2011, 39: 427-442.PubMed
79.
Zurück zum Zitat Titov N, Andrews G, Johnston L, Robinson E, Spence J: Transdiagnostic Internet treatment for anxiety disorders: a randomized controlled trial. Behav Res Ther. 2010, 48: 890-899.PubMed Titov N, Andrews G, Johnston L, Robinson E, Spence J: Transdiagnostic Internet treatment for anxiety disorders: a randomized controlled trial. Behav Res Ther. 2010, 48: 890-899.PubMed
80.
Zurück zum Zitat Opris D, Pintea S, Garcia-Palacios A, Botella C, Szamoskozi S, David D: Virtual reality exposure therapy in anxiety disorders: a quantitative meta-analysis. Depress Anxiety. 2012, 29: 85-93.PubMed Opris D, Pintea S, Garcia-Palacios A, Botella C, Szamoskozi S, David D: Virtual reality exposure therapy in anxiety disorders: a quantitative meta-analysis. Depress Anxiety. 2012, 29: 85-93.PubMed
81.
Zurück zum Zitat Powers MB, Emmelkamp PM: Virtual reality exposure therapy for anxiety disorders: a meta-analysis. J Anxiety Disord. 2008, 22: 561-569.PubMed Powers MB, Emmelkamp PM: Virtual reality exposure therapy for anxiety disorders: a meta-analysis. J Anxiety Disord. 2008, 22: 561-569.PubMed
82.
Zurück zum Zitat Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Ruther E: Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry. 2007, 8: 175-187.PubMed Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Ruther E: Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry. 2007, 8: 175-187.PubMed
83.
Zurück zum Zitat Hofmann SG, Sawyer AT, Korte KJ, Smits JA: Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? a meta-analytic review. Int J Cogn Ther. 2009, 2: 160-175.PubMedCentralPubMed Hofmann SG, Sawyer AT, Korte KJ, Smits JA: Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? a meta-analytic review. Int J Cogn Ther. 2009, 2: 160-175.PubMedCentralPubMed
86.
Zurück zum Zitat Brambilla P, Cipriani A, Hotopf M, Barbui C: Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry. 2005, 38: 69-77.PubMed Brambilla P, Cipriani A, Hotopf M, Barbui C: Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry. 2005, 38: 69-77.PubMed
87.
Zurück zum Zitat Hu X, Bull S, Hunkeler E, Ming E, Lee J, Fireman B, Markson L: Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004, 65: 959-965.PubMed Hu X, Bull S, Hunkeler E, Ming E, Lee J, Fireman B, Markson L: Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004, 65: 959-965.PubMed
88.
Zurück zum Zitat Cascade E, Kalali AH, Kennedy SH: Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont). 2009, 6: 16-18. Cascade E, Kalali AH, Kennedy SH: Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont). 2009, 6: 16-18.
89.
Zurück zum Zitat Hirschfeld R: Long-term side effects of SSRIs: sexual dysfunction and weight gain. J Clin Psychiatry. 2003, 64 (Suppl 18): 20-24.PubMed Hirschfeld R: Long-term side effects of SSRIs: sexual dysfunction and weight gain. J Clin Psychiatry. 2003, 64 (Suppl 18): 20-24.PubMed
90.
Zurück zum Zitat Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J: An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2009, 7: 1314-1321.PubMed Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J: An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2009, 7: 1314-1321.PubMed
91.
Zurück zum Zitat de Abajo FJ, Garcia-Rodriguez LA: Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. 2008, 65: 795-803.PubMed de Abajo FJ, Garcia-Rodriguez LA: Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. 2008, 65: 795-803.PubMed
92.
Zurück zum Zitat Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, Orwoll E, Bliziotes MM: Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007, 167: 1246-1251.PubMed Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, Orwoll E, Bliziotes MM: Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007, 167: 1246-1251.PubMed
93.
Zurück zum Zitat Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA, Nicholson GC, Pasco JA: Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol. 2008, 23: 84-87.PubMed Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA, Nicholson GC, Pasco JA: Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol. 2008, 23: 84-87.PubMed
94.
Zurück zum Zitat Eom CS, Lee HK, Ye S, Park SM, Cho KH: Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res. 2012, 27: 1186-1195.PubMed Eom CS, Lee HK, Ye S, Park SM, Cho KH: Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res. 2012, 27: 1186-1195.PubMed
95.
Zurück zum Zitat Smith JM: Clinical implications of treating depressed older adults with SSRIs: possible risk of hyponatremia. J Gerontol Nurs. 2010, 36: 22-27. quiz 28-29PubMed Smith JM: Clinical implications of treating depressed older adults with SSRIs: possible risk of hyponatremia. J Gerontol Nurs. 2010, 36: 22-27. quiz 28-29PubMed
96.
Zurück zum Zitat Shelton RC: The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry. 2006, 67 (Suppl 4): 3-7.PubMed Shelton RC: The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry. 2006, 67 (Suppl 4): 3-7.PubMed
99.
Zurück zum Zitat Barbui C, Esposito E, Cipriani A: Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ. 2009, 180: 291-297.PubMedCentralPubMed Barbui C, Esposito E, Cipriani A: Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ. 2009, 180: 291-297.PubMedCentralPubMed
100.
Zurück zum Zitat Olmer A, Iancu I, Strous RD: Exposure to antidepressant medications and suicide attempts in adult depressed inpatients. J Nerv Ment Dis. 2012, 200: 531-534.PubMed Olmer A, Iancu I, Strous RD: Exposure to antidepressant medications and suicide attempts in adult depressed inpatients. J Nerv Ment Dis. 2012, 200: 531-534.PubMed
101.
Zurück zum Zitat Degner D, Grohmann R, Bleich S, Ruther E: New antidepressant drugs. What side effects and interactions are to be expected?. MMW Fortschr Med. 2000, 142: 35-38. 40PubMed Degner D, Grohmann R, Bleich S, Ruther E: New antidepressant drugs. What side effects and interactions are to be expected?. MMW Fortschr Med. 2000, 142: 35-38. 40PubMed
102.
Zurück zum Zitat Chouinard G: Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004, 65 (Suppl 5): 7-12.PubMed Chouinard G: Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004, 65 (Suppl 5): 7-12.PubMed
103.
Zurück zum Zitat Ciraulo DA, Nace EP: Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. Am J Addict. 2000, 9: 276-279. discussion 280-274PubMed Ciraulo DA, Nace EP: Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. Am J Addict. 2000, 9: 276-279. discussion 280-274PubMed
104.
Zurück zum Zitat Petrovic M, Mariman A, Warie H, Afschrift M, Pevernagie D: Is there a rationale for prescription of benzodiazepines in the elderly? Review of the literature. Acta Clin Belg. 2003, 58: 27-36.PubMed Petrovic M, Mariman A, Warie H, Afschrift M, Pevernagie D: Is there a rationale for prescription of benzodiazepines in the elderly? Review of the literature. Acta Clin Belg. 2003, 58: 27-36.PubMed
105.
Zurück zum Zitat Allain H, Bentue-Ferrer D, Polard E, Akwa Y, Patat A: Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging. 2005, 22: 749-765.PubMed Allain H, Bentue-Ferrer D, Polard E, Akwa Y, Patat A: Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging. 2005, 22: 749-765.PubMed
106.
Zurück zum Zitat Barker MJ, Greenwood KM, Jackson M, Crowe SF: Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004, 18: 37-48.PubMed Barker MJ, Greenwood KM, Jackson M, Crowe SF: Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004, 18: 37-48.PubMed
107.
Zurück zum Zitat Barker MJ, Greenwood KM, Jackson M, Crowe SF: An evaluation of persisting cognitive effects after withdrawal from long-term benzodiazepine use. J Int Neuropsychol Soc. 2005, 11: 281-289.PubMed Barker MJ, Greenwood KM, Jackson M, Crowe SF: An evaluation of persisting cognitive effects after withdrawal from long-term benzodiazepine use. J Int Neuropsychol Soc. 2005, 11: 281-289.PubMed
108.
Zurück zum Zitat Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, Kapczinski FF, de Lima MS, dos Santos Souza JJ: Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006, 3: CD006115-PubMed Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, Kapczinski FF, de Lima MS, dos Santos Souza JJ: Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006, 3: CD006115-PubMed
109.
Zurück zum Zitat Baker RA, Pikalov A, Tran QV, Kremenets T, Arani RB, Doraiswamy PM: Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull. 2009, 42: 11-31.PubMed Baker RA, Pikalov A, Tran QV, Kremenets T, Arani RB, Doraiswamy PM: Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull. 2009, 42: 11-31.PubMed
110.
Zurück zum Zitat Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, Sharma V, Beaulieu S: Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006, 8: 721-739.PubMed Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, Sharma V, Beaulieu S: Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006, 8: 721-739.PubMed
111.
Zurück zum Zitat Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, Sharma V, Silverstone P, Alda M, Baruch P, et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005, 7 (Suppl 3): 5-69.PubMed Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, Sharma V, Silverstone P, Alda M, Baruch P, et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005, 7 (Suppl 3): 5-69.PubMed
112.
Zurück zum Zitat Sumiyoshi T, Roy A, Anil AE, Jayathilake K, Ertugrul A, Meltzer HY: A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. J Clin Psychopharmacol. 2004, 24: 345-348.PubMed Sumiyoshi T, Roy A, Anil AE, Jayathilake K, Ertugrul A, Meltzer HY: A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. J Clin Psychopharmacol. 2004, 24: 345-348.PubMed
113.
Zurück zum Zitat Citrome LL, Holt RI, Zachry WM, Clewell JD, Orth PA, Karagianis JL, Hoffmann VP: Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother. 2007, 41: 1593-1603.PubMed Citrome LL, Holt RI, Zachry WM, Clewell JD, Orth PA, Karagianis JL, Hoffmann VP: Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother. 2007, 41: 1593-1603.PubMed
114.
Zurück zum Zitat Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ: Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006, 163: 1821-1825.PubMed Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ: Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006, 163: 1821-1825.PubMed
115.
Zurück zum Zitat Depping AM, Komossa K, Kissling W, Leucht S: Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010, CD008120- Depping AM, Komossa K, Kissling W, Leucht S: Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010, CD008120-
116.
Zurück zum Zitat LaLonde CD, Van Lieshout RJ: Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol. 2011, 31: 326-333.PubMed LaLonde CD, Van Lieshout RJ: Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol. 2011, 31: 326-333.PubMed
117.
Zurück zum Zitat Torrent C, Martinez-Aran A, Daban C, Amann B, Balanza-Martinez V, Del Mar Bonnin C, Cruz N, Franco C, Tabares-Seisdedos R, Vieta E: Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Compr Psychiatry. 2011, 52: 613-622.PubMed Torrent C, Martinez-Aran A, Daban C, Amann B, Balanza-Martinez V, Del Mar Bonnin C, Cruz N, Franco C, Tabares-Seisdedos R, Vieta E: Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Compr Psychiatry. 2011, 52: 613-622.PubMed
118.
Zurück zum Zitat Correll CU, Sheridan EM, DelBello MP: Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010, 12: 116-141.PubMed Correll CU, Sheridan EM, DelBello MP: Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010, 12: 116-141.PubMed
119.
Zurück zum Zitat Doyle A, Pollack M: Establishment of remission criteria for anxiety disorders. J Clin Psychiatry. 2003, 64 (Suppl 15): 40-45.PubMed Doyle A, Pollack M: Establishment of remission criteria for anxiety disorders. J Clin Psychiatry. 2003, 64 (Suppl 15): 40-45.PubMed
120.
Zurück zum Zitat Kjernisted KD, Bleau P: Long-term goals in the management of acute and chronic anxiety disorders. Can J Psychiatry. 2004, 49: 51S-63S.PubMed Kjernisted KD, Bleau P: Long-term goals in the management of acute and chronic anxiety disorders. Can J Psychiatry. 2004, 49: 51S-63S.PubMed
121.
Zurück zum Zitat Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE: The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006, 63: 415-424.PubMedCentralPubMed Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE: The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006, 63: 415-424.PubMedCentralPubMed
122.
Zurück zum Zitat Grant BF, Hasin DS, Stinson FS, Dawson DA, Goldstein RB, Smith S, Huang B, Saha TD: The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006, 67: 363-374.PubMed Grant BF, Hasin DS, Stinson FS, Dawson DA, Goldstein RB, Smith S, Huang B, Saha TD: The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006, 67: 363-374.PubMed
123.
Zurück zum Zitat Kinley DJ, Cox BJ, Clara I, Goodwin RD, Sareen J: Panic attacks and their relation to psychological and physical functioning in Canadians: results from a nationally representative sample. Can J Psychiatry. 2009, 54: 113-122.PubMed Kinley DJ, Cox BJ, Clara I, Goodwin RD, Sareen J: Panic attacks and their relation to psychological and physical functioning in Canadians: results from a nationally representative sample. Can J Psychiatry. 2009, 54: 113-122.PubMed
124.
Zurück zum Zitat Goodwin RD, Lieb R, Hoefler M, Pfister H, Bittner A, Beesdo K, Wittchen HU: Panic attack as a risk factor for severe psychopathology. Am J Psychiatry. 2004, 161: 2207-2214.PubMed Goodwin RD, Lieb R, Hoefler M, Pfister H, Bittner A, Beesdo K, Wittchen HU: Panic attack as a risk factor for severe psychopathology. Am J Psychiatry. 2004, 161: 2207-2214.PubMed
125.
Zurück zum Zitat Kjernisted K, McIntosh D: Venlafaxine extended release (XR) in the treatment of panic disorder. Ther Clin Risk Manag. 2007, 3: 59-69.PubMedCentralPubMed Kjernisted K, McIntosh D: Venlafaxine extended release (XR) in the treatment of panic disorder. Ther Clin Risk Manag. 2007, 3: 59-69.PubMedCentralPubMed
126.
Zurück zum Zitat Culpepper L: Identifying and treating panic disorder in primary care. J Clin Psychiatry. 2004, 65 (Suppl 5): 19-23.PubMed Culpepper L: Identifying and treating panic disorder in primary care. J Clin Psychiatry. 2004, 65 (Suppl 5): 19-23.PubMed
127.
Zurück zum Zitat Craske MG, Tsao JC: Assessment and treatment of nocturnal panic attacks. Sleep Med Rev. 2005, 9: 173-184.PubMed Craske MG, Tsao JC: Assessment and treatment of nocturnal panic attacks. Sleep Med Rev. 2005, 9: 173-184.PubMed
128.
Zurück zum Zitat Romans S, Cohen M, Forte T: Rates of depression and anxiety in urban and rural Canada. Soc Psychiatry Psychiatr Epidemiol. 2011, 46: 567-575.PubMed Romans S, Cohen M, Forte T: Rates of depression and anxiety in urban and rural Canada. Soc Psychiatry Psychiatr Epidemiol. 2011, 46: 567-575.PubMed
129.
Zurück zum Zitat Galderisi S, Mancuso F, Mucci A, Garramone S, Zamboli R, Maj M: Alexithymia and cognitive dysfunctions in patients with panic disorder. Psychother Psychosom. 2008, 77: 182-188.PubMed Galderisi S, Mancuso F, Mucci A, Garramone S, Zamboli R, Maj M: Alexithymia and cognitive dysfunctions in patients with panic disorder. Psychother Psychosom. 2008, 77: 182-188.PubMed
130.
Zurück zum Zitat Deckersbach T, Moshier SJ, Tuschen-Caffier B, Otto MW: Memory dysfunction in panic disorder: an investigation of the role of chronic benzodiazepine use. Depress Anxiety. 2011, 28: 999-1007.PubMed Deckersbach T, Moshier SJ, Tuschen-Caffier B, Otto MW: Memory dysfunction in panic disorder: an investigation of the role of chronic benzodiazepine use. Depress Anxiety. 2011, 28: 999-1007.PubMed
131.
Zurück zum Zitat Pastucha P, Prasko J, Grambal A, Latalova K, Sigmundova Z, Sykorova T, Tichackova A: Panic disorder and dissociation - comparison with healthy controls. Neuro Endocrinol Lett. 2009, 30: 774-778.PubMed Pastucha P, Prasko J, Grambal A, Latalova K, Sigmundova Z, Sykorova T, Tichackova A: Panic disorder and dissociation - comparison with healthy controls. Neuro Endocrinol Lett. 2009, 30: 774-778.PubMed
132.
Zurück zum Zitat Kessler H, Roth J, von Wietersheim J, Deighton RM, Traue HC: Emotion recognition patterns in patients with panic disorder. Depress Anxiety. 2007, 24: 223-226.PubMed Kessler H, Roth J, von Wietersheim J, Deighton RM, Traue HC: Emotion recognition patterns in patients with panic disorder. Depress Anxiety. 2007, 24: 223-226.PubMed
133.
Zurück zum Zitat Tull MT, Roemer L: Emotion regulation difficulties associated with the experience of uncued panic attacks: evidence of experiential avoidance, emotional nonacceptance, and decreased emotional clarity. Behav Ther. 2007, 38: 378-391.PubMed Tull MT, Roemer L: Emotion regulation difficulties associated with the experience of uncued panic attacks: evidence of experiential avoidance, emotional nonacceptance, and decreased emotional clarity. Behav Ther. 2007, 38: 378-391.PubMed
134.
Zurück zum Zitat Batelaan N, Smit F, de Graaf R, van Balkom A, Vollebergh W, Beekman A: Economic costs of full-blown and subthreshold panic disorder. J Affect Disord. 2007, 104: 127-136.PubMed Batelaan N, Smit F, de Graaf R, van Balkom A, Vollebergh W, Beekman A: Economic costs of full-blown and subthreshold panic disorder. J Affect Disord. 2007, 104: 127-136.PubMed
135.
Zurück zum Zitat Gros DF, Frueh BC, Magruder KM: Prevalence and features of panic disorder and comparison to posttraumatic stress disorder in VA primary care. Gen Hosp Psychiatry. 2011, 33: 482-488.PubMed Gros DF, Frueh BC, Magruder KM: Prevalence and features of panic disorder and comparison to posttraumatic stress disorder in VA primary care. Gen Hosp Psychiatry. 2011, 33: 482-488.PubMed
136.
Zurück zum Zitat de Graaf R, Tuithof M, van Dorsselaer S, Ten Have M: Comparing the effects on work performance of mental and physical disorders. Soc Psychiatry Psychiatr Epidemiol. 2012, 47: 1873-1883.PubMed de Graaf R, Tuithof M, van Dorsselaer S, Ten Have M: Comparing the effects on work performance of mental and physical disorders. Soc Psychiatry Psychiatr Epidemiol. 2012, 47: 1873-1883.PubMed
137.
Zurück zum Zitat Mathew AR, Norton PJ, Zvolensky MJ, Buckner JD, Smits JA: Smoking behavior and alcohol consumption in individuals with panic attacks. J Cogn Psychother. 2011, 25: 61-70.PubMedCentralPubMed Mathew AR, Norton PJ, Zvolensky MJ, Buckner JD, Smits JA: Smoking behavior and alcohol consumption in individuals with panic attacks. J Cogn Psychother. 2011, 25: 61-70.PubMedCentralPubMed
138.
Zurück zum Zitat Bienvenu OJ, Onyike CU, Stein MB, Chen LS, Samuels J, Nestadt G, Eaton WW: Agoraphobia in adults: incidence and longitudinal relationship with panic. Br J Psychiatry. 2006, 188: 432-438.PubMed Bienvenu OJ, Onyike CU, Stein MB, Chen LS, Samuels J, Nestadt G, Eaton WW: Agoraphobia in adults: incidence and longitudinal relationship with panic. Br J Psychiatry. 2006, 188: 432-438.PubMed
139.
Zurück zum Zitat Korczak DJ, Goldstein BI, Levitt AJ: Panic disorder, cardiac diagnosis and emergency department utilization in an epidemiologic community sample. Gen Hosp Psychiatry. 2007, 29: 335-339.PubMed Korczak DJ, Goldstein BI, Levitt AJ: Panic disorder, cardiac diagnosis and emergency department utilization in an epidemiologic community sample. Gen Hosp Psychiatry. 2007, 29: 335-339.PubMed
140.
Zurück zum Zitat Senaratne R, Van Ameringen M, Mancini C, Patterson B, Bennett M: The prevalence of migraine headaches in an anxiety disorders clinic sample. CNS Neurosci Ther. 2010, 16: 76-82.PubMed Senaratne R, Van Ameringen M, Mancini C, Patterson B, Bennett M: The prevalence of migraine headaches in an anxiety disorders clinic sample. CNS Neurosci Ther. 2010, 16: 76-82.PubMed
141.
Zurück zum Zitat Yamada K, Moriwaki K, Oiso H, Ishigooka J: High prevalence of comorbidity of migraine in outpatients with panic disorder and effectiveness of psychopharmacotherapy for both disorders: a retrospective open label study. Psychiatry Res. 2011, 185: 145-148.PubMed Yamada K, Moriwaki K, Oiso H, Ishigooka J: High prevalence of comorbidity of migraine in outpatients with panic disorder and effectiveness of psychopharmacotherapy for both disorders: a retrospective open label study. Psychiatry Res. 2011, 185: 145-148.PubMed
142.
Zurück zum Zitat Marshall EC, Zvolensky MJ, Sachs-Ericsson N, Schmidt NB, Bernstein A: Panic attacks and physical health problems in a representative sample: singular and interactive associations with psychological problems, and interpersonal and physical disability. J Anxiety Disord. 2008, 22: 78-87.PubMed Marshall EC, Zvolensky MJ, Sachs-Ericsson N, Schmidt NB, Bernstein A: Panic attacks and physical health problems in a representative sample: singular and interactive associations with psychological problems, and interpersonal and physical disability. J Anxiety Disord. 2008, 22: 78-87.PubMed
143.
Zurück zum Zitat Craske MG, Kircanski K, Epstein A, Wittchen HU, Pine DS, Lewis-Fernandez R, Hinton D: Panic disorder: a review of DSM-IV panic disorder and proposals for DSM-V. Depress Anxiety. 2010, 27: 93-112.PubMed Craske MG, Kircanski K, Epstein A, Wittchen HU, Pine DS, Lewis-Fernandez R, Hinton D: Panic disorder: a review of DSM-IV panic disorder and proposals for DSM-V. Depress Anxiety. 2010, 27: 93-112.PubMed
144.
Zurück zum Zitat American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, text revision (DSM-IV-TR). 2000, Washington, DC: American Psychiatric Association, Fourth American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, text revision (DSM-IV-TR). 2000, Washington, DC: American Psychiatric Association, Fourth
145.
Zurück zum Zitat Wittchen HU, Gloster AT, Beesdo-Baum K, Fava GA, Craske MG: Agoraphobia: a review of the diagnostic classificatory position and criteria. Depress Anxiety. 2010, 27: 113-133.PubMed Wittchen HU, Gloster AT, Beesdo-Baum K, Fava GA, Craske MG: Agoraphobia: a review of the diagnostic classificatory position and criteria. Depress Anxiety. 2010, 27: 113-133.PubMed
146.
Zurück zum Zitat Clum GA, Surls R: A meta-analysis of treatments for panic disorder. J Consult Clin Psychol. 1993, 61: 317-326.PubMed Clum GA, Surls R: A meta-analysis of treatments for panic disorder. J Consult Clin Psychol. 1993, 61: 317-326.PubMed
147.
Zurück zum Zitat Gould R, Otto M, Pollack M: A meta-analysis of treatment outcome for panic disorder. Clin Psychol Psychother. 1995, 15: 819-844. Gould R, Otto M, Pollack M: A meta-analysis of treatment outcome for panic disorder. Clin Psychol Psychother. 1995, 15: 819-844.
148.
Zurück zum Zitat Marchand A, Roberge P, Primiano S, Germain V: A randomized, controlled clinical trial of standard, group and brief cognitive-behavioral therapy for panic disorder with agoraphobia: a two-year follow-up. J Anxiety Disord. 2009, 23: 1139-1147.PubMed Marchand A, Roberge P, Primiano S, Germain V: A randomized, controlled clinical trial of standard, group and brief cognitive-behavioral therapy for panic disorder with agoraphobia: a two-year follow-up. J Anxiety Disord. 2009, 23: 1139-1147.PubMed
149.
Zurück zum Zitat Roberge P, Marchand A, Reinharz D, Savard P: Cognitive-behavioral treatment for panic disorder with agoraphobia: a randomized, controlled trial and cost-effectiveness analysis. Behav Modif. 2008, 32: 333-351.PubMed Roberge P, Marchand A, Reinharz D, Savard P: Cognitive-behavioral treatment for panic disorder with agoraphobia: a randomized, controlled trial and cost-effectiveness analysis. Behav Modif. 2008, 32: 333-351.PubMed
150.
Zurück zum Zitat Meyerbroker K, Emmelkamp PM: Virtual reality exposure therapy in anxiety disorders: a systematic review of process-and-outcome studies. Depress Anxiety. 2010, 27: 933-944.PubMed Meyerbroker K, Emmelkamp PM: Virtual reality exposure therapy in anxiety disorders: a systematic review of process-and-outcome studies. Depress Anxiety. 2010, 27: 933-944.PubMed
151.
Zurück zum Zitat Botella C, García-Palacios A, Villa H, Baños RM, Quero S, Alcañiz M, Riva G: Virtual reality exposure in the treatment of panic disorder and agoraphobia: A controlled study. Clin Psychol Psychother. 2007, 14: 164-175. Botella C, García-Palacios A, Villa H, Baños RM, Quero S, Alcañiz M, Riva G: Virtual reality exposure in the treatment of panic disorder and agoraphobia: A controlled study. Clin Psychol Psychother. 2007, 14: 164-175.
152.
Zurück zum Zitat Malbos E, Rapee RM, Kavakli M: Isolating the effect of virtual reality based exposure therapy for agoraphobia: a comparative trial. Stud Health Technol Inform. 2011, 167: 45-50.PubMed Malbos E, Rapee RM, Kavakli M: Isolating the effect of virtual reality based exposure therapy for agoraphobia: a comparative trial. Stud Health Technol Inform. 2011, 167: 45-50.PubMed
153.
Zurück zum Zitat Perez-Ara MA, Quero S, Botella C, Banos R, Andreu-Mateu S, Garcia-Palacios A, Breton-Lopez J: Virtual reality interoceptive exposure for the treatment of panic disorder and agoraphobia. Stud Health Technol Inform. 2010, 154: 77-81.PubMed Perez-Ara MA, Quero S, Botella C, Banos R, Andreu-Mateu S, Garcia-Palacios A, Breton-Lopez J: Virtual reality interoceptive exposure for the treatment of panic disorder and agoraphobia. Stud Health Technol Inform. 2010, 154: 77-81.PubMed
154.
Zurück zum Zitat Vincelli F, Anolli L, Bouchard S, Wiederhold BK, Zurloni V, Riva G: Experiential cognitive therapy in the treatment of panic disorders with agoraphobia: a controlled study. Cyberpsychol Behav. 2003, 6: 321-328.PubMed Vincelli F, Anolli L, Bouchard S, Wiederhold BK, Zurloni V, Riva G: Experiential cognitive therapy in the treatment of panic disorders with agoraphobia: a controlled study. Cyberpsychol Behav. 2003, 6: 321-328.PubMed
155.
Zurück zum Zitat Hecker J, Losee M, Fritzler B, Fink C: Self-directed versus therapist-directed cognitive behavioural treatment for panic disorder. J Anxiety Disord. 1996, 10: 253-265. Hecker J, Losee M, Fritzler B, Fink C: Self-directed versus therapist-directed cognitive behavioural treatment for panic disorder. J Anxiety Disord. 1996, 10: 253-265.
156.
Zurück zum Zitat Lidren DM, Watkins PL, Gould RA, Clum GA, Asterino M, Tulloch HL: A comparison of bibliotherapy and group therapy in the treatment of panic disorder. J Consult Clin Psychol. 1994, 62: 865-869.PubMed Lidren DM, Watkins PL, Gould RA, Clum GA, Asterino M, Tulloch HL: A comparison of bibliotherapy and group therapy in the treatment of panic disorder. J Consult Clin Psychol. 1994, 62: 865-869.PubMed
157.
Zurück zum Zitat Carlbring P, Maurin T, Sjomark J, Maurin L, Westling BE, Ekselius L, Cuijpers P, Andersson G: All at once or one at a time? A randomized controlled trial comparing two ways to deliver bibliotherapy for panic disorder. Cogn Behav Ther. 2011, 40: 228-235.PubMed Carlbring P, Maurin T, Sjomark J, Maurin L, Westling BE, Ekselius L, Cuijpers P, Andersson G: All at once or one at a time? A randomized controlled trial comparing two ways to deliver bibliotherapy for panic disorder. Cogn Behav Ther. 2011, 40: 228-235.PubMed
158.
Zurück zum Zitat Nordin S, Carlbring P, Cuijpers P, Andersson G: Expanding the limits of bibliotherapy for panic disorder: randomized trial of self-help without support but with a clear deadline. Behav Ther. 2010, 41: 267-276.PubMed Nordin S, Carlbring P, Cuijpers P, Andersson G: Expanding the limits of bibliotherapy for panic disorder: randomized trial of self-help without support but with a clear deadline. Behav Ther. 2010, 41: 267-276.PubMed
159.
Zurück zum Zitat McNamee G, O’Sullivan G, Lelliott P, Marks I: Telephone-guided treatment for housebound agoraphobics with panic disorder: exposure versus relaxation. Behav Ther. 1989, 20: 491-497. McNamee G, O’Sullivan G, Lelliott P, Marks I: Telephone-guided treatment for housebound agoraphobics with panic disorder: exposure versus relaxation. Behav Ther. 1989, 20: 491-497.
160.
Zurück zum Zitat Swinson RP, Fergus KD, Cox BJ, Wickwire K: Efficacy of telephone-administered behavioral therapy for panic disorder with agoraphobia. Behav Res Ther. 1995, 33: 465-469.PubMed Swinson RP, Fergus KD, Cox BJ, Wickwire K: Efficacy of telephone-administered behavioral therapy for panic disorder with agoraphobia. Behav Res Ther. 1995, 33: 465-469.PubMed
161.
Zurück zum Zitat Bouchard S, Paquin B, Payeur R, Allard M, Rivard V, Fournier T, Renaud P, Lapierre J: Delivering cognitive-behavior therapy for panic disorder with agoraphobia in videoconference. Telemed J E Health. 2004, 10: 13-25.PubMed Bouchard S, Paquin B, Payeur R, Allard M, Rivard V, Fournier T, Renaud P, Lapierre J: Delivering cognitive-behavior therapy for panic disorder with agoraphobia in videoconference. Telemed J E Health. 2004, 10: 13-25.PubMed
162.
Zurück zum Zitat Carlbring P, Ekselius L, Andersson G: Treatment of panic disorder via the Internet: a randomized trial of CBT vs. applied relaxation. J Behav Ther Exp Psychiatry. 2003, 34: 129-140.PubMed Carlbring P, Ekselius L, Andersson G: Treatment of panic disorder via the Internet: a randomized trial of CBT vs. applied relaxation. J Behav Ther Exp Psychiatry. 2003, 34: 129-140.PubMed
163.
Zurück zum Zitat Newman MG, Kenardy J, Herman S, Taylor CB: Comparison of palmtop-computer-assisted brief cognitive-behavioral treatment to cognitive-behavioral treatment for panic disorder. J Consult Clin Psychol. 1997, 65: 178-183.PubMed Newman MG, Kenardy J, Herman S, Taylor CB: Comparison of palmtop-computer-assisted brief cognitive-behavioral treatment to cognitive-behavioral treatment for panic disorder. J Consult Clin Psychol. 1997, 65: 178-183.PubMed
164.
Zurück zum Zitat Bergstrom J, Andersson G, Ljotsson B, Ruck C, Andreewitch S, Karlsson A, Carlbring P, Andersson E, Lindefors N: Internet-versus group-administered cognitive behaviour therapy for panic disorder in a psychiatric setting: a randomised trial. BMC Psychiatry. 2010, 10: 54-PubMedCentralPubMed Bergstrom J, Andersson G, Ljotsson B, Ruck C, Andreewitch S, Karlsson A, Carlbring P, Andersson E, Lindefors N: Internet-versus group-administered cognitive behaviour therapy for panic disorder in a psychiatric setting: a randomised trial. BMC Psychiatry. 2010, 10: 54-PubMedCentralPubMed
165.
Zurück zum Zitat Carlbring P, Bohman S, Brunt S, Buhrman M, Westling BE, Ekselius L, Andersson G: Remote treatment of panic disorder: a randomized trial of internet-based cognitive behavior therapy supplemented with telephone calls. Am J Psychiatry. 2006, 163: 2119-2125.PubMed Carlbring P, Bohman S, Brunt S, Buhrman M, Westling BE, Ekselius L, Andersson G: Remote treatment of panic disorder: a randomized trial of internet-based cognitive behavior therapy supplemented with telephone calls. Am J Psychiatry. 2006, 163: 2119-2125.PubMed
166.
Zurück zum Zitat Kiropoulos LA, Klein B, Austin DW, Gilson K, Pier C, Mitchell J, Ciechomski L: Is internet-based CBT for panic disorder and agoraphobia as effective as face-to-face CBT?. J Anxiety Disord. 2008, 22: 1273-1284.PubMed Kiropoulos LA, Klein B, Austin DW, Gilson K, Pier C, Mitchell J, Ciechomski L: Is internet-based CBT for panic disorder and agoraphobia as effective as face-to-face CBT?. J Anxiety Disord. 2008, 22: 1273-1284.PubMed
167.
Zurück zum Zitat Wims E, Titov N, Andrews G, Choi I: Clinician-assisted Internet-based treatment is effective for panic: a randomized controlled trial. Aust N Z J Psychiatry. 2010, 44: 599-607.PubMed Wims E, Titov N, Andrews G, Choi I: Clinician-assisted Internet-based treatment is effective for panic: a randomized controlled trial. Aust N Z J Psychiatry. 2010, 44: 599-607.PubMed
168.
Zurück zum Zitat Klein B, Austin D, Pier C, Kiropoulos L, Shandley K, Mitchell J, Gilson K, Ciechomski L: Internet-based treatment for panic disorder: does frequency of therapist contact make a difference?. Cogn Behav Ther. 2009, 38: 100-113.PubMed Klein B, Austin D, Pier C, Kiropoulos L, Shandley K, Mitchell J, Gilson K, Ciechomski L: Internet-based treatment for panic disorder: does frequency of therapist contact make a difference?. Cogn Behav Ther. 2009, 38: 100-113.PubMed
169.
Zurück zum Zitat Ruwaard J, Broeksteeg J, Schrieken B, Emmelkamp P, Lange A: Web-based therapist-assisted cognitive behavioral treatment of panic symptoms: a randomized controlled trial with a three-year follow-up. J Anxiety Disord. 2010, 24: 387-396.PubMed Ruwaard J, Broeksteeg J, Schrieken B, Emmelkamp P, Lange A: Web-based therapist-assisted cognitive behavioral treatment of panic symptoms: a randomized controlled trial with a three-year follow-up. J Anxiety Disord. 2010, 24: 387-396.PubMed
170.
Zurück zum Zitat Clark DM, Salkovskis PM, Hackmann A, Wells A, Ludgate J, Gelder M: Brief cognitive therapy for panic disorder: a randomized controlled trial. J Consult Clin Psychol. 1999, 67: 583-589.PubMed Clark DM, Salkovskis PM, Hackmann A, Wells A, Ludgate J, Gelder M: Brief cognitive therapy for panic disorder: a randomized controlled trial. J Consult Clin Psychol. 1999, 67: 583-589.PubMed
171.
Zurück zum Zitat Bohni MK, Spindler H, Arendt M, Hougaard E, Rosenberg NK: A randomized study of massed three-week cognitive behavioural therapy schedule for panic disorder. Acta Psychiatr Scand. 2009, 120: 187-195.PubMed Bohni MK, Spindler H, Arendt M, Hougaard E, Rosenberg NK: A randomized study of massed three-week cognitive behavioural therapy schedule for panic disorder. Acta Psychiatr Scand. 2009, 120: 187-195.PubMed
172.
Zurück zum Zitat Dow MG, Kenardy JA, Johnston DW, Newman MG, Taylor CB, Thomson A: Prognostic indices with brief and standard CBT for panic disorder: II. Moderators of outcome. Psychol Med. 2007, 37: 1503-1509.PubMed Dow MG, Kenardy JA, Johnston DW, Newman MG, Taylor CB, Thomson A: Prognostic indices with brief and standard CBT for panic disorder: II. Moderators of outcome. Psychol Med. 2007, 37: 1503-1509.PubMed
173.
Zurück zum Zitat Craske MG, Roy-Byrne P, Stein MB, Sullivan G, Hazlett-Stevens H, Bystritsky A, Sherbourne C: CBT intensity and outcome for panic disorder in a primary care setting. Behav Ther. 2006, 37: 112-119.PubMed Craske MG, Roy-Byrne P, Stein MB, Sullivan G, Hazlett-Stevens H, Bystritsky A, Sherbourne C: CBT intensity and outcome for panic disorder in a primary care setting. Behav Ther. 2006, 37: 112-119.PubMed
174.
Zurück zum Zitat Haby MM, Donnelly M, Corry J, Vos T: Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: a meta-regression of factors that may predict outcome. Aust N Z J Psychiatry. 2006, 40: 9-19.PubMed Haby MM, Donnelly M, Corry J, Vos T: Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: a meta-regression of factors that may predict outcome. Aust N Z J Psychiatry. 2006, 40: 9-19.PubMed
175.
Zurück zum Zitat Dow MG, Kenardy JA, Johnston DW, Newman MG, Taylor CB, Thomson A: Prognostic indices with brief and standard CBT for panic disorder: I. Predictors of outcome. Psychol Med. 2007, 37: 1493-1502.PubMed Dow MG, Kenardy JA, Johnston DW, Newman MG, Taylor CB, Thomson A: Prognostic indices with brief and standard CBT for panic disorder: I. Predictors of outcome. Psychol Med. 2007, 37: 1493-1502.PubMed
176.
Zurück zum Zitat Bouchard S, Gauthier J, Nouwen A, Ivers H, Vallieres A, Simard S, Fournier T: Temporal relationship between dysfunctional beliefs, self-efficacy and panic apprehension in the treatment of panic disorder with agoraphobia. J Behav Ther Exp Psychiatry. 2007, 38: 275-292.PubMed Bouchard S, Gauthier J, Nouwen A, Ivers H, Vallieres A, Simard S, Fournier T: Temporal relationship between dysfunctional beliefs, self-efficacy and panic apprehension in the treatment of panic disorder with agoraphobia. J Behav Ther Exp Psychiatry. 2007, 38: 275-292.PubMed
177.
Zurück zum Zitat Feske U, Goldstein AJ: Eye movement desensitization and reprocessing treatment for panic disorder: a controlled outcome and partial dismantling study. J Consult Clin Psychol. 1997, 65: 1026-1035.PubMed Feske U, Goldstein AJ: Eye movement desensitization and reprocessing treatment for panic disorder: a controlled outcome and partial dismantling study. J Consult Clin Psychol. 1997, 65: 1026-1035.PubMed
178.
Zurück zum Zitat Goldstein AJ, de Beurs E, Chambless DL, Wilson KA: EMDR for panic disorder with agoraphobia: comparison with waiting list and credible attention-placebo control conditions. J Consult Clin Psychol. 2000, 68: 947-956.PubMed Goldstein AJ, de Beurs E, Chambless DL, Wilson KA: EMDR for panic disorder with agoraphobia: comparison with waiting list and credible attention-placebo control conditions. J Consult Clin Psychol. 2000, 68: 947-956.PubMed
179.
Zurück zum Zitat Furukawa TA, Watanabe N, Churchill R: Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry. 2006, 188: 305-312.PubMed Furukawa TA, Watanabe N, Churchill R: Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry. 2006, 188: 305-312.PubMed
180.
Zurück zum Zitat Furukawa TA, Watanabe N, Churchill R: Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev. 2007, CD004364- Furukawa TA, Watanabe N, Churchill R: Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev. 2007, CD004364-
181.
Zurück zum Zitat Mitte K: A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord. 2005, 88: 27-45.PubMed Mitte K: A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord. 2005, 88: 27-45.PubMed
182.
Zurück zum Zitat Watanabe N, Churchill R, Furukawa TA: Combined psychotherapy plus benzodiazepines for panic disorder. Cochrane Database Syst Rev. 2009, CD005335- Watanabe N, Churchill R, Furukawa TA: Combined psychotherapy plus benzodiazepines for panic disorder. Cochrane Database Syst Rev. 2009, CD005335-
183.
Zurück zum Zitat Koszycki D, Taljaard M, Segal Z, Bradwejn J: A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder. Psychol Med. 2011, 41: 373-383.PubMed Koszycki D, Taljaard M, Segal Z, Bradwejn J: A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder. Psychol Med. 2011, 41: 373-383.PubMed
184.
Zurück zum Zitat Kim YW, Lee SH, Choi TK, Suh SY, Kim B, Kim CM, Cho SJ, Kim MJ, Yook K, Ryu M, et al: Effectiveness of mindfulness-based cognitive therapy as an adjuvant to pharmacotherapy in patients with panic disorder or generalized anxiety disorder. Depress Anxiety. 2009, 26: 601-606.PubMed Kim YW, Lee SH, Choi TK, Suh SY, Kim B, Kim CM, Cho SJ, Kim MJ, Yook K, Ryu M, et al: Effectiveness of mindfulness-based cognitive therapy as an adjuvant to pharmacotherapy in patients with panic disorder or generalized anxiety disorder. Depress Anxiety. 2009, 26: 601-606.PubMed
185.
Zurück zum Zitat Kim B, Lee SH, Kim YW, Choi TK, Yook K, Suh SY, Cho SJ, Yook KH: Effectiveness of a mindfulness-based cognitive therapy program as an adjunct to pharmacotherapy in patients with panic disorder. J Anxiety Disord. 2010, 24: 590-595.PubMed Kim B, Lee SH, Kim YW, Choi TK, Yook K, Suh SY, Cho SJ, Yook KH: Effectiveness of a mindfulness-based cognitive therapy program as an adjunct to pharmacotherapy in patients with panic disorder. J Anxiety Disord. 2010, 24: 590-595.PubMed
186.
Zurück zum Zitat Schmidt NB, Wollaway-Bickel K, Trakowski JH, Santiago HT, Vasey M: Antidepressant discontinuation in the context of cognitive behavioral treatment for panic disorder. Behav Res Ther. 2002, 40: 67-73.PubMed Schmidt NB, Wollaway-Bickel K, Trakowski JH, Santiago HT, Vasey M: Antidepressant discontinuation in the context of cognitive behavioral treatment for panic disorder. Behav Res Ther. 2002, 40: 67-73.PubMed
187.
Zurück zum Zitat Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH: Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: further evaluation. Behav Res Ther. 2010, 48: 720-727.PubMed Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH: Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: further evaluation. Behav Res Ther. 2010, 48: 720-727.PubMed
188.
Zurück zum Zitat Bruce T, Spiegel D, Hegel M: Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria and Dartmouth studies. J Consult Clin Psychol. 1999, 67: 151-156.PubMed Bruce T, Spiegel D, Hegel M: Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria and Dartmouth studies. J Consult Clin Psychol. 1999, 67: 151-156.PubMed
189.
Zurück zum Zitat Katon W, Russo J, Sherbourne C, Stein MB, Craske M, Fan MY, Roy-Byrne P: Incremental cost-effectiveness of a collaborative care intervention for panic disorder. Psychol Med. 2006, 36: 353-363.PubMed Katon W, Russo J, Sherbourne C, Stein MB, Craske M, Fan MY, Roy-Byrne P: Incremental cost-effectiveness of a collaborative care intervention for panic disorder. Psychol Med. 2006, 36: 353-363.PubMed
190.
Zurück zum Zitat Cottraux J, Note ID, Cungi C, Legeron P, Heim F, Chneiweiss L, Bernard G, Bouvard M: A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry. 1995, 167: 635-641.PubMed Cottraux J, Note ID, Cungi C, Legeron P, Heim F, Chneiweiss L, Bernard G, Bouvard M: A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry. 1995, 167: 635-641.PubMed
191.
Zurück zum Zitat Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH: Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2010, 67: 365-370.PubMed Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH: Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2010, 67: 365-370.PubMed
192.
Zurück zum Zitat Siegmund A, Golfels F, Finck C, Halisch A, Rath D, Plag J, Strohle A: D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res. 2011, 45: 1042-1047.PubMed Siegmund A, Golfels F, Finck C, Halisch A, Rath D, Plag J, Strohle A: D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res. 2011, 45: 1042-1047.PubMed
193.
Zurück zum Zitat Nations KR, Smits JA, Tolin DF, Rothbaum BO, Hofmann SG, Tart CD, Lee A, Schipper J, Sjogren M, Xue D, et al: Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2012, 73: 647-653.PubMed Nations KR, Smits JA, Tolin DF, Rothbaum BO, Hofmann SG, Tart CD, Lee A, Schipper J, Sjogren M, Xue D, et al: Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2012, 73: 647-653.PubMed
194.
Zurück zum Zitat Fava GA, Rafanelli C, Grandi S, Conti S, Ruini C, Mangelli L, Belluardo P: Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychol Med. 2001, 31: 891-898.PubMed Fava GA, Rafanelli C, Grandi S, Conti S, Ruini C, Mangelli L, Belluardo P: Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychol Med. 2001, 31: 891-898.PubMed
195.
Zurück zum Zitat Bakker A, van Balkom A, Spinhoven P: SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002, 106: 163-167.PubMed Bakker A, van Balkom A, Spinhoven P: SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002, 106: 163-167.PubMed
196.
Zurück zum Zitat Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH: An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry. 2001, 158: 1989-1992.PubMed Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH: An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry. 2001, 158: 1989-1992.PubMed
197.
Zurück zum Zitat Andrisano C, Chiesa A, Serretti A: Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol. 2013, 28: 33-45.PubMed Andrisano C, Chiesa A, Serretti A: Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol. 2013, 28: 33-45.PubMed
198.
Zurück zum Zitat Stahl SM, Gergel I, Li D: Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2003, 64: 1322-1327.PubMed Stahl SM, Gergel I, Li D: Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2003, 64: 1322-1327.PubMed
199.
Zurück zum Zitat Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T: The effect of citalopram in panic disorder. Br J Psychiatry. 1997, 170: 549-553.PubMed Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T: The effect of citalopram in panic disorder. Br J Psychiatry. 1997, 170: 549-553.PubMed
200.
Zurück zum Zitat Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ: Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol. 2003, 18: 279-284.PubMed Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ: Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol. 2003, 18: 279-284.PubMed
201.
Zurück zum Zitat Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD: Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. 1998, 155: 1570-1577.PubMed Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD: Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. 1998, 155: 1570-1577.PubMed
202.
Zurück zum Zitat Michelson D, Allgulander C, Dantendorfer K, Knezevic A, Maierhofer D, Micev V, Paunovic V, Timotijevic I, Sarkar N, Skoglund L, Pemberton S: Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry. 2001, 179: 514-518.PubMed Michelson D, Allgulander C, Dantendorfer K, Knezevic A, Maierhofer D, Micev V, Paunovic V, Timotijevic I, Sarkar N, Skoglund L, Pemberton S: Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry. 2001, 179: 514-518.PubMed
203.
Zurück zum Zitat Ribeiro L, Busnello J, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello E, Kapczinski F: Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res. 2001, 34: 1303-1307.PubMed Ribeiro L, Busnello J, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello E, Kapczinski F: Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res. 2001, 34: 1303-1307.PubMed
204.
Zurück zum Zitat Tiller JW, Bouwer C, Behnke K: Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci. 1999, 249 (Suppl 1): S7-10.PubMed Tiller JW, Bouwer C, Behnke K: Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci. 1999, 249 (Suppl 1): S7-10.PubMed
205.
Zurück zum Zitat Black DW, Wesner R, Bowers W, Gabel J: A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry. 1993, 50: 44-50.PubMed Black DW, Wesner R, Bowers W, Gabel J: A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry. 1993, 50: 44-50.PubMed
206.
Zurück zum Zitat Asnis G, Hameedi F, Goddard A, Potkin S, Black D, Jameel M, Desagani K, Woods S: Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res. 2001, 103: 1-14.PubMed Asnis G, Hameedi F, Goddard A, Potkin S, Black D, Jameel M, Desagani K, Woods S: Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res. 2001, 103: 1-14.PubMed
207.
Zurück zum Zitat Bakish D, Hooper CL, Filteau MJ, Charbonneau Y, Fraser G, West DL, Thibaudeau C, Raine D: A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull. 1996, 32: 135-141.PubMed Bakish D, Hooper CL, Filteau MJ, Charbonneau Y, Fraser G, West DL, Thibaudeau C, Raine D: A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull. 1996, 32: 135-141.PubMed
208.
Zurück zum Zitat Den Boer JA, Westenberg HG: Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl). 1990, 102: 85-94. Den Boer JA, Westenberg HG: Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl). 1990, 102: 85-94.
209.
Zurück zum Zitat Hoehn-Saric R, McLeod DR, Hipsley PA: Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol. 1993, 13: 321-326.PubMed Hoehn-Saric R, McLeod DR, Hipsley PA: Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol. 1993, 13: 321-326.PubMed
210.
Zurück zum Zitat Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA: Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. Br J Gen Pract. 1997, 47: 150-155.PubMedCentralPubMed Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA: Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. Br J Gen Pract. 1997, 47: 150-155.PubMedCentralPubMed
211.
Zurück zum Zitat Bakker A, van Dyck R, Spinhoven P, van Balkom AJ: Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry. 1999, 60: 831-838.PubMed Bakker A, van Dyck R, Spinhoven P, van Balkom AJ: Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry. 1999, 60: 831-838.PubMed
212.
Zurück zum Zitat Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP: Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998, 155: 36-42.PubMed Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP: Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998, 155: 36-42.PubMed
213.
Zurück zum Zitat Lecrubier Y, Bakker A, Dunbar G, Judge R: A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997, 95: 145-152.PubMed Lecrubier Y, Bakker A, Dunbar G, Judge R: A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997, 95: 145-152.PubMed
214.
Zurück zum Zitat Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM: Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry. 1995, 167: 374-379.PubMed Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM: Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry. 1995, 167: 374-379.PubMed
215.
Zurück zum Zitat Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y: A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007, 194: 233-242. Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y: A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007, 194: 233-242.
216.
Zurück zum Zitat Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B: A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007, 24: 1-14.PubMed Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B: A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007, 24: 1-14.PubMed
217.
Zurück zum Zitat Prosser JM, Yard S, Steele A, Cohen LJ, Galynker II: A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. BMC Psychiatry. 2009, 9: 25-PubMedCentralPubMed Prosser JM, Yard S, Steele A, Cohen LJ, Galynker II: A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. BMC Psychiatry. 2009, 9: 25-PubMedCentralPubMed
218.
Zurück zum Zitat Nardi AE, Valenca AM, Freire RC, Mochcovitch MD, Amrein R, Sardinha A, Levitan MN, Nascimento I, de-Melo-Neto VL, King AL, et al: Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Braz J Med Biol Res. 2011, 44: 366-373.PubMed Nardi AE, Valenca AM, Freire RC, Mochcovitch MD, Amrein R, Sardinha A, Levitan MN, Nascimento I, de-Melo-Neto VL, King AL, et al: Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Braz J Med Biol Res. 2011, 44: 366-373.PubMed
219.
Zurück zum Zitat Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, Bellodi L: Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2004, 37: 206-210.PubMed Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, Bellodi L: Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2004, 37: 206-210.PubMed
220.
Zurück zum Zitat Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, Rosenthal M, Weise C: Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry. 1998, 173: 54-60.PubMed Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, Rosenthal M, Weise C: Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry. 1998, 173: 54-60.PubMed
221.
Zurück zum Zitat Pohl RB, Wolkow RM, Clary CM: Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry. 1998, 155: 1189-1195.PubMed Pohl RB, Wolkow RM, Clary CM: Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry. 1998, 155: 1189-1195.PubMed
222.
Zurück zum Zitat Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R: Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998, 55: 1010-1016.PubMed Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R: Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998, 55: 1010-1016.PubMed
223.
Zurück zum Zitat Pollack M, Rapaport M, Clary C, Mardekian J, Wolkow R: Sertraline treatment of panic disorder: response in patients at risk for poor outcome. J Clin Psychiatry. 2000, 61: 922-927.PubMed Pollack M, Rapaport M, Clary C, Mardekian J, Wolkow R: Sertraline treatment of panic disorder: response in patients at risk for poor outcome. J Clin Psychiatry. 2000, 61: 922-927.PubMed
224.
Zurück zum Zitat Lepola U, Arato M, Zhu Y, Austin C: Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry. 2003, 64: 654-662.PubMed Lepola U, Arato M, Zhu Y, Austin C: Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry. 2003, 64: 654-662.PubMed
225.
Zurück zum Zitat Sheehan DV, Burnham DB, Iyengar MK, Perera P: Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry. 2005, 66: 34-40.PubMed Sheehan DV, Burnham DB, Iyengar MK, Perera P: Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry. 2005, 66: 34-40.PubMed
226.
Zurück zum Zitat Perna G, Dacco S, Menotti R, Caldirola D: Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition. Neuropsychiatr Dis Treat. 2011, 7: 621-637.PubMedCentralPubMed Perna G, Dacco S, Menotti R, Caldirola D: Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition. Neuropsychiatr Dis Treat. 2011, 7: 621-637.PubMedCentralPubMed
227.
Zurück zum Zitat Pollack MH, Worthington JJ, Otto MW, Maki KM, Smoller JW, Manfro GG, Rudolph R, Rosenbaum JF: Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull. 1996, 32: 667-670.PubMed Pollack MH, Worthington JJ, Otto MW, Maki KM, Smoller JW, Manfro GG, Rudolph R, Rosenbaum JF: Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull. 1996, 32: 667-670.PubMed
228.
Zurück zum Zitat Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T: Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry. 2005, 187: 352-359.PubMed Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T: Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry. 2005, 187: 352-359.PubMed
229.
Zurück zum Zitat Liebowitz MR, Asnis G, Mangano R, Tzanis E: A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. J Clin Psychiatry. 2009, 70: 550-561.PubMed Liebowitz MR, Asnis G, Mangano R, Tzanis E: A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. J Clin Psychiatry. 2009, 70: 550-561.PubMed
230.
Zurück zum Zitat Simon NM, Kaufman RE, Hoge EA, Worthington JJ, Herlands NN, Owens ME, Pollack MH: Open-label support for duloxetine for the treatment of panic disorder. CNS Neurosci Ther. 2009, 15: 19-23.PubMed Simon NM, Kaufman RE, Hoge EA, Worthington JJ, Herlands NN, Owens ME, Pollack MH: Open-label support for duloxetine for the treatment of panic disorder. CNS Neurosci Ther. 2009, 15: 19-23.PubMed
231.
Zurück zum Zitat Blaya C, Seganfredo AC, Dornelles M, Torres M, Paludo A, Heldt E, Manfro GG: The efficacy of milnacipran in panic disorder: an open trial. Int Clin Psychopharmacol. 2007, 22: 153-158.PubMed Blaya C, Seganfredo AC, Dornelles M, Torres M, Paludo A, Heldt E, Manfro GG: The efficacy of milnacipran in panic disorder: an open trial. Int Clin Psychopharmacol. 2007, 22: 153-158.PubMed
232.
Zurück zum Zitat Kruger MB, Dahl AA: The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci. 1999, 249 (Suppl 1): S19-24.PubMed Kruger MB, Dahl AA: The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci. 1999, 249 (Suppl 1): S19-24.PubMed
233.
Zurück zum Zitat Modigh K, Westberg P, Eriksson E: Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1992, 12: 251-261.PubMed Modigh K, Westberg P, Eriksson E: Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1992, 12: 251-261.PubMed
234.
Zurück zum Zitat Cox BJ, Endler NS, Lee PS, Swinson RP: A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. J Behav Ther Exp Psychiatry. 1992, 23: 175-182.PubMed Cox BJ, Endler NS, Lee PS, Swinson RP: A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. J Behav Ther Exp Psychiatry. 1992, 23: 175-182.PubMed
235.
Zurück zum Zitat Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators. Br J Psychiatry. 1992, 160: 191-202. discussion 202-195 Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators. Br J Psychiatry. 1992, 160: 191-202. discussion 202-195
236.
Zurück zum Zitat Andersch S, Rosenberg NK, Kullingsjo H, Ottosson JO, Bech P, Bruun-Hansen J, Hanson L, Lorentzen K, Mellergard M, Rasmussen S, et al: Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatr Scand Suppl. 1991, 365: 18-27.PubMed Andersch S, Rosenberg NK, Kullingsjo H, Ottosson JO, Bech P, Bruun-Hansen J, Hanson L, Lorentzen K, Mellergard M, Rasmussen S, et al: Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatr Scand Suppl. 1991, 365: 18-27.PubMed
237.
Zurück zum Zitat Taylor CB, Hayward C, King R, Ehlers A, Margraf J, Maddock R, Clark D, Roth WT, Agras WS: Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 1990, 10: 112-118.PubMed Taylor CB, Hayward C, King R, Ehlers A, Margraf J, Maddock R, Clark D, Roth WT, Agras WS: Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 1990, 10: 112-118.PubMed
238.
Zurück zum Zitat Barlow D, Gorman J, Shear M, Woods S: Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 2000, 283: 2529-2536.PubMed Barlow D, Gorman J, Shear M, Woods S: Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 2000, 283: 2529-2536.PubMed
239.
Zurück zum Zitat Marchand A, Coutu MF, Dupuis G, Fleet R, Borgeat F, Todorov C, Mainguy N: Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. Cogn Behav Ther. 2008, 37: 146-159.PubMed Marchand A, Coutu MF, Dupuis G, Fleet R, Borgeat F, Todorov C, Mainguy N: Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. Cogn Behav Ther. 2008, 37: 146-159.PubMed
240.
Zurück zum Zitat Sheehan DV, Ballenger J, Jacobsen G: Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry. 1980, 37: 51-59.PubMed Sheehan DV, Ballenger J, Jacobsen G: Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry. 1980, 37: 51-59.PubMed
241.
Zurück zum Zitat Uhlenhuth EH, Warner TD, Matuzas W: Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. J Clin Psychopharmacol. 2002, 22: 275-284.PubMed Uhlenhuth EH, Warner TD, Matuzas W: Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. J Clin Psychopharmacol. 2002, 22: 275-284.PubMed
242.
Zurück zum Zitat Loerch B, Graf-Morgenstern M, Hautzinger M, Schlegel S, Hain C, Sandmann J, Benkert O: Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry. 1999, 174: 205-212.PubMed Loerch B, Graf-Morgenstern M, Hautzinger M, Schlegel S, Hain C, Sandmann J, Benkert O: Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry. 1999, 174: 205-212.PubMed
243.
Zurück zum Zitat Nardi AE, Lopes FL, Valenca AM, Freire RC, Nascimento I, Veras AB, Mezzasalma MA, de-Melo-Neto VL, Soares-Filho GL, King AL, et al: Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder. Psychiatry Res. 2010, 175: 260-265.PubMed Nardi AE, Lopes FL, Valenca AM, Freire RC, Nascimento I, Veras AB, Mezzasalma MA, de-Melo-Neto VL, Soares-Filho GL, King AL, et al: Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder. Psychiatry Res. 2010, 175: 260-265.PubMed
244.
Zurück zum Zitat Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M: Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry. 2002, 63: 31-37.PubMed Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M: Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry. 2002, 63: 31-37.PubMed
245.
Zurück zum Zitat Boshuisen M, Slaap B, Vester-Blokland E, den Boer J: The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol. 2001, 16: 363-368.PubMed Boshuisen M, Slaap B, Vester-Blokland E, den Boer J: The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol. 2001, 16: 363-368.PubMed
246.
Zurück zum Zitat Sarchiapone M, Amore M, De Risio S, Carli V, Faia V, Poterzio F, Balista C, Camardese G, Ferrari G: Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol. 2003, 18: 35-38.PubMed Sarchiapone M, Amore M, De Risio S, Carli V, Faia V, Poterzio F, Balista C, Camardese G, Ferrari G: Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol. 2003, 18: 35-38.PubMed
247.
Zurück zum Zitat Sheehan DV, Davidson J, Manschreck T, Van Wyck Fleet J: Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol. 1983, 3: 28-31.PubMed Sheehan DV, Davidson J, Manschreck T, Van Wyck Fleet J: Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol. 1983, 3: 28-31.PubMed
248.
Zurück zum Zitat Simon NM, Emmanuel N, Ballenger J, Worthington JJ, Kinrys G, Korbly NB, Farach FJ, Pollack MH: Bupropion sustained release for panic disorder. Psychopharmacol Bull. 2003, 37: 66-72.PubMed Simon NM, Emmanuel N, Ballenger J, Worthington JJ, Kinrys G, Korbly NB, Farach FJ, Pollack MH: Bupropion sustained release for panic disorder. Psychopharmacol Bull. 2003, 37: 66-72.PubMed
249.
Zurück zum Zitat Boyer W: Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol. 1995, 10: 45-49.PubMed Boyer W: Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol. 1995, 10: 45-49.PubMed
250.
Zurück zum Zitat Tesar GE, Rosenbaum JF, Pollack MH, Otto MW, Sachs GS, Herman JB, Cohen LS, Spier SA: Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry. 1991, 52: 69-76.PubMed Tesar GE, Rosenbaum JF, Pollack MH, Otto MW, Sachs GS, Herman JB, Cohen LS, Spier SA: Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry. 1991, 52: 69-76.PubMed
251.
Zurück zum Zitat Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK: Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry. 1990, 23: 90-93.PubMed Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK: Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry. 1990, 23: 90-93.PubMed
252.
Zurück zum Zitat Moylan S, Staples J, Ward SA, Rogerson J, Stein DJ, Berk M: The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. J Clin Psychopharmacol. 2011, 31: 647-652.PubMed Moylan S, Staples J, Ward SA, Rogerson J, Stein DJ, Berk M: The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. J Clin Psychopharmacol. 2011, 31: 647-652.PubMed
253.
Zurück zum Zitat Marquez M, Arenoso H, Caruso N: Efficacy of alprazolam sublingual tablets in the treatment of the acute phase of panic disorders. Actas Esp Psiquiatr. 2011, 39: 88-94.PubMed Marquez M, Arenoso H, Caruso N: Efficacy of alprazolam sublingual tablets in the treatment of the acute phase of panic disorders. Actas Esp Psiquiatr. 2011, 39: 88-94.PubMed
254.
Zurück zum Zitat Sheehan D, Raj A, Harnett-Sheehan K, Soto S, Knapp E: The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand. 1993, 88: 1-11.PubMed Sheehan D, Raj A, Harnett-Sheehan K, Soto S, Knapp E: The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand. 1993, 88: 1-11.PubMed
255.
Zurück zum Zitat Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G: Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol. 1994, 14: 111-118.PubMed Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G: Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol. 1994, 14: 111-118.PubMed
256.
Zurück zum Zitat Moroz G, Rosenbaum JF: Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry. 1999, 60: 604-612.PubMed Moroz G, Rosenbaum JF: Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry. 1999, 60: 604-612.PubMed
257.
Zurück zum Zitat Rosenbaum JF, Moroz G, Bowden CL: Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. J Clin Psychopharmacol. 1997, 17: 390-400.PubMed Rosenbaum JF, Moroz G, Bowden CL: Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. J Clin Psychopharmacol. 1997, 17: 390-400.PubMed
258.
Zurück zum Zitat Valenca A, Nardi A, Nascimento I, Mezzasalma M, Lopes F, Zin W: Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatr. 2000, 58: 1025-1029.PubMed Valenca A, Nardi A, Nascimento I, Mezzasalma M, Lopes F, Zin W: Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatr. 2000, 58: 1025-1029.PubMed
259.
Zurück zum Zitat Charney DS, Woods SW: Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry. 1989, 50: 418-423.PubMed Charney DS, Woods SW: Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry. 1989, 50: 418-423.PubMed
260.
Zurück zum Zitat de Jonghe F, Swinkels J, Tuynman-Qua H, Jonkers F: A comparative study of suriclone, lorazepam and placebo in anxiety disorder. Pharmacopsychiatry. 1989, 22: 266-271.PubMed de Jonghe F, Swinkels J, Tuynman-Qua H, Jonkers F: A comparative study of suriclone, lorazepam and placebo in anxiety disorder. Pharmacopsychiatry. 1989, 22: 266-271.PubMed
261.
Zurück zum Zitat Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS: Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry. 1986, 47: 458-460.PubMed Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS: Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry. 1986, 47: 458-460.PubMed
262.
Zurück zum Zitat Noyes R, Anderson DJ, Clancy J, Crowe RR, Slymen DJ, Ghoneim MM, Hinrichs JV: Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry. 1984, 41: 287-292.PubMed Noyes R, Anderson DJ, Clancy J, Crowe RR, Slymen DJ, Ghoneim MM, Hinrichs JV: Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry. 1984, 41: 287-292.PubMed
263.
Zurück zum Zitat Noyes R, Burrows GD, Reich JH, Judd FK, Garvey MJ, Norman TR, Cook BL, Marriott P: Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry. 1996, 57: 349-355.PubMed Noyes R, Burrows GD, Reich JH, Judd FK, Garvey MJ, Norman TR, Cook BL, Marriott P: Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry. 1996, 57: 349-355.PubMed
264.
Zurück zum Zitat Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F, Otto MW: Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol. 2003, 17: 276-282.PubMed Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F, Otto MW: Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol. 2003, 17: 276-282.PubMed
265.
Zurück zum Zitat Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D: Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry. 2001, 58: 681-686.PubMed Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D: Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry. 2001, 58: 681-686.PubMed
266.
Zurück zum Zitat Katzelnick DJ, Saidi J, Vanelli MR, Jefferson JW, Harper JM, McCrary KE: Time to response in panic disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone. Psychiatry (Edgmont). 2006, 3: 39-49. Katzelnick DJ, Saidi J, Vanelli MR, Jefferson JW, Harper JM, McCrary KE: Time to response in panic disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone. Psychiatry (Edgmont). 2006, 3: 39-49.
267.
Zurück zum Zitat Galynker I, Khan A, Grebchenko Y, Ten A, Malaya L, Yanowitch P, Cohen LJ: Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression [Letter]. J Clin Psychiatry. 2005, 66: 544-PubMed Galynker I, Khan A, Grebchenko Y, Ten A, Malaya L, Yanowitch P, Cohen LJ: Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression [Letter]. J Clin Psychiatry. 2005, 66: 544-PubMed
268.
Zurück zum Zitat Hollifield M, Thompson PM, Ruiz JE, Uhlenhuth EH: Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety. 2005, 21: 33-40.PubMed Hollifield M, Thompson PM, Ruiz JE, Uhlenhuth EH: Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety. 2005, 21: 33-40.PubMed
269.
Zurück zum Zitat Hoge EA, Worthington JJ, Kaufman RE, Delong HR, Pollack MH, Simon NM: Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008, 13: 522-527.PubMed Hoge EA, Worthington JJ, Kaufman RE, Delong HR, Pollack MH, Simon NM: Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008, 13: 522-527.PubMed
270.
Zurück zum Zitat Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D'Amico M, Cicconetti A, Penna L, Peca S, Carano A, et al: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006, 26: 45-49.PubMed Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D'Amico M, Cicconetti A, Penna L, Peca S, Carano A, et al: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006, 26: 45-49.PubMed
271.
Zurück zum Zitat Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH: An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006, 67: 381-385.PubMed Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH: An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006, 67: 381-385.PubMed
272.
Zurück zum Zitat Baetz M, Bowen RC: Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry. 1998, 43: 73-77.PubMed Baetz M, Bowen RC: Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry. 1998, 43: 73-77.PubMed
273.
Zurück zum Zitat Keck PE, Taylor VE, Tugrul KC, McElroy SL, Bennett JA: Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry. 1993, 33: 542-546.PubMed Keck PE, Taylor VE, Tugrul KC, McElroy SL, Bennett JA: Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry. 1993, 33: 542-546.PubMed
274.
Zurück zum Zitat Woodman CL, Noyes R: Panic disorder: treatment with valproate. J Clin Psychiatry. 1994, 55: 134-136.PubMed Woodman CL, Noyes R: Panic disorder: treatment with valproate. J Clin Psychiatry. 1994, 55: 134-136.PubMed
275.
Zurück zum Zitat Primeau F, Fontaine R, Beauclair L: Valproic acid and panic disorder. Can J Psychiatry. 1990, 35: 248-250.PubMed Primeau F, Fontaine R, Beauclair L: Valproic acid and panic disorder. Can J Psychiatry. 1990, 35: 248-250.PubMed
276.
Zurück zum Zitat Papp LA: Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry. 2006, 67: 1573-1576.PubMed Papp LA: Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry. 2006, 67: 1573-1576.PubMed
277.
Zurück zum Zitat Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T: Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000, 20: 467-471.PubMed Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T: Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000, 20: 467-471.PubMed
278.
Zurück zum Zitat Zwanzger P, Eser D, Nothdurfter C, Baghai TC, Moller HJ, Padberg F, Rupprecht R: Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. Pharmacopsychiatry. 2009, 42: 266-269.PubMed Zwanzger P, Eser D, Nothdurfter C, Baghai TC, Moller HJ, Padberg F, Rupprecht R: Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. Pharmacopsychiatry. 2009, 42: 266-269.PubMed
279.
Zurück zum Zitat Sheehan DV, Sheehan KH, Raj BA, Janavs J: An open-label study of tiagabine in panic disorder. Psychopharmacol Bull. 2007, 40: 32-40.PubMed Sheehan DV, Sheehan KH, Raj BA, Janavs J: An open-label study of tiagabine in panic disorder. Psychopharmacol Bull. 2007, 40: 32-40.PubMed
280.
Zurück zum Zitat Uhde TW, Stein MB, Post RM: Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry. 1988, 145: 1104-1109.PubMed Uhde TW, Stein MB, Post RM: Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry. 1988, 145: 1104-1109.PubMed
281.
Zurück zum Zitat Perugi G, Frare F, Toni C, Tusini G, Vannucchi G, Akiskal HS: Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year "open" follow-up study. Eur Arch Psychiatry Clin Neurosci. 2010, 260: 553-560.PubMed Perugi G, Frare F, Toni C, Tusini G, Vannucchi G, Akiskal HS: Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year "open" follow-up study. Eur Arch Psychiatry Clin Neurosci. 2010, 260: 553-560.PubMed
282.
Zurück zum Zitat Sheehan DV, Raj AB, Sheehan KH, Soto S: Is buspirone effective for panic disorder?. J Clin Psychopharmacol. 1990, 10: 3-11.PubMed Sheehan DV, Raj AB, Sheehan KH, Soto S: Is buspirone effective for panic disorder?. J Clin Psychopharmacol. 1990, 10: 3-11.PubMed
283.
Zurück zum Zitat Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B, Quadrino LM, Heninger GR: Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry. 1986, 47: 580-586.PubMed Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B, Quadrino LM, Heninger GR: Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry. 1986, 47: 580-586.PubMed
284.
Zurück zum Zitat Munjack DJ, Crocker B, Cabe D, Brown R, Usigli R, Zulueta A, McManus M, McDowell D, Palmer R, Leonard M: Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol. 1989, 9: 22-27.PubMed Munjack DJ, Crocker B, Cabe D, Brown R, Usigli R, Zulueta A, McManus M, McDowell D, Palmer R, Leonard M: Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol. 1989, 9: 22-27.PubMed
285.
Zurück zum Zitat Ravaris CL, Friedman MJ, Hauri PJ, McHugo GJ: A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. J Clin Psychopharmacol. 1991, 11: 344-350.PubMed Ravaris CL, Friedman MJ, Hauri PJ, McHugo GJ: A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. J Clin Psychopharmacol. 1991, 11: 344-350.PubMed
286.
Zurück zum Zitat Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L: Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000, 20: 556-559.PubMed Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L: Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000, 20: 556-559.PubMed
287.
Zurück zum Zitat Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjodin I, Penttinen JT, Pedersen T, Lehto HJ: A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry. 1998, 59: 528-534.PubMed Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjodin I, Penttinen JT, Pedersen T, Lehto HJ: A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry. 1998, 59: 528-534.PubMed
288.
Zurück zum Zitat Dannon PN, Iancu I, Lowengrub K, Gonopolsky Y, Musin E, Grunhaus L, Kotler M: A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol. 2007, 30: 326-334.PubMed Dannon PN, Iancu I, Lowengrub K, Gonopolsky Y, Musin E, Grunhaus L, Kotler M: A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol. 2007, 30: 326-334.PubMed
289.
Zurück zum Zitat Lecrubier Y, Judge R: Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997, 95: 153-160.PubMed Lecrubier Y, Judge R: Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997, 95: 153-160.PubMed
290.
Zurück zum Zitat Nardi AE, Freire RC, Mochcovitch MD, Amrein R, Levitan MN, King AL, Valenca AM, Veras AB, Paes F, Sardinha A, et al: A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2012, 32: 120-126.PubMed Nardi AE, Freire RC, Mochcovitch MD, Amrein R, Levitan MN, King AL, Valenca AM, Veras AB, Paes F, Sardinha A, et al: A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2012, 32: 120-126.PubMed
291.
Zurück zum Zitat Curtis GC, Massana J, Udina C, Ayuso JL, Cassano GB, Perugi G: Maintenance drug therapy of panic disorder. J Psychiatr Res. 1993, 27 (Suppl 1): 127-142.PubMed Curtis GC, Massana J, Udina C, Ayuso JL, Cassano GB, Perugi G: Maintenance drug therapy of panic disorder. J Psychiatr Res. 1993, 27 (Suppl 1): 127-142.PubMed
292.
Zurück zum Zitat Mavissakalian M, Perel JM: Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry. 1992, 49: 318-323.PubMed Mavissakalian M, Perel JM: Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry. 1992, 49: 318-323.PubMed
293.
Zurück zum Zitat Rickels K, Schweizer E: Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol. 1998, 18: 12S-18S.PubMed Rickels K, Schweizer E: Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol. 1998, 18: 12S-18S.PubMed
294.
Zurück zum Zitat Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E: Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry. 2007, 68: 58-68.PubMed Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E: Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry. 2007, 68: 58-68.PubMed
295.
Zurück zum Zitat Mavissakalian MR, Perel JM: Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry. 1999, 56: 821-827.PubMed Mavissakalian MR, Perel JM: Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry. 1999, 56: 821-827.PubMed
296.
Zurück zum Zitat Nardi AE, Freire RC, Valenca AM, Amrein R, de Cerqueira AC, Lopes FL, Nascimento I, Mezzasalma MA, Veras AB, Sardinha A, et al: Tapering clonazepam in patients with panic disorder after at least 3 years of treatment. J Clin Psychopharmacol. 2010, 30: 290-293.PubMed Nardi AE, Freire RC, Valenca AM, Amrein R, de Cerqueira AC, Lopes FL, Nascimento I, Mezzasalma MA, Veras AB, Sardinha A, et al: Tapering clonazepam in patients with panic disorder after at least 3 years of treatment. J Clin Psychopharmacol. 2010, 30: 290-293.PubMed
297.
Zurück zum Zitat Mannu P, Rinaldi S, Fontani V, Castagna A, Margotti ML: Noninvasive brain stimulation by radioelectric asymmetric conveyor in the treatment of agoraphobia: open-label, naturalistic study. Patient Prefer Adherence. 2011, 5: 575-580.PubMedCentralPubMed Mannu P, Rinaldi S, Fontani V, Castagna A, Margotti ML: Noninvasive brain stimulation by radioelectric asymmetric conveyor in the treatment of agoraphobia: open-label, naturalistic study. Patient Prefer Adherence. 2011, 5: 575-580.PubMedCentralPubMed
298.
Zurück zum Zitat Mannu P, Rinaldi S, Fontani V, Castagna A, Margotti ML: Radio electric treatment vs. escitalopram in the treatment of panic disorders associated with major depression: an open-label, naturalistic study. Acupunct Electrother Res. 2009, 34: 135-149.PubMed Mannu P, Rinaldi S, Fontani V, Castagna A, Margotti ML: Radio electric treatment vs. escitalopram in the treatment of panic disorders associated with major depression: an open-label, naturalistic study. Acupunct Electrother Res. 2009, 34: 135-149.PubMed
299.
Zurück zum Zitat Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S: Repetitive transcranial magnetic stimulation (rTMS) in the treatment of panic disorder (PD) with comorbid major depression. J Affect Disord. 2007, 102: 277-280.PubMed Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S: Repetitive transcranial magnetic stimulation (rTMS) in the treatment of panic disorder (PD) with comorbid major depression. J Affect Disord. 2007, 102: 277-280.PubMed
300.
Zurück zum Zitat Prasko J, Zalesky R, Bares M, Horacek J, Kopecek M, Novak T, Paskova B: The effect of repetitive transcranial magnetic stimulation (rTMS) add on serotonin reuptake inhibitors in patients with panic disorder: a randomized, double blind sham controlled study. Neuro Endocrinol Lett. 2007, 28: 33-38.PubMed Prasko J, Zalesky R, Bares M, Horacek J, Kopecek M, Novak T, Paskova B: The effect of repetitive transcranial magnetic stimulation (rTMS) add on serotonin reuptake inhibitors in patients with panic disorder: a randomized, double blind sham controlled study. Neuro Endocrinol Lett. 2007, 28: 33-38.PubMed
301.
Zurück zum Zitat Meuret AE, Rosenfield D, Seidel A, Bhaskara L, Hofmann SG: Respiratory and cognitive mediators of treatment change in panic disorder: evidence for intervention specificity. J Consult Clin Psychol. 2010, 78: 691-704.PubMedCentralPubMed Meuret AE, Rosenfield D, Seidel A, Bhaskara L, Hofmann SG: Respiratory and cognitive mediators of treatment change in panic disorder: evidence for intervention specificity. J Consult Clin Psychol. 2010, 78: 691-704.PubMedCentralPubMed
302.
Zurück zum Zitat Wollburg E, Roth WT, Kim S: Effects of breathing training on voluntary hypo- and hyperventilation in patients with panic disorder and episodic anxiety. Appl Psychophysiol Biofeedback. 2011, 36: 81-91.PubMed Wollburg E, Roth WT, Kim S: Effects of breathing training on voluntary hypo- and hyperventilation in patients with panic disorder and episodic anxiety. Appl Psychophysiol Biofeedback. 2011, 36: 81-91.PubMed
303.
Zurück zum Zitat Wedekind D, Broocks A, Weiss N, Engel K, Neubert K, Bandelow B: A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. World J Biol Psychiatry. 2010, 11: 904-913.PubMed Wedekind D, Broocks A, Weiss N, Engel K, Neubert K, Bandelow B: A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. World J Biol Psychiatry. 2010, 11: 904-913.PubMed
304.
Zurück zum Zitat Strohle A, Graetz B, Scheel M, Wittmann A, Feller C, Heinz A, Dimeo F: The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects. J Psychiatr Res. 2009, 43: 1013-1017.PubMed Strohle A, Graetz B, Scheel M, Wittmann A, Feller C, Heinz A, Dimeo F: The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects. J Psychiatr Res. 2009, 43: 1013-1017.PubMed
305.
Zurück zum Zitat Stinson FS, Dawson DA, Patricia Chou S, Smith S, Goldstein RB, June Ruan W, Grant BF: The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2007, 37: 1047-1059.PubMed Stinson FS, Dawson DA, Patricia Chou S, Smith S, Goldstein RB, June Ruan W, Grant BF: The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2007, 37: 1047-1059.PubMed
306.
Zurück zum Zitat LeBeau RT, Glenn D, Liao B, Wittchen HU, Beesdo-Baum K, Ollendick T, Craske MG: Specific phobia: a review of DSM-IV specific phobia and preliminary recommendations for DSM-V. Depress Anxiety. 2010, 27: 148-167.PubMed LeBeau RT, Glenn D, Liao B, Wittchen HU, Beesdo-Baum K, Ollendick T, Craske MG: Specific phobia: a review of DSM-IV specific phobia and preliminary recommendations for DSM-V. Depress Anxiety. 2010, 27: 148-167.PubMed
307.
Zurück zum Zitat Becker ES, Rinck M, Turke V, Kause P, Goodwin R, Neumer S, Margraf J: Epidemiology of specific phobia subtypes: findings from the Dresden Mental Health Study. Eur Psychiatry. 2007, 22: 69-74.PubMed Becker ES, Rinck M, Turke V, Kause P, Goodwin R, Neumer S, Margraf J: Epidemiology of specific phobia subtypes: findings from the Dresden Mental Health Study. Eur Psychiatry. 2007, 22: 69-74.PubMed
308.
Zurück zum Zitat Benjet C, Borges G, Stein D, Mendez E, Medina-Mora M: Epidemiology of fears and specific phobia in adolescence: results from the Mexican Adolescent Mental Health Survey. J Clin Psychiatry. 2012, 73: 152-158.PubMed Benjet C, Borges G, Stein D, Mendez E, Medina-Mora M: Epidemiology of fears and specific phobia in adolescence: results from the Mexican Adolescent Mental Health Survey. J Clin Psychiatry. 2012, 73: 152-158.PubMed
309.
Zurück zum Zitat Trumpf J, Margraf J, Vriends N, Meyer AH, Becker ES: Specific phobia predicts psychopathology in young women. Soc Psychiatry Psychiatr Epidemiol. 2010, 45: 1161-1166.PubMedCentralPubMed Trumpf J, Margraf J, Vriends N, Meyer AH, Becker ES: Specific phobia predicts psychopathology in young women. Soc Psychiatry Psychiatr Epidemiol. 2010, 45: 1161-1166.PubMedCentralPubMed
310.
Zurück zum Zitat Choy Y, Fyer AJ, Goodwin RD: Specific phobia and comorbid depression: a closer look at the National Comorbidity Survey data. Compr Psychiatry. 2007, 48: 132-136.PubMed Choy Y, Fyer AJ, Goodwin RD: Specific phobia and comorbid depression: a closer look at the National Comorbidity Survey data. Compr Psychiatry. 2007, 48: 132-136.PubMed
311.
Zurück zum Zitat Hood H, Antony M: Evidence-based assessment and treatment of specific phobias in adults, Chapt.2. Intensive one-session treatment of specific phobias. Edited by: Davis T, Ollendick T, Öst L-G. 2012, New York: Springer, 19-42. Autism and Child Psychopathology Series Hood H, Antony M: Evidence-based assessment and treatment of specific phobias in adults, Chapt.2. Intensive one-session treatment of specific phobias. Edited by: Davis T, Ollendick T, Öst L-G. 2012, New York: Springer, 19-42. Autism and Child Psychopathology Series
312.
Zurück zum Zitat Parsons TD, Rizzo AA: Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: a meta-analysis. J Behav Ther Exp Psychiatry. 2008, 39: 250-261.PubMed Parsons TD, Rizzo AA: Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: a meta-analysis. J Behav Ther Exp Psychiatry. 2008, 39: 250-261.PubMed
313.
Zurück zum Zitat Ollendick TH, Ost LG, Reuterskiold L, Costa N, Cederlund R, Sirbu C, Davis TE, Jarrett MA: One-session treatment of specific phobias in youth: a randomized clinical trial in the United States and Sweden. J Consult Clin Psychol. 2009, 77: 504-516.PubMed Ollendick TH, Ost LG, Reuterskiold L, Costa N, Cederlund R, Sirbu C, Davis TE, Jarrett MA: One-session treatment of specific phobias in youth: a randomized clinical trial in the United States and Sweden. J Consult Clin Psychol. 2009, 77: 504-516.PubMed
314.
Zurück zum Zitat Craske MG, Kircanski K, Zelikowsky M, Mystkowski J, Chowdhury N, Baker A: Optimizing inhibitory learning during exposure therapy. Behav Res Ther. 2008, 46: 5-27.PubMed Craske MG, Kircanski K, Zelikowsky M, Mystkowski J, Chowdhury N, Baker A: Optimizing inhibitory learning during exposure therapy. Behav Res Ther. 2008, 46: 5-27.PubMed
315.
Zurück zum Zitat Öst L-G, Fellenius J, Sterner U: Applied tension, exposure in vivo, and tension-only in the treatment of blood phobia. Behav Res Ther. 1991, 29: 561-574.PubMed Öst L-G, Fellenius J, Sterner U: Applied tension, exposure in vivo, and tension-only in the treatment of blood phobia. Behav Res Ther. 1991, 29: 561-574.PubMed
316.
Zurück zum Zitat Hellstrom K, Fellenius J, Öst L-G: One versus five sessions of applied tension in the treatment of blood phobia. Behav Res Ther. 1996, 34: 101-112.PubMed Hellstrom K, Fellenius J, Öst L-G: One versus five sessions of applied tension in the treatment of blood phobia. Behav Res Ther. 1996, 34: 101-112.PubMed
317.
Zurück zum Zitat Kettwich SC, Sibbitt WL, Brandt JR, Johnson CR, Wong CS, Bankhurst AD: Needle phobia and stress-reducing medical devices in pediatric and adult chemotherapy patients. J Pediatr Oncol Nurs. 2007, 24: 20-28.PubMed Kettwich SC, Sibbitt WL, Brandt JR, Johnson CR, Wong CS, Bankhurst AD: Needle phobia and stress-reducing medical devices in pediatric and adult chemotherapy patients. J Pediatr Oncol Nurs. 2007, 24: 20-28.PubMed
318.
Zurück zum Zitat Vika M, Skaret E, Raadal M, Ost LG, Kvale G: One- vs. five-session treatment of intra-oral injection phobia: a randomized clinical study. Eur J Oral Sci. 2009, 117: 279-285.PubMed Vika M, Skaret E, Raadal M, Ost LG, Kvale G: One- vs. five-session treatment of intra-oral injection phobia: a randomized clinical study. Eur J Oral Sci. 2009, 117: 279-285.PubMed
319.
Zurück zum Zitat Krijn M, Emmelkamp PM, Olafsson RP, Bouwman M, van Gerwen LJ, Spinhoven P, Schuemie MJ, van der Mast CA: Fear of flying treatment methods: virtual reality exposure vs. cognitive behavioral therapy. Aviat Space Environ Med. 2007, 78: 121-128.PubMed Krijn M, Emmelkamp PM, Olafsson RP, Bouwman M, van Gerwen LJ, Spinhoven P, Schuemie MJ, van der Mast CA: Fear of flying treatment methods: virtual reality exposure vs. cognitive behavioral therapy. Aviat Space Environ Med. 2007, 78: 121-128.PubMed
320.
Zurück zum Zitat Van Gerwen LJ, Spinhoven P, Van Dyck R: Behavioral and cognitive group treatment for fear of flying: a randomized controlled trial. J Behav Ther Exp Psychiatry. 2006, 37: 358-371.PubMed Van Gerwen LJ, Spinhoven P, Van Dyck R: Behavioral and cognitive group treatment for fear of flying: a randomized controlled trial. J Behav Ther Exp Psychiatry. 2006, 37: 358-371.PubMed
321.
Zurück zum Zitat Wiederhold BK, Jang DP, Gevirtz RG, Kim SI, Kim IY, Wiederhold MD: The treatment of fear of flying: a controlled study of imaginal and virtual reality graded exposure therapy. IEEE Trans Inf Technol Biomed. 2002, 6: 218-223.PubMed Wiederhold BK, Jang DP, Gevirtz RG, Kim SI, Kim IY, Wiederhold MD: The treatment of fear of flying: a controlled study of imaginal and virtual reality graded exposure therapy. IEEE Trans Inf Technol Biomed. 2002, 6: 218-223.PubMed
322.
Zurück zum Zitat Rothbaum BO, Hodges L, Smith S, Lee JH, Price L: A controlled study of virtual reality exposure therapy for the fear of flying. J Consult Clin Psychol. 2000, 68: 1020-1026.PubMed Rothbaum BO, Hodges L, Smith S, Lee JH, Price L: A controlled study of virtual reality exposure therapy for the fear of flying. J Consult Clin Psychol. 2000, 68: 1020-1026.PubMed
323.
Zurück zum Zitat Tortella-Feliu M, Botella C, Llabres J, Breton-Lopez JM, del Amo AR, Banos RM, Gelabert JM: Virtual reality versus computer-aided exposure treatments for fear of flying. Behav Modif. 2011, 35: 3-30.PubMed Tortella-Feliu M, Botella C, Llabres J, Breton-Lopez JM, del Amo AR, Banos RM, Gelabert JM: Virtual reality versus computer-aided exposure treatments for fear of flying. Behav Modif. 2011, 35: 3-30.PubMed
324.
Zurück zum Zitat Rothbaum BO, Anderson P, Zimand E, Hodges L, Lang D, Wilson J: Virtual reality exposure therapy and standard (in vivo) exposure therapy in the treatment of fear of flying. Behav Ther. 2006, 37: 80-90.PubMed Rothbaum BO, Anderson P, Zimand E, Hodges L, Lang D, Wilson J: Virtual reality exposure therapy and standard (in vivo) exposure therapy in the treatment of fear of flying. Behav Ther. 2006, 37: 80-90.PubMed
325.
Zurück zum Zitat Kim S, Palin F, Anderson P, Edwards S, Lindner G, Rothbaum BO: Use of skills learned in CBT for fear of flying: managing flying anxiety after September 11th. J Anxiety Disord. 2008, 22: 301-309.PubMedCentralPubMed Kim S, Palin F, Anderson P, Edwards S, Lindner G, Rothbaum BO: Use of skills learned in CBT for fear of flying: managing flying anxiety after September 11th. J Anxiety Disord. 2008, 22: 301-309.PubMedCentralPubMed
326.
Zurück zum Zitat Anderson P, Jacobs CH, Lindner GK, Edwards S, Zimand E, Hodges L, Rothbaum BO: Cognitive behavior therapy for fear of flying: sustainability of treatment gains after September 11. Behav Ther. 2006, 37: 91-97.PubMed Anderson P, Jacobs CH, Lindner GK, Edwards S, Zimand E, Hodges L, Rothbaum BO: Cognitive behavior therapy for fear of flying: sustainability of treatment gains after September 11. Behav Ther. 2006, 37: 91-97.PubMed
327.
Zurück zum Zitat Emmelkamp PM, Krijn M, Hulsbosch AM, de Vries S, Schuemie MJ, van der Mast CA: Virtual reality treatment versus exposure in vivo: a comparative evaluation in acrophobia. Behav Res Ther. 2002, 40: 509-516.PubMed Emmelkamp PM, Krijn M, Hulsbosch AM, de Vries S, Schuemie MJ, van der Mast CA: Virtual reality treatment versus exposure in vivo: a comparative evaluation in acrophobia. Behav Res Ther. 2002, 40: 509-516.PubMed
328.
Zurück zum Zitat Rothbaum BO, Hodges LF, Kooper R, Opdyke D, Williford JS, North M: Effectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia. Am J Psychiatry. 1995, 152: 626-628.PubMed Rothbaum BO, Hodges LF, Kooper R, Opdyke D, Williford JS, North M: Effectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia. Am J Psychiatry. 1995, 152: 626-628.PubMed
329.
Zurück zum Zitat Krijn M, Emmelkamp PM, Olafsson RP, Schuemie MJ, van der Mast CA: Do self-statements enhance the effectiveness of virtual reality exposure therapy? A comparative evaluation in acrophobia. Cyberpsychol Behav. 2007, 10: 362-370.PubMed Krijn M, Emmelkamp PM, Olafsson RP, Schuemie MJ, van der Mast CA: Do self-statements enhance the effectiveness of virtual reality exposure therapy? A comparative evaluation in acrophobia. Cyberpsychol Behav. 2007, 10: 362-370.PubMed
330.
Zurück zum Zitat Malbos E, Mestre DR, Note ID, Gellato C: Virtual reality and claustrophobia: multiple components therapy involving game editor virtual environments exposure. Cyberpsychol Behav. 2008, 11: 695-697.PubMed Malbos E, Mestre DR, Note ID, Gellato C: Virtual reality and claustrophobia: multiple components therapy involving game editor virtual environments exposure. Cyberpsychol Behav. 2008, 11: 695-697.PubMed
331.
Zurück zum Zitat Michaliszyn D, Marchand A, Bouchard S, Martel MO, Poirier-Bisson J: A randomized, controlled clinical trial of in virtuo and in vivo exposure for spider phobia. Cyberpsychol Behav Soc Netw. 2010, 13: 689-695.PubMed Michaliszyn D, Marchand A, Bouchard S, Martel MO, Poirier-Bisson J: A randomized, controlled clinical trial of in virtuo and in vivo exposure for spider phobia. Cyberpsychol Behav Soc Netw. 2010, 13: 689-695.PubMed
332.
Zurück zum Zitat Bouchard S, Cote S, St-Jacques J, Robillard G, Renaud P: Effectiveness of virtual reality exposure in the treatment of arachnophobia using 3D games. Technol Health Care. 2006, 14: 19-27.PubMed Bouchard S, Cote S, St-Jacques J, Robillard G, Renaud P: Effectiveness of virtual reality exposure in the treatment of arachnophobia using 3D games. Technol Health Care. 2006, 14: 19-27.PubMed
333.
Zurück zum Zitat Granado LC, Ranvaud R, Pelaez JR: A spiderless arachnophobia therapy: comparison between placebo and treatment groups and six-month follow-up study. Neural Plast. 2007, 2007: 10241-PubMedCentralPubMed Granado LC, Ranvaud R, Pelaez JR: A spiderless arachnophobia therapy: comparison between placebo and treatment groups and six-month follow-up study. Neural Plast. 2007, 2007: 10241-PubMedCentralPubMed
334.
Zurück zum Zitat Andersson G, Waara J, Jonsson U, Malmaeus F, Carlbring P, Ost LG: Internet-based self-help versus one-session exposure in the treatment of spider phobia: a randomized controlled trial. Cogn Behav Ther. 2009, 38: 114-120.PubMed Andersson G, Waara J, Jonsson U, Malmaeus F, Carlbring P, Ost LG: Internet-based self-help versus one-session exposure in the treatment of spider phobia: a randomized controlled trial. Cogn Behav Ther. 2009, 38: 114-120.PubMed
335.
Zurück zum Zitat Muller BH, Kull S, Wilhelm FH, Michael T: One-session computer-based exposure treatment for spider-fearful individuals--efficacy of a minimal self-help intervention in a randomised controlled trial. J Behav Ther Exp Psychiatry. 2011, 42: 179-184.PubMed Muller BH, Kull S, Wilhelm FH, Michael T: One-session computer-based exposure treatment for spider-fearful individuals--efficacy of a minimal self-help intervention in a randomised controlled trial. J Behav Ther Exp Psychiatry. 2011, 42: 179-184.PubMed
336.
Zurück zum Zitat Botella C, Quero S, Banos RM, Garcia-Palacios A, Breton-Lopez J, Alcaniz M, Fabregat S: Telepsychology and self-help: the treatment of phobias using the internet. Cyberpsychol Behav. 2008, 11: 659-664.PubMed Botella C, Quero S, Banos RM, Garcia-Palacios A, Breton-Lopez J, Alcaniz M, Fabregat S: Telepsychology and self-help: the treatment of phobias using the internet. Cyberpsychol Behav. 2008, 11: 659-664.PubMed
337.
Zurück zum Zitat Botella C, Breton-Lopez J, Quero S, Banos R, Garcia-Palacios A: Treating cockroach phobia with augmented reality. Behav Ther. 2010, 41: 401-413.PubMed Botella C, Breton-Lopez J, Quero S, Banos R, Garcia-Palacios A: Treating cockroach phobia with augmented reality. Behav Ther. 2010, 41: 401-413.PubMed
338.
Zurück zum Zitat Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M: Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004, 61: 1136-1144.PubMed Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M: Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004, 61: 1136-1144.PubMed
339.
Zurück zum Zitat Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R: A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. J Psychiatr Res. 2007, 41: 466-471.PubMed Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R: A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. J Psychiatr Res. 2007, 41: 466-471.PubMed
340.
Zurück zum Zitat de Quervain DJ, Bentz D, Michael T, Bolt OC, Wiederhold BK, Margraf J, Wilhelm FH: Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci U S A. 2011, 108: 6621-6625.PubMedCentralPubMed de Quervain DJ, Bentz D, Michael T, Bolt OC, Wiederhold BK, Margraf J, Wilhelm FH: Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci U S A. 2011, 108: 6621-6625.PubMedCentralPubMed
341.
Zurück zum Zitat Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, Roozendaal B, de Quervain DJ: Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci U S A. 2006, 103: 5585-5590.PubMedCentralPubMed Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, Roozendaal B, de Quervain DJ: Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci U S A. 2006, 103: 5585-5590.PubMedCentralPubMed
342.
Zurück zum Zitat Meyerbroeker K, Powers MB, van Stegeren A, Emmelkamp PM: Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial. Psychother Psychosom. 2012, 81: 29-37.PubMed Meyerbroeker K, Powers MB, van Stegeren A, Emmelkamp PM: Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial. Psychother Psychosom. 2012, 81: 29-37.PubMed
343.
Zurück zum Zitat Powers MB, Smits JA, Otto MW, Sanders C, Emmelkamp PM: Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord. 2009, 23: 350-356.PubMed Powers MB, Smits JA, Otto MW, Sanders C, Emmelkamp PM: Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord. 2009, 23: 350-356.PubMed
344.
Zurück zum Zitat Kozak AT, Spates CR, McChargue DE, Bailey KC, Schneider KL, Liepman MR: Naltrexone renders one-session exposure therapy less effective: a controlled pilot study. J Anxiety Disord. 2007, 21: 142-152.PubMed Kozak AT, Spates CR, McChargue DE, Bailey KC, Schneider KL, Liepman MR: Naltrexone renders one-session exposure therapy less effective: a controlled pilot study. J Anxiety Disord. 2007, 21: 142-152.PubMed
345.
Zurück zum Zitat Benjamin J, Ben-Zion I, Karbofsky E, Dannon P: Double-blind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology (Berl). 2000, 149: 194-196. Benjamin J, Ben-Zion I, Karbofsky E, Dannon P: Double-blind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology (Berl). 2000, 149: 194-196.
346.
Zurück zum Zitat Alamy S, Wei Z, Varia I, Davidson JR, Connor KM: Escitalopram in specific phobia: results of a placebo-controlled pilot trial. J Psychopharmacol. 2008, 22: 157-161.PubMed Alamy S, Wei Z, Varia I, Davidson JR, Connor KM: Escitalopram in specific phobia: results of a placebo-controlled pilot trial. J Psychopharmacol. 2008, 22: 157-161.PubMed
347.
Zurück zum Zitat Abene MV, Hamilton JD: Resolution of fear of flying with fluoxetine treatment. J Anxiety Disord. 1998, 12: 599-603.PubMed Abene MV, Hamilton JD: Resolution of fear of flying with fluoxetine treatment. J Anxiety Disord. 1998, 12: 599-603.PubMed
348.
Zurück zum Zitat Balon R: Fluvoxamine for phobia of storms. Acta Psychiatr Scand. 1999, 100: 244-245. discussion 245-246PubMed Balon R: Fluvoxamine for phobia of storms. Acta Psychiatr Scand. 1999, 100: 244-245. discussion 245-246PubMed
349.
Zurück zum Zitat Choy Y, Fyer AJ, Lipsitz JD: Treatment of specific phobia in adults. Clin Psychol Rev. 2007, 27: 266-286.PubMed Choy Y, Fyer AJ, Lipsitz JD: Treatment of specific phobia in adults. Clin Psychol Rev. 2007, 27: 266-286.PubMed
350.
Zurück zum Zitat Wilhelm FH, Roth WT: Acute and delayed effects of alprazolam on flight phobics during exposure. Behav Res Ther. 1997, 35: 831-841.PubMed Wilhelm FH, Roth WT: Acute and delayed effects of alprazolam on flight phobics during exposure. Behav Res Ther. 1997, 35: 831-841.PubMed
351.
Zurück zum Zitat Johren P, Jackowski J, Gangler P, Sartory G, Thom A: Fear reduction in patients with dental treatment phobia. Br J Oral Maxillofac Surg. 2000, 38: 612-616.PubMed Johren P, Jackowski J, Gangler P, Sartory G, Thom A: Fear reduction in patients with dental treatment phobia. Br J Oral Maxillofac Surg. 2000, 38: 612-616.PubMed
352.
Zurück zum Zitat Tschirch FT, Suter K, Froehlich JM, Studler U, Nidecker A, Eckhardt B, Beranek-Chiu J, Surber C, Weishaupt D: Multicenter trial: comparison of two different formulations and application systems of low-dose nasal midazolam for routine magnetic resonance imaging of claustrophobic patients. J Magn Reson Imaging. 2008, 28: 866-872.PubMed Tschirch FT, Suter K, Froehlich JM, Studler U, Nidecker A, Eckhardt B, Beranek-Chiu J, Surber C, Weishaupt D: Multicenter trial: comparison of two different formulations and application systems of low-dose nasal midazolam for routine magnetic resonance imaging of claustrophobic patients. J Magn Reson Imaging. 2008, 28: 866-872.PubMed
353.
Zurück zum Zitat Tschirch FT, Gopfert K, Frohlich JM, Brunner G, Weishaupt D: Low-dose intranasal versus oral midazolam for routine body MRI of claustrophobic patients. Eur Radiol. 2007, 17: 1403-1410.PubMed Tschirch FT, Gopfert K, Frohlich JM, Brunner G, Weishaupt D: Low-dose intranasal versus oral midazolam for routine body MRI of claustrophobic patients. Eur Radiol. 2007, 17: 1403-1410.PubMed
354.
Zurück zum Zitat Mather AA, Stein MB, Sareen J: Social anxiety disorder and social fears in the Canadian military: prevalence, comorbidity, impairment, and treatment-seeking. J Psychiatr Res. 2010, 44: 887-893.PubMed Mather AA, Stein MB, Sareen J: Social anxiety disorder and social fears in the Canadian military: prevalence, comorbidity, impairment, and treatment-seeking. J Psychiatr Res. 2010, 44: 887-893.PubMed
355.
Zurück zum Zitat Beesdo K, Bittner A, Pine DS, Stein MB, Hofler M, Lieb R, Wittchen HU: Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry. 2007, 64: 903-912.PubMed Beesdo K, Bittner A, Pine DS, Stein MB, Hofler M, Lieb R, Wittchen HU: Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry. 2007, 64: 903-912.PubMed
356.
Zurück zum Zitat Shields M: Social anxiety disorder--beyond shyness. Health Rep. 2004, 15 (Suppl): 45-61.PubMed Shields M: Social anxiety disorder--beyond shyness. Health Rep. 2004, 15 (Suppl): 45-61.PubMed
357.
Zurück zum Zitat Magee W, Eaton W, Wittchen H, McGonagle K, Kessler R: Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 1996, 53: 159-168.PubMed Magee W, Eaton W, Wittchen H, McGonagle K, Kessler R: Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 1996, 53: 159-168.PubMed
358.
Zurück zum Zitat Stein M, Walker J, Forde D: Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. Am J Psychiatry. 1994, 151: 408-412.PubMed Stein M, Walker J, Forde D: Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. Am J Psychiatry. 1994, 151: 408-412.PubMed
359.
Zurück zum Zitat Schneier F, Johnson J, Hornig C, Liebowitz M, Weissman M: Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992, 49: 282-288.PubMed Schneier F, Johnson J, Hornig C, Liebowitz M, Weissman M: Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992, 49: 282-288.PubMed
360.
Zurück zum Zitat Ohayon MM, Schatzberg AF: Social phobia and depression: prevalence and comorbidity. J Psychosom Res. 2010, 68: 235-243.PubMed Ohayon MM, Schatzberg AF: Social phobia and depression: prevalence and comorbidity. J Psychosom Res. 2010, 68: 235-243.PubMed
361.
Zurück zum Zitat Stein DJ, Ruscio AM, Lee S, Petukhova M, Alonso J, Andrade LH, Benjet C, Bromet E, Demyttenaere K, Florescu S, et al: Subtyping social anxiety disorder in developed and developing countries. Depress Anxiety. 2010, 27: 390-403.PubMedCentralPubMed Stein DJ, Ruscio AM, Lee S, Petukhova M, Alonso J, Andrade LH, Benjet C, Bromet E, Demyttenaere K, Florescu S, et al: Subtyping social anxiety disorder in developed and developing countries. Depress Anxiety. 2010, 27: 390-403.PubMedCentralPubMed
362.
Zurück zum Zitat Ramsawh HJ, Raffa SD, Edelen MO, Rende R, Keller MB: Anxiety in middle adulthood: effects of age and time on the 14-year course of panic disorder, social phobia and generalized anxiety disorder. Psychol Med. 2009, 39: 615-624.PubMedCentralPubMed Ramsawh HJ, Raffa SD, Edelen MO, Rende R, Keller MB: Anxiety in middle adulthood: effects of age and time on the 14-year course of panic disorder, social phobia and generalized anxiety disorder. Psychol Med. 2009, 39: 615-624.PubMedCentralPubMed
363.
Zurück zum Zitat Ruscio AM, Brown TA, Chiu WT, Sareen J, Stein MB, Kessler RC: Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med. 2008, 38: 15-28.PubMedCentralPubMed Ruscio AM, Brown TA, Chiu WT, Sareen J, Stein MB, Kessler RC: Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med. 2008, 38: 15-28.PubMedCentralPubMed
364.
Zurück zum Zitat Acarturk C, Smit F, de Graaf R, van Straten A, ten Have M, Cuijpers P: Incidence of social phobia and identification of its risk indicators: a model for prevention. Acta Psychiatr Scand. 2009, 119: 62-70.PubMed Acarturk C, Smit F, de Graaf R, van Straten A, ten Have M, Cuijpers P: Incidence of social phobia and identification of its risk indicators: a model for prevention. Acta Psychiatr Scand. 2009, 119: 62-70.PubMed
365.
Zurück zum Zitat Kessler R, Stein M, Berglund P: Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry. 1998, 155: 613-619.PubMed Kessler R, Stein M, Berglund P: Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry. 1998, 155: 613-619.PubMed
366.
Zurück zum Zitat Wong N, Sarver DE, Beidel DC: Quality of life impairments among adults with social phobia: the impact of subtype. J Anxiety Disord. 2012, 26: 50-57.PubMedCentralPubMed Wong N, Sarver DE, Beidel DC: Quality of life impairments among adults with social phobia: the impact of subtype. J Anxiety Disord. 2012, 26: 50-57.PubMedCentralPubMed
367.
Zurück zum Zitat Aderka IM, Hofmann SG, Nickerson A, Hermesh H, Gilboa-Schechtman E, Marom S: Functional impairment in social anxiety disorder. J Anxiety Disord. 2012, 26: 393-400.PubMed Aderka IM, Hofmann SG, Nickerson A, Hermesh H, Gilboa-Schechtman E, Marom S: Functional impairment in social anxiety disorder. J Anxiety Disord. 2012, 26: 393-400.PubMed
368.
Zurück zum Zitat Tolman RM, Himle J, Bybee D, Abelson JL, Hoffman J, Van Etten-Lee M: Impact of social anxiety disorder on employment among women receiving welfare benefits. Psychiatr Serv. 2009, 60: 61-66.PubMed Tolman RM, Himle J, Bybee D, Abelson JL, Hoffman J, Van Etten-Lee M: Impact of social anxiety disorder on employment among women receiving welfare benefits. Psychiatr Serv. 2009, 60: 61-66.PubMed
369.
Zurück zum Zitat Moitra E, Beard C, Weisberg RB, Keller MB: Occupational impairment and social anxiety disorder in a sample of primary care patients. J Affect Disord. 2011, 130: 209-212.PubMed Moitra E, Beard C, Weisberg RB, Keller MB: Occupational impairment and social anxiety disorder in a sample of primary care patients. J Affect Disord. 2011, 130: 209-212.PubMed
370.
Zurück zum Zitat Acarturk C, Smit F, de Graaf R, van Straten A, Ten Have M, Cuijpers P: Economic costs of social phobia: a population-based study. J Affect Disord. 2009, 115: 421-429.PubMed Acarturk C, Smit F, de Graaf R, van Straten A, Ten Have M, Cuijpers P: Economic costs of social phobia: a population-based study. J Affect Disord. 2009, 115: 421-429.PubMed
371.
Zurück zum Zitat Smit F, Cuijpers P, Oostenbrink J, Batelaan N, de Graaf R, Beekman A: Costs of nine common mental disorders: implications for curative and preventive psychiatry. J Ment Health Policy Econ. 2006, 9: 193-200.PubMed Smit F, Cuijpers P, Oostenbrink J, Batelaan N, de Graaf R, Beekman A: Costs of nine common mental disorders: implications for curative and preventive psychiatry. J Ment Health Policy Econ. 2006, 9: 193-200.PubMed
372.
Zurück zum Zitat Filho AS, Hetem LA, Ferrari MC, Trzesniak C, Martin-Santos R, Borduqui T, de Lima Osorio F, Loureiro SR, Busatto Filho G, Zuardi AW, Crippa JA: Social anxiety disorder: what are we losing with the current diagnostic criteria?. Acta Psychiatr Scand. 2010, 121: 216-226.PubMed Filho AS, Hetem LA, Ferrari MC, Trzesniak C, Martin-Santos R, Borduqui T, de Lima Osorio F, Loureiro SR, Busatto Filho G, Zuardi AW, Crippa JA: Social anxiety disorder: what are we losing with the current diagnostic criteria?. Acta Psychiatr Scand. 2010, 121: 216-226.PubMed
373.
Zurück zum Zitat Cox BJ, Turnbull DL, Robinson JA, Grant BF, Stein MB: The effect of avoidant personality disorder on the persistence of generalized social anxiety disorder in the general population: results from a longitudinal, nationally representative mental health survey. Depress Anxiety. 2011, 28: 250-255.PubMed Cox BJ, Turnbull DL, Robinson JA, Grant BF, Stein MB: The effect of avoidant personality disorder on the persistence of generalized social anxiety disorder in the general population: results from a longitudinal, nationally representative mental health survey. Depress Anxiety. 2011, 28: 250-255.PubMed
374.
Zurück zum Zitat Kelly MM, Walters C, Phillips KA: Social anxiety and its relationship to functional impairment in body dysmorphic disorder. Behav Ther. 2010, 41: 143-153.PubMed Kelly MM, Walters C, Phillips KA: Social anxiety and its relationship to functional impairment in body dysmorphic disorder. Behav Ther. 2010, 41: 143-153.PubMed
375.
Zurück zum Zitat Coles ME, Phillips KA, Menard W, Pagano ME, Fay C, Weisberg RB, Stout RL: Body dysmorphic disorder and social phobia: cross-sectional and prospective data. Depress Anxiety. 2006, 23: 26-33.PubMedCentralPubMed Coles ME, Phillips KA, Menard W, Pagano ME, Fay C, Weisberg RB, Stout RL: Body dysmorphic disorder and social phobia: cross-sectional and prospective data. Depress Anxiety. 2006, 23: 26-33.PubMedCentralPubMed
376.
Zurück zum Zitat Book SW, Thomas SE, Randall PK, Randall CL: Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. J Anxiety Disord. 2008, 22: 310-318.PubMedCentralPubMed Book SW, Thomas SE, Randall PK, Randall CL: Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. J Anxiety Disord. 2008, 22: 310-318.PubMedCentralPubMed
377.
Zurück zum Zitat Bernardi S, Faraone SV, Cortese S, Kerridge BT, Pallanti S, Wang S, Blanco C: The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychol Med. 2012, 42: 875-887.PubMedCentralPubMed Bernardi S, Faraone SV, Cortese S, Kerridge BT, Pallanti S, Wang S, Blanco C: The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychol Med. 2012, 42: 875-887.PubMedCentralPubMed
378.
Zurück zum Zitat Van Ameringen M, Mancini C, Simpson W, Patterson B: Adult attention deficit hyperactivity disorder in an anxiety disorders population. CNS Neurosci Ther. 2011, 17: 221-226.PubMed Van Ameringen M, Mancini C, Simpson W, Patterson B: Adult attention deficit hyperactivity disorder in an anxiety disorders population. CNS Neurosci Ther. 2011, 17: 221-226.PubMed
379.
Zurück zum Zitat Stern RG, Petti TA, Bopp K, Tobia A: Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. J Clin Psychopharmacol. 2009, 29: 206-209.PubMed Stern RG, Petti TA, Bopp K, Tobia A: Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. J Clin Psychopharmacol. 2009, 29: 206-209.PubMed
380.
Zurück zum Zitat Bogels SM, Alden L, Beidel DC, Clark LA, Pine DS, Stein MB, Voncken M: Social anxiety disorder: questions and answers for the DSM-V. Depress Anxiety. 2010, 27: 168-189.PubMed Bogels SM, Alden L, Beidel DC, Clark LA, Pine DS, Stein MB, Voncken M: Social anxiety disorder: questions and answers for the DSM-V. Depress Anxiety. 2010, 27: 168-189.PubMed
381.
Zurück zum Zitat Taylor S: Meta-analysis of cognitive-behavioral treatments for social phobia. J Behav Ther Exp Psychiatry. 1996, 27: 1-9.PubMed Taylor S: Meta-analysis of cognitive-behavioral treatments for social phobia. J Behav Ther Exp Psychiatry. 1996, 27: 1-9.PubMed
382.
Zurück zum Zitat Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B: Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol. 2003, 71: 1058-1067.PubMed Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B: Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol. 2003, 71: 1058-1067.PubMed
383.
Zurück zum Zitat Clark D, Agras W: The assessment and treatment of performance anxiety in musicians. Am J Psychiatry. 1991, 148: 598-605.PubMed Clark D, Agras W: The assessment and treatment of performance anxiety in musicians. Am J Psychiatry. 1991, 148: 598-605.PubMed
384.
Zurück zum Zitat Heimberg R, Liebowitz M, Hope D, Schneier F, Holt C, Welkowitz L, Juster H, Campeas R, Bruch M, Cloitre M, et al: Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry. 1998, 55: 1133-1141.PubMed Heimberg R, Liebowitz M, Hope D, Schneier F, Holt C, Welkowitz L, Juster H, Campeas R, Bruch M, Cloitre M, et al: Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry. 1998, 55: 1133-1141.PubMed
385.
Zurück zum Zitat Otto M, Pollack M, Gould R, Worthington J, McArdle E, Rosenbaum J: A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord. 2000, 14: 345-358.PubMed Otto M, Pollack M, Gould R, Worthington J, McArdle E, Rosenbaum J: A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord. 2000, 14: 345-358.PubMed
386.
Zurück zum Zitat Gelernter C, Uhde T, Cimbolic P, Arnkoff D, Vittone B, Tancer M, Bartko J: Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry. 1991, 48: 938-945.PubMed Gelernter C, Uhde T, Cimbolic P, Arnkoff D, Vittone B, Tancer M, Bartko J: Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry. 1991, 48: 938-945.PubMed
387.
Zurück zum Zitat Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM: Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004, 61: 1005-1013.PubMed Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM: Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004, 61: 1005-1013.PubMed
388.
Zurück zum Zitat Liebowitz M, Heimberg R, Schneier F, Hope D, Davies S, Holt C, Goetz D, Juster H, Lin S, Bruch M, et al: Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety. 1999, 10: 89-98.PubMed Liebowitz M, Heimberg R, Schneier F, Hope D, Davies S, Holt C, Goetz D, Juster H, Lin S, Bruch M, et al: Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety. 1999, 10: 89-98.PubMed
389.
Zurück zum Zitat Haug T, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu H, Wold J: Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry. 2003, 182: 312-318.PubMed Haug T, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu H, Wold J: Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry. 2003, 182: 312-318.PubMed
390.
Zurück zum Zitat Stangier U, Heidenreich T, Peitz M, Lauterbach W, Clark DM: Cognitive therapy for social phobia: individual versus group treatment. Behav Res Ther. 2003, 41: 991-1007.PubMed Stangier U, Heidenreich T, Peitz M, Lauterbach W, Clark DM: Cognitive therapy for social phobia: individual versus group treatment. Behav Res Ther. 2003, 41: 991-1007.PubMed
391.
Zurück zum Zitat Mortberg E, Clark DM, Sundin O, Aberg Wistedt A: Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: a randomized controlled trial. Acta Psychiatr Scand. 2007, 115: 142-154.PubMed Mortberg E, Clark DM, Sundin O, Aberg Wistedt A: Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: a randomized controlled trial. Acta Psychiatr Scand. 2007, 115: 142-154.PubMed
392.
393.
Zurück zum Zitat Salaberria K, Echeburua E: Long-term outcome of cognitive therapy's contribution to self-exposure in vivo to the treatment of generalized social phobia. Behav Modif. 1998, 22: 262-284.PubMed Salaberria K, Echeburua E: Long-term outcome of cognitive therapy's contribution to self-exposure in vivo to the treatment of generalized social phobia. Behav Modif. 1998, 22: 262-284.PubMed
394.
Zurück zum Zitat Clark DM, Ehlers A, Hackmann A, McManus F, Fennell M, Grey N, Waddington L, Wild J: Cognitive therapy versus exposure and applied relaxation in social phobia: a randomized controlled trial. J Consult Clin Psychol. 2006, 74: 568-578.PubMed Clark DM, Ehlers A, Hackmann A, McManus F, Fennell M, Grey N, Waddington L, Wild J: Cognitive therapy versus exposure and applied relaxation in social phobia: a randomized controlled trial. J Consult Clin Psychol. 2006, 74: 568-578.PubMed
395.
Zurück zum Zitat Borgeat F, Stankovic M, Khazaal Y, Rouget BW, Baumann MC, Riquier F, O'Connor K, Jermann F, Zullino D, Bondolfi G: Does the form or the amount of exposure make a difference in the cognitive-behavioral therapy treatment of social phobia?. J Nerv Ment Dis. 2009, 197: 507-513.PubMed Borgeat F, Stankovic M, Khazaal Y, Rouget BW, Baumann MC, Riquier F, O'Connor K, Jermann F, Zullino D, Bondolfi G: Does the form or the amount of exposure make a difference in the cognitive-behavioral therapy treatment of social phobia?. J Nerv Ment Dis. 2009, 197: 507-513.PubMed
396.
Zurück zum Zitat Smits JA, Powers MB, Buxkamper R, Telch MJ: The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: a controlled investigation. Behav Res Ther. 2006, 44: 1773-1785.PubMed Smits JA, Powers MB, Buxkamper R, Telch MJ: The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: a controlled investigation. Behav Res Ther. 2006, 44: 1773-1785.PubMed
397.
Zurück zum Zitat Alden LE, Taylor CT: Relational treatment strategies increase social approach behaviors in patients with generalized social anxiety disorder. J Anxiety Disord. 2011, 25: 309-318.PubMed Alden LE, Taylor CT: Relational treatment strategies increase social approach behaviors in patients with generalized social anxiety disorder. J Anxiety Disord. 2011, 25: 309-318.PubMed
398.
Zurück zum Zitat Lipsitz JD, Gur M, Vermes D, Petkova E, Cheng J, Miller N, Laino J, Liebowitz MR, Fyer AJ: A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder. Depress Anxiety. 2008, 25: 542-553.PubMed Lipsitz JD, Gur M, Vermes D, Petkova E, Cheng J, Miller N, Laino J, Liebowitz MR, Fyer AJ: A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder. Depress Anxiety. 2008, 25: 542-553.PubMed
399.
Zurück zum Zitat Stangier U, Schramm E, Heidenreich T, Berger M, Clark DM: Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: a randomized controlled trial. Arch Gen Psychiatry. 2011, 68: 692-700.PubMed Stangier U, Schramm E, Heidenreich T, Berger M, Clark DM: Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: a randomized controlled trial. Arch Gen Psychiatry. 2011, 68: 692-700.PubMed
400.
Zurück zum Zitat Borge FM, Hoffart A, Sexton H, Clark DM, Markowitz JC, McManus F: Residential cognitive therapy versus residential interpersonal therapy for social phobia: a randomized clinical trial. J Anxiety Disord. 2008, 22: 991-1010.PubMed Borge FM, Hoffart A, Sexton H, Clark DM, Markowitz JC, McManus F: Residential cognitive therapy versus residential interpersonal therapy for social phobia: a randomized clinical trial. J Anxiety Disord. 2008, 22: 991-1010.PubMed
401.
Zurück zum Zitat Koszycki D, Benger M, Shlik J, Bradwejn J: Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder. Behav Res Ther. 2007, 45: 2518-2526.PubMed Koszycki D, Benger M, Shlik J, Bradwejn J: Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder. Behav Res Ther. 2007, 45: 2518-2526.PubMed
402.
Zurück zum Zitat Schmidt NB, Richey JA, Buckner JD, Timpano KR: Attention training for generalized social anxiety disorder. J Abnorm Psychol. 2009, 118: 5-14.PubMed Schmidt NB, Richey JA, Buckner JD, Timpano KR: Attention training for generalized social anxiety disorder. J Abnorm Psychol. 2009, 118: 5-14.PubMed
403.
Zurück zum Zitat Li S, Tan J, Qian M, Liu X: Continual training of attentional bias in social anxiety. Behav Res Ther. 2008, 46: 905-912.PubMed Li S, Tan J, Qian M, Liu X: Continual training of attentional bias in social anxiety. Behav Res Ther. 2008, 46: 905-912.PubMed
404.
Zurück zum Zitat Berger T, Hohl E, Caspar F: Internet-based treatment for social phobia: a randomized controlled trial. J Clin Psychol. 2009, 65: 1021-1035.PubMed Berger T, Hohl E, Caspar F: Internet-based treatment for social phobia: a randomized controlled trial. J Clin Psychol. 2009, 65: 1021-1035.PubMed
405.
Zurück zum Zitat Carlbring P, Gunnarsdottir M, Hedensjo L, Andersson G, Ekselius L, Furmark T: Treatment of social phobia: randomised trial of internet-delivered cognitive-behavioural therapy with telephone support. Br J Psychiatry. 2007, 190: 123-128.PubMed Carlbring P, Gunnarsdottir M, Hedensjo L, Andersson G, Ekselius L, Furmark T: Treatment of social phobia: randomised trial of internet-delivered cognitive-behavioural therapy with telephone support. Br J Psychiatry. 2007, 190: 123-128.PubMed
406.
Zurück zum Zitat Titov N, Andrews G, Choi I, Schwencke G, Mahoney A: Shyness 3: randomized controlled trial of guided versus unguided Internet-based CBT for social phobia. Aust N Z J Psychiatry. 2008, 42: 1030-1040.PubMed Titov N, Andrews G, Choi I, Schwencke G, Mahoney A: Shyness 3: randomized controlled trial of guided versus unguided Internet-based CBT for social phobia. Aust N Z J Psychiatry. 2008, 42: 1030-1040.PubMed
407.
Zurück zum Zitat Titov N, Andrews G, Schwencke G: Shyness 2: treating social phobia online: replication and extension. Aust N Z J Psychiatry. 2008, 42: 595-605.PubMed Titov N, Andrews G, Schwencke G: Shyness 2: treating social phobia online: replication and extension. Aust N Z J Psychiatry. 2008, 42: 595-605.PubMed
408.
Zurück zum Zitat Titov N, Andrews G, Schwencke G, Drobny J, Einstein D: Shyness 1: distance treatment of social phobia over the Internet. Aust N Z J Psychiatry. 2008, 42: 585-594.PubMed Titov N, Andrews G, Schwencke G, Drobny J, Einstein D: Shyness 1: distance treatment of social phobia over the Internet. Aust N Z J Psychiatry. 2008, 42: 585-594.PubMed
409.
Zurück zum Zitat Andersson G, Carlbring P, Holmstrom A, Sparthan E, Furmark T, Nilsson-Ihrfelt E, Buhrman M, Ekselius L: Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial. J Consult Clin Psychol. 2006, 74: 677-686.PubMed Andersson G, Carlbring P, Holmstrom A, Sparthan E, Furmark T, Nilsson-Ihrfelt E, Buhrman M, Ekselius L: Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial. J Consult Clin Psychol. 2006, 74: 677-686.PubMed
410.
Zurück zum Zitat Furmark T, Carlbring P, Hedman E, Sonnenstein A, Clevberger P, Bohman B, Eriksson A, Hallen A, Frykman M, Holmstrom A, et al: Guided and unguided self-help for social anxiety disorder: randomised controlled trial. Br J Psychiatry. 2009, 195: 440-447.PubMed Furmark T, Carlbring P, Hedman E, Sonnenstein A, Clevberger P, Bohman B, Eriksson A, Hallen A, Frykman M, Holmstrom A, et al: Guided and unguided self-help for social anxiety disorder: randomised controlled trial. Br J Psychiatry. 2009, 195: 440-447.PubMed
411.
Zurück zum Zitat Berger T, Caspar F, Richardson R, Kneubuhler B, Sutter D, Andersson G: Internet-based treatment of social phobia: a randomized controlled trial comparing unguided with two types of guided self-help. Behav Res Ther. 2011, 49: 158-169.PubMed Berger T, Caspar F, Richardson R, Kneubuhler B, Sutter D, Andersson G: Internet-based treatment of social phobia: a randomized controlled trial comparing unguided with two types of guided self-help. Behav Res Ther. 2011, 49: 158-169.PubMed
412.
Zurück zum Zitat Rapee RM, Abbott MJ, Baillie AJ, Gaston JE: Treatment of social phobia through pure self-help and therapist-augmented self-help. Br J Psychiatry. 2007, 191: 246-252.PubMed Rapee RM, Abbott MJ, Baillie AJ, Gaston JE: Treatment of social phobia through pure self-help and therapist-augmented self-help. Br J Psychiatry. 2007, 191: 246-252.PubMed
413.
Zurück zum Zitat Tillfors M, Carlbring P, Furmark T, Lewenhaupt S, Spak M, Eriksson A, Westling BE, Andersson G: Treating university students with social phobia and public speaking fears: Internet delivered self-help with or without live group exposure sessions. Depress Anxiety. 2008, 25: 708-717.PubMed Tillfors M, Carlbring P, Furmark T, Lewenhaupt S, Spak M, Eriksson A, Westling BE, Andersson G: Treating university students with social phobia and public speaking fears: Internet delivered self-help with or without live group exposure sessions. Depress Anxiety. 2008, 25: 708-717.PubMed
414.
Zurück zum Zitat Hedman E, Andersson G, Ljotsson B, Andersson E, Ruck C, Mortberg E, Lindefors N: Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: a randomized controlled non-inferiority trial. PLoS One. 2011, 6: e18001-PubMedCentralPubMed Hedman E, Andersson G, Ljotsson B, Andersson E, Ruck C, Mortberg E, Lindefors N: Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: a randomized controlled non-inferiority trial. PLoS One. 2011, 6: e18001-PubMedCentralPubMed
415.
Zurück zum Zitat Andrews G, Davies M, Titov N: Effectiveness randomized controlled trial of face to face versus Internet cognitive behaviour therapy for social phobia. Aust N Z J Psychiatry. 2011, 45: 337-340.PubMed Andrews G, Davies M, Titov N: Effectiveness randomized controlled trial of face to face versus Internet cognitive behaviour therapy for social phobia. Aust N Z J Psychiatry. 2011, 45: 337-340.PubMed
416.
Zurück zum Zitat Hedman E, Andersson E, Ljotsson B, Andersson G, Ruck C, Lindefors N: Cost-effectiveness of Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: results from a randomized controlled trial. Behav Res Ther. 2011, 49: 729-736.PubMed Hedman E, Andersson E, Ljotsson B, Andersson G, Ruck C, Lindefors N: Cost-effectiveness of Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: results from a randomized controlled trial. Behav Res Ther. 2011, 49: 729-736.PubMed
417.
Zurück zum Zitat Prasko J, Dockery C, Horacek J, Houbova P, Kosova J, Klaschka J, Paskova B, Praskova H, Seifertova D, Zalesky R, Hoschl C: Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. Neuro Endocrinol Lett. 2006, 27: 473-481.PubMed Prasko J, Dockery C, Horacek J, Houbova P, Kosova J, Klaschka J, Paskova B, Praskova H, Seifertova D, Zalesky R, Hoschl C: Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. Neuro Endocrinol Lett. 2006, 27: 473-481.PubMed
418.
Zurück zum Zitat Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen H, Turk CL, Vermes D, Erwin BA, Schmidt AB, Juster HR, et al: A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry. 2010, 67: 286-295.PubMedCentralPubMed Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen H, Turk CL, Vermes D, Erwin BA, Schmidt AB, Juster HR, et al: A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry. 2010, 67: 286-295.PubMedCentralPubMed
419.
Zurück zum Zitat Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR: A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008, 63: 544-549.PubMed Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR: A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008, 63: 544-549.PubMed
420.
Zurück zum Zitat Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW: Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006, 63: 298-304.PubMed Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW: Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006, 63: 298-304.PubMed
421.
Zurück zum Zitat Knijnik DZ, Blanco C, Salum GA, Moraes CU, Mombach C, Almeida E, Pereira M, Strapasson A, Manfro GG, Eizirik CL: A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder. Eur Psychiatry. 2008, 23: 567-574.PubMedCentralPubMed Knijnik DZ, Blanco C, Salum GA, Moraes CU, Mombach C, Almeida E, Pereira M, Strapasson A, Manfro GG, Eizirik CL: A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder. Eur Psychiatry. 2008, 23: 567-574.PubMedCentralPubMed
422.
Zurück zum Zitat Watanabe N, Furukawa TA, Chen J, Kinoshita Y, Nakano Y, Ogawa S, Funayama T, Ietsugu T, Noda Y: Change in quality of life and their predictors in the long-term follow-up after group cognitive behavioral therapy for social anxiety disorder: a prospective cohort study. BMC Psychiatry. 2010, 10: 81-PubMedCentralPubMed Watanabe N, Furukawa TA, Chen J, Kinoshita Y, Nakano Y, Ogawa S, Funayama T, Ietsugu T, Noda Y: Change in quality of life and their predictors in the long-term follow-up after group cognitive behavioral therapy for social anxiety disorder: a prospective cohort study. BMC Psychiatry. 2010, 10: 81-PubMedCentralPubMed
423.
Zurück zum Zitat Carlbring P, Nordgren LB, Furmark T, Andersson G: Long-term outcome of Internet-delivered cognitive-behavioural therapy for social phobia: a 30-month follow-up. Behav Res Ther. 2009, 47: 848-850.PubMed Carlbring P, Nordgren LB, Furmark T, Andersson G: Long-term outcome of Internet-delivered cognitive-behavioural therapy for social phobia: a 30-month follow-up. Behav Res Ther. 2009, 47: 848-850.PubMed
424.
Zurück zum Zitat Hedman E, Furmark T, Carlbring P, Ljotsson B, Ruck C, Lindefors N, Andersson G: A 5-year follow-up of internet-based cognitive behavior therapy for social anxiety disorder. J Med Internet Res. 2011, 13: e39-PubMedCentralPubMed Hedman E, Furmark T, Carlbring P, Ljotsson B, Ruck C, Lindefors N, Andersson G: A 5-year follow-up of internet-based cognitive behavior therapy for social anxiety disorder. J Med Internet Res. 2011, 13: e39-PubMedCentralPubMed
425.
Zurück zum Zitat Mortberg E, Clark DM, Bejerot S: Intensive group cognitive therapy and individual cognitive therapy for social phobia: sustained improvement at 5-year follow-up. J Anxiety Disord. 2011, 25: 994-1000.PubMed Mortberg E, Clark DM, Bejerot S: Intensive group cognitive therapy and individual cognitive therapy for social phobia: sustained improvement at 5-year follow-up. J Anxiety Disord. 2011, 25: 994-1000.PubMed
426.
Zurück zum Zitat van der Linden G, Stein D, van Balkom A: The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2000, 15 (Suppl 2): S15-23.PubMed van der Linden G, Stein D, van Balkom A: The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2000, 15 (Suppl 2): S15-23.PubMed
427.
Zurück zum Zitat Canton J, Scott KM, Glue P: Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012, 8: 203-215.PubMedCentralPubMed Canton J, Scott KM, Glue P: Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012, 8: 203-215.PubMedCentralPubMed
428.
Zurück zum Zitat Stein DJ, Ipser JC, Balkom AJ: Pharmacotherapy for social phobia. Cochrane Database Syst Rev. 2004, : CD001206- Stein DJ, Ipser JC, Balkom AJ: Pharmacotherapy for social phobia. Cochrane Database Syst Rev. 2004, : CD001206-
429.
Zurück zum Zitat Hedges DW, Brown BL, Shwalb DA, Godfrey K, Larcher AM: The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol. 2007, 21: 102-111.PubMed Hedges DW, Brown BL, Shwalb DA, Godfrey K, Larcher AM: The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol. 2007, 21: 102-111.PubMed
430.
Zurück zum Zitat Kasper S, Stein D, Loft H, Nil R: Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry. 2005, 186: 222-226.PubMed Kasper S, Stein D, Loft H, Nil R: Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry. 2005, 186: 222-226.PubMed
431.
Zurück zum Zitat Lader M, Stender K, Burger V, Nil R: Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004, 19: 241-248.PubMed Lader M, Stender K, Burger V, Nil R: Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004, 19: 241-248.PubMed
432.
Zurück zum Zitat Pallanti S, Quercioli L: Resistant social anxiety disorder response to escitalopram. Clin Pract Epidemiol Ment Health. 2006, 2: 35-PubMedCentralPubMed Pallanti S, Quercioli L: Resistant social anxiety disorder response to escitalopram. Clin Pract Epidemiol Ment Health. 2006, 2: 35-PubMedCentralPubMed
433.
Zurück zum Zitat van Vliet I, den Boer J, Westenberg H: Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl). 1994, 115: 128-134. van Vliet I, den Boer J, Westenberg H: Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl). 1994, 115: 128-134.
434.
Zurück zum Zitat Stein M, Fyer A, Davidson J, Pollack M, Wiita B: Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999, 156: 756-760.PubMed Stein M, Fyer A, Davidson J, Pollack M, Wiita B: Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999, 156: 756-760.PubMed
435.
Zurück zum Zitat Asakura S, Tajima O, Koyama T: Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2007, 10: 263-274.PubMed Asakura S, Tajima O, Koyama T: Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2007, 10: 263-274.PubMed
436.
Zurück zum Zitat Davidson J, Yaryura-Tobias J, Du Pont R, Stallings L, Barbato L, van dHR, Li D: Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004, 24: 118-125.PubMed Davidson J, Yaryura-Tobias J, Du Pont R, Stallings L, Barbato L, van dHR, Li D: Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004, 24: 118-125.PubMed
437.
Zurück zum Zitat Westenberg H, Stein D, Yang H, Li D, Barbato L: A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004, 24: 49-55.PubMed Westenberg H, Stein D, Yang H, Li D, Barbato L: A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004, 24: 49-55.PubMed
438.
Zurück zum Zitat Allgulander C: Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand. 1999, 100: 193-198.PubMed Allgulander C: Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand. 1999, 100: 193-198.PubMed
439.
Zurück zum Zitat Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G: Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol. 2004, 19: 387-396.PubMed Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G: Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol. 2004, 19: 387-396.PubMed
440.
Zurück zum Zitat Baldwin D, Bobes J, Stein D, Scharwachter I, Faure M: Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999, 175: 120-126.PubMed Baldwin D, Bobes J, Stein D, Scharwachter I, Faure M: Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999, 175: 120-126.PubMed
441.
Zurück zum Zitat Liebowitz M, Gelenberg A, Munjack D: Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005, 62: 190-198.PubMed Liebowitz M, Gelenberg A, Munjack D: Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005, 62: 190-198.PubMed
442.
Zurück zum Zitat Liebowitz M, Stein M, Tancer M, Carpenter D, Oakes R, Pitts C: A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002, 63: 66-74.PubMed Liebowitz M, Stein M, Tancer M, Carpenter D, Oakes R, Pitts C: A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002, 63: 66-74.PubMed
443.
Zurück zum Zitat Stein D, Berk M, Els C, Emsley R, Gittelson L, Wilson D, Oakes R, Hunter B: A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. S Afr Med J. 1999, 89: 402-406.PubMed Stein D, Berk M, Els C, Emsley R, Gittelson L, Wilson D, Oakes R, Hunter B: A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. S Afr Med J. 1999, 89: 402-406.PubMed
444.
Zurück zum Zitat Stein M, Liebowitz M, Lydiard R, Pitts C, Bushnell W, Gergel I: Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998, 280: 708-713.PubMed Stein M, Liebowitz M, Lydiard R, Pitts C, Bushnell W, Gergel I: Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998, 280: 708-713.PubMed
445.
Zurück zum Zitat Katzelnick D, Kobak K, Greist J, Jefferson J, Mantle J, Serlin R: Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995, 152: 1368-1371.PubMed Katzelnick D, Kobak K, Greist J, Jefferson J, Mantle J, Serlin R: Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995, 152: 1368-1371.PubMed
446.
Zurück zum Zitat Liebowitz M, De Martinis N, Weihs K, Londborg P, Smith W, Chung H, Fayyad R, Clary C: Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry. 2003, 64: 785-792.PubMed Liebowitz M, De Martinis N, Weihs K, Londborg P, Smith W, Chung H, Fayyad R, Clary C: Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry. 2003, 64: 785-792.PubMed
447.
Zurück zum Zitat Van Ameringen M, Lane R, Walker J, Bowen R, Chokka P, Goldner E, Johnston D, Lavallee Y, Nandy S, Pecknold J, et al: Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001, 158: 275-281.PubMed Van Ameringen M, Lane R, Walker J, Bowen R, Chokka P, Goldner E, Johnston D, Lavallee Y, Nandy S, Pecknold J, et al: Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001, 158: 275-281.PubMed
448.
Zurück zum Zitat Blomhoff S, Haug T, Hellstrom K, Holme I, Humble M, Madsbu H, Wold J: Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry. 2001, 179: 23-30.PubMed Blomhoff S, Haug T, Hellstrom K, Holme I, Humble M, Madsbu H, Wold J: Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry. 2001, 179: 23-30.PubMed
449.
Zurück zum Zitat Kobak K, Greist J, Jefferson J, Katzelnick D: Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002, 22: 257-262.PubMed Kobak K, Greist J, Jefferson J, Katzelnick D: Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002, 22: 257-262.PubMed
450.
Zurück zum Zitat Atmaca M, Kuloglu M, Tezcan E, Unal A: Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002, 17: 401-405.PubMed Atmaca M, Kuloglu M, Tezcan E, Unal A: Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002, 17: 401-405.PubMed
451.
Zurück zum Zitat Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, Jacobsson E, Flyckt K, Grohp M, Bergstrom M, et al: Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry. 2005, 58: 132-142.PubMed Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, Jacobsson E, Flyckt K, Grohp M, Bergstrom M, et al: Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry. 2005, 58: 132-142.PubMed
452.
Zurück zum Zitat Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L: Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry. 2004, 65: 222-229.PubMed Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L: Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry. 2004, 65: 222-229.PubMed
453.
Zurück zum Zitat Schutters S, van Megen H, Van Veen J, Schruers K, Westenberg H: Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo. Hum Psychopharmacol Clin Exp. 2011, 26: 72-76. Schutters S, van Megen H, Van Veen J, Schruers K, Westenberg H: Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo. Hum Psychopharmacol Clin Exp. 2011, 26: 72-76.
454.
Zurück zum Zitat Liebowitz M, Mangano R, Bradwejn J, Asnis G: A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry. 2005, 66: 238-247.PubMed Liebowitz M, Mangano R, Bradwejn J, Asnis G: A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry. 2005, 66: 238-247.PubMed
455.
Zurück zum Zitat Rickels K, Mangano R, Khan A: A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol. 2004, 24: 488-496.PubMed Rickels K, Mangano R, Khan A: A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol. 2004, 24: 488-496.PubMed
456.
Zurück zum Zitat Stein M, Pollack M, Bystritsky A, Kelsey J, Mangano R: Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005, 177: 280-288. Stein M, Pollack M, Bystritsky A, Kelsey J, Mangano R: Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005, 177: 280-288.
457.
Zurück zum Zitat Simon NM, Worthington JJ, Moshier SJ, Marks EH, Hoge EA, Brandes M, Delong H, Pollack MH: Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. CNS Spectr. 2010, 15: 367-373.PubMed Simon NM, Worthington JJ, Moshier SJ, Marks EH, Hoge EA, Brandes M, Delong H, Pollack MH: Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. CNS Spectr. 2010, 15: 367-373.PubMed
458.
Zurück zum Zitat Gringras M: An uncontrolled trial of clomipramine (Anafranil) in the treatment of phobic and obsessional states in general practice. J Int Med Res. 1977, 5 (Suppl 5): 111-115.PubMed Gringras M: An uncontrolled trial of clomipramine (Anafranil) in the treatment of phobic and obsessional states in general practice. J Int Med Res. 1977, 5 (Suppl 5): 111-115.PubMed
459.
Zurück zum Zitat Beaumont G: A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders. J Int Med Res. 1977, 5 (Suppl 5): 116-123.PubMed Beaumont G: A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders. J Int Med Res. 1977, 5 (Suppl 5): 116-123.PubMed
460.
Zurück zum Zitat Simpson H, Schneier F, Campeas R, Marshall R, Fallon B, Davies S, Klein D, Liebowitz M: Imipramine in the treatment of social phobia. J Clin Psychopharmacol. 1998, 18: 132-135.PubMed Simpson H, Schneier F, Campeas R, Marshall R, Fallon B, Davies S, Klein D, Liebowitz M: Imipramine in the treatment of social phobia. J Clin Psychopharmacol. 1998, 18: 132-135.PubMed
461.
Zurück zum Zitat Liebowitz M, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, et al: Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry. 1992, 49: 290-300.PubMed Liebowitz M, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, et al: Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry. 1992, 49: 290-300.PubMed
462.
Zurück zum Zitat Versiani M, Nardi A, Mundim F, Alves A, Liebowitz M, Amrein R: Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry. 1992, 161: 353-360.PubMed Versiani M, Nardi A, Mundim F, Alves A, Liebowitz M, Amrein R: Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry. 1992, 161: 353-360.PubMed
463.
Zurück zum Zitat International Multicenter Clinical Trial Group on Moclobemide in Social Phobia: Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci. 1997, 247: 71-80. International Multicenter Clinical Trial Group on Moclobemide in Social Phobia: Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci. 1997, 247: 71-80.
464.
Zurück zum Zitat Stein D, Cameron A, Amrein R, Montgomery S: Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol. 2002, 17: 161-170.PubMed Stein D, Cameron A, Amrein R, Montgomery S: Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol. 2002, 17: 161-170.PubMed
465.
Zurück zum Zitat Noyes R, Moroz G, Davidson J, Liebowitz M, Davidson A, Siegel J, Bell J, Cain J, Curlik S, Kent T, et al: Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997, 17: 247-254.PubMed Noyes R, Moroz G, Davidson J, Liebowitz M, Davidson A, Siegel J, Bell J, Cain J, Curlik S, Kent T, et al: Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997, 17: 247-254.PubMed
466.
Zurück zum Zitat Schneier F, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz M: Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry. 1998, 172: 70-77.PubMed Schneier F, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz M: Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry. 1998, 172: 70-77.PubMed
467.
Zurück zum Zitat Schutters SI, Van Megen HJ, Van Veen JF, Denys DA, Westenberg HG: Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2010, 25: 302-304.PubMed Schutters SI, Van Megen HJ, Van Veen JF, Denys DA, Westenberg HG: Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2010, 25: 302-304.PubMed
468.
Zurück zum Zitat Muehlbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Pedrosa Gil F, Leiberich PK, Rother N, Bachler E, Fartacek R, et al: Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005, 25: 580-583.PubMed Muehlbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Pedrosa Gil F, Leiberich PK, Rother N, Bachler E, Fartacek R, et al: Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005, 25: 580-583.PubMed
469.
Zurück zum Zitat Emmanuel NP, Brawman-Mintzer O, Morton WA, Book SW, Johnson MR, Lorberbaum JP, Ballenger JC, Lydiard RB: Bupropion-SR in treatment of social phobia. Depress Anxiety. 2000, 12: 111-113.PubMed Emmanuel NP, Brawman-Mintzer O, Morton WA, Book SW, Johnson MR, Lorberbaum JP, Ballenger JC, Lydiard RB: Bupropion-SR in treatment of social phobia. Depress Anxiety. 2000, 12: 111-113.PubMed
470.
Zurück zum Zitat Davidson J, Potts N, Richichi E, Krishnan R, Ford S, Smith R, Wilson W: Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993, 13: 423-428.PubMed Davidson J, Potts N, Richichi E, Krishnan R, Ford S, Smith R, Wilson W: Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993, 13: 423-428.PubMed
471.
Zurück zum Zitat Munjack D, Baltazar P, Bohn P, Cabe D, Appleton A: Clonazepam in the treatment of social phobia: a pilot study. J Clin Psychiatry. 1990, 51 (Suppl): 35-40. discussion 50-33PubMed Munjack D, Baltazar P, Bohn P, Cabe D, Appleton A: Clonazepam in the treatment of social phobia: a pilot study. J Clin Psychiatry. 1990, 51 (Suppl): 35-40. discussion 50-33PubMed
472.
Zurück zum Zitat Versiani M, Nardi A, Figuera I, Marques C: Double-blind placebo controlled trial with bromazepam in social phobia. J Bras Psiquiatr. 1997, 46: 167-171. Versiani M, Nardi A, Figuera I, Marques C: Double-blind placebo controlled trial with bromazepam in social phobia. J Bras Psiquiatr. 1997, 46: 167-171.
473.
Zurück zum Zitat Seedat S, Stein M: Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004, 65: 244-248.PubMed Seedat S, Stein M: Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004, 65: 244-248.PubMed
474.
Zurück zum Zitat Pande A, Feltner D, Jefferson J, Davidson J, Pollack M, Stein M, Lydiard R, Futterer R, Robinson P, Slomkowski M, et al: Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004, 24: 141-149.PubMed Pande A, Feltner D, Jefferson J, Davidson J, Pollack M, Stein M, Lydiard R, Futterer R, Robinson P, Slomkowski M, et al: Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004, 24: 141-149.PubMed
475.
Zurück zum Zitat Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R: Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol. 2011, 26: 213-220.PubMed Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R: Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol. 2011, 26: 213-220.PubMed
476.
Zurück zum Zitat Pande A, Davidson J, Jefferson J, Janney C, Katzelnick D, Weisler R, Greist J, Sutherland S: Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999, 19: 341-348.PubMed Pande A, Davidson J, Jefferson J, Janney C, Katzelnick D, Weisler R, Greist J, Sutherland S: Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999, 19: 341-348.PubMed
477.
Zurück zum Zitat Urbano MR, Spiegel DR, Laguerta N, Shrader CJ, Rowe DF, Hategan LF: Gabapentin and tiagabine for social anxiety: a randomized, double-blind, crossover study of 8 adults [Letter]. Prim Care Companion J Clin Psychiatry. 2009, 11: 123-PubMedCentralPubMed Urbano MR, Spiegel DR, Laguerta N, Shrader CJ, Rowe DF, Hategan LF: Gabapentin and tiagabine for social anxiety: a randomized, double-blind, crossover study of 8 adults [Letter]. Prim Care Companion J Clin Psychiatry. 2009, 11: 123-PubMedCentralPubMed
478.
Zurück zum Zitat Zhang W, Connor KM, Davidson JR: Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol. 2005, 19: 551-553.PubMed Zhang W, Connor KM, Davidson JR: Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol. 2005, 19: 551-553.PubMed
479.
Zurück zum Zitat Simon NM, Worthington JJ, Doyle AC, Hoge EA, Kinrys G, Fischmann D, Link N, Pollack MH: An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004, 65: 1219-1222.PubMed Simon NM, Worthington JJ, Doyle AC, Hoge EA, Kinrys G, Fischmann D, Link N, Pollack MH: An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004, 65: 1219-1222.PubMed
480.
Zurück zum Zitat Stein MB, Ravindran LN, Simon NM, Liebowitz MR, Khan A, Brawman-Mintzer O, Lydiard RB, Pollack MH: Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry. 2010, 71: 627-631.PubMed Stein MB, Ravindran LN, Simon NM, Liebowitz MR, Khan A, Brawman-Mintzer O, Lydiard RB, Pollack MH: Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry. 2010, 71: 627-631.PubMed
481.
Zurück zum Zitat Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M: Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol. 2003, 18: 169-172.PubMed Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M: Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol. 2003, 18: 169-172.PubMed
482.
Zurück zum Zitat Dunlop BW, Papp L, Garlow SJ, Weiss PS, Knight BT, Ninan PT: Tiagabine for social anxiety disorder. Hum Psychopharmacol. 2007, 22: 241-244.PubMed Dunlop BW, Papp L, Garlow SJ, Weiss PS, Knight BT, Ninan PT: Tiagabine for social anxiety disorder. Hum Psychopharmacol. 2007, 22: 241-244.PubMed
483.
Zurück zum Zitat Van Ameringen M, Mancini C, Pipe B, Oakman J, Bennett M: An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry. 2004, 65: 1674-1678.PubMed Van Ameringen M, Mancini C, Pipe B, Oakman J, Bennett M: An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry. 2004, 65: 1674-1678.PubMed
484.
Zurück zum Zitat Turner SM, Beidel DC, Jacob RG: Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol. 1994, 62: 350-358.PubMed Turner SM, Beidel DC, Jacob RG: Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol. 1994, 62: 350-358.PubMed
485.
Zurück zum Zitat van Vliet I, den Boer J, Westenberg H, Pian K: Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry. 1997, 58: 164-168.PubMed van Vliet I, den Boer J, Westenberg H, Pian K: Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry. 1997, 58: 164-168.PubMed
486.
Zurück zum Zitat Ravindran LN, Kim DS, Letamendi AM, Stein MB: A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol. 2009, 29: 561-564.PubMed Ravindran LN, Kim DS, Letamendi AM, Stein MB: A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol. 2009, 29: 561-564.PubMed
487.
Zurück zum Zitat Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T: Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009, 26: 212-221.PubMed Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T: Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009, 26: 212-221.PubMed
488.
Zurück zum Zitat Falloon IR, Lloyd GG, Harpin RE: The treatment of social phobia. Real-life rehearsal with nonprofessional therapists. J Nerv Ment Dis. 1981, 169: 180-184.PubMed Falloon IR, Lloyd GG, Harpin RE: The treatment of social phobia. Real-life rehearsal with nonprofessional therapists. J Nerv Ment Dis. 1981, 169: 180-184.PubMed
489.
Zurück zum Zitat Simpson HB, Schneier FR, Marshall RD, Campeas RB, Vermes D, Silvestre J, Davies S, Liebowitz MR: Low dose selegiline (L-Deprenyl) in social phobia. Depress Anxiety. 1998, 7: 126-129.PubMed Simpson HB, Schneier FR, Marshall RD, Campeas RB, Vermes D, Silvestre J, Davies S, Liebowitz MR: Low dose selegiline (L-Deprenyl) in social phobia. Depress Anxiety. 1998, 7: 126-129.PubMed
490.
Zurück zum Zitat Villarreal G, Johnson MR, Rubey R, Lydiard RB, Ballanger JC: Treatment of social phobia with the dopamine agonist pergolide. Depress Anxiety. 2000, 11: 45-47.PubMed Villarreal G, Johnson MR, Rubey R, Lydiard RB, Ballanger JC: Treatment of social phobia with the dopamine agonist pergolide. Depress Anxiety. 2000, 11: 45-47.PubMed
491.
Zurück zum Zitat Van Ameringen M, Mancini C, Wilson C: Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord. 1996, 39: 115-121.PubMed Van Ameringen M, Mancini C, Wilson C: Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord. 1996, 39: 115-121.PubMed
492.
Zurück zum Zitat Stein M, Sareen J, Hami S, Chao J: Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001, 158: 1725-1727.PubMed Stein M, Sareen J, Hami S, Chao J: Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001, 158: 1725-1727.PubMed
493.
Zurück zum Zitat Barnett S, Kramer M, Casat C, Connor K, Davidson J: Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002, 16: 365-368.PubMed Barnett S, Kramer M, Casat C, Connor K, Davidson J: Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002, 16: 365-368.PubMed
494.
Zurück zum Zitat Schutters SI, van Megen HJ, Westenberg HG: Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study [Letter]. J Clin Psychiatry. 2005, 66: 540-542.PubMed Schutters SI, van Megen HJ, Westenberg HG: Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study [Letter]. J Clin Psychiatry. 2005, 66: 540-542.PubMed
495.
Zurück zum Zitat Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JR: Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2007, 31: 1464-1469.PubMed Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JR: Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2007, 31: 1464-1469.PubMed
496.
Zurück zum Zitat Worthington J, Kinrys G, Wygant L, Pollack M: Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005, 20: 9-11.PubMed Worthington J, Kinrys G, Wygant L, Pollack M: Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005, 20: 9-11.PubMed
497.
Zurück zum Zitat Donovan MR, Glue P, Kolluri S, Emir B: Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. J Affect Disord. 2010, 123: 9-16.PubMed Donovan MR, Glue P, Kolluri S, Emir B: Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. J Affect Disord. 2010, 123: 9-16.PubMed
498.
Zurück zum Zitat Greist JH, Liu-Dumaw M, Schweizer E, Feltner D: Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol. 2011, 26: 243-251.PubMed Greist JH, Liu-Dumaw M, Schweizer E, Feltner D: Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol. 2011, 26: 243-251.PubMed
499.
Zurück zum Zitat Stein D, Westenberg H, Yang H, Li D, Barbato L: Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol. 2003, 6: 317-323.PubMed Stein D, Westenberg H, Yang H, Li D, Barbato L: Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol. 2003, 6: 317-323.PubMed
500.
Zurück zum Zitat Versiani M, Amrein R, Montgomery S: Social phobia: long-term treatment outcome and prediction of response--a moclobemide study. Int Clin Psychopharmacol. 1997, 12: 239-254.PubMed Versiani M, Amrein R, Montgomery S: Social phobia: long-term treatment outcome and prediction of response--a moclobemide study. Int Clin Psychopharmacol. 1997, 12: 239-254.PubMed
501.
Zurück zum Zitat Fontani V, Mannu P, Castagna A, Rinaldi S: Social anxiety disorder: radio electric asymmetric conveyor brain stimulation versus sertraline. Patient Prefer Adherence. 2011, 5: 581-586.PubMedCentralPubMed Fontani V, Mannu P, Castagna A, Rinaldi S: Social anxiety disorder: radio electric asymmetric conveyor brain stimulation versus sertraline. Patient Prefer Adherence. 2011, 5: 581-586.PubMedCentralPubMed
502.
Zurück zum Zitat Kobak K, Taylor L, Warner G, Futterer R: St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol. 2005, 25: 51-58.PubMed Kobak K, Taylor L, Warner G, Futterer R: St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol. 2005, 25: 51-58.PubMed
503.
Zurück zum Zitat Gwynn RC, McQuistion HL, McVeigh KH, Garg RK, Frieden TR, Thorpe LE: Prevalence, diagnosis, and treatment of depression and generalized anxiety disorder in a diverse urban community. Psychiatr Serv. 2008, 59: 641-647.PubMed Gwynn RC, McQuistion HL, McVeigh KH, Garg RK, Frieden TR, Thorpe LE: Prevalence, diagnosis, and treatment of depression and generalized anxiety disorder in a diverse urban community. Psychiatr Serv. 2008, 59: 641-647.PubMed
504.
Zurück zum Zitat Asnaani A, Richey JA, Dimaite R, Hinton DE, Hofmann SG: A cross-ethnic comparison of lifetime prevalence rates of anxiety disorders. J Nerv Ment Dis. 2010, 198: 551-555.PubMedCentralPubMed Asnaani A, Richey JA, Dimaite R, Hinton DE, Hofmann SG: A cross-ethnic comparison of lifetime prevalence rates of anxiety disorders. J Nerv Ment Dis. 2010, 198: 551-555.PubMedCentralPubMed
505.
Zurück zum Zitat Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, Smith SM, Saha TD, Huang B: Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005, 35: 1747-1759.PubMed Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, Smith SM, Saha TD, Huang B: Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005, 35: 1747-1759.PubMed
506.
Zurück zum Zitat Albano A, Chorpita B, Barlow D: Childhood anxiety disorders. Child psychopathology. Edited by: Mash E, Barkley R. 2003, New York, NY: Guilford, 279-329. 2 Albano A, Chorpita B, Barlow D: Childhood anxiety disorders. Child psychopathology. Edited by: Mash E, Barkley R. 2003, New York, NY: Guilford, 279-329. 2
507.
Zurück zum Zitat Beesdo K, Pine DS, Lieb R, Wittchen HU: Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch Gen Psychiatry. 2010, 67: 47-57.PubMed Beesdo K, Pine DS, Lieb R, Wittchen HU: Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch Gen Psychiatry. 2010, 67: 47-57.PubMed
508.
Zurück zum Zitat Ansseau M, Fischler B, Dierick M, Albert A, Leyman S, Mignon A: Socioeconomic correlates of generalized anxiety disorder and major depression in primary care: the GADIS II study (Generalized Anxiety and Depression Impact Survey II). Depress Anxiety. 2008, 25: 506-513.PubMed Ansseau M, Fischler B, Dierick M, Albert A, Leyman S, Mignon A: Socioeconomic correlates of generalized anxiety disorder and major depression in primary care: the GADIS II study (Generalized Anxiety and Depression Impact Survey II). Depress Anxiety. 2008, 25: 506-513.PubMed
509.
Zurück zum Zitat Byers AL, Yaffe K, Covinsky KE, Friedman MB, Bruce ML: High occurrence of mood and anxiety disorders among older adults: the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2010, 67: 489-496.PubMedCentralPubMed Byers AL, Yaffe K, Covinsky KE, Friedman MB, Bruce ML: High occurrence of mood and anxiety disorders among older adults: the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2010, 67: 489-496.PubMedCentralPubMed
510.
Zurück zum Zitat Mackenzie CS, Reynolds K, Chou KL, Pagura J, Sareen J: Prevalence and correlates of generalized anxiety disorder in a national sample of older adults. Am J Geriatr Psychiatry. 2011, 19: 305-315.PubMed Mackenzie CS, Reynolds K, Chou KL, Pagura J, Sareen J: Prevalence and correlates of generalized anxiety disorder in a national sample of older adults. Am J Geriatr Psychiatry. 2011, 19: 305-315.PubMed
511.
Zurück zum Zitat Revicki DA, Travers K, Wyrwich KW, Svedsater H, Locklear J, Mattera MS, Sheehan DV, Montgomery S: Humanistic and economic burden of generalized anxiety disorder in North America and Europe. J Affect Disord. 2012, 140: 103-112.PubMed Revicki DA, Travers K, Wyrwich KW, Svedsater H, Locklear J, Mattera MS, Sheehan DV, Montgomery S: Humanistic and economic burden of generalized anxiety disorder in North America and Europe. J Affect Disord. 2012, 140: 103-112.PubMed
512.
Zurück zum Zitat Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S: An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World J Biol Psychiatry. 2012, 13: 510-516.PubMed Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S: An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World J Biol Psychiatry. 2012, 13: 510-516.PubMed
513.
Zurück zum Zitat Weisberg RB, Beard C, Pagano ME, Maki KM, Culpepper L, Keller MB: Impairment and functioning in a sample of primary care patients with generalized anxiety disorder: results from the primary care anxiety project. Prim Care Companion J Clin Psychiatry. 2010, 12: doi 10.4088/PCC.4009m00890blu Weisberg RB, Beard C, Pagano ME, Maki KM, Culpepper L, Keller MB: Impairment and functioning in a sample of primary care patients with generalized anxiety disorder: results from the primary care anxiety project. Prim Care Companion J Clin Psychiatry. 2010, 12: doi 10.4088/PCC.4009m00890blu
514.
Zurück zum Zitat Zhu B, Zhao Z, Ye W, Marciniak MD, Swindle R: The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder. J Nerv Ment Dis. 2009, 197: 136-139.PubMed Zhu B, Zhao Z, Ye W, Marciniak MD, Swindle R: The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder. J Nerv Ment Dis. 2009, 197: 136-139.PubMed
515.
Zurück zum Zitat Romera I, Fernandez-Perez S, Montejo AL, Caballero F, Caballero L, Arbesu JA, Delgado-Cohen H, Desaiah D, Polavieja P, Gilaberte I: Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: prevalence of painful somatic symptoms, functioning and health status. J Affect Disord. 2010, 127: 160-168.PubMed Romera I, Fernandez-Perez S, Montejo AL, Caballero F, Caballero L, Arbesu JA, Delgado-Cohen H, Desaiah D, Polavieja P, Gilaberte I: Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: prevalence of painful somatic symptoms, functioning and health status. J Affect Disord. 2010, 127: 160-168.PubMed
516.
Zurück zum Zitat Garcia-Campayo J, Caballero F, Perez M, Lopez V: Pain related factors in newly diagnosed generalized anxiety disorder patients. Actas Esp Psiquiatr. 2012, 40: 177-186.PubMed Garcia-Campayo J, Caballero F, Perez M, Lopez V: Pain related factors in newly diagnosed generalized anxiety disorder patients. Actas Esp Psiquiatr. 2012, 40: 177-186.PubMed
517.
Zurück zum Zitat Beesdo K, Hoyer J, Jacobi F, Low NC, Hofler M, Wittchen HU: Association between generalized anxiety levels and pain in a community sample: evidence for diagnostic specificity. J Anxiety Disord. 2009, 23: 684-693.PubMed Beesdo K, Hoyer J, Jacobi F, Low NC, Hofler M, Wittchen HU: Association between generalized anxiety levels and pain in a community sample: evidence for diagnostic specificity. J Anxiety Disord. 2009, 23: 684-693.PubMed
518.
Zurück zum Zitat Martens EJ, de Jonge P, Na B, Cohen BE, Lett H, Whooley MA: Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease:The Heart and Soul Study. Arch Gen Psychiatry. 2010, 67: 750-758.PubMed Martens EJ, de Jonge P, Na B, Cohen BE, Lett H, Whooley MA: Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease:The Heart and Soul Study. Arch Gen Psychiatry. 2010, 67: 750-758.PubMed
519.
Zurück zum Zitat Tyrer P, Seivewright H, Johnson T: The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med. 2004, 34: 1385-1394.PubMed Tyrer P, Seivewright H, Johnson T: The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med. 2004, 34: 1385-1394.PubMed
520.
Zurück zum Zitat Covin R, Ouimet AJ, Seeds PM, Dozois DJ: A meta-analysis of CBT for pathological worry among clients with GAD. J Anxiety Disord. 2008, 22: 108-116.PubMed Covin R, Ouimet AJ, Seeds PM, Dozois DJ: A meta-analysis of CBT for pathological worry among clients with GAD. J Anxiety Disord. 2008, 22: 108-116.PubMed
521.
Zurück zum Zitat Linden M, Zubraegel D, Baer T, Franke U, Schlattmann P: Efficacy of cognitive behaviour therapy in generalized anxiety disorders. Results of a controlled clinical trial (Berlin CBT-GAD Study). Psychother Psychosom. 2005, 74: 36-42.PubMed Linden M, Zubraegel D, Baer T, Franke U, Schlattmann P: Efficacy of cognitive behaviour therapy in generalized anxiety disorders. Results of a controlled clinical trial (Berlin CBT-GAD Study). Psychother Psychosom. 2005, 74: 36-42.PubMed
522.
Zurück zum Zitat Borkovec T, Newman M, Pincus A, Lytle R: A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. J Consult Clin Psychol. 2002, 70: 288-298.PubMed Borkovec T, Newman M, Pincus A, Lytle R: A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. J Consult Clin Psychol. 2002, 70: 288-298.PubMed
523.
Zurück zum Zitat Ferrero A, Piero A, Fassina S, Massola T, Lanteri A, Daga GA, Fassino S: A 12-month comparison of brief psychodynamic psychotherapy and pharmacotherapy treatment in subjects with generalised anxiety disorders in a community setting. Eur Psychiatry. 2007, 22: 530-539.PubMed Ferrero A, Piero A, Fassina S, Massola T, Lanteri A, Daga GA, Fassino S: A 12-month comparison of brief psychodynamic psychotherapy and pharmacotherapy treatment in subjects with generalised anxiety disorders in a community setting. Eur Psychiatry. 2007, 22: 530-539.PubMed
524.
Zurück zum Zitat Robinson E, Titov N, Andrews G, McIntyre K, Schwencke G, Solley K: Internet treatment for generalized anxiety disorder: a randomized controlled trial comparing clinician vs. technician assistance. PLoS One. 2010, 5: e10942-PubMedCentralPubMed Robinson E, Titov N, Andrews G, McIntyre K, Schwencke G, Solley K: Internet treatment for generalized anxiety disorder: a randomized controlled trial comparing clinician vs. technician assistance. PLoS One. 2010, 5: e10942-PubMedCentralPubMed
525.
Zurück zum Zitat Paxling B, Almlov J, Dahlin M, Carlbring P, Breitholtz E, Eriksson T, Andersson G: Guided internet-delivered cognitive behavior therapy for generalized anxiety disorder: a randomized controlled trial. Cogn Behav Ther. 2011, 40: 159-173.PubMed Paxling B, Almlov J, Dahlin M, Carlbring P, Breitholtz E, Eriksson T, Andersson G: Guided internet-delivered cognitive behavior therapy for generalized anxiety disorder: a randomized controlled trial. Cogn Behav Ther. 2011, 40: 159-173.PubMed
526.
Zurück zum Zitat Gorini A, Pallavicini F, Algeri D, Repetto C, Gaggioli A, Riva G: Virtual reality in the treatment of generalized anxiety disorders. Stud Health Technol Inform. 2010, 154: 39-43.PubMed Gorini A, Pallavicini F, Algeri D, Repetto C, Gaggioli A, Riva G: Virtual reality in the treatment of generalized anxiety disorders. Stud Health Technol Inform. 2010, 154: 39-43.PubMed
527.
Zurück zum Zitat den Boer PC, Wiersma D, Ten Vaarwerk I, Span MM, Stant AD, Van den Bosch RJ: Cognitive self-therapy for chronic depression and anxiety: a multi-centre randomized controlled study. Psychol Med. 2007, 37: 329-339.PubMed den Boer PC, Wiersma D, Ten Vaarwerk I, Span MM, Stant AD, Van den Bosch RJ: Cognitive self-therapy for chronic depression and anxiety: a multi-centre randomized controlled study. Psychol Med. 2007, 37: 329-339.PubMed
528.
Zurück zum Zitat Wells A, Welford M, King P, Papageorgiou C, Wisely J, Mendel E: A pilot randomized trial of metacognitive therapy vs applied relaxation in the treatment of adults with generalized anxiety disorder. Behav Res Ther. 2010, 48: 429-434.PubMed Wells A, Welford M, King P, Papageorgiou C, Wisely J, Mendel E: A pilot randomized trial of metacognitive therapy vs applied relaxation in the treatment of adults with generalized anxiety disorder. Behav Res Ther. 2010, 48: 429-434.PubMed
529.
Zurück zum Zitat Conrad A, Isaac L, Roth WT: The psychophysiology of generalized anxiety disorder: 2. Effects of applied relaxation. Psychophysiology. 2008, 45: 377-388.PubMed Conrad A, Isaac L, Roth WT: The psychophysiology of generalized anxiety disorder: 2. Effects of applied relaxation. Psychophysiology. 2008, 45: 377-388.PubMed
530.
Zurück zum Zitat Dugas MJ, Brillon P, Savard P, Turcotte J, Gaudet A, Ladouceur R, Leblanc R, Gervais NJ: A randomized clinical trial of cognitive-behavioral therapy and applied relaxation for adults with generalized anxiety disorder. Behav Ther. 2010, 41: 46-58.PubMedCentralPubMed Dugas MJ, Brillon P, Savard P, Turcotte J, Gaudet A, Ladouceur R, Leblanc R, Gervais NJ: A randomized clinical trial of cognitive-behavioral therapy and applied relaxation for adults with generalized anxiety disorder. Behav Ther. 2010, 41: 46-58.PubMedCentralPubMed
531.
Zurück zum Zitat Dubois O, Salamon R, Germain C, Poirier MF, Vaugeois C, Banwarth B, Mouaffak F, Galinowski A, Olie JP: Balneotherapy versus paroxetine in the treatment of generalized anxiety disorder. Complement Ther Med. 2010, 18: 1-7.PubMed Dubois O, Salamon R, Germain C, Poirier MF, Vaugeois C, Banwarth B, Mouaffak F, Galinowski A, Olie JP: Balneotherapy versus paroxetine in the treatment of generalized anxiety disorder. Complement Ther Med. 2010, 18: 1-7.PubMed
532.
Zurück zum Zitat Dugas MJ, Marchand A, Ladouceur R: Further validation of a cognitive-behavioral model of generalized anxiety disorder: diagnostic and symptom specificity. J Anxiety Disord. 2005, 19: 329-343.PubMed Dugas MJ, Marchand A, Ladouceur R: Further validation of a cognitive-behavioral model of generalized anxiety disorder: diagnostic and symptom specificity. J Anxiety Disord. 2005, 19: 329-343.PubMed
533.
Zurück zum Zitat Roemer L, Orsillo SM, Salters-Pedneault K: Efficacy of an acceptance-based behavior therapy for generalized anxiety disorder: evaluation in a randomized controlled trial. J Consult Clin Psychol. 2008, 76: 1083-1089.PubMedCentralPubMed Roemer L, Orsillo SM, Salters-Pedneault K: Efficacy of an acceptance-based behavior therapy for generalized anxiety disorder: evaluation in a randomized controlled trial. J Consult Clin Psychol. 2008, 76: 1083-1089.PubMedCentralPubMed
534.
Zurück zum Zitat van der Heiden C, Muris P, van der Molen HT: Randomized controlled trial on the effectiveness of metacognitive therapy and intolerance-of-uncertainty therapy for generalized anxiety disorder. Behav Res Ther. 2012, 50: 100-109.PubMed van der Heiden C, Muris P, van der Molen HT: Randomized controlled trial on the effectiveness of metacognitive therapy and intolerance-of-uncertainty therapy for generalized anxiety disorder. Behav Res Ther. 2012, 50: 100-109.PubMed
535.
Zurück zum Zitat Hoyer J, Beesdo K, Gloster AT, Runge J, Hofler M, Becker ES: Worry exposure versus applied relaxation in the treatment of generalized anxiety disorder. Psychother Psychosom. 2009, 78: 106-115.PubMed Hoyer J, Beesdo K, Gloster AT, Runge J, Hofler M, Becker ES: Worry exposure versus applied relaxation in the treatment of generalized anxiety disorder. Psychother Psychosom. 2009, 78: 106-115.PubMed
536.
Zurück zum Zitat Riskind JH, Williams NL, Joiner TE: The looming cognitive style: A cognitive vulnerability for anxiety disorders. J Social Clin Psychol. 2006, 25: 779-801. Riskind JH, Williams NL, Joiner TE: The looming cognitive style: A cognitive vulnerability for anxiety disorders. J Social Clin Psychol. 2006, 25: 779-801.
537.
Zurück zum Zitat Leichsenring F, Salzer S, Jaeger U, Kachele H, Kreische R, Leweke F, Ruger U, Winkelbach C, Leibing E: Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trial. Am J Psychiatry. 2009, 166: 875-881.PubMed Leichsenring F, Salzer S, Jaeger U, Kachele H, Kreische R, Leweke F, Ruger U, Winkelbach C, Leibing E: Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trial. Am J Psychiatry. 2009, 166: 875-881.PubMed
538.
Zurück zum Zitat Newman MG, Castonguay LG, Borkovec TD, Fisher AJ, Boswell JF, Szkodny LE, Nordberg SS: A randomized controlled trial of cognitive-behavioral therapy for generalized anxiety disorder with integrated techniques from emotion-focused and interpersonal therapies. J Consult Clin Psychol. 2011, 79: 171-181.PubMedCentralPubMed Newman MG, Castonguay LG, Borkovec TD, Fisher AJ, Boswell JF, Szkodny LE, Nordberg SS: A randomized controlled trial of cognitive-behavioral therapy for generalized anxiety disorder with integrated techniques from emotion-focused and interpersonal therapies. J Consult Clin Psychol. 2011, 79: 171-181.PubMedCentralPubMed
539.
Zurück zum Zitat Aviram A, Westra HA: The impact of motivational interviewing on resistance in cognitive behavioural therapy for generalized anxiety disorder. Psychother Res. 2011, 21: 698-708.PubMed Aviram A, Westra HA: The impact of motivational interviewing on resistance in cognitive behavioural therapy for generalized anxiety disorder. Psychother Res. 2011, 21: 698-708.PubMed
540.
Zurück zum Zitat Westra HA, Arkowitz H, Dozois DJ: Adding a motivational interviewing pretreatment to cognitive behavioral therapy for generalized anxiety disorder: a preliminary randomized controlled trial. J Anxiety Disord. 2009, 23: 1106-1117.PubMedCentralPubMed Westra HA, Arkowitz H, Dozois DJ: Adding a motivational interviewing pretreatment to cognitive behavioral therapy for generalized anxiety disorder: a preliminary randomized controlled trial. J Anxiety Disord. 2009, 23: 1106-1117.PubMedCentralPubMed
541.
Zurück zum Zitat Crits-Christoph P, Newman MG, Rickels K, Gallop R, Gibbons MB, Hamilton JL, Ring-Kurtz S, Pastva AM: Combined medication and cognitive therapy for generalized anxiety disorder. J Anxiety Disord. 2011, 25: 1087-1094.PubMedCentralPubMed Crits-Christoph P, Newman MG, Rickels K, Gallop R, Gibbons MB, Hamilton JL, Ring-Kurtz S, Pastva AM: Combined medication and cognitive therapy for generalized anxiety disorder. J Anxiety Disord. 2011, 25: 1087-1094.PubMedCentralPubMed
542.
Zurück zum Zitat Gosselin P, Ladouceur R, Morin CM, Dugas MJ, Baillargeon L: Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol. 2006, 74: 908-919.PubMed Gosselin P, Ladouceur R, Morin CM, Dugas MJ, Baillargeon L: Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol. 2006, 74: 908-919.PubMed
543.
Zurück zum Zitat Salzer S, Winkelbach C, Leweke F, Leibing E, Leichsenring F: Long-term effects of short-term psychodynamic psychotherapy and cognitive-behavioural therapy in generalized anxiety disorder: 12-month follow-up. Can J Psychiatry. 2011, 56: 503-508.PubMed Salzer S, Winkelbach C, Leweke F, Leibing E, Leichsenring F: Long-term effects of short-term psychodynamic psychotherapy and cognitive-behavioural therapy in generalized anxiety disorder: 12-month follow-up. Can J Psychiatry. 2011, 56: 503-508.PubMed
544.
Zurück zum Zitat Davidson J, Bose A, Korotzer A, Zheng H: Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety. 2004, 19: 234-240.PubMed Davidson J, Bose A, Korotzer A, Zheng H: Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety. 2004, 19: 234-240.PubMed
545.
Zurück zum Zitat Goodman WK, Bose A, Wang Q: Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005, 87: 161-167.PubMed Goodman WK, Bose A, Wang Q: Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005, 87: 161-167.PubMed
546.
Zurück zum Zitat Bielski RJ, Bose A, Chang CC: A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry. 2005, 17: 65-69.PubMed Bielski RJ, Bose A, Chang CC: A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry. 2005, 17: 65-69.PubMed
547.
Zurück zum Zitat Baldwin DS, Huusom AK, Maehlum E: Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry. 2006, 189: 264-272.PubMed Baldwin DS, Huusom AK, Maehlum E: Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry. 2006, 189: 264-272.PubMed
548.
Zurück zum Zitat Bose A, Korotzer A, Gommoll C, Li D: Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety. 2008, 25: 854-861.PubMed Bose A, Korotzer A, Gommoll C, Li D: Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety. 2008, 25: 854-861.PubMed
549.
Zurück zum Zitat Bystritsky A, Kerwin L, Feusner JD, Vapnik T: A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder. Psychopharmacol Bull. 2008, 41: 46-51.PubMed Bystritsky A, Kerwin L, Feusner JD, Vapnik T: A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder. Psychopharmacol Bull. 2008, 41: 46-51.PubMed
550.
Zurück zum Zitat Lenze EJ, Rollman BL, Shear MK, Dew MA, Pollock BG, Ciliberti C, Costantino M, Snyder S, Shi P, Spitznagel E, et al: Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA. 2009, 301: 295-303.PubMedCentralPubMed Lenze EJ, Rollman BL, Shear MK, Dew MA, Pollock BG, Ciliberti C, Costantino M, Snyder S, Shi P, Spitznagel E, et al: Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA. 2009, 301: 295-303.PubMedCentralPubMed
551.
Zurück zum Zitat Merideth C, Cutler AJ, She F, Eriksson H: Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 2012, 27: 40-54.PubMed Merideth C, Cutler AJ, She F, Eriksson H: Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 2012, 27: 40-54.PubMed
552.
Zurück zum Zitat Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, et al: Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety. 2010, 27: 417-425.PubMed Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, et al: Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety. 2010, 27: 417-425.PubMed
553.
Zurück zum Zitat Kapczinski F, Lima MS, Souza JS, Schmitt R: Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003, CD003592- Kapczinski F, Lima MS, Souza JS, Schmitt R: Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003, CD003592-
554.
Zurück zum Zitat Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D: Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003, 160: 749-756.PubMed Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D: Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003, 160: 749-756.PubMed
555.
Zurück zum Zitat Pollack M, Zaninelli R, Goddard A, McCafferty J, Bellew K, Burnham D, Iyengar M: Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001, 62: 350-357.PubMed Pollack M, Zaninelli R, Goddard A, McCafferty J, Bellew K, Burnham D, Iyengar M: Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001, 62: 350-357.PubMed
556.
Zurück zum Zitat Ball S, Kuhn A, Wall D, Shekhar A, Goddard A: Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry. 2005, 66: 94-99.PubMed Ball S, Kuhn A, Wall D, Shekhar A, Goddard A: Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry. 2005, 66: 94-99.PubMed
557.
Zurück zum Zitat Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H: Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010, 13: 305-320.PubMed Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H: Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010, 13: 305-320.PubMed
558.
Zurück zum Zitat Kim TS, Pae CU, Yoon SJ, Bahk WM, Jun TY, Rhee WI, Chae JH: Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin Neurosci. 2006, 60: 347-351.PubMed Kim TS, Pae CU, Yoon SJ, Bahk WM, Jun TY, Rhee WI, Chae JH: Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin Neurosci. 2006, 60: 347-351.PubMed
559.
Zurück zum Zitat Allgulander C, Dahl A, Austin C, Morris P, Sogaard J, Fayyad R, Kutcher S, Clary C: Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry. 2004, 161: 1642-1649.PubMed Allgulander C, Dahl A, Austin C, Morris P, Sogaard J, Fayyad R, Kutcher S, Clary C: Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry. 2004, 161: 1642-1649.PubMed
560.
Zurück zum Zitat Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K: Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006, 67: 874-881.PubMed Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K: Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006, 67: 874-881.PubMed
561.
Zurück zum Zitat Mokhber N, Azarpazhooh MR, Khajehdaluee M, Velayati A, Hopwood M: Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder. Psychiatry Clin Neurosci. 2010, 64: 128-133.PubMed Mokhber N, Azarpazhooh MR, Khajehdaluee M, Velayati A, Hopwood M: Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder. Psychiatry Clin Neurosci. 2010, 64: 128-133.PubMed
562.
Zurück zum Zitat Varia I, Rauscher F: Treatment of generalized anxiety disorder with citalopram. Int Clin Psychopharmacol. 2002, 17: 103-107.PubMed Varia I, Rauscher F: Treatment of generalized anxiety disorder with citalopram. Int Clin Psychopharmacol. 2002, 17: 103-107.PubMed
563.
Zurück zum Zitat Simon NM, Zalta AK, Worthington JJ, Hoge EA, Christian KM, Stevens JC, Pollack MH: Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depress Anxiety. 2006, 23: 373-376.PubMed Simon NM, Zalta AK, Worthington JJ, Hoge EA, Christian KM, Stevens JC, Pollack MH: Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depress Anxiety. 2006, 23: 373-376.PubMed
564.
Zurück zum Zitat Gross PK, Nourse R, Wasser TE, Krulewicz S: Effects of paroxetine CR on depressive and anxiety symptoms: in a community sample of adult Hispanic women with major depression or generalized anxiety disorder. Psychiatry (Edgmont). 2006, 3: 64-68. Gross PK, Nourse R, Wasser TE, Krulewicz S: Effects of paroxetine CR on depressive and anxiety symptoms: in a community sample of adult Hispanic women with major depression or generalized anxiety disorder. Psychiatry (Edgmont). 2006, 3: 64-68.
565.
Zurück zum Zitat Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington JJ, Zhang W, Davidson JR, Pollack MH: Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008, 197: 675-681. Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington JJ, Zhang W, Davidson JR, Pollack MH: Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008, 197: 675-681.
566.
Zurück zum Zitat Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J: Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008, 25: 182-189.PubMed Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J: Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008, 25: 182-189.PubMed
567.
Zurück zum Zitat Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, Ball SG, Russell JM: Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry. 2007, 9: 100-107.PubMedCentralPubMed Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, Ball SG, Russell JM: Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry. 2007, 9: 100-107.PubMedCentralPubMed
568.
Zurück zum Zitat Wu WY, Wang G, Ball SG, Desaiah D, Ang QQ: Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China. Chin Med J (Engl). 2011, 124: 3260-3268. Wu WY, Wang G, Ball SG, Desaiah D, Ang QQ: Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China. Chin Med J (Engl). 2011, 124: 3260-3268.
569.
Zurück zum Zitat Allgulander C, Hartford J, Russell J, Ball S, Erickson J, Raskin J, Rynn M: Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin. 2007, 23: 1245-1252.PubMed Allgulander C, Hartford J, Russell J, Ball S, Erickson J, Raskin J, Rynn M: Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin. 2007, 23: 1245-1252.PubMed
570.
Zurück zum Zitat Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J: Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol. 2007, 22: 167-174.PubMed Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J: Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol. 2007, 22: 167-174.PubMed
571.
Zurück zum Zitat Allgulander C, Nutt D, Detke M, Erickson J, Spann M, Walker D, Ball SG, Russell JM: A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol. 2008, 22: 417-425.PubMed Allgulander C, Nutt D, Detke M, Erickson J, Spann M, Walker D, Ball SG, Russell JM: A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol. 2008, 22: 417-425.PubMed
572.
Zurück zum Zitat Davidson J, Du Pont R, Hedges D, Haskins J: Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999, 60: 528-535.PubMed Davidson J, Du Pont R, Hedges D, Haskins J: Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999, 60: 528-535.PubMed
573.
Zurück zum Zitat Nimatoudis I, Zissis N, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G: Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol. 2004, 19: 331-336.PubMed Nimatoudis I, Zissis N, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G: Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol. 2004, 19: 331-336.PubMed
574.
Zurück zum Zitat Rickels K, Pollack M, Sheehan D, Haskins J: Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000, 157: 968-974.PubMed Rickels K, Pollack M, Sheehan D, Haskins J: Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000, 157: 968-974.PubMed
575.
Zurück zum Zitat Katz I, Reynolds C, Alexopoulos G, Hackett D: Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc. 2002, 50: 18-25.PubMed Katz I, Reynolds C, Alexopoulos G, Hackett D: Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc. 2002, 50: 18-25.PubMed
576.
Zurück zum Zitat Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC: Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006, 67: 771-782.PubMed Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC: Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006, 67: 771-782.PubMed
577.
Zurück zum Zitat Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, Baldinetti F, Bandelow B: Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol. 2009, 24: 87-96.PubMed Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, Baldinetti F, Bandelow B: Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol. 2009, 24: 87-96.PubMed
578.
Zurück zum Zitat Allgulander C, Hackett D, Salinas E: Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001, 179: 15-22.PubMed Allgulander C, Hackett D, Salinas E: Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001, 179: 15-22.PubMed
579.
Zurück zum Zitat Gelenberg A, Lydiard R, Rudolph R, Aguiar L, Haskins J, Salinas E: Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000, 283: 3082-3088.PubMed Gelenberg A, Lydiard R, Rudolph R, Aguiar L, Haskins J, Salinas E: Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000, 283: 3082-3088.PubMed
580.
Zurück zum Zitat Lenox-Smith AJ, Reynolds A: A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract. 2003, 53: 772-777.PubMedCentralPubMed Lenox-Smith AJ, Reynolds A: A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract. 2003, 53: 772-777.PubMedCentralPubMed
581.
Zurück zum Zitat Hoehn-Saric R, McLeod D, Zimmerli W: Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry. 1988, 49: 293-301.PubMed Hoehn-Saric R, McLeod D, Zimmerli W: Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry. 1988, 49: 293-301.PubMed
582.
Zurück zum Zitat Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L: Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand. 1997, 95: 444-450.PubMed Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L: Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand. 1997, 95: 444-450.PubMed
583.
Zurück zum Zitat Rickels K, Downing R, Schweizer E, Hassman H: Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993, 50: 884-895.PubMed Rickels K, Downing R, Schweizer E, Hassman H: Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993, 50: 884-895.PubMed
584.
Zurück zum Zitat Stein DJ, Ahokas AA, de Bodinat C: Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008, 28: 561-566.PubMed Stein DJ, Ahokas AA, de Bodinat C: Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008, 28: 561-566.PubMed
585.
Zurück zum Zitat Stein D, Marquez M, Hoschl C, Ahokas A, Oh K-S, Jarema M, Avedisova A, Vavrusova L, Olivier V: Efficacy and tolerability of agomelatine in generalized anxiety disorder: A randomised double blind placebo controlled trial with escitalopram as active control [poster]. 28th CINP Congress; Jun 3-7; Stockholm, Sweden. 2012 Stein D, Marquez M, Hoschl C, Ahokas A, Oh K-S, Jarema M, Avedisova A, Vavrusova L, Olivier V: Efficacy and tolerability of agomelatine in generalized anxiety disorder: A randomised double blind placebo controlled trial with escitalopram as active control [poster]. 28th CINP Congress; Jun 3-7; Stockholm, Sweden. 2012
586.
Zurück zum Zitat Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV: Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012, 22: 858-866.PubMed Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV: Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012, 22: 858-866.PubMed
587.
Zurück zum Zitat Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV: Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol. 2012, 22: 847-857.PubMed Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV: Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol. 2012, 22: 847-857.PubMed
588.
Zurück zum Zitat Gambi F, De Berardis D, Campanella D, Carano A, Sepede G, Salini G, Mezzano D, Cicconetti A, Penna L, Salerno RM, Ferro FM: Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol. 2005, 19: 483-487.PubMed Gambi F, De Berardis D, Campanella D, Carano A, Sepede G, Salini G, Mezzano D, Cicconetti A, Penna L, Salerno RM, Ferro FM: Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol. 2005, 19: 483-487.PubMed
589.
Zurück zum Zitat Mitte K, Noack P, Steil R, Hautzinger M: A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol. 2005, 25: 141-150.PubMed Mitte K, Noack P, Steil R, Hautzinger M: A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol. 2005, 25: 141-150.PubMed
590.
Zurück zum Zitat Lydiard R, Ballenger J, Rickels K: A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997, 58 (Suppl 11): 11-18.PubMed Lydiard R, Ballenger J, Rickels K: A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997, 58 (Suppl 11): 11-18.PubMed
591.
Zurück zum Zitat Moller H, Volz H, Reimann I, Stoll K: Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol. 2001, 21: 59-65.PubMed Moller H, Volz H, Reimann I, Stoll K: Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol. 2001, 21: 59-65.PubMed
592.
Zurück zum Zitat Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC: Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005, 62: 1022-1030.PubMed Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC: Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005, 62: 1022-1030.PubMed
593.
Zurück zum Zitat Lydiard RB, Rickels K, Herman B, Feltner DE: Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol. 2010, 13: 229-241.PubMed Lydiard RB, Rickels K, Herman B, Feltner DE: Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol. 2010, 13: 229-241.PubMed
594.
Zurück zum Zitat Llorca P, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher J, Sermet E, Servant D: Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry. 2002, 63: 1020-1027.PubMed Llorca P, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher J, Sermet E, Servant D: Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry. 2002, 63: 1020-1027.PubMed
595.
Zurück zum Zitat Rickels K, Schweizer E, De Martinis N, Mandos L, Mercer C: Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1997, 17: 272-277.PubMed Rickels K, Schweizer E, De Martinis N, Mandos L, Mercer C: Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1997, 17: 272-277.PubMed
596.
Zurück zum Zitat Rickels K, DeMartinis N, Aufdembrinke B: A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. J Clin Psychopharmacol. 2000, 20: 12-18.PubMed Rickels K, DeMartinis N, Aufdembrinke B: A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. J Clin Psychopharmacol. 2000, 20: 12-18.PubMed
597.
Zurück zum Zitat Feltner D, Crockatt J, Dubovsky S, Cohn C, Shrivastava R, Targum S, Liu-Dumaw M, Carter C, Pande A: A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003, 23: 240-249.PubMed Feltner D, Crockatt J, Dubovsky S, Cohn C, Shrivastava R, Targum S, Liu-Dumaw M, Carter C, Pande A: A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003, 23: 240-249.PubMed
598.
Zurück zum Zitat Laakmann G, Schule C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S: Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl). 1998, 136: 357-366. Laakmann G, Schule C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S: Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl). 1998, 136: 357-366.
599.
Zurück zum Zitat Fresquet A, Sust M, Lloret A, Murphy M, Carter F, Campbell G, Marion-Landais G: Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder. Ann Pharmacother. 2000, 34: 147-153.PubMed Fresquet A, Sust M, Lloret A, Murphy M, Carter F, Campbell G, Marion-Landais G: Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder. Ann Pharmacother. 2000, 34: 147-153.PubMed
600.
Zurück zum Zitat Woelk H, Schlafke S: A multi-center, double-blind, randomised study of the lavender oil preparation Silexan in comparison to lorazepam for generalized anxiety disorder. Phytomedicine. 2010, 17: 94-99.PubMed Woelk H, Schlafke S: A multi-center, double-blind, randomised study of the lavender oil preparation Silexan in comparison to lorazepam for generalized anxiety disorder. Phytomedicine. 2010, 17: 94-99.PubMed
601.
Zurück zum Zitat Herrera-Arellano A, Jimenez-Ferrer E, Zamilpa A, Morales-Valdez M, Garcia-Valencia CE, Tortoriello J: Efficacy and tolerability of a standardized herbal product from galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam. Planta Med. 2007, 73: 713-717.PubMed Herrera-Arellano A, Jimenez-Ferrer E, Zamilpa A, Morales-Valdez M, Garcia-Valencia CE, Tortoriello J: Efficacy and tolerability of a standardized herbal product from galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam. Planta Med. 2007, 73: 713-717.PubMed
602.
Zurück zum Zitat Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H: A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011, 31: 418-428.PubMed Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H: A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011, 31: 418-428.PubMed
603.
Zurück zum Zitat Stein DJ, Bandelow B, Merideth C, Olausson B, Szamosi J, Eriksson H: Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol. 2011, 26: 614-628.PubMed Stein DJ, Bandelow B, Merideth C, Olausson B, Szamosi J, Eriksson H: Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol. 2011, 26: 614-628.PubMed
604.
Zurück zum Zitat Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Struzik L, Gendron A: Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord. 2008, 22: 1480-1486.PubMed Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Struzik L, Gendron A: Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord. 2008, 22: 1480-1486.PubMed
605.
Zurück zum Zitat Altamura AC, Serati M, Buoli M, Dell'Osso B: Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol. 2011, 26: 201-205.PubMed Altamura AC, Serati M, Buoli M, Dell'Osso B: Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol. 2011, 26: 201-205.PubMed
606.
Zurück zum Zitat Brawman-Mintzer O, Knapp RG, Nietert PJ: Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005, 66: 1321-1325.PubMed Brawman-Mintzer O, Knapp RG, Nietert PJ: Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005, 66: 1321-1325.PubMed
607.
Zurück zum Zitat Pandina GJ, Canuso CM, Turkoz I, Kujawa M, Mahmoud RA: Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull. 2007, 40: 41-57.PubMed Pandina GJ, Canuso CM, Turkoz I, Kujawa M, Mahmoud RA: Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull. 2007, 40: 41-57.PubMed
608.
Zurück zum Zitat Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J: Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006, 59: 211-215.PubMed Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J: Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006, 59: 211-215.PubMed
609.
Zurück zum Zitat Menza MA, Dobkin RD, Marin H: An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder [Letter]. J Clin Psychopharmacol. 2007, 27: 207-210.PubMed Menza MA, Dobkin RD, Marin H: An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder [Letter]. J Clin Psychopharmacol. 2007, 27: 207-210.PubMed
610.
Zurück zum Zitat Gabriel A: The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): An open label naturalistic study. Clin Ter. 2011, 162: 113-118.PubMed Gabriel A: The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): An open label naturalistic study. Clin Ter. 2011, 162: 113-118.PubMed
611.
Zurück zum Zitat Lohoff FW, Etemad B, Mandos LA, Gallop R, Rickels K: Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol. 2010, 30: 185-189.PubMed Lohoff FW, Etemad B, Mandos LA, Gallop R, Rickels K: Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol. 2010, 30: 185-189.PubMed
612.
Zurück zum Zitat Snyderman SH, Rynn MA, Rickels K: Open-label pilot study of ziprasidone for refractory generalized anxiety disorder [Letter]. J Clin Psychopharmacol. 2005, 25: 497-499.PubMed Snyderman SH, Rynn MA, Rickels K: Open-label pilot study of ziprasidone for refractory generalized anxiety disorder [Letter]. J Clin Psychopharmacol. 2005, 25: 497-499.PubMed
613.
Zurück zum Zitat Pohl R, Feltner D, Fieve R, Pande A: Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005, 25: 151-158.PubMed Pohl R, Feltner D, Fieve R, Pande A: Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005, 25: 151-158.PubMed
614.
Zurück zum Zitat Aliyev NA, Aliyev ZN: Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry. 2008, 23: 109-114.PubMed Aliyev NA, Aliyev ZN: Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry. 2008, 23: 109-114.PubMed
615.
Zurück zum Zitat Pollack MH, Tiller J, Xie F, Trivedi MH: Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol. 2008, 28: 308-316.PubMed Pollack MH, Tiller J, Xie F, Trivedi MH: Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol. 2008, 28: 308-316.PubMed
616.
Zurück zum Zitat Rosenthal M: Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry. 2003, 64: 1245-1249.PubMed Rosenthal M: Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry. 2003, 64: 1245-1249.PubMed
617.
Zurück zum Zitat Rickels K, Shiovitz TM, Ramey TS, Weaver JJ, Knapp LE, Miceli JJ: Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol. 2012, 27: 142-150.PubMed Rickels K, Shiovitz TM, Ramey TS, Weaver JJ, Knapp LE, Miceli JJ: Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol. 2012, 27: 142-150.PubMed
618.
Zurück zum Zitat Pollack M, Worthington J, Manfro G, Otto M, Zucker B: Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry. 1997, 58 (Suppl 11): 19-23.PubMed Pollack M, Worthington J, Manfro G, Otto M, Zucker B: Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry. 1997, 58 (Suppl 11): 19-23.PubMed
619.
Zurück zum Zitat Lader M, Scotto J: A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl). 1998, 139: 402-406. Lader M, Scotto J: A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl). 1998, 139: 402-406.
620.
Zurück zum Zitat Guaiana G, Barbui C, Cipriani A: Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev. 2010, CD006815- Guaiana G, Barbui C, Cipriani A: Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev. 2010, CD006815-
621.
Zurück zum Zitat Meibach RC, Dunner D, Wilson LG, Ishiki D, Dager SR: Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial. J Clin Psychiatry. 1987, 48: 355-358.PubMed Meibach RC, Dunner D, Wilson LG, Ishiki D, Dager SR: Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial. J Clin Psychiatry. 1987, 48: 355-358.PubMed
622.
Zurück zum Zitat Feusner JD, Kerwin L, Saxena S, Bystritsky A: Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull. 2009, 42: 81-93.PubMed Feusner JD, Kerwin L, Saxena S, Bystritsky A: Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull. 2009, 42: 81-93.PubMed
623.
Zurück zum Zitat Baldwin DS, Nutt DJ: On assessing potential efficacy for vortioxetine in generalized anxiety disorder. Eur Neuropsychopharmacol. 2012, 22: 841-843.PubMed Baldwin DS, Nutt DJ: On assessing potential efficacy for vortioxetine in generalized anxiety disorder. Eur Neuropsychopharmacol. 2012, 22: 841-843.PubMed
624.
Zurück zum Zitat Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, Russell JM: Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2008, 18: 673-681.PubMed Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, Russell JM: Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2008, 18: 673-681.PubMed
625.
Zurück zum Zitat Allgulander C, Florea I, Huusom AK: Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006, 9: 495-505.PubMed Allgulander C, Florea I, Huusom AK: Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006, 9: 495-505.PubMed
626.
Zurück zum Zitat Stocchi F, Nordera G, Jokinen R, Lepola U, Hewett K, Bryson H, Iyengar M: Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003, 64: 250-258.PubMed Stocchi F, Nordera G, Jokinen R, Lepola U, Hewett K, Bryson H, Iyengar M: Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003, 64: 250-258.PubMed
627.
Zurück zum Zitat Rickels K, Etemad B, Khalid-Khan S, Lohoff FW, Rynn MA, Gallop RJ: Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry. 2010, 67: 1274-1281.PubMed Rickels K, Etemad B, Khalid-Khan S, Lohoff FW, Rynn MA, Gallop RJ: Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry. 2010, 67: 1274-1281.PubMed
628.
Zurück zum Zitat Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC: Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008, 23: 18-28.PubMed Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC: Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008, 23: 18-28.PubMed
629.
Zurück zum Zitat Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H: Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011, 26: 11-24.PubMed Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H: Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011, 26: 11-24.PubMed
630.
Zurück zum Zitat Bystritsky A, Kaplan JT, Feusner JD, Kerwin LE, Wadekar M, Burock M, Wu AD, Iacoboni M: A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder. J Clin Psychiatry. 2008, 69: 1092-1098.PubMed Bystritsky A, Kaplan JT, Feusner JD, Kerwin LE, Wadekar M, Burock M, Wu AD, Iacoboni M: A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder. J Clin Psychiatry. 2008, 69: 1092-1098.PubMed
631.
Zurück zum Zitat Bystritsky A, Kerwin LE, Feusner JD: A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder: 6-month follow-up [Letter]. J Clin Psychiatry. 2009, 70: 431-432.PubMed Bystritsky A, Kerwin LE, Feusner JD: A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder: 6-month follow-up [Letter]. J Clin Psychiatry. 2009, 70: 431-432.PubMed
632.
Zurück zum Zitat Kasper S, Gastpar M, Muller WE, Volz HP, Moller HJ, Dienel A, Schlafke S: Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol. 2010, 25: 277-287.PubMed Kasper S, Gastpar M, Muller WE, Volz HP, Moller HJ, Dienel A, Schlafke S: Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol. 2010, 25: 277-287.PubMed
633.
Zurück zum Zitat Miyasaka LS, Atallah AN, Soares BG: Passiflora for anxiety disorder. Cochrane Database Syst Rev. 2007, CD004518- Miyasaka LS, Atallah AN, Soares BG: Passiflora for anxiety disorder. Cochrane Database Syst Rev. 2007, CD004518-
634.
Zurück zum Zitat Andreatini R, Sartori VA, Seabra ML, Leite JR: Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res. 2002, 16: 650-654.PubMed Andreatini R, Sartori VA, Seabra ML, Leite JR: Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res. 2002, 16: 650-654.PubMed
635.
Zurück zum Zitat Miyasaka LS, Atallah AN, Soares BG: Valerian for anxiety disorders. Cochrane Database Syst Rev. 2006, CD004515- Miyasaka LS, Atallah AN, Soares BG: Valerian for anxiety disorders. Cochrane Database Syst Rev. 2006, CD004515-
636.
Zurück zum Zitat Herring MP, Jacob ML, Suveg C, Dishman RK, O'Connor PJ: Feasibility of exercise training for the short-term treatment of generalized anxiety disorder: a randomized controlled trial. Psychother Psychosom. 2012, 81: 21-28.PubMed Herring MP, Jacob ML, Suveg C, Dishman RK, O'Connor PJ: Feasibility of exercise training for the short-term treatment of generalized anxiety disorder: a randomized controlled trial. Psychother Psychosom. 2012, 81: 21-28.PubMed
637.
Zurück zum Zitat Pilkington K, Kirkwood G, Rampes H, Cummings M, Richardson J: Acupuncture for anxiety and anxiety disorders--a systematic literature review. Acupunct Med. 2007, 25: 1-10.PubMed Pilkington K, Kirkwood G, Rampes H, Cummings M, Richardson J: Acupuncture for anxiety and anxiety disorders--a systematic literature review. Acupunct Med. 2007, 25: 1-10.PubMed
638.
Zurück zum Zitat Lu CF, Smith LN, Gau CH: Exploring the zen meditation experiences of patients with generalized anxiety disorder: a focus-group approach. J Nurs Res. 2012, 20: 43-52.PubMed Lu CF, Smith LN, Gau CH: Exploring the zen meditation experiences of patients with generalized anxiety disorder: a focus-group approach. J Nurs Res. 2012, 20: 43-52.PubMed
639.
Zurück zum Zitat Katzman MA, Vermani M, Gerbarg PL, Brown RP, Iorio C, Davis M, Cameron C, Tsirgielis D: A multicomponent yoga-based, breath intervention program as an adjunctive treatment in patients suffering from generalized anxiety disorder with or without comorbidities. Int J Yoga. 2012, 5: 57-65.PubMedCentralPubMed Katzman MA, Vermani M, Gerbarg PL, Brown RP, Iorio C, Davis M, Cameron C, Tsirgielis D: A multicomponent yoga-based, breath intervention program as an adjunctive treatment in patients suffering from generalized anxiety disorder with or without comorbidities. Int J Yoga. 2012, 5: 57-65.PubMedCentralPubMed
640.
Zurück zum Zitat Youngstedt SD, Kline CE, Ginsberg JP, Zielinski MR, Hardin JW: Bright light treatment for high-anxious young adults: a randomized controlled pilot study. Depress Anxiety. 2011, 28: 324-332.PubMed Youngstedt SD, Kline CE, Ginsberg JP, Zielinski MR, Hardin JW: Bright light treatment for high-anxious young adults: a randomized controlled pilot study. Depress Anxiety. 2011, 28: 324-332.PubMed
641.
Zurück zum Zitat Ruscio AM, Stein DJ, Chiu WT, Kessler RC: The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010, 15: 53-63.PubMedCentralPubMed Ruscio AM, Stein DJ, Chiu WT, Kessler RC: The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010, 15: 53-63.PubMedCentralPubMed
642.
Zurück zum Zitat Adam Y, Meinlschmidt G, Gloster AT, Lieb R: Obsessive-compulsive disorder in the community: 12-month prevalence, comorbidity and impairment. Soc Psychiatry Psychiatr Epidemiol. 2012, 47: 339-349.PubMed Adam Y, Meinlschmidt G, Gloster AT, Lieb R: Obsessive-compulsive disorder in the community: 12-month prevalence, comorbidity and impairment. Soc Psychiatry Psychiatr Epidemiol. 2012, 47: 339-349.PubMed
643.
Zurück zum Zitat Rosario-Campos MC, Leckman JF, Mercadante MT, Shavitt RG, Prado HS, Sada P, Zamignani D, Miguel EC: Adults with early-onset obsessive-compulsive disorder. Am J Psychiatry. 2001, 158: 1899-1903.PubMed Rosario-Campos MC, Leckman JF, Mercadante MT, Shavitt RG, Prado HS, Sada P, Zamignani D, Miguel EC: Adults with early-onset obsessive-compulsive disorder. Am J Psychiatry. 2001, 158: 1899-1903.PubMed
644.
Zurück zum Zitat Veldhuis J, Dieleman JP, Wohlfarth T, Storosum JG, van Den Brink W, Sturkenboom MC, Denys D: Incidence and prevalence of "diagnosed OCD" in a primary care, treatment seeking, population. Int J Psychiatry Clin Pract. 2012, 16: 85-92.PubMed Veldhuis J, Dieleman JP, Wohlfarth T, Storosum JG, van Den Brink W, Sturkenboom MC, Denys D: Incidence and prevalence of "diagnosed OCD" in a primary care, treatment seeking, population. Int J Psychiatry Clin Pract. 2012, 16: 85-92.PubMed
645.
Zurück zum Zitat Torres AR, Prince MJ, Bebbington PE, Bhugra D, Brugha TS, Farrell M, Jenkins R, Lewis G, Meltzer H, Singleton N: Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000. Am J Psychiatry. 2006, 163: 1978-1985.PubMed Torres AR, Prince MJ, Bebbington PE, Bhugra D, Brugha TS, Farrell M, Jenkins R, Lewis G, Meltzer H, Singleton N: Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000. Am J Psychiatry. 2006, 163: 1978-1985.PubMed
646.
Zurück zum Zitat Grisham JR, Fullana MA, Mataix-Cols D, Moffitt TE, Caspi A, Poulton R: Risk factors prospectively associated with adult obsessive-compulsive symptom dimensions and obsessive-compulsive disorder. Psychol Med. 2011, : 1-12. Grisham JR, Fullana MA, Mataix-Cols D, Moffitt TE, Caspi A, Poulton R: Risk factors prospectively associated with adult obsessive-compulsive symptom dimensions and obsessive-compulsive disorder. Psychol Med. 2011, : 1-12.
647.
Zurück zum Zitat Hauschildt M, Jelinek L, Randjbar S, Hottenrott B, Moritz S: Generic and illness-specific quality of life in obsessive-compulsive disorder. Behav Cogn Psychother. 2010, 38: 417-436.PubMed Hauschildt M, Jelinek L, Randjbar S, Hottenrott B, Moritz S: Generic and illness-specific quality of life in obsessive-compulsive disorder. Behav Cogn Psychother. 2010, 38: 417-436.PubMed
648.
Zurück zum Zitat Eisen JL, Mancebo MA, Pinto A, Coles ME, Pagano ME, Stout R, Rasmussen SA: Impact of obsessive-compulsive disorder on quality of life. Compr Psychiatry. 2006, 47: 270-275.PubMedCentralPubMed Eisen JL, Mancebo MA, Pinto A, Coles ME, Pagano ME, Stout R, Rasmussen SA: Impact of obsessive-compulsive disorder on quality of life. Compr Psychiatry. 2006, 47: 270-275.PubMedCentralPubMed
649.
Zurück zum Zitat Vikas A, Avasthi A, Sharan P: Psychosocial impact of obsessive-compulsive disorder on patients and their caregivers: a comparative study with depressive disorder. Int J Soc Psychiatry. 2011, 57: 45-56.PubMed Vikas A, Avasthi A, Sharan P: Psychosocial impact of obsessive-compulsive disorder on patients and their caregivers: a comparative study with depressive disorder. Int J Soc Psychiatry. 2011, 57: 45-56.PubMed
650.
Zurück zum Zitat Rampacher F, Lennertz L, Vogeley A, Schulze-Rauschenbach S, Kathmann N, Falkai P, Wagner M: ation processing in patients with OCD compared to patients with unipolar depresEvidence for specific cognitive deficits in visual informsion. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34: 984-991.PubMed Rampacher F, Lennertz L, Vogeley A, Schulze-Rauschenbach S, Kathmann N, Falkai P, Wagner M: ation processing in patients with OCD compared to patients with unipolar depresEvidence for specific cognitive deficits in visual informsion. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34: 984-991.PubMed
651.
Zurück zum Zitat Aigner M, Sachs G, Bruckmuller E, Winklbaur B, Zitterl W, Kryspin-Exner I, Gur R, Katschnig H: Cognitive and emotion recognition deficits in obsessive-compulsive disorder. Psychiatry Res. 2007, 149: 121-128.PubMed Aigner M, Sachs G, Bruckmuller E, Winklbaur B, Zitterl W, Kryspin-Exner I, Gur R, Katschnig H: Cognitive and emotion recognition deficits in obsessive-compulsive disorder. Psychiatry Res. 2007, 149: 121-128.PubMed
652.
Zurück zum Zitat Torres AR, Ramos-Cerqueira AT, Ferrao YA, Fontenelle LF, do Rosario MC, Miguel EC: Suicidality in obsessive-compulsive disorder: prevalence and relation to symptom dimensions and comorbid conditions. J Clin Psychiatry. 2011, 72: 17-26. quiz 119-120PubMed Torres AR, Ramos-Cerqueira AT, Ferrao YA, Fontenelle LF, do Rosario MC, Miguel EC: Suicidality in obsessive-compulsive disorder: prevalence and relation to symptom dimensions and comorbid conditions. J Clin Psychiatry. 2011, 72: 17-26. quiz 119-120PubMed
653.
Zurück zum Zitat Eaton WW, Martins SS, Nestadt G, Bienvenu OJ, Clarke D, Alexandre P: The burden of mental disorders. Epidemiol Rev. 2008, 30: 1-14.PubMedCentralPubMed Eaton WW, Martins SS, Nestadt G, Bienvenu OJ, Clarke D, Alexandre P: The burden of mental disorders. Epidemiol Rev. 2008, 30: 1-14.PubMedCentralPubMed
654.
Zurück zum Zitat Leckman JF, Denys D, Simpson HB, Mataix-Cols D, Hollander E, Saxena S, Miguel EC, Rauch SL, Goodman WK, Phillips KA, Stein DJ: Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. Depress Anxiety. 2010, 27: 507-527.PubMedCentralPubMed Leckman JF, Denys D, Simpson HB, Mataix-Cols D, Hollander E, Saxena S, Miguel EC, Rauch SL, Goodman WK, Phillips KA, Stein DJ: Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. Depress Anxiety. 2010, 27: 507-527.PubMedCentralPubMed
655.
Zurück zum Zitat Abramowitz JS: Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol. 1997, 65: 44-52.PubMed Abramowitz JS: Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol. 1997, 65: 44-52.PubMed
656.
Zurück zum Zitat Eddy K, Dutra L, Bradley R, Westen D: A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004, 24: 1011-1030.PubMed Eddy K, Dutra L, Bradley R, Westen D: A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004, 24: 1011-1030.PubMed
657.
Zurück zum Zitat Noordik E, van der Klink JJ, Klingen EF, Nieuwenhuijsen K, van Dijk FJ: Exposure-in-vivo containing interventions to improve work functioning of workers with anxiety disorder: a systematic review. BMC Public Health. 2010, 10: 598-PubMedCentralPubMed Noordik E, van der Klink JJ, Klingen EF, Nieuwenhuijsen K, van Dijk FJ: Exposure-in-vivo containing interventions to improve work functioning of workers with anxiety disorder: a systematic review. BMC Public Health. 2010, 10: 598-PubMedCentralPubMed
658.
Zurück zum Zitat Foa E, Liebowitz M, Kozak M, Davies S, Campeas R, Franklin M, Huppert J, Kjernisted K, Rowan V, Schmidt A, et al: Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005, 162: 151-161.PubMed Foa E, Liebowitz M, Kozak M, Davies S, Campeas R, Franklin M, Huppert J, Kjernisted K, Rowan V, Schmidt A, et al: Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005, 162: 151-161.PubMed
659.
Zurück zum Zitat Sousa MB, Isolan LR, Oliveira RR, Manfro GG, Cordioli AV: A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder. J Clin Psychiatry. 2006, 67: 1133-1139.PubMed Sousa MB, Isolan LR, Oliveira RR, Manfro GG, Cordioli AV: A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder. J Clin Psychiatry. 2006, 67: 1133-1139.PubMed
660.
Zurück zum Zitat Belotto-Silva C, Diniz JB, Malavazzi DM, Valerio C, Fossaluza V, Borcato S, Seixas AA, Morelli D, Miguel EC, Shavitt RG: Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial. J Anxiety Disord. 2012, 26: 25-31.PubMed Belotto-Silva C, Diniz JB, Malavazzi DM, Valerio C, Fossaluza V, Borcato S, Seixas AA, Morelli D, Miguel EC, Shavitt RG: Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial. J Anxiety Disord. 2012, 26: 25-31.PubMed
661.
Zurück zum Zitat Jones MK, Menzies RG: Danger ideation reduction therapy (DIRT) for obsessive-compulsive washers. A controlled trial. Behav Res Ther. 1998, 36: 959-970.PubMed Jones MK, Menzies RG: Danger ideation reduction therapy (DIRT) for obsessive-compulsive washers. A controlled trial. Behav Res Ther. 1998, 36: 959-970.PubMed
662.
Zurück zum Zitat Krochmalik A, Jones MK, Menzies RG, Kirkby K: The superiority of danger ideation reduction therapy (DIRT) over exposure and response prevention (ERP) in treating compulsive washing. Behaviour Change. 2004, 21: 251-268. Krochmalik A, Jones MK, Menzies RG, Kirkby K: The superiority of danger ideation reduction therapy (DIRT) over exposure and response prevention (ERP) in treating compulsive washing. Behaviour Change. 2004, 21: 251-268.
663.
Zurück zum Zitat Jonsson H, Hougaard E, Bennedsen BE: Randomized comparative study of group versus individual cognitive behavioural therapy for obsessive compulsive disorder. Acta Psychiatr Scand. 2011, 123: 387-397.PubMed Jonsson H, Hougaard E, Bennedsen BE: Randomized comparative study of group versus individual cognitive behavioural therapy for obsessive compulsive disorder. Acta Psychiatr Scand. 2011, 123: 387-397.PubMed
664.
Zurück zum Zitat Jaurrieta N, Jimenez-Murcia S, Alonso P, Granero R, Segalas C, Labad J, Menchon JM: Individual versus group cognitive behavioral treatment for obsessive-compulsive disorder: follow up. Psychiatry Clin Neurosci. 2008, 62: 697-704.PubMed Jaurrieta N, Jimenez-Murcia S, Alonso P, Granero R, Segalas C, Labad J, Menchon JM: Individual versus group cognitive behavioral treatment for obsessive-compulsive disorder: follow up. Psychiatry Clin Neurosci. 2008, 62: 697-704.PubMed
665.
Zurück zum Zitat O'Connor K, Freeston MH, Gareau D, Careau Y, Dufour MJ, Aardema F, Todorov C: Group versus individual treatment in obsessions without compulsions. Clin Psychol Psychother. 2005, 12: 87-96. O'Connor K, Freeston MH, Gareau D, Careau Y, Dufour MJ, Aardema F, Todorov C: Group versus individual treatment in obsessions without compulsions. Clin Psychol Psychother. 2005, 12: 87-96.
666.
Zurück zum Zitat Belloch A, Cabedo E, Carrio C, Fernandez-Alvarez H, Garcia F, Larsson C: Group versus individual cognitive treatment for obsessive-compulsive disorder: changes in non-OCD symptoms and cognitions at post-treatment and one-year follow-up. Psychiatry Res. 2011, 187: 174-179.PubMed Belloch A, Cabedo E, Carrio C, Fernandez-Alvarez H, Garcia F, Larsson C: Group versus individual cognitive treatment for obsessive-compulsive disorder: changes in non-OCD symptoms and cognitions at post-treatment and one-year follow-up. Psychiatry Res. 2011, 187: 174-179.PubMed
667.
Zurück zum Zitat Cabedo E, Belloch A, Carrio C, Larsson C, Fernandez-Alvarez H, Garcia F: Group versus individual cognitive treatment for obsessive-compulsive disorder: changes in severity at post-treatment and one-year follow-up. Behav Cogn Psychother. 2010, 38: 227-232.PubMed Cabedo E, Belloch A, Carrio C, Larsson C, Fernandez-Alvarez H, Garcia F: Group versus individual cognitive treatment for obsessive-compulsive disorder: changes in severity at post-treatment and one-year follow-up. Behav Cogn Psychother. 2010, 38: 227-232.PubMed
668.
Zurück zum Zitat Kozak M, Foa E: Mastery of obsessive–compulsive disorder: A cognitive–behavioral approach. 1997, San Antonio, TX: The Psychological Corporation Kozak M, Foa E: Mastery of obsessive–compulsive disorder: A cognitive–behavioral approach. 1997, San Antonio, TX: The Psychological Corporation
669.
Zurück zum Zitat Abramowitz JS, Foa EB, Franklin ME: Exposure and ritual prevention for obsessive-compulsive disorder: effects of intensive versus twice-weekly sessions. J Consult Clin Psychol. 2003, 71: 394-398.PubMed Abramowitz JS, Foa EB, Franklin ME: Exposure and ritual prevention for obsessive-compulsive disorder: effects of intensive versus twice-weekly sessions. J Consult Clin Psychol. 2003, 71: 394-398.PubMed
670.
Zurück zum Zitat Tolin DF, Diefenbach GJ, Gilliam CM: Stepped care versus standard cognitive-behavioral therapy for obsessive-compulsive disorder: a preliminary study of efficacy and costs. Depress Anxiety. 2011, 28: 314-323.PubMedCentralPubMed Tolin DF, Diefenbach GJ, Gilliam CM: Stepped care versus standard cognitive-behavioral therapy for obsessive-compulsive disorder: a preliminary study of efficacy and costs. Depress Anxiety. 2011, 28: 314-323.PubMedCentralPubMed
671.
Zurück zum Zitat Twohig MP, Hayes SC, Plumb JC, Pruitt LD, Collins AB, Hazlett-Stevens H, Woidneck MR: A randomized clinical trial of acceptance and commitment therapy versus progressive relaxation training for obsessive-compulsive disorder. J Consult Clin Psychol. 2010, 78: 705-716.PubMedCentralPubMed Twohig MP, Hayes SC, Plumb JC, Pruitt LD, Collins AB, Hazlett-Stevens H, Woidneck MR: A randomized clinical trial of acceptance and commitment therapy versus progressive relaxation training for obsessive-compulsive disorder. J Consult Clin Psychol. 2010, 78: 705-716.PubMedCentralPubMed
672.
Zurück zum Zitat Wilhelm S, Steketee G, Fama JM, Buhlmann U, Teachman BA, Golan E: Modular cognitive therapy for obsessive-compulsive disorder: a wait-list controlled trial. J Cogn Psychother. 2009, 23: 294-305.PubMedCentralPubMed Wilhelm S, Steketee G, Fama JM, Buhlmann U, Teachman BA, Golan E: Modular cognitive therapy for obsessive-compulsive disorder: a wait-list controlled trial. J Cogn Psychother. 2009, 23: 294-305.PubMedCentralPubMed
673.
Zurück zum Zitat Freeston MH, Ladouceur R, Gagnon F, Thibodeau N, Rheaume J, Letarte H, Bujold A: Cognitive-behavioral treatment of obsessive thoughts: a controlled study. J Consult Clin Psychol. 1997, 65: 405-413.PubMed Freeston MH, Ladouceur R, Gagnon F, Thibodeau N, Rheaume J, Letarte H, Bujold A: Cognitive-behavioral treatment of obsessive thoughts: a controlled study. J Consult Clin Psychol. 1997, 65: 405-413.PubMed
674.
Zurück zum Zitat O'Connor KP, Aardema F, Bouthillier D, Fournier S, Guay S, Robillard S, Pelissier MC, Landry P, Todorov C, Tremblay M, Pitre D: Evaluation of an inference-based approach to treating obsessive-compulsive disorder. Cogn Behav Ther. 2005, 34: 148-163.PubMed O'Connor KP, Aardema F, Bouthillier D, Fournier S, Guay S, Robillard S, Pelissier MC, Landry P, Todorov C, Tremblay M, Pitre D: Evaluation of an inference-based approach to treating obsessive-compulsive disorder. Cogn Behav Ther. 2005, 34: 148-163.PubMed
675.
Zurück zum Zitat Park HS, Shin YW, Ha TH, Shin MS, Kim YY, Lee YH, Kwon JS: Effect of cognitive training focusing on organizational strategies in patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci. 2006, 60: 718-726.PubMed Park HS, Shin YW, Ha TH, Shin MS, Kim YY, Lee YH, Kwon JS: Effect of cognitive training focusing on organizational strategies in patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci. 2006, 60: 718-726.PubMed
676.
Zurück zum Zitat Buhlmann U, Deckersbach T, Engelhard I, Cook LM, Rauch SL, Kathmann N, Wilhelm S, Savage CR: Cognitive retraining for organizational impairment in obsessive-compulsive disorder. Psychiatry Res. 2006, 144: 109-116.PubMed Buhlmann U, Deckersbach T, Engelhard I, Cook LM, Rauch SL, Kathmann N, Wilhelm S, Savage CR: Cognitive retraining for organizational impairment in obsessive-compulsive disorder. Psychiatry Res. 2006, 144: 109-116.PubMed
677.
Zurück zum Zitat Hanstede M, Gidron Y, Nyklicek I: The effects of a mindfulness intervention on obsessive-compulsive symptoms in a non-clinical student population. J Nerv Ment Dis. 2008, 196: 776-779.PubMed Hanstede M, Gidron Y, Nyklicek I: The effects of a mindfulness intervention on obsessive-compulsive symptoms in a non-clinical student population. J Nerv Ment Dis. 2008, 196: 776-779.PubMed
678.
Zurück zum Zitat Simpson HB, Zuckoff AM, Maher MJ, Page JR, Franklin ME, Foa EB, Schmidt AB, Wang Y: Challenges using motivational interviewing as an adjunct to exposure therapy for obsessive-compulsive disorder. Behav Res Ther. 2010, 48: 941-948.PubMedCentralPubMed Simpson HB, Zuckoff AM, Maher MJ, Page JR, Franklin ME, Foa EB, Schmidt AB, Wang Y: Challenges using motivational interviewing as an adjunct to exposure therapy for obsessive-compulsive disorder. Behav Res Ther. 2010, 48: 941-948.PubMedCentralPubMed
679.
Zurück zum Zitat Meyer E, Souza F, Heldt E, Knapp P, Cordioli A, Shavitt RG, Leukefeld C: A randomized clinical trial to examine enhancing cognitive-behavioral group therapy for obsessive-compulsive disorder with motivational interviewing and thought mapping. Behav Cogn Psychother. 2010, 38: 319-336.PubMed Meyer E, Souza F, Heldt E, Knapp P, Cordioli A, Shavitt RG, Leukefeld C: A randomized clinical trial to examine enhancing cognitive-behavioral group therapy for obsessive-compulsive disorder with motivational interviewing and thought mapping. Behav Cogn Psychother. 2010, 38: 319-336.PubMed
680.
Zurück zum Zitat Nazari H, Momeni N, Jariani M, Tarrahi MJ: Comparison of eye movement desensitization and reprocessing with citalopram in treatment of obsessive-compulsive disorder. Int J Psychiatry Clin Pract. 2011, 15: 270-274.PubMed Nazari H, Momeni N, Jariani M, Tarrahi MJ: Comparison of eye movement desensitization and reprocessing with citalopram in treatment of obsessive-compulsive disorder. Int J Psychiatry Clin Pract. 2011, 15: 270-274.PubMed
681.
Zurück zum Zitat Tolin DF, Hannan S, Maltby N, Diefenbach GJ, Worhunsky P, Brady RE: A randomized controlled trial of self-directed versus therapist-directed cognitive-behavioral therapy for obsessive-compulsive disorder patients with prior medication trials. Behav Ther. 2007, 38: 179-191.PubMed Tolin DF, Hannan S, Maltby N, Diefenbach GJ, Worhunsky P, Brady RE: A randomized controlled trial of self-directed versus therapist-directed cognitive-behavioral therapy for obsessive-compulsive disorder patients with prior medication trials. Behav Ther. 2007, 38: 179-191.PubMed
682.
Zurück zum Zitat Lovell K, Cox D, Haddock G, Jones C, Raines D, Garvey R, Roberts C, Hadley S: Telephone administered cognitive behaviour therapy for treatment of obsessive compulsive disorder: randomised controlled non-inferiority trial. BMJ. 2006, 333: 883-PubMedCentralPubMed Lovell K, Cox D, Haddock G, Jones C, Raines D, Garvey R, Roberts C, Hadley S: Telephone administered cognitive behaviour therapy for treatment of obsessive compulsive disorder: randomised controlled non-inferiority trial. BMJ. 2006, 333: 883-PubMedCentralPubMed
683.
Zurück zum Zitat Moritz S, Jelinek L, Hauschildt M, Naber D: How to treat the untreated: effectiveness of a self-help metacognitive training program (myMCT) for obsessive-compulsive disorder. Dialogues Clin Neurosci. 2010, 12: 209-220.PubMedCentralPubMed Moritz S, Jelinek L, Hauschildt M, Naber D: How to treat the untreated: effectiveness of a self-help metacognitive training program (myMCT) for obsessive-compulsive disorder. Dialogues Clin Neurosci. 2010, 12: 209-220.PubMedCentralPubMed
684.
Zurück zum Zitat Moritz S, Jelinek L: Further evidence for the efficacy of association splitting as a self-help technique for reducing obsessive thoughts. Depress Anxiety. 2011, 28: 574-581.PubMed Moritz S, Jelinek L: Further evidence for the efficacy of association splitting as a self-help technique for reducing obsessive thoughts. Depress Anxiety. 2011, 28: 574-581.PubMed
685.
Zurück zum Zitat Andersson E, Enander J, Andren P, Hedman E, Ljotsson B, Hursti T, Bergstrom J, Kaldo V, Lindefors N, Andersson G, Ruck C: Internet-based cognitive behaviour therapy for obsessive-compulsive disorder: a randomized controlled trial. Psychol Med. 2012, 1-11. Andersson E, Enander J, Andren P, Hedman E, Ljotsson B, Hursti T, Bergstrom J, Kaldo V, Lindefors N, Andersson G, Ruck C: Internet-based cognitive behaviour therapy for obsessive-compulsive disorder: a randomized controlled trial. Psychol Med. 2012, 1-11.
686.
Zurück zum Zitat Tumur I, Kaltenthaler E, Ferriter M, Beverley C, Parry G: Computerised cognitive behaviour therapy for obsessive-compulsive disorder: a systematic review. Psychother Psychosom. 2007, 76: 196-202.PubMed Tumur I, Kaltenthaler E, Ferriter M, Beverley C, Parry G: Computerised cognitive behaviour therapy for obsessive-compulsive disorder: a systematic review. Psychother Psychosom. 2007, 76: 196-202.PubMed
687.
Zurück zum Zitat Greist JH, Marks IM, Baer L, Kobak KA, Wenzel KW, Hirsch MJ, Mantle JM, Clary CM: Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. J Clin Psychiatry. 2002, 63: 138-145.PubMed Greist JH, Marks IM, Baer L, Kobak KA, Wenzel KW, Hirsch MJ, Mantle JM, Clary CM: Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. J Clin Psychiatry. 2002, 63: 138-145.PubMed
688.
Zurück zum Zitat Kenwright M, Marks I, Graham C, Franses A, Mataix-Cols D: Brief scheduled phone support from a clinician to enhance computer-aided self-help for obsessive-compulsive disorder: randomized controlled trial. J Clin Psychol. 2005, 61: 1499-1508.PubMed Kenwright M, Marks I, Graham C, Franses A, Mataix-Cols D: Brief scheduled phone support from a clinician to enhance computer-aided self-help for obsessive-compulsive disorder: randomized controlled trial. J Clin Psychol. 2005, 61: 1499-1508.PubMed
689.
Zurück zum Zitat Lebowitz ER, Panza KE, Su J, Bloch MH: Family accommodation in obsessive-compulsive disorder. Expert Rev Neurother. 2012, 12: 229-238.PubMedCentralPubMed Lebowitz ER, Panza KE, Su J, Bloch MH: Family accommodation in obsessive-compulsive disorder. Expert Rev Neurother. 2012, 12: 229-238.PubMedCentralPubMed
690.
Zurück zum Zitat Rachman S, Elliott CM, Shafran R, Radomsky AS: Separating hoarding from OCD. Behav Res Ther. 2009, 47: 520-522.PubMed Rachman S, Elliott CM, Shafran R, Radomsky AS: Separating hoarding from OCD. Behav Res Ther. 2009, 47: 520-522.PubMed
691.
Zurück zum Zitat Muroff J, Steketee G, Bratiotis C, Ross A: Group cognitive and behavioral therapy and bibliotherapy for hoarding: a pilot trial. Depress Anxiety. 2012, 29: 597-604.PubMed Muroff J, Steketee G, Bratiotis C, Ross A: Group cognitive and behavioral therapy and bibliotherapy for hoarding: a pilot trial. Depress Anxiety. 2012, 29: 597-604.PubMed
692.
Zurück zum Zitat Foa EB, Franklin ME, Moser J: Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?. Biol Psychiatry. 2002, 52: 987-997.PubMed Foa EB, Franklin ME, Moser J: Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?. Biol Psychiatry. 2002, 52: 987-997.PubMed
693.
Zurück zum Zitat Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, et al: A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry. 2008, 165: 621-630.PubMedCentralPubMed Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, et al: A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry. 2008, 165: 621-630.PubMedCentralPubMed
694.
Zurück zum Zitat Simpson HB, Liebowitz MR, Foa EB, Kozak MJ, Schmidt AB, Rowan V, Petkova E, Kjernisted K, Huppert JD, Franklin ME, et al: Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety. 2004, 19: 225-233.PubMed Simpson HB, Liebowitz MR, Foa EB, Kozak MJ, Schmidt AB, Rowan V, Petkova E, Kjernisted K, Huppert JD, Franklin ME, et al: Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety. 2004, 19: 225-233.PubMed
695.
Zurück zum Zitat van Oppen P, van Balkom AJ, de Haan E, van Dyck R: Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. J Clin Psychiatry. 2005, 66: 1415-1422.PubMed van Oppen P, van Balkom AJ, de Haan E, van Dyck R: Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. J Clin Psychiatry. 2005, 66: 1415-1422.PubMed
696.
Zurück zum Zitat O'Connor KP, Aardema F, Robillard S, Guay S, Pelissier MC, Todorov C, Borgeat F, Leblanc V, Grenier S, Doucet P: Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder. Acta Psychiatr Scand. 2006, 113: 408-419.PubMed O'Connor KP, Aardema F, Robillard S, Guay S, Pelissier MC, Todorov C, Borgeat F, Leblanc V, Grenier S, Doucet P: Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder. Acta Psychiatr Scand. 2006, 113: 408-419.PubMed
697.
Zurück zum Zitat Kordon A, Kahl KG, Broocks A, Voderholzer U, Rasche-Rauchle H, Hohagen F: Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up. Eur Arch Psychiatry Clin Neurosci. 2005, 255: 48-50.PubMed Kordon A, Kahl KG, Broocks A, Voderholzer U, Rasche-Rauchle H, Hohagen F: Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up. Eur Arch Psychiatry Clin Neurosci. 2005, 255: 48-50.PubMed
698.
Zurück zum Zitat Chasson GS, Buhlmann U, Tolin DF, Rao SR, Reese HE, Rowley T, Welsh KS, Wilhelm S: Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther. 2010, 48: 675-679.PubMed Chasson GS, Buhlmann U, Tolin DF, Rao SR, Reese HE, Rowley T, Welsh KS, Wilhelm S: Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther. 2010, 48: 675-679.PubMed
699.
Zurück zum Zitat Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB: D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007, 62: 835-838.PubMed Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB: D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007, 62: 835-838.PubMed
700.
Zurück zum Zitat Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jenike MA, Rauch SL: Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008, 165: 335-341. quiz 409PubMed Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jenike MA, Rauch SL: Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008, 165: 335-341. quiz 409PubMed
701.
Zurück zum Zitat Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M, et al: D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007, 22: 230-237.PubMed Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M, et al: D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007, 22: 230-237.PubMed
702.
Zurück zum Zitat Braga DT, Manfro GG, Niederauer K, Cordioli AV: Full remission and relapse of obsessive-compulsive symptoms after cognitive-behavioral group therapy: a two-year follow-up. Rev Bras Psiquiatr. 2010, 32: 164-168.PubMed Braga DT, Manfro GG, Niederauer K, Cordioli AV: Full remission and relapse of obsessive-compulsive symptoms after cognitive-behavioral group therapy: a two-year follow-up. Rev Bras Psiquiatr. 2010, 32: 164-168.PubMed
703.
Zurück zum Zitat Whittal ML, Robichaud M, Thordarson DS, McLean PD: Group and individual treatment of obsessive-compulsive disorder using cognitive therapy and exposure plus response prevention: a 2-year follow-up of two randomized trials. J Consult Clin Psychol. 2008, 76: 1003-1014.PubMed Whittal ML, Robichaud M, Thordarson DS, McLean PD: Group and individual treatment of obsessive-compulsive disorder using cognitive therapy and exposure plus response prevention: a 2-year follow-up of two randomized trials. J Consult Clin Psychol. 2008, 76: 1003-1014.PubMed
704.
Zurück zum Zitat Anand N, Sudhir PM, Math SB, Thennarasu K, Janardhan Reddy YC: Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study. J Anxiety Disord. 2011, 25: 939-945.PubMed Anand N, Sudhir PM, Math SB, Thennarasu K, Janardhan Reddy YC: Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study. J Anxiety Disord. 2011, 25: 939-945.PubMed
705.
Zurück zum Zitat Stein DJ, Andersen EW, Tonnoir B, Fineberg N: Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007, 23: 701-711.PubMed Stein DJ, Andersen EW, Tonnoir B, Fineberg N: Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007, 23: 701-711.PubMed
706.
Zurück zum Zitat Khan MN, Hotiana UA, Ahmad S: Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial. J Ayub Med Coll Abbottabad. 2007, 19: 58-63. Khan MN, Hotiana UA, Ahmad S: Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial. J Ayub Med Coll Abbottabad. 2007, 19: 58-63.
707.
Zurück zum Zitat Shim G, Park HY, Jang JH, Kim E, Hwang JY, Kim SN, Jang GE, Kwon JS: What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study. Int Clin Psychopharmacol. 2011, 26: 284-290.PubMed Shim G, Park HY, Jang JH, Kim E, Hwang JY, Kim SN, Jang GE, Kwon JS: What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study. Int Clin Psychopharmacol. 2011, 26: 284-290.PubMed
708.
Zurück zum Zitat Dougherty DD, Jameson M, Deckersbach T, Loh R, Thompson-Hollands J, Jenike M, Keuthen NJ: Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2009, 24: 306-311.PubMed Dougherty DD, Jameson M, Deckersbach T, Loh R, Thompson-Hollands J, Jenike M, Keuthen NJ: Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2009, 24: 306-311.PubMed
709.
Zurück zum Zitat Rabinowitz I, Baruch Y, Barak Y: High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2008, 23: 49-53.PubMed Rabinowitz I, Baruch Y, Barak Y: High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2008, 23: 49-53.PubMed
710.
Zurück zum Zitat Bergeron R, Ravindran A, Chaput Y, Goldner E, Swinson R, van AM, Austin C, Hadrava V: Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. J Clin Psychopharmacol. 2002, 22: 148-154.PubMed Bergeron R, Ravindran A, Chaput Y, Goldner E, Swinson R, van AM, Austin C, Hadrava V: Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. J Clin Psychopharmacol. 2002, 22: 148-154.PubMed
711.
Zurück zum Zitat Piccinelli M, Pini S, Bellantuono C, Wilkinson G: Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 1995, 166: 424-443.PubMed Piccinelli M, Pini S, Bellantuono C, Wilkinson G: Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 1995, 166: 424-443.PubMed
712.
Zurück zum Zitat Zitterl W, Meszaros K, Hornik K, Twaroch T, Dossenbach M, Zitterl-Eglseer K, Zapotoczky HG: Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder. Wien Klin Wochenschr. 1999, 111: 439-442.PubMed Zitterl W, Meszaros K, Hornik K, Twaroch T, Dossenbach M, Zitterl-Eglseer K, Zapotoczky HG: Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder. Wien Klin Wochenschr. 1999, 111: 439-442.PubMed
713.
Zurück zum Zitat Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC: Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995, 52: 53-60.PubMed Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC: Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995, 52: 53-60.PubMed
714.
Zurück zum Zitat Ackerman DL, Greenland S: Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002, 22: 309-317.PubMed Ackerman DL, Greenland S: Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002, 22: 309-317.PubMed
715.
Zurück zum Zitat Sayyah M, Boostani H, Pakseresht S, Malayeri A: Comparison of silybum marianum (L.) gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34: 362-365.PubMed Sayyah M, Boostani H, Pakseresht S, Malayeri A: Comparison of silybum marianum (L.) gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34: 362-365.PubMed
716.
Zurück zum Zitat Lopez-Ibor JJ, Saiz J, Cottraux J, Note I, Vinas R, Bourgeois M, Hernandez M, Gomez-Perez JC: Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol. 1996, 6: 111-118.PubMed Lopez-Ibor JJ, Saiz J, Cottraux J, Note I, Vinas R, Bourgeois M, Hernandez M, Gomez-Perez JC: Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol. 1996, 6: 111-118.PubMed
717.
Zurück zum Zitat Mundo E, Maina G, Uslenghi C: Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2000, 15: 69-76.PubMed Mundo E, Maina G, Uslenghi C: Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2000, 15: 69-76.PubMed
718.
Zurück zum Zitat Mundo E, Rouillon F, Figuera M, Stigler M: Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol. 2001, 16: 461-468.PubMed Mundo E, Rouillon F, Figuera M, Stigler M: Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol. 2001, 16: 461-468.PubMed
719.
Zurück zum Zitat Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM: A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003, 64: 640-647.PubMed Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM: A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003, 64: 640-647.PubMed
720.
Zurück zum Zitat Zohar J, Judge R: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry. 1996, 169: 468-474.PubMed Zohar J, Judge R: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry. 1996, 169: 468-474.PubMed
721.
Zurück zum Zitat Denys D, van der Wee N, van Megen HJ, Westenberg HG: A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol. 2003, 23: 568-575.PubMed Denys D, van der Wee N, van Megen HJ, Westenberg HG: A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol. 2003, 23: 568-575.PubMed
722.
Zurück zum Zitat Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB: Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry. 2003, 64: 1113-1121.PubMed Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB: Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry. 2003, 64: 1113-1121.PubMed
723.
Zurück zum Zitat Hoehn-Saric R, Ninan P, Black D, Stahl S, Greist J, Lydiard B, McElroy S, Zajecka J, Chapman D, Clary C, Harrison W: Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000, 57: 76-82.PubMed Hoehn-Saric R, Ninan P, Black D, Stahl S, Greist J, Lydiard B, McElroy S, Zajecka J, Chapman D, Clary C, Harrison W: Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000, 57: 76-82.PubMed
724.
Zurück zum Zitat Bisserbe J, Lane R, Flament M: A double-blind comparison of sertraline and clomipramine in outpatients with obsessive compulsive disorder. Eur Psychiatry. 1997, 12: 82-93.PubMed Bisserbe J, Lane R, Flament M: A double-blind comparison of sertraline and clomipramine in outpatients with obsessive compulsive disorder. Eur Psychiatry. 1997, 12: 82-93.PubMed
725.
Zurück zum Zitat Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, Robinson DG, Crits-Christoph P, Mandel FS, Austin C: High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006, 67: 15-22.PubMed Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, Robinson DG, Crits-Christoph P, Mandel FS, Austin C: High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006, 67: 15-22.PubMed
726.
Zurück zum Zitat Montgomery S, Kasper S, Stein D, Bang Hedegaard K, Lemming O: Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001, 16: 75-86.PubMed Montgomery S, Kasper S, Stein D, Bang Hedegaard K, Lemming O: Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001, 16: 75-86.PubMed
727.
Zurück zum Zitat Pallanti S, Quercioli L, Bruscoli M: Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry. 2004, 65: 1394-1399.PubMed Pallanti S, Quercioli L, Bruscoli M: Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry. 2004, 65: 1394-1399.PubMed
728.
Zurück zum Zitat Vulink NC, Denys D, Fluitman SB, Meinardi JC, Westenberg HG: Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry. 2009, 70: 1001-1008.PubMed Vulink NC, Denys D, Fluitman SB, Meinardi JC, Westenberg HG: Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry. 2009, 70: 1001-1008.PubMed
729.
Zurück zum Zitat Pallanti S, Quercioli L, Koran LM: Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry. 2002, 63: 796-801.PubMed Pallanti S, Quercioli L, Koran LM: Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry. 2002, 63: 796-801.PubMed
730.
Zurück zum Zitat Marazziti D, Golia F, Consoli G, Presta S, Pfanner C, Carlini M, Mungai F, Catena Dell'osso M: Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr. 2008, 13: 971-976.PubMed Marazziti D, Golia F, Consoli G, Presta S, Pfanner C, Carlini M, Mungai F, Catena Dell'osso M: Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr. 2008, 13: 971-976.PubMed
731.
Zurück zum Zitat Albert U, Aguglia E, Maina G, Bogetto F: Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry. 2002, 63: 1004-1009.PubMed Albert U, Aguglia E, Maina G, Bogetto F: Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry. 2002, 63: 1004-1009.PubMed
732.
Zurück zum Zitat Yaryura-Tobias JA, Neziroglu FA: Venlafaxine in obsessive-compulsive disorder [Letter]. Arch Gen Psychiatry. 1996, 53: 653-654.PubMed Yaryura-Tobias JA, Neziroglu FA: Venlafaxine in obsessive-compulsive disorder [Letter]. Arch Gen Psychiatry. 1996, 53: 653-654.PubMed
733.
Zurück zum Zitat Denys D, van Megen HJ, van der Wee N, Westenberg HG: A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry. 2004, 65: 37-43.PubMed Denys D, van Megen HJ, van der Wee N, Westenberg HG: A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry. 2004, 65: 37-43.PubMed
734.
Zurück zum Zitat Dell'osso B, Mundo E, Marazziti D, Altamura AC: Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol. 2008, 22: 210-213.PubMed Dell'osso B, Mundo E, Marazziti D, Altamura AC: Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol. 2008, 22: 210-213.PubMed
735.
Zurück zum Zitat Blay S, Black DW: A case of obsessive-compulsive disorder responding to duloxetine. Prim Care Companion J Clin Psychiatry. 2007, 9: 234-235. Blay S, Black DW: A case of obsessive-compulsive disorder responding to duloxetine. Prim Care Companion J Clin Psychiatry. 2007, 9: 234-235.
736.
Zurück zum Zitat Yeh YW, Chen CH, Kuo SC, Wang SC, Chen CK, Feng HM: High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission. Clin Neuropharmacol. 2009, 32: 174-176.PubMed Yeh YW, Chen CH, Kuo SC, Wang SC, Chen CK, Feng HM: High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission. Clin Neuropharmacol. 2009, 32: 174-176.PubMed
737.
Zurück zum Zitat Vallejo J, Olivares J, Marcos T, Bulbena A, Menchon JM: Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. Br J Psychiatry. 1992, 161: 665-670.PubMed Vallejo J, Olivares J, Marcos T, Bulbena A, Menchon JM: Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. Br J Psychiatry. 1992, 161: 665-670.PubMed
738.
Zurück zum Zitat Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML: Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry. 1997, 154: 1261-1264.PubMed Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML: Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry. 1997, 154: 1261-1264.PubMed
739.
Zurück zum Zitat Joffe R, Swinson R: Tranylcypromine in primary obsessive-compulsive disorder. J Anxiety Disord. 1990, 4: 365-367. Joffe R, Swinson R: Tranylcypromine in primary obsessive-compulsive disorder. J Anxiety Disord. 1990, 4: 365-367.
740.
Zurück zum Zitat Stein DJ, Spadaccini E, Hollander E: Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995, 10: 11-18.PubMed Stein DJ, Spadaccini E, Hollander E: Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995, 10: 11-18.PubMed
741.
Zurück zum Zitat Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ: Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology (Berl). 1998, 136: 205-216. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ: Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology (Berl). 1998, 136: 205-216.
742.
Zurück zum Zitat Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, Goetz D, Klein DF: Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry. 1998, 55: 918-924.PubMed Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, Goetz D, Klein DF: Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry. 1998, 55: 918-924.PubMed
743.
Zurück zum Zitat Koran LM, Sallee FR, Pallanti S: Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry. 1997, 154: 396-401.PubMed Koran LM, Sallee FR, Pallanti S: Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry. 1997, 154: 396-401.PubMed
744.
Zurück zum Zitat Koran LM, Aboujaoude E, Ward H, Shapira NA, Sallee FR, Gamel N, Elliott M: Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2006, 26: 79-83.PubMed Koran LM, Aboujaoude E, Ward H, Shapira NA, Sallee FR, Gamel N, Elliott M: Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2006, 26: 79-83.PubMed
745.
Zurück zum Zitat Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS: Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990, 47: 577-585.PubMed Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS: Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990, 47: 577-585.PubMed
746.
Zurück zum Zitat Diniz JB, Shavitt RG, Pereira CA, Hounie AG, Pimentel I, Koran LM, Dainesi SM, Miguel EC: Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J Psychopharmacol. 2010, 24: 297-307.PubMed Diniz JB, Shavitt RG, Pereira CA, Hounie AG, Pimentel I, Koran LM, Dainesi SM, Miguel EC: Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J Psychopharmacol. 2010, 24: 297-307.PubMed
747.
Zurück zum Zitat Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC: A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol. 2011, 31: 763-768.PubMed Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC: A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol. 2011, 31: 763-768.PubMed
748.
Zurück zum Zitat Koran L, Gamel N, Choung H, Smith E, Aboujaoude E: Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry. 2005, 66: 515-520.PubMed Koran L, Gamel N, Choung H, Smith E, Aboujaoude E: Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry. 2005, 66: 515-520.PubMed
749.
Zurück zum Zitat Vulink NC, Denys D, Westenberg HG: Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. J Clin Psychiatry. 2005, 66: 228-230.PubMed Vulink NC, Denys D, Westenberg HG: Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. J Clin Psychiatry. 2005, 66: 228-230.PubMed
750.
Zurück zum Zitat Muscatello MR, Bruno A, Pandolfo G, Mico U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA: Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2011, 31: 174-179.PubMed Muscatello MR, Bruno A, Pandolfo G, Mico U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA: Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2011, 31: 174-179.PubMed
751.
Zurück zum Zitat Pessina E, Albert U, Bogetto F, Maina G: Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol. 2009, 24: 265-269.PubMed Pessina E, Albert U, Bogetto F, Maina G: Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol. 2009, 24: 265-269.PubMed
752.
Zurück zum Zitat Ak M, Bulut SD, Bozkurt A, Ozsahin A: Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study. Adv Ther. 2011, 28: 341-348.PubMed Ak M, Bulut SD, Bozkurt A, Ozsahin A: Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study. Adv Ther. 2011, 28: 341-348.PubMed
753.
Zurück zum Zitat Delle Chiaie R, Scarciglia P, Pasquini M, Caredda M, Biondi M: Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study. Clin Pract Epidemiol Ment Health. 2011, 7: 107-111.PubMedCentralPubMed Delle Chiaie R, Scarciglia P, Pasquini M, Caredda M, Biondi M: Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study. Clin Pract Epidemiol Ment Health. 2011, 7: 107-111.PubMedCentralPubMed
754.
Zurück zum Zitat Sayyah M, Boostani H, Ghaffari SM, Hoseini A: Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety. 2012, 29: 850-854.PubMed Sayyah M, Boostani H, Ghaffari SM, Hoseini A: Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety. 2012, 29: 850-854.PubMed
755.
Zurück zum Zitat Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O: The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum Psychopharmacol. 2011, 26: 51-57.PubMed Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O: The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum Psychopharmacol. 2011, 26: 51-57.PubMed
756.
Zurück zum Zitat McDougle C, Epperson C, Pelton G, Wasylink S, Price L: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000, 57: 794-801.PubMed McDougle C, Epperson C, Pelton G, Wasylink S, Price L: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000, 57: 794-801.PubMed
757.
Zurück zum Zitat Hollander E, Baldini Rossi N, Sood E, Pallanti S: Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003, 6: 397-401.PubMed Hollander E, Baldini Rossi N, Sood E, Pallanti S: Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003, 6: 397-401.PubMed
758.
Zurück zum Zitat Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR: Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005, 66: 736-743.PubMed Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR: Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005, 66: 736-743.PubMed
759.
Zurück zum Zitat Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L: Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005, 15: 69-74.PubMed Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L: Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005, 15: 69-74.PubMed
760.
Zurück zum Zitat Maina G, Pessina E, Albert U, Bogetto F: 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2008, 18: 364-372.PubMed Maina G, Pessina E, Albert U, Bogetto F: 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2008, 18: 364-372.PubMed
761.
Zurück zum Zitat Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT, et al: Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013, 70: 1190-1199.PubMedCentralPubMed Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT, et al: Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013, 70: 1190-1199.PubMedCentralPubMed
762.
Zurück zum Zitat Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S: Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004, 65: 565-568.PubMed Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S: Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004, 65: 565-568.PubMed
763.
Zurück zum Zitat Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK: A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004, 55: 553-555.PubMed Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK: A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004, 55: 553-555.PubMed
764.
Zurück zum Zitat Fineberg NA, Sivakumaran T, Roberts A, Gale T: Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol. 2005, 20: 223-226.PubMed Fineberg NA, Sivakumaran T, Roberts A, Gale T: Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol. 2005, 20: 223-226.PubMed
765.
Zurück zum Zitat Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry. 2005, 5: 5-PubMedCentralPubMed Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry. 2005, 5: 5-PubMedCentralPubMed
766.
Zurück zum Zitat Denys D, de Geus F, van Megen H, Westenberg H: A double blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004, 65: 1040-1048.PubMed Denys D, de Geus F, van Megen H, Westenberg H: A double blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004, 65: 1040-1048.PubMed
767.
Zurück zum Zitat Savas HA, Yumru M, Ozen ME: Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study. Clin Drug Investig. 2008, 28: 439-442.PubMed Savas HA, Yumru M, Ozen ME: Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study. Clin Drug Investig. 2008, 28: 439-442.PubMed
768.
Zurück zum Zitat Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F: Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2008, 28: 550-554.PubMed Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F: Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2008, 28: 550-554.PubMed
769.
Zurück zum Zitat McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH: Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994, 51: 302-308.PubMed McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH: Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994, 51: 302-308.PubMed
770.
Zurück zum Zitat Metin O, Yazici K, Tot S, Yazici AE: Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol. 2003, 18: 463-467.PubMed Metin O, Yazici K, Tot S, Yazici AE: Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol. 2003, 18: 463-467.PubMed
771.
Zurück zum Zitat Hollander E, Kaplan A, Stahl SM: A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry. 2003, 4: 30-34.PubMed Hollander E, Kaplan A, Stahl SM: A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry. 2003, 4: 30-34.PubMed
772.
Zurück zum Zitat Crockett BA, Churchill E, Davidson JR: A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann Clin Psychiatry. 2004, 16: 127-132.PubMed Crockett BA, Churchill E, Davidson JR: A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann Clin Psychiatry. 2004, 16: 127-132.PubMed
773.
Zurück zum Zitat Hewlett WA, Vinogradov S, Agras WS: Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol. 1992, 12: 420-430.PubMed Hewlett WA, Vinogradov S, Agras WS: Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol. 1992, 12: 420-430.PubMed
774.
Zurück zum Zitat Dannon P, Sasson Y, Hirschmann S, Iancu I, Grunhaus L, Zohar J: Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol. 2000, 10: 165-169.PubMed Dannon P, Sasson Y, Hirschmann S, Iancu I, Grunhaus L, Zohar J: Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol. 2000, 10: 165-169.PubMed
775.
Zurück zum Zitat Mundo E, Guglielmo E, Bellodi L: Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol. 1998, 13: 219-224.PubMed Mundo E, Guglielmo E, Bellodi L: Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol. 1998, 13: 219-224.PubMed
776.
Zurück zum Zitat Blier P, Bergeron R: Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol. 1996, 11: 37-44.PubMed Blier P, Bergeron R: Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol. 1996, 11: 37-44.PubMed
777.
Zurück zum Zitat Sayyah M, Boostani H, Pakseresht S, Malayeri A: A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder. Psychiatry Res. 2011, 189: 403-406.PubMed Sayyah M, Boostani H, Pakseresht S, Malayeri A: A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder. Psychiatry Res. 2011, 189: 403-406.PubMed
778.
Zurück zum Zitat Askari N, Moin M, Sanati M, Tajdini M, Hosseini SM, Modabbernia A, Najand B, Salimi S, Tabrizi M, Ashrafi M, et al: Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2012, 26: 883-892.PubMed Askari N, Moin M, Sanati M, Tajdini M, Hosseini SM, Modabbernia A, Najand B, Salimi S, Tabrizi M, Ashrafi M, et al: Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2012, 26: 883-892.PubMed
779.
Zurück zum Zitat Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB: Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013, 38: 2475-2483.PubMedCentralPubMed Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB: Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013, 38: 2475-2483.PubMedCentralPubMed
780.
Zurück zum Zitat Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C: Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012, 72: 964-970.PubMedCentralPubMed Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C: Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012, 72: 964-970.PubMedCentralPubMed
781.
Zurück zum Zitat Aboujaoude E, Barry JJ, Gamel N: Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol. 2009, 29: 51-55.PubMed Aboujaoude E, Barry JJ, Gamel N: Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol. 2009, 29: 51-55.PubMed
782.
Zurück zum Zitat Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, Jenike MA: A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010, 30: 34-39.PubMed Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, Jenike MA: A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010, 30: 34-39.PubMed
783.
Zurück zum Zitat Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S: Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013, 47: 175-180.PubMed Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S: Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013, 47: 175-180.PubMed
784.
Zurück zum Zitat Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E: Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs. 2009, 23: 1047-1055.PubMed Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E: Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs. 2009, 23: 1047-1055.PubMed
785.
Zurück zum Zitat Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I: A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol. 2010, 25: 509-513.PubMed Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I: A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol. 2010, 25: 509-513.PubMed
786.
Zurück zum Zitat Afshar H, Roohafza H, Mohammad-Beigi H, Haghighi M, Jahangard L, Shokouh P, Sadeghi M, Hafezian H: N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012, 32: 797-803.PubMed Afshar H, Roohafza H, Mohammad-Beigi H, Haghighi M, Jahangard L, Shokouh P, Sadeghi M, Hafezian H: N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012, 32: 797-803.PubMed
787.
Zurück zum Zitat Van Ameringen M, Patterson B, Simpson W, Turna J: N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case series. J Obsess Compul Rel Dis. 2013, 2: 48-52. Van Ameringen M, Patterson B, Simpson W, Turna J: N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case series. J Obsess Compul Rel Dis. 2013, 2: 48-52.
788.
Zurück zum Zitat Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, et al: Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry. 2005, 58: 424-428.PubMed Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, et al: Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry. 2005, 58: 424-428.PubMed
789.
Zurück zum Zitat Pittenger C, Kelmendi B, Wasylink S, Bloch MH, Coric V: Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psychopharmacol. 2008, 28: 363-367.PubMed Pittenger C, Kelmendi B, Wasylink S, Bloch MH, Coric V: Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psychopharmacol. 2008, 28: 363-367.PubMed
790.
Zurück zum Zitat McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR: A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol. 1991, 11: 175-184.PubMed McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR: A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol. 1991, 11: 175-184.PubMed
791.
Zurück zum Zitat Pigott TA, Pato MT, L'Heureux F, Hill JL, Grover GN, Bernstein SE, Murphy DL: A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1991, 11: 242-248.PubMed Pigott TA, Pato MT, L'Heureux F, Hill JL, Grover GN, Bernstein SE, Murphy DL: A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1991, 11: 242-248.PubMed
792.
Zurück zum Zitat Jenike MA, Baer L, Buttolph L: Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. J Clin Psychiatry. 1991, 52: 13-14.PubMed Jenike MA, Baer L, Buttolph L: Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. J Clin Psychiatry. 1991, 52: 13-14.PubMed
793.
Zurück zum Zitat Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL: A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1992, 12: 11-18.PubMed Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL: A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1992, 12: 11-18.PubMed
794.
Zurück zum Zitat Rodriguez CI, Bender J, Marcus SM, Snape M, Rynn M, Simpson HB: Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial [Letter]. J Clin Psychiatry. 2010, 71: 1247-1249.PubMedCentralPubMed Rodriguez CI, Bender J, Marcus SM, Snape M, Rynn M, Simpson HB: Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial [Letter]. J Clin Psychiatry. 2010, 71: 1247-1249.PubMedCentralPubMed
795.
Zurück zum Zitat Rubio G, Jimenez-Arriero MA, Martinez-Gras I, Manzanares J, Palomo T: The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2006, 26: 341-344.PubMed Rubio G, Jimenez-Arriero MA, Martinez-Gras I, Manzanares J, Palomo T: The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2006, 26: 341-344.PubMed
796.
Zurück zum Zitat Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E: Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011, 72: 716-721.PubMed Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E: Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011, 72: 716-721.PubMed
797.
Zurück zum Zitat Mowla A, Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F: Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial. CNS Spectr. 2010, 15: 613-617.PubMed Mowla A, Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F: Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial. CNS Spectr. 2010, 15: 613-617.PubMed
798.
Zurück zum Zitat Van Ameringen M, Mancini C, Patterson B, Bennett M: Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety. 2006, 23: 1-5.PubMed Van Ameringen M, Mancini C, Patterson B, Bennett M: Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety. 2006, 23: 1-5.PubMed
799.
Zurück zum Zitat Bruno A, Mico U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D'Arrigo C, Spina E, Zoccali RA, Muscatello MR: Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol. 2012, 26: 1456-1462.PubMed Bruno A, Mico U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D'Arrigo C, Spina E, Zoccali RA, Muscatello MR: Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol. 2012, 26: 1456-1462.PubMed
800.
Zurück zum Zitat Kumar TC, Khanna S: Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry. 2000, 34: 527-528.PubMed Kumar TC, Khanna S: Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry. 2000, 34: 527-528.PubMed
801.
Zurück zum Zitat Di Nicola M, Tedeschi D, Martinotti G, De Vita O, Monetta M, Pozzi G, Janiri L: Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series. J Clin Psychopharmacol. 2011, 31: 675-677.PubMed Di Nicola M, Tedeschi D, Martinotti G, De Vita O, Monetta M, Pozzi G, Janiri L: Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series. J Clin Psychopharmacol. 2011, 31: 675-677.PubMed
802.
Zurück zum Zitat Oulis P, Mourikis I, Konstantakopoulos G: Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol. 2011, 26: 221-224.PubMed Oulis P, Mourikis I, Konstantakopoulos G: Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol. 2011, 26: 221-224.PubMed
803.
Zurück zum Zitat Onder E, Tural U, Gokbakan M: Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?. Eur Arch Psychiatry Clin Neurosci. 2008, 258: 319-323.PubMed Onder E, Tural U, Gokbakan M: Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?. Eur Arch Psychiatry Clin Neurosci. 2008, 258: 319-323.PubMed
804.
Zurück zum Zitat Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL: Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [Letter]. J Clin Psychiatry. 1998, 59: 480-481.PubMed Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL: Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [Letter]. J Clin Psychiatry. 1998, 59: 480-481.PubMed
805.
Zurück zum Zitat Goldsmith TB, Shapira NA, Keck PE: Rapid remission of OCD with tramadol hydrochloride [Letter]. Am J Psychiatry. 1999, 156: 660-661.PubMed Goldsmith TB, Shapira NA, Keck PE: Rapid remission of OCD with tramadol hydrochloride [Letter]. Am J Psychiatry. 1999, 156: 660-661.PubMed
806.
Zurück zum Zitat Shapira NA, Keck PE, Goldsmith TD, McConville BJ, Eis M, McElroy SL: Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety. 1997, 6: 170-173.PubMed Shapira NA, Keck PE, Goldsmith TD, McConville BJ, Eis M, McElroy SL: Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety. 1997, 6: 170-173.PubMed
807.
Zurück zum Zitat Amiaz R, Fostick L, Gershon A, Zohar J: Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol. 2008, 18: 455-461.PubMed Amiaz R, Fostick L, Gershon A, Zohar J: Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol. 2008, 18: 455-461.PubMed
808.
Zurück zum Zitat Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M: Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005, 66: 353-359.PubMed Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M: Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005, 66: 353-359.PubMed
809.
Zurück zum Zitat Soomro GM, Altman D, Rajagopal S, Oakley-Browne M: Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008, CD001765- Soomro GM, Altman D, Rajagopal S, Oakley-Browne M: Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008, CD001765-
810.
Zurück zum Zitat Stein DJ, Andersen EW, Overo KF: Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Rev Bras Psiquiatr. 2007, 29: 303-307.PubMed Stein DJ, Andersen EW, Overo KF: Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Rev Bras Psiquiatr. 2007, 29: 303-307.PubMed
811.
Zurück zum Zitat Stein DJ, Carey PD, Lochner C, Seedat S, Fineberg N, Andersen EW: Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy. CNS Spectr. 2008, 13: 492-498.PubMed Stein DJ, Carey PD, Lochner C, Seedat S, Fineberg N, Andersen EW: Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy. CNS Spectr. 2008, 13: 492-498.PubMed
812.
Zurück zum Zitat Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V: Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. J Affect Disord. 2010, 121: 175-179.PubMedCentralPubMed Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V: Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. J Affect Disord. 2010, 121: 175-179.PubMedCentralPubMed
813.
Zurück zum Zitat Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB: Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007, 164: 5-53.PubMed Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB: Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007, 164: 5-53.PubMed
814.
Zurück zum Zitat Decloedt EH, Stein DJ: Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2010, 6: 233-242.PubMedCentralPubMed Decloedt EH, Stein DJ: Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2010, 6: 233-242.PubMedCentralPubMed
815.
Zurück zum Zitat Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ: Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006, CD005473- Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ: Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006, CD005473-
816.
Zurück zum Zitat Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF: A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006, 11: 622-632.PubMed Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF: A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006, 11: 622-632.PubMed
817.
Zurück zum Zitat Komossa K, Depping AM, Meyer M, Kissling W, Leucht S: Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010, CD008141- Komossa K, Depping AM, Meyer M, Kissling W, Leucht S: Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010, CD008141-
818.
Zurück zum Zitat Fineberg NA, Tonnoir B, Lemming O, Stein DJ: Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2007, 17: 430-439.PubMed Fineberg NA, Tonnoir B, Lemming O, Stein DJ: Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2007, 17: 430-439.PubMed
819.
Zurück zum Zitat Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D: Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry. 2002, 159: 88-95.PubMed Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D: Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry. 2002, 159: 88-95.PubMed
820.
Zurück zum Zitat Romano S, Goodman W, Tamura R, Gonzales J: Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol. 2001, 21: 46-52.PubMed Romano S, Goodman W, Tamura R, Gonzales J: Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol. 2001, 21: 46-52.PubMed
821.
Zurück zum Zitat Katz RJ, DeVeaugh-Geiss J, Landau P: Clomipramine in obsessive-compulsive disorder. Biol Psychiatry. 1990, 28: 401-414.PubMed Katz RJ, DeVeaugh-Geiss J, Landau P: Clomipramine in obsessive-compulsive disorder. Biol Psychiatry. 1990, 28: 401-414.PubMed
822.
Zurück zum Zitat Rasmussen S, Hackett E, DuBoff E, Greist J, Halaris A, Koran LM, Liebowitz M, Lydiard RB, McElroy S, Mendels J, O'Connor K: A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1997, 12: 309-316.PubMed Rasmussen S, Hackett E, DuBoff E, Greist J, Halaris A, Koran LM, Liebowitz M, Lydiard RB, McElroy S, Mendels J, O'Connor K: A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1997, 12: 309-316.PubMed
823.
Zurück zum Zitat Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G: Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull. 1996, 32: 167-173.PubMed Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G: Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull. 1996, 32: 167-173.PubMed
824.
Zurück zum Zitat Koran LM, Bromberg D, Hornfeldt CS, Shepski JC, Wang S, Hollander E: Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder. Compr Psychiatry. 2010, 51: 373-379.PubMed Koran LM, Bromberg D, Hornfeldt CS, Shepski JC, Wang S, Hollander E: Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder. Compr Psychiatry. 2010, 51: 373-379.PubMed
825.
Zurück zum Zitat Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S: Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol. 2006, 9: 95-100.PubMed Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S: Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol. 2006, 9: 95-100.PubMed
826.
Zurück zum Zitat Kumar N, Chadda RK: Augmentation effect of repetitive transcranial magnetic stimulation over the supplementary motor cortex in treatment refractory patients with obsessive compulsive disorder. Indian J Psychiatry. 2011, 53: 340-342.PubMedCentralPubMed Kumar N, Chadda RK: Augmentation effect of repetitive transcranial magnetic stimulation over the supplementary motor cortex in treatment refractory patients with obsessive compulsive disorder. Indian J Psychiatry. 2011, 53: 340-342.PubMedCentralPubMed
827.
Zurück zum Zitat Mantovani A, Simpson HB, Fallon BA, Rossi S, Lisanby SH: Randomized sham-controlled trial of repetitive transcranial magnetic stimulation in treatment-resistant obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2010, 13: 217-227.PubMed Mantovani A, Simpson HB, Fallon BA, Rossi S, Lisanby SH: Randomized sham-controlled trial of repetitive transcranial magnetic stimulation in treatment-resistant obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2010, 13: 217-227.PubMed
828.
Zurück zum Zitat Ruffini C, Locatelli M, Lucca A, Benedetti F, Insacco C, Smeraldi E: Augmentation effect of repetitive transcranial magnetic stimulation over the orbitofrontal cortex in drug-resistant obsessive-compulsive disorder patients: a controlled investigation. Prim Care Companion J Clin Psychiatry. 2009, 11: 226-230.PubMedCentralPubMed Ruffini C, Locatelli M, Lucca A, Benedetti F, Insacco C, Smeraldi E: Augmentation effect of repetitive transcranial magnetic stimulation over the orbitofrontal cortex in drug-resistant obsessive-compulsive disorder patients: a controlled investigation. Prim Care Companion J Clin Psychiatry. 2009, 11: 226-230.PubMedCentralPubMed
829.
Zurück zum Zitat Sachdev PS, Loo CK, Mitchell PB, McFarquhar TF, Malhi GS: Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation. Psychol Med. 2007, 37: 1645-1649.PubMed Sachdev PS, Loo CK, Mitchell PB, McFarquhar TF, Malhi GS: Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation. Psychol Med. 2007, 37: 1645-1649.PubMed
830.
Zurück zum Zitat Sarkhel S, Sinha VK, Praharaj SK: Adjunctive high-frequency right prefrontal repetitive transcranial magnetic stimulation (rTMS) was not effective in obsessive-compulsive disorder but improved secondary depression. J Anxiety Disord. 2010, 24: 535-539.PubMed Sarkhel S, Sinha VK, Praharaj SK: Adjunctive high-frequency right prefrontal repetitive transcranial magnetic stimulation (rTMS) was not effective in obsessive-compulsive disorder but improved secondary depression. J Anxiety Disord. 2010, 24: 535-539.PubMed
831.
Zurück zum Zitat Prasko J, Paskova B, Zalesky R, Novak T, Kopecek M, Bares M, Horacek J: The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double blind, sham controlled study. Neuro Endocrinol Lett. 2006, 27: 327-332.PubMed Prasko J, Paskova B, Zalesky R, Novak T, Kopecek M, Bares M, Horacek J: The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double blind, sham controlled study. Neuro Endocrinol Lett. 2006, 27: 327-332.PubMed
832.
Zurück zum Zitat Greenberg BD, Gabriels LA, Malone DA, Rezai AR, Friehs GM, Okun MS, Shapira NA, Foote KD, Cosyns PR, Kubu CS, et al: Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry. 2010, 15: 64-79.PubMedCentralPubMed Greenberg BD, Gabriels LA, Malone DA, Rezai AR, Friehs GM, Okun MS, Shapira NA, Foote KD, Cosyns PR, Kubu CS, et al: Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry. 2010, 15: 64-79.PubMedCentralPubMed
833.
Zurück zum Zitat Goodman WK, Foote KD, Greenberg BD, Ricciuti N, Bauer R, Ward H, Shapira NA, Wu SS, Hill CL, Rasmussen SA, Okun MS: Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design. Biol Psychiatry. 2010, 67: 535-542.PubMed Goodman WK, Foote KD, Greenberg BD, Ricciuti N, Bauer R, Ward H, Shapira NA, Wu SS, Hill CL, Rasmussen SA, Okun MS: Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design. Biol Psychiatry. 2010, 67: 535-542.PubMed
834.
Zurück zum Zitat Abelson JL, Curtis GC, Sagher O, Albucher RC, Harrigan M, Taylor SF, Martis B, Giordani B: Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychiatry. 2005, 57: 510-516.PubMed Abelson JL, Curtis GC, Sagher O, Albucher RC, Harrigan M, Taylor SF, Martis B, Giordani B: Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychiatry. 2005, 57: 510-516.PubMed
835.
Zurück zum Zitat Liu K, Zhang H, Liu C, Guan Y, Lang L, Cheng Y, Sun B, Wang H, Zuo C, Pan L, et al: Stereotactic treatment of refractory obsessive compulsive disorder by bilateral capsulotomy with 3 years follow-up. J Clin Neurosci. 2008, 15: 622-629.PubMed Liu K, Zhang H, Liu C, Guan Y, Lang L, Cheng Y, Sun B, Wang H, Zuo C, Pan L, et al: Stereotactic treatment of refractory obsessive compulsive disorder by bilateral capsulotomy with 3 years follow-up. J Clin Neurosci. 2008, 15: 622-629.PubMed
836.
Zurück zum Zitat Ruck C, Karlsson A, Steele JD, Edman G, Meyerson BA, Ericson K, Nyman H, Asberg M, Svanborg P: Capsulotomy for obsessive-compulsive disorder: long-term follow-up of 25 patients. Arch Gen Psychiatry. 2008, 65: 914-921.PubMed Ruck C, Karlsson A, Steele JD, Edman G, Meyerson BA, Ericson K, Nyman H, Asberg M, Svanborg P: Capsulotomy for obsessive-compulsive disorder: long-term follow-up of 25 patients. Arch Gen Psychiatry. 2008, 65: 914-921.PubMed
837.
Zurück zum Zitat Lopes AC, Greenberg BD, Noren G, Canteras MM, Busatto GF, de Mathis ME, Taub A, D'Alcante CC, Hoexter MQ, Gouvea FS, et al: Treatment of resistant obsessive-compulsive disorder with ventral capsular/ventral striatal gamma capsulotomy: a pilot prospective study. J Neuropsychiatry Clin Neurosci. 2009, 21: 381-392.PubMed Lopes AC, Greenberg BD, Noren G, Canteras MM, Busatto GF, de Mathis ME, Taub A, D'Alcante CC, Hoexter MQ, Gouvea FS, et al: Treatment of resistant obsessive-compulsive disorder with ventral capsular/ventral striatal gamma capsulotomy: a pilot prospective study. J Neuropsychiatry Clin Neurosci. 2009, 21: 381-392.PubMed
838.
Zurück zum Zitat Csigo K, Harsanyi A, Demeter G, Rajkai C, Nemeth A, Racsmany M: Long-term follow-up of patients with obsessive-compulsive disorder treated by anterior capsulotomy: a neuropsychological study. J Affect Disord. 2010, 126: 198-205.PubMed Csigo K, Harsanyi A, Demeter G, Rajkai C, Nemeth A, Racsmany M: Long-term follow-up of patients with obsessive-compulsive disorder treated by anterior capsulotomy: a neuropsychological study. J Affect Disord. 2010, 126: 198-205.PubMed
839.
Zurück zum Zitat Ruck C, Larsson KJ, Mataix-Cols D: Predictors of medium and long-term outcome following capsulotomy for obsessive-compulsive disorder: one site may not fit all. Eur Neuropsychopharmacol. 2012, 22: 406-414.PubMed Ruck C, Larsson KJ, Mataix-Cols D: Predictors of medium and long-term outcome following capsulotomy for obsessive-compulsive disorder: one site may not fit all. Eur Neuropsychopharmacol. 2012, 22: 406-414.PubMed
840.
Zurück zum Zitat Jung HH, Kim CH, Chang JH, Park YG, Chung SS, Chang JW: Bilateral anterior cingulotomy for refractory obsessive-compulsive disorder: Long-term follow-up results. Stereotact Funct Neurosurg. 2006, 84: 184-189.PubMed Jung HH, Kim CH, Chang JH, Park YG, Chung SS, Chang JW: Bilateral anterior cingulotomy for refractory obsessive-compulsive disorder: Long-term follow-up results. Stereotact Funct Neurosurg. 2006, 84: 184-189.PubMed
841.
Zurück zum Zitat Dougherty DD, Baer L, Cosgrove GR, Cassem EH, Price BH, Nierenberg AA, Jenike MA, Rauch SL: Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. Am J Psychiatry. 2002, 159: 269-275.PubMed Dougherty DD, Baer L, Cosgrove GR, Cassem EH, Price BH, Nierenberg AA, Jenike MA, Rauch SL: Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. Am J Psychiatry. 2002, 159: 269-275.PubMed
842.
Zurück zum Zitat Kim CH, Chang JW, Koo MS, Kim JW, Suh HS, Park IH, Lee HS: Anterior cingulotomy for refractory obsessive-compulsive disorder. Acta Psychiatr Scand. 2003, 107: 283-290.PubMed Kim CH, Chang JW, Koo MS, Kim JW, Suh HS, Park IH, Lee HS: Anterior cingulotomy for refractory obsessive-compulsive disorder. Acta Psychiatr Scand. 2003, 107: 283-290.PubMed
843.
Zurück zum Zitat Krisanaprakornkit T, Krisanaprakornkit W, Piyavhatkul N, Laopaiboon M: Meditation therapy for anxiety disorders. Cochrane Database Syst Rev. 2006, CD004998- Krisanaprakornkit T, Krisanaprakornkit W, Piyavhatkul N, Laopaiboon M: Meditation therapy for anxiety disorders. Cochrane Database Syst Rev. 2006, CD004998-
844.
Zurück zum Zitat Abrantes AM, Strong DR, Cohn A, Cameron AY, Greenberg BD, Mancebo MC, Brown RA: Acute changes in obsessions and compulsions following moderate-intensity aerobic exercise among patients with obsessive-compulsive disorder. J Anxiety Disord. 2009, 23: 923-927.PubMed Abrantes AM, Strong DR, Cohn A, Cameron AY, Greenberg BD, Mancebo MC, Brown RA: Acute changes in obsessions and compulsions following moderate-intensity aerobic exercise among patients with obsessive-compulsive disorder. J Anxiety Disord. 2009, 23: 923-927.PubMed
845.
Zurück zum Zitat Brown RA, Abrantes AM, Strong DR, Mancebo MC, Menard J, Rasmussen SA, Greenberg BD: A pilot study of moderate-intensity aerobic exercise for obsessive compulsive disorder. J Nerv Ment Dis. 2007, 195: 514-520.PubMed Brown RA, Abrantes AM, Strong DR, Mancebo MC, Menard J, Rasmussen SA, Greenberg BD: A pilot study of moderate-intensity aerobic exercise for obsessive compulsive disorder. J Nerv Ment Dis. 2007, 195: 514-520.PubMed
846.
Zurück zum Zitat Pakseresht S, Boostani H, Sayyah M: Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study. J Complement Integr Med. 2011, 8: 10.2202/1553-3840.1465 Pakseresht S, Boostani H, Sayyah M: Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study. J Complement Integr Med. 2011, 8: 10.2202/1553-3840.1465
847.
Zurück zum Zitat Taylor LH, Kobak KA: An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry. 2000, 61: 575-578.PubMed Taylor LH, Kobak KA: An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry. 2000, 61: 575-578.PubMed
848.
Zurück zum Zitat Van Ameringen M, Mancini C, Patterson B, Boyle MH: Post-traumatic stress disorder in Canada. CNS Neurosci Ther. 2008, 14: 171-181.PubMed Van Ameringen M, Mancini C, Patterson B, Boyle MH: Post-traumatic stress disorder in Canada. CNS Neurosci Ther. 2008, 14: 171-181.PubMed
849.
Zurück zum Zitat Pietrzak RH, Goldstein RB, Southwick SM, Grant BF: Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord. 2011, 25: 456-465.PubMedCentralPubMed Pietrzak RH, Goldstein RB, Southwick SM, Grant BF: Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord. 2011, 25: 456-465.PubMedCentralPubMed
850.
Zurück zum Zitat Darves-Bornoz JM, Alonso J, de Girolamo G, de Graaf R, Haro JM, Kovess-Masfety V, Lepine JP, Nachbaur G, Negre-Pages L, Vilagut G, Gasquet I: Main traumatic events in Europe: PTSD in the European study of the epidemiology of mental disorders survey. J Trauma Stress. 2008, 21: 455-462.PubMed Darves-Bornoz JM, Alonso J, de Girolamo G, de Graaf R, Haro JM, Kovess-Masfety V, Lepine JP, Nachbaur G, Negre-Pages L, Vilagut G, Gasquet I: Main traumatic events in Europe: PTSD in the European study of the epidemiology of mental disorders survey. J Trauma Stress. 2008, 21: 455-462.PubMed
851.
Zurück zum Zitat Stein MB, Walker JR, Hazen AL, Forde DR: Full and partial posttraumatic stress disorder: findings from a community survey. Am J Psychiatry. 1997, 154: 1114-1119.PubMed Stein MB, Walker JR, Hazen AL, Forde DR: Full and partial posttraumatic stress disorder: findings from a community survey. Am J Psychiatry. 1997, 154: 1114-1119.PubMed
852.
Zurück zum Zitat Bravo-Mehmedbasic A, Kucukalic A, Kulenovic AD, Suljic E: Impact of chronic posttraumatic stress disorder on the quality of life of war survivors. Psychiatr Danub. 2010, 22: 430-435.PubMed Bravo-Mehmedbasic A, Kucukalic A, Kulenovic AD, Suljic E: Impact of chronic posttraumatic stress disorder on the quality of life of war survivors. Psychiatr Danub. 2010, 22: 430-435.PubMed
853.
Zurück zum Zitat Pietrzak RH, Goldstein MB, Malley JC, Johnson DC, Southwick SM: Subsyndromal posttraumatic stress disorder is associated with health and psychosocial difficulties in veterans of Operations Enduring Freedom and Iraqi Freedom. Depress Anxiety. 2009, 26: 739-744.PubMed Pietrzak RH, Goldstein MB, Malley JC, Johnson DC, Southwick SM: Subsyndromal posttraumatic stress disorder is associated with health and psychosocial difficulties in veterans of Operations Enduring Freedom and Iraqi Freedom. Depress Anxiety. 2009, 26: 739-744.PubMed
854.
Zurück zum Zitat Westphal M, Olfson M, Gameroff MJ, Wickramaratne P, Pilowsky DJ, Neugebauer R, Lantigua R, Shea S, Neria Y: Functional impairment in adults with past posttraumatic stress disorder: findings from primary care. Depress Anxiety. 2011, 28: 686-695.PubMedCentralPubMed Westphal M, Olfson M, Gameroff MJ, Wickramaratne P, Pilowsky DJ, Neugebauer R, Lantigua R, Shea S, Neria Y: Functional impairment in adults with past posttraumatic stress disorder: findings from primary care. Depress Anxiety. 2011, 28: 686-695.PubMedCentralPubMed
855.
Zurück zum Zitat Rona RJ, Jones M, Iversen A, Hull L, Greenberg N, Fear NT, Hotopf M, Wessely S: The impact of posttraumatic stress disorder on impairment in the UK military at the time of the Iraq war. J Psychiatr Res. 2009, 43: 649-655.PubMed Rona RJ, Jones M, Iversen A, Hull L, Greenberg N, Fear NT, Hotopf M, Wessely S: The impact of posttraumatic stress disorder on impairment in the UK military at the time of the Iraq war. J Psychiatr Res. 2009, 43: 649-655.PubMed
856.
Zurück zum Zitat Asmundson GJ, Wright KD, Stein MB: Pain and PTSD symptoms in female veterans. Eur J Pain. 2004, 8: 345-350.PubMed Asmundson GJ, Wright KD, Stein MB: Pain and PTSD symptoms in female veterans. Eur J Pain. 2004, 8: 345-350.PubMed
857.
Zurück zum Zitat Poundja J, Fikretoglu D, Guay S, Brunet A: Validation of the French version of the brief pain inventory in Canadian veterans suffering from traumatic stress. J Pain Symptom Manage. 2007, 33: 720-726.PubMed Poundja J, Fikretoglu D, Guay S, Brunet A: Validation of the French version of the brief pain inventory in Canadian veterans suffering from traumatic stress. J Pain Symptom Manage. 2007, 33: 720-726.PubMed
858.
Zurück zum Zitat Villano CL, Rosenblum A, Magura S, Fong C, Cleland C, Betzler TF: Prevalence and correlates of posttraumatic stress disorder and chronic severe pain in psychiatric outpatients. J Rehabil Res Dev. 2007, 44: 167-178.PubMed Villano CL, Rosenblum A, Magura S, Fong C, Cleland C, Betzler TF: Prevalence and correlates of posttraumatic stress disorder and chronic severe pain in psychiatric outpatients. J Rehabil Res Dev. 2007, 44: 167-178.PubMed
859.
Zurück zum Zitat Lowe B, Kroenke K, Spitzer RL, Williams JB, Mussell M, Rose M, Wingenfeld K, Sauer N, Spitzer C: Trauma exposure and posttraumatic stress disorder in primary care patients: cross-sectional criterion standard study. J Clin Psychiatry. 2011, 72: 304-312.PubMed Lowe B, Kroenke K, Spitzer RL, Williams JB, Mussell M, Rose M, Wingenfeld K, Sauer N, Spitzer C: Trauma exposure and posttraumatic stress disorder in primary care patients: cross-sectional criterion standard study. J Clin Psychiatry. 2011, 72: 304-312.PubMed
860.
Zurück zum Zitat Babson K, Feldner M, Badour C, Trainor C, Blumenthal H, Sachs-Ericsson N, Schmidt N: Posttraumatic stress and sleep: differential relations across types of symptoms and sleep problems. J Anxiety Disord. 2011, 25: 706-713.PubMedCentralPubMed Babson K, Feldner M, Badour C, Trainor C, Blumenthal H, Sachs-Ericsson N, Schmidt N: Posttraumatic stress and sleep: differential relations across types of symptoms and sleep problems. J Anxiety Disord. 2011, 25: 706-713.PubMedCentralPubMed
861.
Zurück zum Zitat Hirsch KA: Sexual dysfunction in male Operation Enduring Freedom/Operation Iraqi Freedom patients with severe post-traumatic stress disorder. Mil Med. 2009, 174: 520-522.PubMed Hirsch KA: Sexual dysfunction in male Operation Enduring Freedom/Operation Iraqi Freedom patients with severe post-traumatic stress disorder. Mil Med. 2009, 174: 520-522.PubMed
862.
Zurück zum Zitat Lagarde G, Doyon J, Brunet A: Memory and executive dysfunctions associated with acute posttraumatic stress disorder. Psychiatry Res. 2010, 177: 144-149.PubMed Lagarde G, Doyon J, Brunet A: Memory and executive dysfunctions associated with acute posttraumatic stress disorder. Psychiatry Res. 2010, 177: 144-149.PubMed
863.
Zurück zum Zitat Reinhard MJ, Wolf G, Cozolino L: Using the MMPI to assess reported cognitive disturbances and somatization as a core feature of complex PTSD. J Trauma Dissociation. 2010, 11: 57-72.PubMed Reinhard MJ, Wolf G, Cozolino L: Using the MMPI to assess reported cognitive disturbances and somatization as a core feature of complex PTSD. J Trauma Dissociation. 2010, 11: 57-72.PubMed
864.
Zurück zum Zitat Frewen PA, Dozois DJ, Neufeld RW, Lanius RA: Meta-analysis of alexithymia in posttraumatic stress disorder. J Trauma Stress. 2008, 21: 243-246.PubMed Frewen PA, Dozois DJ, Neufeld RW, Lanius RA: Meta-analysis of alexithymia in posttraumatic stress disorder. J Trauma Stress. 2008, 21: 243-246.PubMed
865.
Zurück zum Zitat Sareen J, Houlahan T, Cox BJ, Asmundson GJ: Anxiety disorders associated with suicidal ideation and suicide attempts in the National Comorbidity Survey. J Nerv Ment Dis. 2005, 193: 450-454.PubMed Sareen J, Houlahan T, Cox BJ, Asmundson GJ: Anxiety disorders associated with suicidal ideation and suicide attempts in the National Comorbidity Survey. J Nerv Ment Dis. 2005, 193: 450-454.PubMed
866.
Zurück zum Zitat Kartha A, Brower V, Saitz R, Samet JH, Keane TM, Liebschutz J: The impact of trauma exposure and post-traumatic stress disorder on healthcare utilization among primary care patients. Med Care. 2008, 46: 388-393.PubMedCentralPubMed Kartha A, Brower V, Saitz R, Samet JH, Keane TM, Liebschutz J: The impact of trauma exposure and post-traumatic stress disorder on healthcare utilization among primary care patients. Med Care. 2008, 46: 388-393.PubMedCentralPubMed
867.
Zurück zum Zitat Fikretoglu D, Brunet A, Guay S, Pedlar D: Mental health treatment seeking by military members with posttraumatic stress disorder: findings on rates, characteristics, and predictors from a nationally representative Canadian military sample. Can J Psychiatry. 2007, 52: 103-110.PubMed Fikretoglu D, Brunet A, Guay S, Pedlar D: Mental health treatment seeking by military members with posttraumatic stress disorder: findings on rates, characteristics, and predictors from a nationally representative Canadian military sample. Can J Psychiatry. 2007, 52: 103-110.PubMed
868.
Zurück zum Zitat Sareen J, Belik SL, Stein MB, Asmundson GJ: Correlates of perceived need for mental health care among active military personnel. Psychiatr Serv. 2010, 61: 50-57.PubMed Sareen J, Belik SL, Stein MB, Asmundson GJ: Correlates of perceived need for mental health care among active military personnel. Psychiatr Serv. 2010, 61: 50-57.PubMed
869.
Zurück zum Zitat Nacasch N, Fostick L, Zohar J: High prevalence of obsessive-compulsive disorder among posttraumatic stress disorder patients. Eur Neuropsychopharmacol. 2011, 21: 876-879.PubMed Nacasch N, Fostick L, Zohar J: High prevalence of obsessive-compulsive disorder among posttraumatic stress disorder patients. Eur Neuropsychopharmacol. 2011, 21: 876-879.PubMed
870.
Zurück zum Zitat Cougle JR, Feldner MT, Keough ME, Hawkins KA, Fitch KE: Comorbid panic attacks among individuals with posttraumatic stress disorder: associations with traumatic event exposure history, symptoms, and impairment. J Anxiety Disord. 2010, 24: 183-188.PubMed Cougle JR, Feldner MT, Keough ME, Hawkins KA, Fitch KE: Comorbid panic attacks among individuals with posttraumatic stress disorder: associations with traumatic event exposure history, symptoms, and impairment. J Anxiety Disord. 2010, 24: 183-188.PubMed
871.
Zurück zum Zitat Ginzburg K, Ein-Dor T, Solomon Z: Comorbidity of posttraumatic stress disorder, anxiety and depression: a 20-year longitudinal study of war veterans. J Affect Disord. 2010, 123: 249-257.PubMed Ginzburg K, Ein-Dor T, Solomon Z: Comorbidity of posttraumatic stress disorder, anxiety and depression: a 20-year longitudinal study of war veterans. J Affect Disord. 2010, 123: 249-257.PubMed
872.
Zurück zum Zitat Post LM, Zoellner LA, Youngstrom E, Feeny NC: Understanding the relationship between co-occurring PTSD and MDD: symptom severity and affect. J Anxiety Disord. 2011, 25: 1123-1130.PubMedCentralPubMed Post LM, Zoellner LA, Youngstrom E, Feeny NC: Understanding the relationship between co-occurring PTSD and MDD: symptom severity and affect. J Anxiety Disord. 2011, 25: 1123-1130.PubMedCentralPubMed
873.
Zurück zum Zitat Fetzner MG, McMillan KA, Sareen J, Asmundson GJ: What is the association between traumatic life events and alcohol abuse/dependence in people with and without PTSD? Findings from a nationally representative sample. Depress Anxiety. 2011, 28: 632-638.PubMed Fetzner MG, McMillan KA, Sareen J, Asmundson GJ: What is the association between traumatic life events and alcohol abuse/dependence in people with and without PTSD? Findings from a nationally representative sample. Depress Anxiety. 2011, 28: 632-638.PubMed
874.
Zurück zum Zitat Pagura J, Stein MB, Bolton JM, Cox BJ, Grant B, Sareen J: Comorbidity of borderline personality disorder and posttraumatic stress disorder in the U.S. population. J Psychiatr Res. 2010, 44: 1190-1198.PubMedCentralPubMed Pagura J, Stein MB, Bolton JM, Cox BJ, Grant B, Sareen J: Comorbidity of borderline personality disorder and posttraumatic stress disorder in the U.S. population. J Psychiatr Res. 2010, 44: 1190-1198.PubMedCentralPubMed
875.
Zurück zum Zitat Friedman MJ, Resick PA, Bryant RA, Brewin CR: Considering PTSD for DSM-5. Depress Anxiety. 2011, 28: 750-769.PubMed Friedman MJ, Resick PA, Bryant RA, Brewin CR: Considering PTSD for DSM-5. Depress Anxiety. 2011, 28: 750-769.PubMed
876.
Zurück zum Zitat Rose S, Bisson J, Churchill R, Wessely S: Psychological debriefing for preventing post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2002, CD000560- Rose S, Bisson J, Churchill R, Wessely S: Psychological debriefing for preventing post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2002, CD000560-
877.
Zurück zum Zitat van Emmerik AA, Kamphuis JH, Hulsbosch AM, Emmelkamp PM: Single session debriefing after psychological trauma: a meta-analysis. Lancet. 2002, 360: 766-771.PubMed van Emmerik AA, Kamphuis JH, Hulsbosch AM, Emmelkamp PM: Single session debriefing after psychological trauma: a meta-analysis. Lancet. 2002, 360: 766-771.PubMed
878.
Zurück zum Zitat Roberts NP, Kitchiner NJ, Kenardy J, Bisson J: Multiple session early psychological interventions for the prevention of post-traumatic stress disorder. Cochrane Database Syst Rev. 2009, CD006869- Roberts NP, Kitchiner NJ, Kenardy J, Bisson J: Multiple session early psychological interventions for the prevention of post-traumatic stress disorder. Cochrane Database Syst Rev. 2009, CD006869-
879.
Zurück zum Zitat Kornor H, Winje D, Ekeberg O, Weisaeth L, Kirkehei I, Johansen K, Steiro A: Early trauma-focused cognitive-behavioural therapy to prevent chronic post-traumatic stress disorder and related symptoms: a systematic review and meta-analysis. BMC Psychiatry. 2008, 8: 81-PubMedCentralPubMed Kornor H, Winje D, Ekeberg O, Weisaeth L, Kirkehei I, Johansen K, Steiro A: Early trauma-focused cognitive-behavioural therapy to prevent chronic post-traumatic stress disorder and related symptoms: a systematic review and meta-analysis. BMC Psychiatry. 2008, 8: 81-PubMedCentralPubMed
880.
Zurück zum Zitat Roberts NP, Kitchiner NJ, Kenardy J, Bisson JI: Early psychological interventions to treat acute traumatic stress symptoms. Cochrane Database Syst Rev. 2010, CD007944- Roberts NP, Kitchiner NJ, Kenardy J, Bisson JI: Early psychological interventions to treat acute traumatic stress symptoms. Cochrane Database Syst Rev. 2010, CD007944-
881.
Zurück zum Zitat Gelpin E, Bonne O, Peri T, Brandes D, Shalev A: Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry. 1996, 57: 390-394.PubMed Gelpin E, Bonne O, Peri T, Brandes D, Shalev A: Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry. 1996, 57: 390-394.PubMed
882.
Zurück zum Zitat Mellman TA, Bustamante V, David D, Fins AI: Hypnotic medication in the aftermath of trauma [letter]. J Clin Psychiatry. 2002, 63: 1183-1184.PubMed Mellman TA, Bustamante V, David D, Fins AI: Hypnotic medication in the aftermath of trauma [letter]. J Clin Psychiatry. 2002, 63: 1183-1184.PubMed
883.
Zurück zum Zitat Fowler M, Garza TH, Slater TM, Maani CV, McGhee LL: The relationship between gabapentin and pregabalin and posttraumatic stress disorder in burned servicemembers. J Burn Care Res. 2012, 33: 612-618.PubMed Fowler M, Garza TH, Slater TM, Maani CV, McGhee LL: The relationship between gabapentin and pregabalin and posttraumatic stress disorder in burned servicemembers. J Burn Care Res. 2012, 33: 612-618.PubMed
884.
Zurück zum Zitat Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, Marmar C: Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry. 2003, 54: 947-949.PubMed Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, Marmar C: Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry. 2003, 54: 947-949.PubMed
885.
Zurück zum Zitat Tarsitani L, De Santis V, Mistretta M, Parmigiani G, Zampetti G, Roselli V, Vitale D, Tritapepe L, Biondi M, Picardi A: Treatment with beta-blockers and incidence of post-traumatic stress disorder after cardiac surgery: a prospective observational study. J Cardiothorac Vasc Anesth. 2011, 26: 265-269.PubMed Tarsitani L, De Santis V, Mistretta M, Parmigiani G, Zampetti G, Roselli V, Vitale D, Tritapepe L, Biondi M, Picardi A: Treatment with beta-blockers and incidence of post-traumatic stress disorder after cardiac surgery: a prospective observational study. J Cardiothorac Vasc Anesth. 2011, 26: 265-269.PubMed
886.
Zurück zum Zitat Sharp S, Thomas C, Rosenberg L, Rosenberg M, Meyer W: Propranolol does not reduce risk for acute stress disorder in pediatric burn trauma. J Trauma. 2010, 68: 193-197.PubMed Sharp S, Thomas C, Rosenberg L, Rosenberg M, Meyer W: Propranolol does not reduce risk for acute stress disorder in pediatric burn trauma. J Trauma. 2010, 68: 193-197.PubMed
887.
Zurück zum Zitat Pastrana Jimenez JI, Catalina Romero C, Garcia Dieguez N, Lopez-Ibor Alino JJ: Pharmacological treatment of acute stress disorder with propranolol and hypnotics. Actas Esp Psiquiatr. 2007, 35: 351-358.PubMed Pastrana Jimenez JI, Catalina Romero C, Garcia Dieguez N, Lopez-Ibor Alino JJ: Pharmacological treatment of acute stress disorder with propranolol and hypnotics. Actas Esp Psiquiatr. 2007, 35: 351-358.PubMed
888.
Zurück zum Zitat McGhee LL, Maani CV, Garza TH, Desocio PA, Gaylord KM, Black IH: The effect of propranolol on posttraumatic stress disorder in burned service members. J Burn Care Res. 2009, 30: 92-97.PubMed McGhee LL, Maani CV, Garza TH, Desocio PA, Gaylord KM, Black IH: The effect of propranolol on posttraumatic stress disorder in burned service members. J Burn Care Res. 2009, 30: 92-97.PubMed
889.
Zurück zum Zitat Pitman R, Sanders K, Zusman R, Healy A, Cheema F, Lasko N, Cahill L, Orr S: Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry. 2002, 51: 189-192.PubMed Pitman R, Sanders K, Zusman R, Healy A, Cheema F, Lasko N, Cahill L, Orr S: Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry. 2002, 51: 189-192.PubMed
890.
Zurück zum Zitat Stoddard FJ, Luthra R, Sorrentino EA, Saxe GN, Drake J, Chang Y, Levine JB, Chedekel DS, Sheridan RL: A randomized controlled trial of sertraline to prevent posttraumatic stress disorder in burned children. J Child Adolesc Psychopharmacol. 2011, 21: 469-477.PubMed Stoddard FJ, Luthra R, Sorrentino EA, Saxe GN, Drake J, Chang Y, Levine JB, Chedekel DS, Sheridan RL: A randomized controlled trial of sertraline to prevent posttraumatic stress disorder in burned children. J Child Adolesc Psychopharmacol. 2011, 21: 469-477.PubMed
891.
Zurück zum Zitat Bryant RA, Creamer M, O'Donnell M, Silove D, McFarlane AC: A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry. 2009, 65: 438-440.PubMed Bryant RA, Creamer M, O'Donnell M, Silove D, McFarlane AC: A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry. 2009, 65: 438-440.PubMed
892.
Zurück zum Zitat Stoddard FJ, Sorrentino EA, Ceranoglu TA, Saxe G, Murphy JM, Drake JE, Ronfeldt H, White GW, Kagan J, Snidman N, et al: Preliminary evidence for the effects of morphine on posttraumatic stress disorder symptoms in one- to four-year-olds with burns. J Burn Care Res. 2009, 30: 836-843.PubMed Stoddard FJ, Sorrentino EA, Ceranoglu TA, Saxe G, Murphy JM, Drake JE, Ronfeldt H, White GW, Kagan J, Snidman N, et al: Preliminary evidence for the effects of morphine on posttraumatic stress disorder symptoms in one- to four-year-olds with burns. J Burn Care Res. 2009, 30: 836-843.PubMed
893.
Zurück zum Zitat Saxe G, Geary M, Bedard K, Bosquet M, Miller A, Koenen K, Stoddard F, Moulton S: Separation anxiety as a mediator between acute morphine administration and PTSD symptoms in injured children. Ann N Y Acad Sci. 2006, 1071: 41-45.PubMed Saxe G, Geary M, Bedard K, Bosquet M, Miller A, Koenen K, Stoddard F, Moulton S: Separation anxiety as a mediator between acute morphine administration and PTSD symptoms in injured children. Ann N Y Acad Sci. 2006, 1071: 41-45.PubMed
894.
Zurück zum Zitat Holbrook TL, Galarneau MR, Dye JL, Quinn K, Dougherty AL: Morphine use after combat injury in Iraq and post-traumatic stress disorder. N Engl J Med. 2010, 362: 110-117.PubMed Holbrook TL, Galarneau MR, Dye JL, Quinn K, Dougherty AL: Morphine use after combat injury in Iraq and post-traumatic stress disorder. N Engl J Med. 2010, 362: 110-117.PubMed
895.
Zurück zum Zitat Stewart CL, Wrobel TA: Evaluation of the efficacy of pharmacotherapy and psychotherapy in treatment of combat-related post-traumatic stress disorder: a meta-analytic review of outcome studies. Mil Med. 2009, 174: 460-469.PubMed Stewart CL, Wrobel TA: Evaluation of the efficacy of pharmacotherapy and psychotherapy in treatment of combat-related post-traumatic stress disorder: a meta-analytic review of outcome studies. Mil Med. 2009, 174: 460-469.PubMed
896.
Zurück zum Zitat Nijdam MJ, Gersons BP, Reitsma JB, de Jongh A, Olff M: Brief eclectic psychotherapy v. eye movement desensitisation and reprocessing therapy for post-traumatic stress disorder: randomised controlled trial. Br J Psychiatry. 2012, 200: 224-231.PubMed Nijdam MJ, Gersons BP, Reitsma JB, de Jongh A, Olff M: Brief eclectic psychotherapy v. eye movement desensitisation and reprocessing therapy for post-traumatic stress disorder: randomised controlled trial. Br J Psychiatry. 2012, 200: 224-231.PubMed
897.
Zurück zum Zitat Resick PA, Nishith P, Weaver TL, Astin MC, Feuer CA: A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. J Consult Clin Psychol. 2002, 70: 867-879.PubMedCentralPubMed Resick PA, Nishith P, Weaver TL, Astin MC, Feuer CA: A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. J Consult Clin Psychol. 2002, 70: 867-879.PubMedCentralPubMed
898.
Zurück zum Zitat Foa EB, Dancu CV, Hembree EA, Jaycox LH, Meadows EA, Street GP: A comparison of exposure therapy, stress inoculation training, and their combination for reducing posttraumatic stress disorder in female assault victims. J Consult Clin Psychol. 1999, 67: 194-200.PubMed Foa EB, Dancu CV, Hembree EA, Jaycox LH, Meadows EA, Street GP: A comparison of exposure therapy, stress inoculation training, and their combination for reducing posttraumatic stress disorder in female assault victims. J Consult Clin Psychol. 1999, 67: 194-200.PubMed
899.
Zurück zum Zitat Resick PA, Galovski TE, O'Brien Uhlmansiek M, Scher CD, Clum GA, Young-Xu Y: A randomized clinical trial to dismantle components of cognitive processing therapy for posttraumatic stress disorder in female victims of interpersonal violence. J Consult Clin Psychol. 2008, 76: 243-258.PubMedCentralPubMed Resick PA, Galovski TE, O'Brien Uhlmansiek M, Scher CD, Clum GA, Young-Xu Y: A randomized clinical trial to dismantle components of cognitive processing therapy for posttraumatic stress disorder in female victims of interpersonal violence. J Consult Clin Psychol. 2008, 76: 243-258.PubMedCentralPubMed
900.
Zurück zum Zitat Galovski TE, Monson C, Bruce SE, Resick PA: Does cognitive-behavioral therapy for PTSD improve perceived health and sleep impairment?. J Trauma Stress. 2009, 22: 197-204.PubMedCentralPubMed Galovski TE, Monson C, Bruce SE, Resick PA: Does cognitive-behavioral therapy for PTSD improve perceived health and sleep impairment?. J Trauma Stress. 2009, 22: 197-204.PubMedCentralPubMed
901.
Zurück zum Zitat Resick PA, Williams LF, Suvak MK, Monson CM, Gradus JL: Long-term outcomes of cognitive-behavioral treatments for posttraumatic stress disorder among female rape survivors. J Consult Clin Psychol. 2012, 80: 201-210.PubMedCentralPubMed Resick PA, Williams LF, Suvak MK, Monson CM, Gradus JL: Long-term outcomes of cognitive-behavioral treatments for posttraumatic stress disorder among female rape survivors. J Consult Clin Psychol. 2012, 80: 201-210.PubMedCentralPubMed
902.
Zurück zum Zitat Bryant RA, Moulds ML, Guthrie RM, Dang ST, Nixon RD: Imaginal exposure alone and imaginal exposure with cognitive restructuring in treatment of posttraumatic stress disorder. J Consult Clin Psychol. 2003, 71: 706-712.PubMed Bryant RA, Moulds ML, Guthrie RM, Dang ST, Nixon RD: Imaginal exposure alone and imaginal exposure with cognitive restructuring in treatment of posttraumatic stress disorder. J Consult Clin Psychol. 2003, 71: 706-712.PubMed
903.
Zurück zum Zitat Ehlers A, Clark D, Hackmann A, McManus F, Fennell M, Herbert C, Mayou R: A randomized controlled trial of cognitive therapy, a self-help booklet, and repeated assessments as early interventions for posttraumatic stress disorder. Arch Gen Psychiatry. 2003, 60: 1024-1032.PubMed Ehlers A, Clark D, Hackmann A, McManus F, Fennell M, Herbert C, Mayou R: A randomized controlled trial of cognitive therapy, a self-help booklet, and repeated assessments as early interventions for posttraumatic stress disorder. Arch Gen Psychiatry. 2003, 60: 1024-1032.PubMed
904.
Zurück zum Zitat Zoellner T, Rabe S, Karl A, Maercker A: Post-traumatic growth as outcome of a cognitive-behavioural therapy trial for motor vehicle accident survivors with PTSD. Psychol Psychother. 2011, 84: 201-213.PubMed Zoellner T, Rabe S, Karl A, Maercker A: Post-traumatic growth as outcome of a cognitive-behavioural therapy trial for motor vehicle accident survivors with PTSD. Psychol Psychother. 2011, 84: 201-213.PubMed
905.
Zurück zum Zitat Kemp M, Drummond P, McDermott B: A wait-list controlled pilot study of eye movement desensitization and reprocessing (EMDR) for children with post-traumatic stress disorder (PTSD) symptoms from motor vehicle accidents. Clinical child psychology and psychiatry. 2010, 15: 5-25.PubMed Kemp M, Drummond P, McDermott B: A wait-list controlled pilot study of eye movement desensitization and reprocessing (EMDR) for children with post-traumatic stress disorder (PTSD) symptoms from motor vehicle accidents. Clinical child psychology and psychiatry. 2010, 15: 5-25.PubMed
906.
Zurück zum Zitat Beck JG, Coffey SF, Foy DW, Keane TM, Blanchard EB: Group cognitive behavior therapy for chronic posttraumatic stress disorder: an initial randomized pilot study. Behav Ther. 2009, 40: 82-92.PubMed Beck JG, Coffey SF, Foy DW, Keane TM, Blanchard EB: Group cognitive behavior therapy for chronic posttraumatic stress disorder: an initial randomized pilot study. Behav Ther. 2009, 40: 82-92.PubMed
907.
Zurück zum Zitat Basoglu M, Salcioglu E, Livanou M: A randomized controlled study of single-session behavioural treatment of earthquake-related post-traumatic stress disorder using an earthquake simulator. Psychol Med. 2007, 37: 203-213.PubMed Basoglu M, Salcioglu E, Livanou M: A randomized controlled study of single-session behavioural treatment of earthquake-related post-traumatic stress disorder using an earthquake simulator. Psychol Med. 2007, 37: 203-213.PubMed
908.
Zurück zum Zitat Hogberg G, Pagani M, Sundin O, Soares J, Aberg-Wistedt A, Tarnell B, Hallstrom T: On treatment with eye movement desensitization and reprocessing of chronic post-traumatic stress disorder in public transportation workers--a randomized controlled trial. Nord J Psychiatry. 2007, 61: 54-61.PubMed Hogberg G, Pagani M, Sundin O, Soares J, Aberg-Wistedt A, Tarnell B, Hallstrom T: On treatment with eye movement desensitization and reprocessing of chronic post-traumatic stress disorder in public transportation workers--a randomized controlled trial. Nord J Psychiatry. 2007, 61: 54-61.PubMed
909.
Zurück zum Zitat Keane TM, Zimering RT, Caddell JM: Implosive (flooding) therapy reduces symptoms of PTSD in Vietnam combat veterans. Behav Ther. 1989, 20: 245-260. Keane TM, Zimering RT, Caddell JM: Implosive (flooding) therapy reduces symptoms of PTSD in Vietnam combat veterans. Behav Ther. 1989, 20: 245-260.
910.
Zurück zum Zitat Forbes D, Lloyd D, Nixon RD, Elliott P, Varker T, Perry D, Bryant RA, Creamer M: A multisite randomized controlled effectiveness trial of cognitive processing therapy for military-related posttraumatic stress disorder. J Anxiety Disord. 2012, 26: 442-452.PubMed Forbes D, Lloyd D, Nixon RD, Elliott P, Varker T, Perry D, Bryant RA, Creamer M: A multisite randomized controlled effectiveness trial of cognitive processing therapy for military-related posttraumatic stress disorder. J Anxiety Disord. 2012, 26: 442-452.PubMed
911.
Zurück zum Zitat Alvarez J, McLean C, Harris AH, Rosen CS, Ruzek JI, Kimerling R: The comparative effectiveness of cognitive processing therapy for male veterans treated in a VHA posttraumatic stress disorder residential rehabilitation program. J Consult Clin Psychol. 2011, 79: 590-599.PubMed Alvarez J, McLean C, Harris AH, Rosen CS, Ruzek JI, Kimerling R: The comparative effectiveness of cognitive processing therapy for male veterans treated in a VHA posttraumatic stress disorder residential rehabilitation program. J Consult Clin Psychol. 2011, 79: 590-599.PubMed
912.
Zurück zum Zitat Macdonald A, Monson CM, Doron-Lamarca S, Resick PA, Palfai TP: Identifying patterns of symptom change during a randomized controlled trial of cognitive processing therapy for military-related posttraumatic stress disorder. J Trauma Stress. 2011, 24: 268-276.PubMed Macdonald A, Monson CM, Doron-Lamarca S, Resick PA, Palfai TP: Identifying patterns of symptom change during a randomized controlled trial of cognitive processing therapy for military-related posttraumatic stress disorder. J Trauma Stress. 2011, 24: 268-276.PubMed
913.
Zurück zum Zitat Monson CM, Schnurr PP, Resick PA, Friedman MJ, Young-Xu Y, Stevens SP: Cognitive processing therapy for veterans with military-related posttraumatic stress disorder. J Consult Clin Psychol. 2006, 74: 898-907.PubMed Monson CM, Schnurr PP, Resick PA, Friedman MJ, Young-Xu Y, Stevens SP: Cognitive processing therapy for veterans with military-related posttraumatic stress disorder. J Consult Clin Psychol. 2006, 74: 898-907.PubMed
914.
Zurück zum Zitat Gros DF, Yoder M, Tuerk PW, Lozano BE, Acierno R: Exposure therapy for PTSD delivered to veterans via telehealth: predictors of treatment completion and outcome and comparison to treatment delivered in person. Behav Ther. 2011, 42: 276-283.PubMed Gros DF, Yoder M, Tuerk PW, Lozano BE, Acierno R: Exposure therapy for PTSD delivered to veterans via telehealth: predictors of treatment completion and outcome and comparison to treatment delivered in person. Behav Ther. 2011, 42: 276-283.PubMed
915.
Zurück zum Zitat van Minnen A, Foa EB: The effect of imaginal exposure length on outcome of treatment for PTSD. J Trauma Stress. 2006, 19: 427-438.PubMed van Minnen A, Foa EB: The effect of imaginal exposure length on outcome of treatment for PTSD. J Trauma Stress. 2006, 19: 427-438.PubMed
916.
Zurück zum Zitat Bryant RA, Moulds ML, Guthrie RM, Dang ST, Mastrodomenico J, Nixon RD, Felmingham KL, Hopwood S, Creamer M: A randomized controlled trial of exposure therapy and cognitive restructuring for posttraumatic stress disorder. J Consult Clin Psychol. 2008, 76: 695-703.PubMed Bryant RA, Moulds ML, Guthrie RM, Dang ST, Mastrodomenico J, Nixon RD, Felmingham KL, Hopwood S, Creamer M: A randomized controlled trial of exposure therapy and cognitive restructuring for posttraumatic stress disorder. J Consult Clin Psychol. 2008, 76: 695-703.PubMed
917.
Zurück zum Zitat Foa EB, Hembree EA, Cahill SP, Rauch SA, Riggs DS, Feeny NC, Yadin E: Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: outcome at academic and community clinics. J Consult Clin Psychol. 2005, 73: 953-964.PubMed Foa EB, Hembree EA, Cahill SP, Rauch SA, Riggs DS, Feeny NC, Yadin E: Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: outcome at academic and community clinics. J Consult Clin Psychol. 2005, 73: 953-964.PubMed
918.
Zurück zum Zitat Paunovic N, Öst L-G: Cognitive-behavior therapy vs exposure therapy in the treatment of PTSD in refugees. Behav Res Ther. 2001, 39: 1183-1197.PubMed Paunovic N, Öst L-G: Cognitive-behavior therapy vs exposure therapy in the treatment of PTSD in refugees. Behav Res Ther. 2001, 39: 1183-1197.PubMed
919.
Zurück zum Zitat Moser JS, Cahill SP, Foa EB: Evidence for poorer outcome in patients with severe negative trauma-related cognitions receiving prolonged exposure plus cognitive restructuring: implications for treatment matching in posttraumatic stress disorder. J Nerv Ment Dis. 2010, 198: 72-75.PubMed Moser JS, Cahill SP, Foa EB: Evidence for poorer outcome in patients with severe negative trauma-related cognitions receiving prolonged exposure plus cognitive restructuring: implications for treatment matching in posttraumatic stress disorder. J Nerv Ment Dis. 2010, 198: 72-75.PubMed
920.
Zurück zum Zitat Grunert BK, Weis JM, Smucker MR, Christianson HF: Imagery rescripting and reprocessing therapy after failed prolonged exposure for post-traumatic stress disorder following industrial injury. J Behav Ther Exp Psychiatry. 2007, 38: 317-328.PubMed Grunert BK, Weis JM, Smucker MR, Christianson HF: Imagery rescripting and reprocessing therapy after failed prolonged exposure for post-traumatic stress disorder following industrial injury. J Behav Ther Exp Psychiatry. 2007, 38: 317-328.PubMed
921.
Zurück zum Zitat Arntz A, Tiesema M, Kindt M: Treatment of PTSD: a comparison of imaginal exposure with and without imagery rescripting. J Behav Ther Exp Psychiatry. 2007, 38: 345-370.PubMed Arntz A, Tiesema M, Kindt M: Treatment of PTSD: a comparison of imaginal exposure with and without imagery rescripting. J Behav Ther Exp Psychiatry. 2007, 38: 345-370.PubMed
922.
Zurück zum Zitat Beidel DC, Frueh BC, Uhde TW, Wong N, Mentrikoski JM: Multicomponent behavioral treatment for chronic combat-related posttraumatic stress disorder: a randomized controlled trial. J Anxiety Disord. 2011, 25: 224-231.PubMedCentralPubMed Beidel DC, Frueh BC, Uhde TW, Wong N, Mentrikoski JM: Multicomponent behavioral treatment for chronic combat-related posttraumatic stress disorder: a randomized controlled trial. J Anxiety Disord. 2011, 25: 224-231.PubMedCentralPubMed
923.
Zurück zum Zitat Bradley R, Greene J, Russ E, Dutra L, Westen D: A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry. 2005, 162: 214-227.PubMed Bradley R, Greene J, Russ E, Dutra L, Westen D: A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry. 2005, 162: 214-227.PubMed
924.
Zurück zum Zitat Kar N: Cognitive behavioral therapy for the treatment of post-traumatic stress disorder: a review. Neuropsychiatr Dis Treat. 2011, 7: 167-181.PubMedCentralPubMed Kar N: Cognitive behavioral therapy for the treatment of post-traumatic stress disorder: a review. Neuropsychiatr Dis Treat. 2011, 7: 167-181.PubMedCentralPubMed
925.
Zurück zum Zitat Schottenbauer MA, Glass CR, Arnkoff DB, Tendick V, Gray SH: Nonresponse and dropout rates in outcome studies on PTSD: review and methodological considerations. Psychiatry. 2008, 71: 134-168.PubMed Schottenbauer MA, Glass CR, Arnkoff DB, Tendick V, Gray SH: Nonresponse and dropout rates in outcome studies on PTSD: review and methodological considerations. Psychiatry. 2008, 71: 134-168.PubMed
926.
Zurück zum Zitat van der Kolk BA, Roth S, Pelcovitz D, Sunday S, Spinazzola J: Disorders of extreme stress: The empirical foundation of a complex adaptation to trauma. J Trauma Stress. 2005, 18: 389-399.PubMed van der Kolk BA, Roth S, Pelcovitz D, Sunday S, Spinazzola J: Disorders of extreme stress: The empirical foundation of a complex adaptation to trauma. J Trauma Stress. 2005, 18: 389-399.PubMed
927.
Zurück zum Zitat Najavits LM: Expanding the boundaries of PTSD treatment. JAMA. 2012, 308: 714-716.PubMed Najavits LM: Expanding the boundaries of PTSD treatment. JAMA. 2012, 308: 714-716.PubMed
928.
Zurück zum Zitat Steil R, Dyer A, Priebe K, Kleindienst N, Bohus M: Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive residential treatment program. J Trauma Stress. 2011, 24: 102-106.PubMed Steil R, Dyer A, Priebe K, Kleindienst N, Bohus M: Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive residential treatment program. J Trauma Stress. 2011, 24: 102-106.PubMed
929.
Zurück zum Zitat Harned MS, Jackson SC, Comtois KA, Linehan MM: Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with borderline personality disorder. J Trauma Stress. 2010, 23: 421-429.PubMed Harned MS, Jackson SC, Comtois KA, Linehan MM: Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with borderline personality disorder. J Trauma Stress. 2010, 23: 421-429.PubMed
930.
Zurück zum Zitat Harned MS, Korslund KE, Foa EB, Linehan MM: Treating PTSD in suicidal and self-injuring women with borderline personality disorder: development and preliminary evaluation of a Dialectical Behavior Therapy Prolonged Exposure Protocol. Behav Res Ther. 2012, 50: 381-386.PubMedCentralPubMed Harned MS, Korslund KE, Foa EB, Linehan MM: Treating PTSD in suicidal and self-injuring women with borderline personality disorder: development and preliminary evaluation of a Dialectical Behavior Therapy Prolonged Exposure Protocol. Behav Res Ther. 2012, 50: 381-386.PubMedCentralPubMed
931.
Zurück zum Zitat Mills KL, Teesson M, Back SE, Brady KT, Baker AL, Hopwood S, Sannibale C, Barrett EL, Merz S, Rosenfeld J, Ewer PL: Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: a randomized controlled trial. JAMA. 2012, 308: 690-699.PubMed Mills KL, Teesson M, Back SE, Brady KT, Baker AL, Hopwood S, Sannibale C, Barrett EL, Merz S, Rosenfeld J, Ewer PL: Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: a randomized controlled trial. JAMA. 2012, 308: 690-699.PubMed
932.
Zurück zum Zitat Cloitre M, Courtois CA, Charuvastra A, Carapezza R, Stolbach BC, Green BL: Treatment of complex PTSD: results of the ISTSS expert clinician survey on best practices. J Trauma Stress. 2011, 24: 615-627.PubMed Cloitre M, Courtois CA, Charuvastra A, Carapezza R, Stolbach BC, Green BL: Treatment of complex PTSD: results of the ISTSS expert clinician survey on best practices. J Trauma Stress. 2011, 24: 615-627.PubMed
933.
Zurück zum Zitat Brunet A, Ashbaugh A, Hebert P: Internet use in the aftermath of trauma. 2010, Amsterdam: NATO Books, IOS Press Brunet A, Ashbaugh A, Hebert P: Internet use in the aftermath of trauma. 2010, Amsterdam: NATO Books, IOS Press
934.
Zurück zum Zitat Spence J, Titov N, Dear BF, Johnston L, Solley K, Lorian C, Wootton B, Zou J, Schwenke G: Randomized controlled trial of Internet-delivered cognitive behavioral therapy for posttraumatic stress disorder. Depress Anxiety. 2011, 28: 541-550.PubMed Spence J, Titov N, Dear BF, Johnston L, Solley K, Lorian C, Wootton B, Zou J, Schwenke G: Randomized controlled trial of Internet-delivered cognitive behavioral therapy for posttraumatic stress disorder. Depress Anxiety. 2011, 28: 541-550.PubMed
935.
Zurück zum Zitat Litz BT, Engel CC, Bryant RA, Papa A: A randomized, controlled proof-of-concept trial of an internet-based, therapist-assisted self-management treatment for posttraumatic stress disorder. Am J Psychiatry. 2007, 164: 1676-1683.PubMed Litz BT, Engel CC, Bryant RA, Papa A: A randomized, controlled proof-of-concept trial of an internet-based, therapist-assisted self-management treatment for posttraumatic stress disorder. Am J Psychiatry. 2007, 164: 1676-1683.PubMed
936.
Zurück zum Zitat Knaevelsrud C, Maercker A: Internet-based treatment for PTSD reduces distress and facilitates the development of a strong therapeutic alliance: a randomized controlled clinical trial. BMC Psychiatry. 2007, 7: 13-PubMedCentralPubMed Knaevelsrud C, Maercker A: Internet-based treatment for PTSD reduces distress and facilitates the development of a strong therapeutic alliance: a randomized controlled clinical trial. BMC Psychiatry. 2007, 7: 13-PubMedCentralPubMed
937.
Zurück zum Zitat Klein B, Mitchell J, Abbott J, Shandley K, Austin D, Gilson K, Kiropoulos L, Cannard G, Redman T: A therapist-assisted cognitive behavior therapy internet intervention for posttraumatic stress disorder: pre-, post- and 3-month follow-up results from an open trial. J Anxiety Disord. 2010, 24: 635-644.PubMed Klein B, Mitchell J, Abbott J, Shandley K, Austin D, Gilson K, Kiropoulos L, Cannard G, Redman T: A therapist-assisted cognitive behavior therapy internet intervention for posttraumatic stress disorder: pre-, post- and 3-month follow-up results from an open trial. J Anxiety Disord. 2010, 24: 635-644.PubMed
938.
Zurück zum Zitat Knaevelsrud C, Liedl A, Maercker A: Posttraumatic growth, optimism and openness as outcomes of a cognitive-behavioural intervention for posttraumatic stress reactions. J Health Psychol. 2010, 15: 1030-1038.PubMed Knaevelsrud C, Liedl A, Maercker A: Posttraumatic growth, optimism and openness as outcomes of a cognitive-behavioural intervention for posttraumatic stress reactions. J Health Psychol. 2010, 15: 1030-1038.PubMed
939.
Zurück zum Zitat Lange A, van de Ven JP, Schrieken B, Emmelkamp PM: Interapy, treatment of posttraumatic stress through the Internet: a controlled trial. J Behav Ther Exp Psychiatry. 2001, 32: 73-90.PubMed Lange A, van de Ven JP, Schrieken B, Emmelkamp PM: Interapy, treatment of posttraumatic stress through the Internet: a controlled trial. J Behav Ther Exp Psychiatry. 2001, 32: 73-90.PubMed
940.
Zurück zum Zitat Lange A, Rietdijk D, Hudcovicova M, van de Ven JP, Schrieken B, Emmelkamp PM: Interapy: a controlled randomized trial of the standardized treatment of posttraumatic stress through the internet. J Consult Clin Psychol. 2003, 71: 901-909.PubMed Lange A, Rietdijk D, Hudcovicova M, van de Ven JP, Schrieken B, Emmelkamp PM: Interapy: a controlled randomized trial of the standardized treatment of posttraumatic stress through the internet. J Consult Clin Psychol. 2003, 71: 901-909.PubMed
941.
Zurück zum Zitat Rothbaum BO, Hodges LF, Ready D, Graap K, Alarcon RD: Virtual reality exposure therapy for Vietnam veterans with posttraumatic stress disorder. J Clin Psychiatry. 2001, 62: 617-622.PubMed Rothbaum BO, Hodges LF, Ready D, Graap K, Alarcon RD: Virtual reality exposure therapy for Vietnam veterans with posttraumatic stress disorder. J Clin Psychiatry. 2001, 62: 617-622.PubMed
942.
Zurück zum Zitat Ready DJ, Gerardi RJ, Backscheider AG, Mascaro N, Rothbaum BO: Comparing virtual reality exposure therapy to present-centered therapy with 11 U.S. Vietnam veterans with PTSD. Cyberpsychol Behav Soc Netw. 2010, 13: 49-54.PubMed Ready DJ, Gerardi RJ, Backscheider AG, Mascaro N, Rothbaum BO: Comparing virtual reality exposure therapy to present-centered therapy with 11 U.S. Vietnam veterans with PTSD. Cyberpsychol Behav Soc Netw. 2010, 13: 49-54.PubMed
943.
Zurück zum Zitat Difede J, Cukor J, Jayasinghe N, Patt I, Jedel S, Spielman L, Giosan C, Hoffman HG: Virtual reality exposure therapy for the treatment of posttraumatic stress disorder following September 11, 2001. J Clin Psychiatry. 2007, 68: 1639-1647.PubMed Difede J, Cukor J, Jayasinghe N, Patt I, Jedel S, Spielman L, Giosan C, Hoffman HG: Virtual reality exposure therapy for the treatment of posttraumatic stress disorder following September 11, 2001. J Clin Psychiatry. 2007, 68: 1639-1647.PubMed
944.
Zurück zum Zitat Germain V, Marchand A, Bouchard S, Drouin MS, Guay S: Effectiveness of cognitive behavioural therapy administered by videoconference for posttraumatic stress disorder. Cogn Behav Ther. 2009, 38: 42-53.PubMed Germain V, Marchand A, Bouchard S, Drouin MS, Guay S: Effectiveness of cognitive behavioural therapy administered by videoconference for posttraumatic stress disorder. Cogn Behav Ther. 2009, 38: 42-53.PubMed
945.
Zurück zum Zitat Hetrick SE, Purcell R, Garner B, Parslow R: Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2010, CD007316- Hetrick SE, Purcell R, Garner B, Parslow R: Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2010, CD007316-
946.
Zurück zum Zitat Cohen JA, Mannarino AP, Perel JM, Staron V: A pilot randomized controlled trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms. J Am Acad Child Adolesc Psychiatry. 2007, 46: 811-819.PubMed Cohen JA, Mannarino AP, Perel JM, Staron V: A pilot randomized controlled trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms. J Am Acad Child Adolesc Psychiatry. 2007, 46: 811-819.PubMed
947.
Zurück zum Zitat Simon NM, Connor KM, Lang AJ, Rauch S, Krulewicz S, LeBeau RT, Davidson JR, Stein MB, Otto MW, Foa EB, Pollack MH: Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry. 2008, 69: 400-405.PubMed Simon NM, Connor KM, Lang AJ, Rauch S, Krulewicz S, LeBeau RT, Davidson JR, Stein MB, Otto MW, Foa EB, Pollack MH: Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry. 2008, 69: 400-405.PubMed
948.
Zurück zum Zitat Rothbaum BO, Cahill SP, Foa EB, Davidson JR, Compton J, Connor KM, Astin MC, Hahn CG: Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Trauma Stress. 2006, 19: 625-638.PubMed Rothbaum BO, Cahill SP, Foa EB, Davidson JR, Compton J, Connor KM, Astin MC, Hahn CG: Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Trauma Stress. 2006, 19: 625-638.PubMed
949.
Zurück zum Zitat Otto M, Hinton D, Korbly N, Chea A, Ba P, Gershuny B, Pollack M: Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone. Behav Res Ther. 2003, 41: 1271-1276.PubMed Otto M, Hinton D, Korbly N, Chea A, Ba P, Gershuny B, Pollack M: Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone. Behav Res Ther. 2003, 41: 1271-1276.PubMed
950.
Zurück zum Zitat Schneier FR, Neria Y, Pavlicova M, Hembree E, Suh EJ, Amsel L, Marshall RD: Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial. Am J Psychiatry. 2012, 169: 80-88.PubMedCentralPubMed Schneier FR, Neria Y, Pavlicova M, Hembree E, Suh EJ, Amsel L, Marshall RD: Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial. Am J Psychiatry. 2012, 169: 80-88.PubMedCentralPubMed
951.
Zurück zum Zitat Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK: Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008, 42: 503-506.PubMed Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK: Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008, 42: 503-506.PubMed
952.
Zurück zum Zitat Brunet A, Poundja J, Tremblay J, Bui E, Thomas E, Orr SP, Azzoug A, Birmes P, Pitman RK: Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials. J Clin Psychopharmacol. 2011, 31: 547-550.PubMed Brunet A, Poundja J, Tremblay J, Bui E, Thomas E, Orr SP, Azzoug A, Birmes P, Pitman RK: Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials. J Clin Psychopharmacol. 2011, 31: 547-550.PubMed
953.
Zurück zum Zitat de Kleine RA, Hendriks GJ, Kusters WJ, Broekman TG, van Minnen A: A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry. 2012, 71: 962-968.PubMed de Kleine RA, Hendriks GJ, Kusters WJ, Broekman TG, van Minnen A: A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry. 2012, 71: 962-968.PubMed
954.
Zurück zum Zitat Litz BT, Salters-Pedneault K, Steenkamp MM, Hermos JA, Bryant RA, Otto MW, Hofmann SG: A randomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res. 2012, 46: 1184-1190.PubMed Litz BT, Salters-Pedneault K, Steenkamp MM, Hermos JA, Bryant RA, Otto MW, Hofmann SG: A randomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res. 2012, 46: 1184-1190.PubMed
955.
Zurück zum Zitat Van Etten M, Taylor S: Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysis. Clin Psychol Psychother. 1998, 5: 126-144. Van Etten M, Taylor S: Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysis. Clin Psychol Psychother. 1998, 5: 126-144.
956.
Zurück zum Zitat Edmond T, Rubin A: Assessing the long-term effects of EMDR: results from an 18-month follow-up study with adult female survivors of CSA. J Child Sex Abus. 2004, 13: 69-86.PubMed Edmond T, Rubin A: Assessing the long-term effects of EMDR: results from an 18-month follow-up study with adult female survivors of CSA. J Child Sex Abus. 2004, 13: 69-86.PubMed
957.
Zurück zum Zitat Wilson SA, Becker LA, Tinker RH: Fifteen-month follow-up of eye movement desensitization and reprocessing (EMDR) treatment for posttraumatic stress disorder and psychological trauma. J Consult Clin Psychol. 1997, 65: 1047-1056.PubMed Wilson SA, Becker LA, Tinker RH: Fifteen-month follow-up of eye movement desensitization and reprocessing (EMDR) treatment for posttraumatic stress disorder and psychological trauma. J Consult Clin Psychol. 1997, 65: 1047-1056.PubMed
958.
Zurück zum Zitat Knaevelsrud C, Maercker A: Long-term effects of an internet-based treatment for posttraumatic stress. Cogn Behav Ther. 2010, 39: 72-77.PubMed Knaevelsrud C, Maercker A: Long-term effects of an internet-based treatment for posttraumatic stress. Cogn Behav Ther. 2010, 39: 72-77.PubMed
959.
Zurück zum Zitat Hogberg G, Pagani M, Sundin O, Soares J, Aberg-Wistedt A, Tarnell B, Hallstrom T: Treatment of post-traumatic stress disorder with eye movement desensitization and reprocessing: outcome is stable in 35-month follow-up. Psychiatry Res. 2008, 159: 101-108.PubMed Hogberg G, Pagani M, Sundin O, Soares J, Aberg-Wistedt A, Tarnell B, Hallstrom T: Treatment of post-traumatic stress disorder with eye movement desensitization and reprocessing: outcome is stable in 35-month follow-up. Psychiatry Res. 2008, 159: 101-108.PubMed
960.
Zurück zum Zitat van der Kolk B, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G: Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry. 1994, 55: 517-522.PubMed van der Kolk B, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G: Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry. 1994, 55: 517-522.PubMed
961.
Zurück zum Zitat Connor K, Sutherland S, Tupler L, Malik M, Davidson J: Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br J Psychiatry. 1999, 175: 17-22.PubMed Connor K, Sutherland S, Tupler L, Malik M, Davidson J: Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br J Psychiatry. 1999, 175: 17-22.PubMed
962.
Zurück zum Zitat Martenyi F, Brown E, Zhang H, Prakash A, Koke S: Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry. 2002, 63: 199-206.PubMed Martenyi F, Brown E, Zhang H, Prakash A, Koke S: Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry. 2002, 63: 199-206.PubMed
963.
Zurück zum Zitat van der Kolk BA, Spinazzola J, Blaustein ME, Hopper JW, Hopper EK, Korn DL, Simpson WB: A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. J Clin Psychiatry. 2007, 68: 37-46.PubMed van der Kolk BA, Spinazzola J, Blaustein ME, Hopper JW, Hopper EK, Korn DL, Simpson WB: A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. J Clin Psychiatry. 2007, 68: 37-46.PubMed
964.
Zurück zum Zitat Martenyi F, Brown EB, Caldwell CD: Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study. J Clin Psychopharmacol. 2007, 27: 166-170.PubMed Martenyi F, Brown EB, Caldwell CD: Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study. J Clin Psychopharmacol. 2007, 27: 166-170.PubMed
965.
Zurück zum Zitat Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR: Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann Clin Psychiatry. 2000, 12: 101-105.PubMed Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR: Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann Clin Psychiatry. 2000, 12: 101-105.PubMed
966.
Zurück zum Zitat Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts C: Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001, 62: 860-868.PubMed Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts C: Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001, 62: 860-868.PubMed
967.
Zurück zum Zitat Marshall R, Beebe K, Oldham M, Zaninelli R: Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry. 2001, 158: 1982-1988.PubMed Marshall R, Beebe K, Oldham M, Zaninelli R: Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry. 2001, 158: 1982-1988.PubMed
968.
Zurück zum Zitat Stein D, Davidson J, Seedat S, Beebe K: Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Expert Opin Pharmacother. 2003, 4: 1829-1838.PubMed Stein D, Davidson J, Seedat S, Beebe K: Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Expert Opin Pharmacother. 2003, 4: 1829-1838.PubMed
969.
Zurück zum Zitat Marshall RD, Lewis-Fernandez R, Blanco C, Simpson HB, Lin SH, Vermes D, Garcia W, Schneier F, Neria Y, Sanchez-Lacay A, Liebowitz MR: A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety. 2007, 24: 77-84.PubMed Marshall RD, Lewis-Fernandez R, Blanco C, Simpson HB, Lin SH, Vermes D, Garcia W, Schneier F, Neria Y, Sanchez-Lacay A, Liebowitz MR: A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety. 2007, 24: 77-84.PubMed
970.
Zurück zum Zitat Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, Krystal JH: Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology. 2012, 37: 996-1004.PubMedCentralPubMed Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, Krystal JH: Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology. 2012, 37: 996-1004.PubMedCentralPubMed
971.
Zurück zum Zitat Davidson J, Rothbaum B, van der Kolk B, Sikes C, Farfel G: Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001, 58: 485-492.PubMed Davidson J, Rothbaum B, van der Kolk B, Sikes C, Farfel G: Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001, 58: 485-492.PubMed
972.
Zurück zum Zitat Brady K, Pearlstein T, Asnis G, Baker D, Rothbaum B, Sikes C, Farfel G: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000, 283: 1837-1844.PubMed Brady K, Pearlstein T, Asnis G, Baker D, Rothbaum B, Sikes C, Farfel G: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000, 283: 1837-1844.PubMed
973.
Zurück zum Zitat Zohar J, Amital D, Miodownik C, Kotler M, Bleich A, Lane R, Austin C: Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol. 2002, 22: 190-195.PubMed Zohar J, Amital D, Miodownik C, Kotler M, Bleich A, Lane R, Austin C: Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol. 2002, 22: 190-195.PubMed
974.
Zurück zum Zitat Tucker P, Potter-Kimball R, Wyatt D, Parker D, Burgin C, Jones D, Masters B: Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Psychopharmacol Bull. 2003, 37: 135-149.PubMed Tucker P, Potter-Kimball R, Wyatt D, Parker D, Burgin C, Jones D, Masters B: Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Psychopharmacol Bull. 2003, 37: 135-149.PubMed
975.
Zurück zum Zitat Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ: Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol. 2006, 26: 259-267.PubMed Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ: Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol. 2006, 26: 259-267.PubMed
976.
Zurück zum Zitat Stein DJ, van der Kolk BA, Austin C, Fayyad R, Clary C: Efficacy of sertraline in posttraumatic stress disorder secondary to interpersonal trauma or childhood abuse. Ann Clin Psychiatry. 2006, 18: 243-249.PubMed Stein DJ, van der Kolk BA, Austin C, Fayyad R, Clary C: Efficacy of sertraline in posttraumatic stress disorder secondary to interpersonal trauma or childhood abuse. Ann Clin Psychiatry. 2006, 18: 243-249.PubMed
977.
Zurück zum Zitat Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM: Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 2007, 68: 711-720.PubMed Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM: Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 2007, 68: 711-720.PubMed
978.
Zurück zum Zitat Panahi Y, Moghaddam BR, Sahebkar A, Nazari MA, Beiraghdar F, Karami G, Saadat AR: A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychol Med. 2011, 41: 2159-2166.PubMed Panahi Y, Moghaddam BR, Sahebkar A, Nazari MA, Beiraghdar F, Karami G, Saadat AR: A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychol Med. 2011, 41: 2159-2166.PubMed
979.
Zurück zum Zitat Marmar C, Schoenfeld F, Weiss D, Metzler T, Zatzick D, Wu R, Smiga S, Tecott L, Neylan T: Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry. 1996, 57 (Suppl 8): 66-70. discussion 71-62PubMed Marmar C, Schoenfeld F, Weiss D, Metzler T, Zatzick D, Wu R, Smiga S, Tecott L, Neylan T: Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry. 1996, 57 (Suppl 8): 66-70. discussion 71-62PubMed
980.
Zurück zum Zitat Escalona R, Canive J, Calais L, Davidson J: Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depress Anxiety. 2002, 15: 29-33.PubMed Escalona R, Canive J, Calais L, Davidson J: Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depress Anxiety. 2002, 15: 29-33.PubMed
981.
Zurück zum Zitat Tucker P, Smith K, Marx B, Jones D, Miranda R, Lensgraf J: Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorder. J Clin Psychopharmacol. 2000, 20: 367-372.PubMed Tucker P, Smith K, Marx B, Jones D, Miranda R, Lensgraf J: Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorder. J Clin Psychopharmacol. 2000, 20: 367-372.PubMed
982.
Zurück zum Zitat Neylan T, Metzler T, Schoenfeld F, Weiss D, Lenoci M, Best S, Lipsey T, Marmar C: Fluvoxamine and sleep disturbances in posttraumatic stress disorder. J Trauma Stress. 2001, 14: 461-467.PubMed Neylan T, Metzler T, Schoenfeld F, Weiss D, Lenoci M, Best S, Lipsey T, Marmar C: Fluvoxamine and sleep disturbances in posttraumatic stress disorder. J Trauma Stress. 2001, 14: 461-467.PubMed
983.
Zurück zum Zitat De Boer M, Op den Velde W, Falger P, Hovens J, De Groen J, Van Duijn H: Fluvoxamine treatment for chronic PTSD: a pilot study. Psychother Psychosom. 1992, 57: 158-163.PubMed De Boer M, Op den Velde W, Falger P, Hovens J, De Groen J, Van Duijn H: Fluvoxamine treatment for chronic PTSD: a pilot study. Psychother Psychosom. 1992, 57: 158-163.PubMed
984.
Zurück zum Zitat Spivak B, Strous RD, Shaked G, Shabash E, Kotler M, Weizman A: Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. J Clin Psychopharmacol. 2006, 26: 152-156.PubMed Spivak B, Strous RD, Shaked G, Shabash E, Kotler M, Weizman A: Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. J Clin Psychopharmacol. 2006, 26: 152-156.PubMed
985.
Zurück zum Zitat Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL: Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry. 2006, 67: 1522-1526.PubMed Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL: Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry. 2006, 67: 1522-1526.PubMed
986.
Zurück zum Zitat Seedat S, Stein D, Emsley R: Open trial of citalopram in adults with post-traumatic stress disorder. Int J Neuropsychopharmacol. 2000, 3: 135-140.PubMed Seedat S, Stein D, Emsley R: Open trial of citalopram in adults with post-traumatic stress disorder. Int J Neuropsychopharmacol. 2000, 3: 135-140.PubMed
987.
Zurück zum Zitat Seedat S, Stein D, Ziervogel C, Middleton T, Kaminer D, Emsley R, Rossouw W: Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder. J Child Adolesc Psychopharmacol. 2002, 12: 37-46.PubMed Seedat S, Stein D, Ziervogel C, Middleton T, Kaminer D, Emsley R, Rossouw W: Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder. J Child Adolesc Psychopharmacol. 2002, 12: 37-46.PubMed
988.
Zurück zum Zitat English BA, Jewell M, Jewell G, Ambrose S, Davis LL: Treatment of chronic posttraumatic stress disorder in combat veterans with citalopram: an open trial. J Clin Psychopharmacol. 2006, 26: 84-88.PubMed English BA, Jewell M, Jewell G, Ambrose S, Davis LL: Treatment of chronic posttraumatic stress disorder in combat veterans with citalopram: an open trial. J Clin Psychopharmacol. 2006, 26: 84-88.PubMed
989.
Zurück zum Zitat Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Pedersen R, Musgnung J: Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry. 2006, 63: 1158-1165.PubMed Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Pedersen R, Musgnung J: Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry. 2006, 63: 1158-1165.PubMed
990.
Zurück zum Zitat Walderhaug E, Kasserman S, Aikins D, Vojvoda D, Nishimura C, Neumeister A: Effects of duloxetine in treatment-refractory men with posttraumatic stress disorder. Pharmacopsychiatry. 2010, 43: 45-49.PubMed Walderhaug E, Kasserman S, Aikins D, Vojvoda D, Nishimura C, Neumeister A: Effects of duloxetine in treatment-refractory men with posttraumatic stress disorder. Pharmacopsychiatry. 2010, 43: 45-49.PubMed
991.
Zurück zum Zitat Villarreal G, Canive JM, Calais LA, Toney G, Smith AK: Duloxetine in military posttraumatic stress disorder. Psychopharmacol Bull. 2010, 43: 26-34.PubMed Villarreal G, Canive JM, Calais LA, Toney G, Smith AK: Duloxetine in military posttraumatic stress disorder. Psychopharmacol Bull. 2010, 43: 26-34.PubMed
992.
Zurück zum Zitat Frank J, Kosten T, Giller E, Dan E: A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry. 1988, 145: 1289-1291.PubMed Frank J, Kosten T, Giller E, Dan E: A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry. 1988, 145: 1289-1291.PubMed
993.
Zurück zum Zitat Kosten T, Frank J, Dan E, McDougle C, Giller E: Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis. 1991, 179: 366-370.PubMed Kosten T, Frank J, Dan E, McDougle C, Giller E: Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis. 1991, 179: 366-370.PubMed
994.
Zurück zum Zitat Davidson J, Kudler H, Smith R, Mahorney S, Lipper S, Hammett E, Saunders W, Cavenar J: Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry. 1990, 47: 259-266.PubMed Davidson J, Kudler H, Smith R, Mahorney S, Lipper S, Hammett E, Saunders W, Cavenar J: Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry. 1990, 47: 259-266.PubMed
995.
Zurück zum Zitat Reist C, Kauffmann C, Haier R, Sangdahl C, De ME, Chicz-De MA, Nelson J: A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry. 1989, 146: 513-516.PubMed Reist C, Kauffmann C, Haier R, Sangdahl C, De ME, Chicz-De MA, Nelson J: A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry. 1989, 146: 513-516.PubMed
996.
Zurück zum Zitat Shestatzky M, Greenberg D, Lerer B: A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res. 1988, 24: 149-155.PubMed Shestatzky M, Greenberg D, Lerer B: A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res. 1988, 24: 149-155.PubMed
997.
Zurück zum Zitat Onder E, Tural U, Aker T: A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake. Eur Psychiatry. 2006, 21: 174-179.PubMed Onder E, Tural U, Aker T: A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake. Eur Psychiatry. 2006, 21: 174-179.PubMed
998.
Zurück zum Zitat Neal L, Shapland W, Fox C: An open trial of moclobemide in the treatment of post-traumatic stress disorder. Int Clin Psychopharmacol. 1997, 12: 231-237.PubMed Neal L, Shapland W, Fox C: An open trial of moclobemide in the treatment of post-traumatic stress disorder. Int Clin Psychopharmacol. 1997, 12: 231-237.PubMed
999.
Zurück zum Zitat Connor K, Davidson J, Weisler R, Ahearn E: A pilot study of mirtazapine in post-traumatic stress disorder. Int Clin Psychopharmacol. 1999, 14: 29-31.PubMed Connor K, Davidson J, Weisler R, Ahearn E: A pilot study of mirtazapine in post-traumatic stress disorder. Int Clin Psychopharmacol. 1999, 14: 29-31.PubMed
1000.
Zurück zum Zitat Davidson JR, Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S, van Meter S: Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry. 2003, 53: 188-191.PubMed Davidson JR, Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S, van Meter S: Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry. 2003, 53: 188-191.PubMed
1001.
Zurück zum Zitat Chung M, Min K, Jun Y, Kim S, Kim W, Jun E: Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol. 2004, 19: 489-494.PubMed Chung M, Min K, Jun Y, Kim S, Kim W, Jun E: Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol. 2004, 19: 489-494.PubMed
1002.
Zurück zum Zitat Alderman CP, Condon JT, Gilbert AL: An open-label study of mirtazapine as treatment for combat-related PTSD. Ann Pharmacother. 2009, 43: 1220-1226.PubMed Alderman CP, Condon JT, Gilbert AL: An open-label study of mirtazapine as treatment for combat-related PTSD. Ann Pharmacother. 2009, 43: 1220-1226.PubMed
1003.
Zurück zum Zitat Canive J, Clark R, Calais L, Qualls C, Tuason V: Bupropion treatment in veterans with posttraumatic stress disorder: an open study. J Clin Psychopharmacol. 1998, 18: 379-383.PubMed Canive J, Clark R, Calais L, Qualls C, Tuason V: Bupropion treatment in veterans with posttraumatic stress disorder: an open study. J Clin Psychopharmacol. 1998, 18: 379-383.PubMed
1004.
Zurück zum Zitat Franciskovic T, Sukovic Z, Janovic S, Stevanovic A, Nemcic-Moro I, Roncevic-Grzeta I, Letica-Crepulja M: Tianeptine in the combined treatment of combat related posttraumatic stress disorder. Psychiatr Danub. 2011, 23: 257-263.PubMed Franciskovic T, Sukovic Z, Janovic S, Stevanovic A, Nemcic-Moro I, Roncevic-Grzeta I, Letica-Crepulja M: Tianeptine in the combined treatment of combat related posttraumatic stress disorder. Psychiatr Danub. 2011, 23: 257-263.PubMed
1005.
Zurück zum Zitat Becker ME, Hertzberg MA, Moore SD, Dennis MF, Bukenya DS, Beckham JC: A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol. 2007, 27: 193-197.PubMed Becker ME, Hertzberg MA, Moore SD, Dennis MF, Bukenya DS, Beckham JC: A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol. 2007, 27: 193-197.PubMed
1006.
Zurück zum Zitat Braun P, Greenberg D, Dasberg H, Lerer B: Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry. 1990, 51: 236-238.PubMed Braun P, Greenberg D, Dasberg H, Lerer B: Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry. 1990, 51: 236-238.PubMed
1007.
Zurück zum Zitat Cates M, Bishop M, Davis L, Lowe J, Woolley T: Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder. Ann Pharmacother. 2004, 38: 1395-1399.PubMed Cates M, Bishop M, Davis L, Lowe J, Woolley T: Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder. Ann Pharmacother. 2004, 38: 1395-1399.PubMed
1008.
Zurück zum Zitat Shalev A, Rogel-Fuchs Y: Auditory startle reflex in post-traumatic stress disorder patients treated with clonazepam. Isr J Psychiatry Relat Sci. 1992, 29: 1-6.PubMed Shalev A, Rogel-Fuchs Y: Auditory startle reflex in post-traumatic stress disorder patients treated with clonazepam. Isr J Psychiatry Relat Sci. 1992, 29: 1-6.PubMed
1009.
Zurück zum Zitat Tucker P, Trautman RP, Wyatt DB, Thompson J, Wu SC, Capece JA, Rosenthal NR: Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007, 68: 201-206.PubMed Tucker P, Trautman RP, Wyatt DB, Thompson J, Wu SC, Capece JA, Rosenthal NR: Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007, 68: 201-206.PubMed
1010.
Zurück zum Zitat Yeh MS, Mari JJ, Costa MC, Andreoli SB, Bressan RA, Mello MF: A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neurosci Ther. 2011, 17: 305-310.PubMed Yeh MS, Mari JJ, Costa MC, Andreoli SB, Bressan RA, Mello MF: A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neurosci Ther. 2011, 17: 305-310.PubMed
1011.
Zurück zum Zitat Hertzberg M, Butterfield M, Feldman M, Beckham J, Sutherland S, Connor K, Davidson J: A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999, 45: 1226-1229.PubMed Hertzberg M, Butterfield M, Feldman M, Beckham J, Sutherland S, Connor K, Davidson J: A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999, 45: 1226-1229.PubMed
1012.
Zurück zum Zitat Lipper S, Davidson J, Grady T, Edinger J, Hammett E, Mahorney S, Cavenar J: Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics. 1986, 27: 849-854.PubMed Lipper S, Davidson J, Grady T, Edinger J, Hammett E, Mahorney S, Cavenar J: Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics. 1986, 27: 849-854.PubMed
1013.
Zurück zum Zitat Wolf M, Alavi A, Mosnaim A: Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry. 1988, 23: 642-644.PubMed Wolf M, Alavi A, Mosnaim A: Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry. 1988, 23: 642-644.PubMed
1014.
Zurück zum Zitat Fesler F: Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1991, 52: 361-364.PubMed Fesler F: Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1991, 52: 361-364.PubMed
1015.
Zurück zum Zitat Clark R, Canive J, Calais L, Qualls C, Tuason V: Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress. 1999, 12: 395-401.PubMed Clark R, Canive J, Calais L, Qualls C, Tuason V: Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress. 1999, 12: 395-401.PubMed
1016.
Zurück zum Zitat Davis LL, Davidson JR, Ward LC, Bartolucci A, Bowden CL, Petty F: Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol. 2008, 28: 84-88.PubMed Davis LL, Davidson JR, Ward LC, Bartolucci A, Bowden CL, Petty F: Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol. 2008, 28: 84-88.PubMed
1017.
Zurück zum Zitat Hamner MB, Faldowski RA, Robert S, Ulmer HG, Horner MD, Lorberbaum JP: A preliminary controlled trial of divalproex in posttraumatic stress disorder. Ann Clin Psychiatry. 2009, 21: 89-94.PubMed Hamner MB, Faldowski RA, Robert S, Ulmer HG, Horner MD, Lorberbaum JP: A preliminary controlled trial of divalproex in posttraumatic stress disorder. Ann Clin Psychiatry. 2009, 21: 89-94.PubMed
1018.
Zurück zum Zitat Davidson JR, Brady K, Mellman TA, Stein MB, Pollack MH: The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. 2007, 27: 85-88.PubMed Davidson JR, Brady K, Mellman TA, Stein MB, Pollack MH: The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. 2007, 27: 85-88.PubMed
1019.
Zurück zum Zitat Hamner M, Brodrick P, Labbate L: Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001, 13: 141-146.PubMed Hamner M, Brodrick P, Labbate L: Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001, 13: 141-146.PubMed
1020.
Zurück zum Zitat Malek-Ahmadi P: Gabapentin and posttraumatic stress disorder. Ann Pharmacother. 2003, 37: 664-666.PubMed Malek-Ahmadi P: Gabapentin and posttraumatic stress disorder. Ann Pharmacother. 2003, 37: 664-666.PubMed
1021.
Zurück zum Zitat Kinrys G, Wygant LE, Pardo TB, Melo M: Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry. 2006, 67: 211-214.PubMed Kinrys G, Wygant LE, Pardo TB, Melo M: Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry. 2006, 67: 211-214.PubMed
1022.
Zurück zum Zitat Pae CU, Marks DM, Han C, Masand PS, Patkar AA: Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. Int Clin Psychopharmacol. 2009, 24: 29-33.PubMed Pae CU, Marks DM, Han C, Masand PS, Patkar AA: Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. Int Clin Psychopharmacol. 2009, 24: 29-33.PubMed
1023.
Zurück zum Zitat Schwartz T: The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol Bull. 2002, 36: 53-57.PubMed Schwartz T: The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol Bull. 2002, 36: 53-57.PubMed
1024.
Zurück zum Zitat Taylor F: Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry. 2003, 64: 1421-1425.PubMed Taylor F: Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry. 2003, 64: 1421-1425.PubMed
1025.
Zurück zum Zitat Berigan T: Treatment of posttraumatic stress disorder with tiagabine. Can J Psychiatry. 2002, 47: 788-PubMed Berigan T: Treatment of posttraumatic stress disorder with tiagabine. Can J Psychiatry. 2002, 47: 788-PubMed
1026.
Zurück zum Zitat Berlant J: Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry. 2004, 4: 24-PubMedCentralPubMed Berlant J: Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry. 2004, 4: 24-PubMedCentralPubMed
1027.
Zurück zum Zitat Berlant J, van Kammen D: Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002, 63: 15-20.PubMed Berlant J, van Kammen D: Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002, 63: 15-20.PubMed
1028.
Zurück zum Zitat Lindley SE, Carlson EB, Hill K: A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol. 2007, 27: 677-681.PubMed Lindley SE, Carlson EB, Hill K: A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol. 2007, 27: 677-681.PubMed
1029.
Zurück zum Zitat Alderman CP, McCarthy LC, Condon JT, Marwood AC, Fuller JR: Topiramate in combat-related posttraumatic stress disorder. Ann Pharmacother. 2009, 43: 635-641.PubMed Alderman CP, McCarthy LC, Condon JT, Marwood AC, Fuller JR: Topiramate in combat-related posttraumatic stress disorder. Ann Pharmacother. 2009, 43: 635-641.PubMed
1030.
Zurück zum Zitat Padala PR, Madison J, Monnahan M, Marcil W, Price P, Ramaswamy S, Din AU, Wilson DR, Petty F: Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol. 2006, 21: 275-280.PubMed Padala PR, Madison J, Monnahan M, Marcil W, Price P, Ramaswamy S, Din AU, Wilson DR, Petty F: Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol. 2006, 21: 275-280.PubMed
1031.
Zurück zum Zitat Villarreal G, Calais LA, Canive JM, Lundy SL, Pickard J, Toney G: Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial. Psychopharmacol Bull. 2007, 40: 6-18.PubMed Villarreal G, Calais LA, Canive JM, Lundy SL, Pickard J, Toney G: Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial. Psychopharmacol Bull. 2007, 40: 6-18.PubMed
1032.
Zurück zum Zitat Mello MF, Costa MC, Schoedl AF, Fiks JP: Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial. Rev Bras Psiquiatr. 2008, 30: 358-361.PubMed Mello MF, Costa MC, Schoedl AF, Fiks JP: Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial. Rev Bras Psiquiatr. 2008, 30: 358-361.PubMed
1033.
Zurück zum Zitat Lambert MT: Aripiprazole in the management of post-traumatic stress disorder symptoms in returning global war on terrorism veterans. Int Clin Psychopharmacol. 2006, 21: 185-187.PubMed Lambert MT: Aripiprazole in the management of post-traumatic stress disorder symptoms in returning global war on terrorism veterans. Int Clin Psychopharmacol. 2006, 21: 185-187.PubMed
1034.
Zurück zum Zitat Kozaric-Kovacic D, Pivac N: Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int J Neuropsychopharmacol. 2007, 10: 253-261.PubMed Kozaric-Kovacic D, Pivac N: Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int J Neuropsychopharmacol. 2007, 10: 253-261.PubMed
1035.
Zurück zum Zitat Byers MG, Allison KM, Wendel CS, Lee JK: Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol. 2010, 30: 225-229.PubMed Byers MG, Allison KM, Wendel CS, Lee JK: Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol. 2010, 30: 225-229.PubMed
1036.
Zurück zum Zitat Butterfield MI, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JR: Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol. 2001, 16: 197-203.PubMed Butterfield MI, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JR: Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol. 2001, 16: 197-203.PubMed
1037.
Zurück zum Zitat Pivac N, Kozaric-Kovacic D, Muck-Seler D: Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology (Berl). 2004, 175: 451-456. Pivac N, Kozaric-Kovacic D, Muck-Seler D: Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology (Berl). 2004, 175: 451-456.
1038.
Zurück zum Zitat Petty F, Brannan S, Casada J, Davis L, Gajewski V, Kramer G, Stone R, Teten A, Worchel J, Young K: Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol. 2001, 16: 331-337.PubMed Petty F, Brannan S, Casada J, Davis L, Gajewski V, Kramer G, Stone R, Teten A, Worchel J, Young K: Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol. 2001, 16: 331-337.PubMed
1039.
Zurück zum Zitat Hamner M, Faldowski R, Ulmer H, Frueh B, Huber M, Arana G: Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol. 2003, 18: 1-8.PubMed Hamner M, Faldowski R, Ulmer H, Frueh B, Huber M, Arana G: Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol. 2003, 18: 1-8.PubMed
1040.
Zurück zum Zitat Monnelly E, Ciraulo D, Knapp C, Keane T: Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol. 2003, 23: 193-196.PubMed Monnelly E, Ciraulo D, Knapp C, Keane T: Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol. 2003, 23: 193-196.PubMed
1041.
Zurück zum Zitat Bartzokis G, Lu P, Turner J, Mintz J, Saunders C: Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry. 2005, 57: 474-479.PubMed Bartzokis G, Lu P, Turner J, Mintz J, Saunders C: Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry. 2005, 57: 474-479.PubMed
1042.
Zurück zum Zitat Reich D, Winternitz S, Hennen J, Watts T, Stanculescu C: A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry. 2004, 65: 1601-1606.PubMed Reich D, Winternitz S, Hennen J, Watts T, Stanculescu C: A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry. 2004, 65: 1601-1606.PubMed
1043.
Zurück zum Zitat Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Jones KM, Vertrees JE, Horney RA, Huang GD, Stock C: Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA. 2011, 306: 493-502.PubMed Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Jones KM, Vertrees JE, Horney RA, Huang GD, Stock C: Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA. 2011, 306: 493-502.PubMed
1044.
Zurück zum Zitat Rothbaum BO, Killeen TK, Davidson JR, Brady KT, Connor KM, Heekin MH: Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry. 2008, 69: 520-525.PubMed Rothbaum BO, Killeen TK, Davidson JR, Brady KT, Connor KM, Heekin MH: Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry. 2008, 69: 520-525.PubMed
1045.
Zurück zum Zitat Stein M, Kline N, Matloff J: Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. Am J Psychiatry. 2002, 159: 1777-1779.PubMed Stein M, Kline N, Matloff J: Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. Am J Psychiatry. 2002, 159: 1777-1779.PubMed
1046.
Zurück zum Zitat Robert S, Hamner MB, Durkalski VL, Brown MW, Ulmer HG: An open-label assessment of aripiprazole in the treatment of PTSD. Psychopharmacol Bull. 2009, 42: 69-80.PubMed Robert S, Hamner MB, Durkalski VL, Brown MW, Ulmer HG: An open-label assessment of aripiprazole in the treatment of PTSD. Psychopharmacol Bull. 2009, 42: 69-80.PubMed
1047.
Zurück zum Zitat Richardson JD, Fikretoglu D, Liu A, McIntosh D: Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review. BMC Psychiatry. 2011, 11: 86-PubMedCentralPubMed Richardson JD, Fikretoglu D, Liu A, McIntosh D: Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review. BMC Psychiatry. 2011, 11: 86-PubMedCentralPubMed
1048.
Zurück zum Zitat Sokolski K, Denson T, Lee R, Reist C: Quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder. Mil Med. 2003, 168: 486-489.PubMed Sokolski K, Denson T, Lee R, Reist C: Quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder. Mil Med. 2003, 168: 486-489.PubMed
1049.
Zurück zum Zitat Hamner M, Deitsch S, Brodrick P, Ulmer H, Lorberbaum J: Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol. 2003, 23: 15-20.PubMed Hamner M, Deitsch S, Brodrick P, Ulmer H, Lorberbaum J: Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol. 2003, 23: 15-20.PubMed
1050.
Zurück zum Zitat Ahearn EP, Mussey M, Johnson C, Krohn A, Krahn D: Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. Int Clin Psychopharmacol. 2006, 21: 29-33.PubMed Ahearn EP, Mussey M, Johnson C, Krohn A, Krahn D: Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. Int Clin Psychopharmacol. 2006, 21: 29-33.PubMed
1051.
Zurück zum Zitat Duffy J, Malloy P: Efficacy of buspirone in the treatment of posttraumatic stress disorder: an open trial. Ann Clin Psychiatry. 1994, 6: 33-37.PubMed Duffy J, Malloy P: Efficacy of buspirone in the treatment of posttraumatic stress disorder: an open trial. Ann Clin Psychiatry. 1994, 6: 33-37.PubMed
1052.
Zurück zum Zitat Wells B, Chu C, Johnson R, Nasdahl C, Ayubi M, Sewell E, Statham P: Buspirone in the treatment of posttraumatic stress disorder. Pharmacotherapy. 1991, 11: 340-343.PubMed Wells B, Chu C, Johnson R, Nasdahl C, Ayubi M, Sewell E, Statham P: Buspirone in the treatment of posttraumatic stress disorder. Pharmacotherapy. 1991, 11: 340-343.PubMed
1053.
Zurück zum Zitat Hertzberg M, Feldman M, Beckham J, Davidson J: Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol. 1996, 16: 294-298.PubMed Hertzberg M, Feldman M, Beckham J, Davidson J: Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol. 1996, 16: 294-298.PubMed
1054.
Zurück zum Zitat Battista MA, Hierholzer R, Khouzam HR, Barlow A, O'Toole S: Pilot trial of memantine in the treatment of posttraumatic stress disorder. Psychiatry. 2007, 70: 167-174.PubMed Battista MA, Hierholzer R, Khouzam HR, Barlow A, O'Toole S: Pilot trial of memantine in the treatment of posttraumatic stress disorder. Psychiatry. 2007, 70: 167-174.PubMed
1055.
Zurück zum Zitat Pollack MH, Hoge EA, Worthington JJ, Moshier SJ, Wechsler RS, Brandes M, Simon NM: Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011, 72: 892-897.PubMed Pollack MH, Hoge EA, Worthington JJ, Moshier SJ, Wechsler RS, Brandes M, Simon NM: Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011, 72: 892-897.PubMed
1056.
Zurück zum Zitat Kinzie J, Leung P: Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis. 1989, 177: 546-550.PubMed Kinzie J, Leung P: Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis. 1989, 177: 546-550.PubMed
1057.
Zurück zum Zitat Neylan TC, Lenoci M, Samuelson KW, Metzler TJ, Henn-Haase C, Hierholzer RW, Lindley SE, Otte C, Schoenfeld FB, Yesavage JA, Marmar CR: No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry. 2006, 163: 2186-2188.PubMed Neylan TC, Lenoci M, Samuelson KW, Metzler TJ, Henn-Haase C, Hierholzer RW, Lindley SE, Otte C, Schoenfeld FB, Yesavage JA, Marmar CR: No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry. 2006, 163: 2186-2188.PubMed
1058.
Zurück zum Zitat Davis LL, Ward C, Rasmusson A, Newell JM, Frazier E, Southwick SM: A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull. 2008, 41: 8-18.PubMed Davis LL, Ward C, Rasmusson A, Newell JM, Frazier E, Southwick SM: A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull. 2008, 41: 8-18.PubMed
1059.
Zurück zum Zitat Abramowitz EG, Barak Y, Ben-Avi I, Knobler HY: Hypnotherapy in the treatment of chronic combat-related PTSD patients suffering from insomnia: a randomized, zolpidem-controlled clinical trial. Int J Clin Exp Hypn. 2008, 56: 270-280.PubMed Abramowitz EG, Barak Y, Ben-Avi I, Knobler HY: Hypnotherapy in the treatment of chronic combat-related PTSD patients suffering from insomnia: a randomized, zolpidem-controlled clinical trial. Int J Clin Exp Hypn. 2008, 56: 270-280.PubMed
1060.
Zurück zum Zitat Stein D, Seedat S, van dLG, Zungu-Dirwayi N: Selective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2000, 15 (Suppl 2): S31-39.PubMed Stein D, Seedat S, van dLG, Zungu-Dirwayi N: Selective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2000, 15 (Suppl 2): S31-39.PubMed
1061.
Zurück zum Zitat Pae CU, Lim HK, Peindl K, Ajwani N, Serretti A, Patkar AA, Lee C: The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol. 2008, 23: 1-8.PubMed Pae CU, Lim HK, Peindl K, Ajwani N, Serretti A, Patkar AA, Lee C: The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol. 2008, 23: 1-8.PubMed
1062.
Zurück zum Zitat Raskind M, Peskind E, Kanter E, Petrie E, Radant A, Thompson C, Dobie D, Hoff D, Rein R, Straits-Troster K, et al: Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003, 160: 371-373.PubMed Raskind M, Peskind E, Kanter E, Petrie E, Radant A, Thompson C, Dobie D, Hoff D, Rein R, Straits-Troster K, et al: Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003, 160: 371-373.PubMed
1063.
Zurück zum Zitat Peskind E, Bonner L, Hoff D, Raskind M: Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. J Geriatr Psychiatry Neurol. 2003, 16: 165-171.PubMed Peskind E, Bonner L, Hoff D, Raskind M: Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. J Geriatr Psychiatry Neurol. 2003, 16: 165-171.PubMed
1064.
Zurück zum Zitat Taylor F, Raskind M: The alpha1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder. J Clin Psychopharmacol. 2002, 22: 82-85.PubMed Taylor F, Raskind M: The alpha1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder. J Clin Psychopharmacol. 2002, 22: 82-85.PubMed
1065.
Zurück zum Zitat Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofer J, O'Connell J, Taylor F, Gross C, et al: A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007, 61: 928-934.PubMed Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofer J, O'Connell J, Taylor F, Gross C, et al: A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007, 61: 928-934.PubMed
1066.
Zurück zum Zitat Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA: Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry. 2008, 63: 629-632.PubMedCentralPubMed Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA: Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry. 2008, 63: 629-632.PubMedCentralPubMed
1067.
Zurück zum Zitat Lubin G, Weizman A, Shmushkevitz M, Valevski A: Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Hum Psychopharmacol. 2002, 17: 181-185.PubMed Lubin G, Weizman A, Shmushkevitz M, Valevski A: Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Hum Psychopharmacol. 2002, 17: 181-185.PubMed
1068.
Zurück zum Zitat Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, Limberger MF, Bohme R, Schmahl CG: Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry. 1999, 60: 598-603.PubMed Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, Limberger MF, Bohme R, Schmahl CG: Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry. 1999, 60: 598-603.PubMed
1069.
Zurück zum Zitat Glover H: A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr J Psychiatry Relat Sci. 1993, 30: 255-263.PubMed Glover H: A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr J Psychiatry Relat Sci. 1993, 30: 255-263.PubMed
1070.
Zurück zum Zitat Bills LJ, Kreisler K: Treatment of flashbacks with naltrexone. Am J Psychiatry. 1993, 150: 1430-PubMed Bills LJ, Kreisler K: Treatment of flashbacks with naltrexone. Am J Psychiatry. 1993, 150: 1430-PubMed
1071.
Zurück zum Zitat Jacobs-Rebhun S, Schnurr PP, Friedman MJ, Peck R, Brophy M, Fuller D: Posttraumatic stress disorder and sleep difficulty [Letter]. Am J Psychiatry. 2000, 157: 1525-1526.PubMed Jacobs-Rebhun S, Schnurr PP, Friedman MJ, Peck R, Brophy M, Fuller D: Posttraumatic stress disorder and sleep difficulty [Letter]. Am J Psychiatry. 2000, 157: 1525-1526.PubMed
1072.
Zurück zum Zitat Davidson J, Connor K, Hertzberg M, Weisler R, Wilson W, Payne V: Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. J Clin Psychopharmacol. 2005, 25: 166-169.PubMed Davidson J, Connor K, Hertzberg M, Weisler R, Wilson W, Payne V: Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. J Clin Psychopharmacol. 2005, 25: 166-169.PubMed
1073.
Zurück zum Zitat Martenyi F, Brown E, Zhang H, Koke S, Prakash A: Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry. 2002, 181: 315-320.PubMed Martenyi F, Brown E, Zhang H, Koke S, Prakash A: Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry. 2002, 181: 315-320.PubMed
1074.
Zurück zum Zitat Davidson J, Pearlstein T, Londborg P, Brady K, Rothbaum B, Bell J, Maddock R, Hegel M, Farfel G: Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry. 2001, 158: 1974-1981.PubMed Davidson J, Pearlstein T, Londborg P, Brady K, Rothbaum B, Bell J, Maddock R, Hegel M, Farfel G: Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry. 2001, 158: 1974-1981.PubMed
1075.
Zurück zum Zitat Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K: Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology. 2006, 184: 21-25.PubMed Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K: Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology. 2006, 184: 21-25.PubMed
1076.
Zurück zum Zitat Kim Y, Asukai N, Konishi T, Kato H, Hirotsune H, Maeda M, Inoue H, Narita H, Iwasaki M: Clinical evaluation of paroxetine in post-traumatic stress disorder (PTSD): 52-week, non-comparative open-label study for clinical use experience. Psychiatry Clin Neurosci. 2008, 62: 646-652.PubMed Kim Y, Asukai N, Konishi T, Kato H, Hirotsune H, Maeda M, Inoue H, Narita H, Iwasaki M: Clinical evaluation of paroxetine in post-traumatic stress disorder (PTSD): 52-week, non-comparative open-label study for clinical use experience. Psychiatry Clin Neurosci. 2008, 62: 646-652.PubMed
1077.
Zurück zum Zitat Londborg P, Hegel M, Goldstein S, Goldstein D, Himmelhoch J, Maddock R, Patterson W, Rausch J, Farfel G: Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry. 2001, 62: 325-331.PubMed Londborg P, Hegel M, Goldstein S, Goldstein D, Himmelhoch J, Maddock R, Patterson W, Rausch J, Farfel G: Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry. 2001, 62: 325-331.PubMed
1078.
Zurück zum Zitat Boggio PS, Rocha M, Oliveira MO, Fecteau S, Cohen RB, Campanha C, Ferreira-Santos E, Meleiro A, Corchs F, Zaghi S, et al: Noninvasive brain stimulation with high-frequency and low-intensity repetitive transcranial magnetic stimulation treatment for posttraumatic stress disorder. J Clin Psychiatry. 2010, 71: 992-999.PubMedCentralPubMed Boggio PS, Rocha M, Oliveira MO, Fecteau S, Cohen RB, Campanha C, Ferreira-Santos E, Meleiro A, Corchs F, Zaghi S, et al: Noninvasive brain stimulation with high-frequency and low-intensity repetitive transcranial magnetic stimulation treatment for posttraumatic stress disorder. J Clin Psychiatry. 2010, 71: 992-999.PubMedCentralPubMed
1079.
Zurück zum Zitat Watts BV, Landon B, Groft A, Young-Xu Y: A sham controlled study of repetitive transcranial magnetic stimulation for posttraumatic stress disorder. Brain Stimul. 2012, 5: 38-43.PubMed Watts BV, Landon B, Groft A, Young-Xu Y: A sham controlled study of repetitive transcranial magnetic stimulation for posttraumatic stress disorder. Brain Stimul. 2012, 5: 38-43.PubMed
1080.
Zurück zum Zitat Osuch EA, Benson BE, Luckenbaugh DA, Geraci M, Post RM, McCann U: Repetitive TMS combined with exposure therapy for PTSD: a preliminary study. J Anxiety Disord. 2009, 23: 54-59.PubMedCentralPubMed Osuch EA, Benson BE, Luckenbaugh DA, Geraci M, Post RM, McCann U: Repetitive TMS combined with exposure therapy for PTSD: a preliminary study. J Anxiety Disord. 2009, 23: 54-59.PubMedCentralPubMed
1081.
Zurück zum Zitat Margoob MA, Ali Z, Andrade C: Efficacy of ECT in chronic, severe, antidepressant- and CBT-refractory PTSD: an open, prospective study. Brain Stimul. 2010, 3: 28-35.PubMed Margoob MA, Ali Z, Andrade C: Efficacy of ECT in chronic, severe, antidepressant- and CBT-refractory PTSD: an open, prospective study. Brain Stimul. 2010, 3: 28-35.PubMed
1082.
Zurück zum Zitat Watts BV: Electroconvulsive therapy for comorbid major depressive disorder and posttraumatic stress disorder. J ECT. 2007, 23: 93-95.PubMed Watts BV: Electroconvulsive therapy for comorbid major depressive disorder and posttraumatic stress disorder. J ECT. 2007, 23: 93-95.PubMed
1083.
Zurück zum Zitat Hollifield M, Sinclair-Lian N, Warner TD, Hammerschlag R: Acupuncture for posttraumatic stress disorder: a randomized controlled pilot trial. J Nerv Ment Dis. 2007, 195: 504-513.PubMed Hollifield M, Sinclair-Lian N, Warner TD, Hammerschlag R: Acupuncture for posttraumatic stress disorder: a randomized controlled pilot trial. J Nerv Ment Dis. 2007, 195: 504-513.PubMed
1084.
Zurück zum Zitat Bormann JE, Thorp S, Wetherell JL, Golshan S: A spiritually based group intervention for combat veterans with posttraumatic stress disorder: feasibility study. J Holist Nurs. 2008, 26: 109-116.PubMedCentralPubMed Bormann JE, Thorp S, Wetherell JL, Golshan S: A spiritually based group intervention for combat veterans with posttraumatic stress disorder: feasibility study. J Holist Nurs. 2008, 26: 109-116.PubMedCentralPubMed
1085.
Zurück zum Zitat Rosenthal JZ, Grosswald S, Ross R, Rosenthal N: Effects of transcendental meditation in veterans of Operation Enduring Freedom and Operation Iraqi Freedom with posttraumatic stress disorder: a pilot study. Mil Med. 2011, 176: 626-630.PubMed Rosenthal JZ, Grosswald S, Ross R, Rosenthal N: Effects of transcendental meditation in veterans of Operation Enduring Freedom and Operation Iraqi Freedom with posttraumatic stress disorder: a pilot study. Mil Med. 2011, 176: 626-630.PubMed
1086.
Zurück zum Zitat Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS: Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008, 65: 805-815.PubMedCentralPubMed Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS: Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008, 65: 805-815.PubMedCentralPubMed
1087.
Zurück zum Zitat Sutter-Dallay AL, Giaconne-Marcesche V, Glatigny-Dallay E, Verdoux H: Women with anxiety disorders during pregnancy are at increased risk of intense postnatal depressive symptoms: a prospective survey of the MATQUID cohort. Eur Psychiatry. 2004, 19: 459-463.PubMed Sutter-Dallay AL, Giaconne-Marcesche V, Glatigny-Dallay E, Verdoux H: Women with anxiety disorders during pregnancy are at increased risk of intense postnatal depressive symptoms: a prospective survey of the MATQUID cohort. Eur Psychiatry. 2004, 19: 459-463.PubMed
1088.
Zurück zum Zitat Buist A, Gotman N, Yonkers KA: Generalized anxiety disorder: course and risk factors in pregnancy. J Affect Disord. 2011, 131: 277-283.PubMedCentralPubMed Buist A, Gotman N, Yonkers KA: Generalized anxiety disorder: course and risk factors in pregnancy. J Affect Disord. 2011, 131: 277-283.PubMedCentralPubMed
1089.
Zurück zum Zitat Ross LE, McLean LM: Anxiety disorders during pregnancy and the postpartum period: A systematic review. J Clin Psychiatry. 2006, 67: 1285-1298.PubMed Ross LE, McLean LM: Anxiety disorders during pregnancy and the postpartum period: A systematic review. J Clin Psychiatry. 2006, 67: 1285-1298.PubMed
1090.
Zurück zum Zitat Zambaldi CF, Cantilino A, Montenegro AC, Paes JA, de Albuquerque TL, Sougey EB: Postpartum obsessive-compulsive disorder: prevalence and clinical characteristics. Compr Psychiatry. 2009, 50: 503-509.PubMed Zambaldi CF, Cantilino A, Montenegro AC, Paes JA, de Albuquerque TL, Sougey EB: Postpartum obsessive-compulsive disorder: prevalence and clinical characteristics. Compr Psychiatry. 2009, 50: 503-509.PubMed
1091.
Zurück zum Zitat Alcorn KL, O'Donovan A, Patrick JC, Creedy D, Devilly GJ: A prospective longitudinal study of the prevalence of post-traumatic stress disorder resulting from childbirth events. Psychol Med. 2010, 40: 1849-1859.PubMed Alcorn KL, O'Donovan A, Patrick JC, Creedy D, Devilly GJ: A prospective longitudinal study of the prevalence of post-traumatic stress disorder resulting from childbirth events. Psychol Med. 2010, 40: 1849-1859.PubMed
1092.
Zurück zum Zitat Forray A, Mayes LC, Magriples U, Epperson CN: Prevalence of post-traumatic stress disorder in pregnant women with prior pregnancy complications. J Matern Fetal Neonatal Med. 2009, 22: 522-527.PubMedCentralPubMed Forray A, Mayes LC, Magriples U, Epperson CN: Prevalence of post-traumatic stress disorder in pregnant women with prior pregnancy complications. J Matern Fetal Neonatal Med. 2009, 22: 522-527.PubMedCentralPubMed
1093.
Zurück zum Zitat Banhidy F, Acs N, Puho E, Czeizel AE: Association between maternal panic disorders and pregnancy complications and delivery outcomes. Eur J Obstet Gynecol Reprod Biol. 2006, 124: 47-52.PubMed Banhidy F, Acs N, Puho E, Czeizel AE: Association between maternal panic disorders and pregnancy complications and delivery outcomes. Eur J Obstet Gynecol Reprod Biol. 2006, 124: 47-52.PubMed
1094.
Zurück zum Zitat Lilliecreutz C, Sydsjo G, Josefsson A: Obstetric and perinatal outcomes among women with blood- and injection phobia during pregnancy. J Affect Disord. 2011, 129: 289-295.PubMed Lilliecreutz C, Sydsjo G, Josefsson A: Obstetric and perinatal outcomes among women with blood- and injection phobia during pregnancy. J Affect Disord. 2011, 129: 289-295.PubMed
1095.
Zurück zum Zitat Chen YH, Lin HC, Lee HC: Pregnancy outcomes among women with panic disorder - do panic attacks during pregnancy matter?. J Affect Disord. 2010, 120: 258-262.PubMed Chen YH, Lin HC, Lee HC: Pregnancy outcomes among women with panic disorder - do panic attacks during pregnancy matter?. J Affect Disord. 2010, 120: 258-262.PubMed
1096.
Zurück zum Zitat Littleton HL, Breitkopf CR, Berenson AB: Correlates of anxiety symptoms during pregnancy and association with perinatal outcomes: a meta-analysis. Am J Obstet Gynecol. 2007, 196: 424-432.PubMed Littleton HL, Breitkopf CR, Berenson AB: Correlates of anxiety symptoms during pregnancy and association with perinatal outcomes: a meta-analysis. Am J Obstet Gynecol. 2007, 196: 424-432.PubMed
1097.
Zurück zum Zitat Rogal SS, Poschman K, Belanger K, Howell HB, Smith MV, Medina J, Yonkers KA: Effects of posttraumatic stress disorder on pregnancy outcomes. J Affect Disord. 2007, 102: 137-143.PubMedCentralPubMed Rogal SS, Poschman K, Belanger K, Howell HB, Smith MV, Medina J, Yonkers KA: Effects of posttraumatic stress disorder on pregnancy outcomes. J Affect Disord. 2007, 102: 137-143.PubMedCentralPubMed
1098.
Zurück zum Zitat Newport DJ, Ji S, Long Q, Knight BT, Zach EB, Smith EN, Morris NJ, Stowe ZN: Maternal depression and anxiety differentially impact fetal exposures during pregnancy. J Clin Psychiatry. 2012, 73: 247-251.PubMed Newport DJ, Ji S, Long Q, Knight BT, Zach EB, Smith EN, Morris NJ, Stowe ZN: Maternal depression and anxiety differentially impact fetal exposures during pregnancy. J Clin Psychiatry. 2012, 73: 247-251.PubMed
1099.
Zurück zum Zitat Lee AM, Lam SK, Sze Mun Lau SM, Chong CS, Chui HW, Fong DY: Prevalence, course, and risk factors for antenatal anxiety and depression. Obstet Gynecol. 2007, 110: 1102-1112.PubMed Lee AM, Lam SK, Sze Mun Lau SM, Chong CS, Chui HW, Fong DY: Prevalence, course, and risk factors for antenatal anxiety and depression. Obstet Gynecol. 2007, 110: 1102-1112.PubMed
1100.
Zurück zum Zitat Challacombe F, Salkovskis P: A preliminary investigation of the impact of maternal obsessive-compulsive disorder and panic disorder on parenting and children. J Anxiety Disord. 2009, 23: 848-857.PubMed Challacombe F, Salkovskis P: A preliminary investigation of the impact of maternal obsessive-compulsive disorder and panic disorder on parenting and children. J Anxiety Disord. 2009, 23: 848-857.PubMed
1101.
Zurück zum Zitat Zelkowitz P, Na S, Wang T, Bardin C, Papageorgiou A: Early maternal anxiety predicts cognitive and behavioural outcomes of VLBW children at 24 months corrected age. Acta Paediatr. 2011, 100: 700-704.PubMed Zelkowitz P, Na S, Wang T, Bardin C, Papageorgiou A: Early maternal anxiety predicts cognitive and behavioural outcomes of VLBW children at 24 months corrected age. Acta Paediatr. 2011, 100: 700-704.PubMed
1102.
Zurück zum Zitat O'Connor T, Heron J, Glover V: Antenatal anxiety predicts child behavioral/emotional problems independently of postnatal depression. J Am Acad Child Adolesc Psychiatry. 2002, 41: 1470-1477.PubMed O'Connor T, Heron J, Glover V: Antenatal anxiety predicts child behavioral/emotional problems independently of postnatal depression. J Am Acad Child Adolesc Psychiatry. 2002, 41: 1470-1477.PubMed
1103.
Zurück zum Zitat Martini J, Knappe S, Beesdo-Baum K, Lieb R, Wittchen HU: Anxiety disorders before birth and self-perceived distress during pregnancy: associations with maternal depression and obstetric, neonatal and early childhood outcomes. Early Hum Dev. 2010, 86: 305-310.PubMed Martini J, Knappe S, Beesdo-Baum K, Lieb R, Wittchen HU: Anxiety disorders before birth and self-perceived distress during pregnancy: associations with maternal depression and obstetric, neonatal and early childhood outcomes. Early Hum Dev. 2010, 86: 305-310.PubMed
1104.
Zurück zum Zitat Seekles W, Cuijpers P, Kok R, Beekman A, van Marwijk H, van Straten A: Psychological treatment of anxiety in primary care: a meta-analysis. Psychol Med. 2012, : 1-11. Seekles W, Cuijpers P, Kok R, Beekman A, van Marwijk H, van Straten A: Psychological treatment of anxiety in primary care: a meta-analysis. Psychol Med. 2012, : 1-11.
1105.
Zurück zum Zitat Lilliecreutz C, Josefsson A, Sydsjo G: An open trial with cognitive behavioral therapy for blood- and injection phobia in pregnant women-a group intervention program. Arch Womens Ment Health. 2010, 13: 259-265.PubMed Lilliecreutz C, Josefsson A, Sydsjo G: An open trial with cognitive behavioral therapy for blood- and injection phobia in pregnant women-a group intervention program. Arch Womens Ment Health. 2010, 13: 259-265.PubMed
1106.
Zurück zum Zitat Challacombe FL, Salkovskis PM: Intensive cognitive-behavioural treatment for women with postnatal obsessive-compulsive disorder: a consecutive case series. Behav Res Ther. 2011, 49: 422-426.PubMed Challacombe FL, Salkovskis PM: Intensive cognitive-behavioural treatment for women with postnatal obsessive-compulsive disorder: a consecutive case series. Behav Res Ther. 2011, 49: 422-426.PubMed
1107.
Zurück zum Zitat Arch JJ, Dimidjian S, Chessick C: Are exposure-based cognitive behavioral therapies safe during pregnancy?. Arch Womens Ment Health. 2012, 15: 445-457.PubMed Arch JJ, Dimidjian S, Chessick C: Are exposure-based cognitive behavioral therapies safe during pregnancy?. Arch Womens Ment Health. 2012, 15: 445-457.PubMed
1108.
Zurück zum Zitat ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008, 111: 1001-1020. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008, 111: 1001-1020.
1109.
Zurück zum Zitat Law R, Bozzo P, Koren G, Einarson A: FDA pregnancy risk categories and the CPS: do they help or are they a hindrance?. Can Fam Physician. 2010, 56: 239-241.PubMedCentralPubMed Law R, Bozzo P, Koren G, Einarson A: FDA pregnancy risk categories and the CPS: do they help or are they a hindrance?. Can Fam Physician. 2010, 56: 239-241.PubMedCentralPubMed
1110.
Zurück zum Zitat Einarson A, Choi J, Einarson TR, Koren G: Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry. 2009, 54: 242-246.PubMed Einarson A, Choi J, Einarson TR, Koren G: Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry. 2009, 54: 242-246.PubMed
1111.
Zurück zum Zitat Malm H, Artama M, Gissler M, Ritvanen A: Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011, 118: 111-120.PubMed Malm H, Artama M, Gissler M, Ritvanen A: Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011, 118: 111-120.PubMed
1112.
Zurück zum Zitat Bellantuono C, Migliarese G, Gentile S: Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Hum Psychopharmacol. 2007, 22: 121-128.PubMed Bellantuono C, Migliarese G, Gentile S: Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Hum Psychopharmacol. 2007, 22: 121-128.PubMed
1113.
Zurück zum Zitat Grigoriadis S, Vonderporten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE: Antidepressant exposure during pregnancy and congenital malformations: is there an association? a systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013, 74: e293-308.PubMed Grigoriadis S, Vonderporten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE: Antidepressant exposure during pregnancy and congenital malformations: is there an association? a systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013, 74: e293-308.PubMed
1114.
Zurück zum Zitat Reis M, Kallen B: Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010, 40: 1723-1733.PubMed Reis M, Kallen B: Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010, 40: 1723-1733.PubMed
1115.
Zurück zum Zitat Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Berard A, Koren G: Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther. 2007, 29: 918-926.PubMed Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Berard A, Koren G: Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther. 2007, 29: 918-926.PubMed
1116.
Zurück zum Zitat Wurst KE, Poole C, Ephross SA, Olshan AF: First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010, 88: 159-170.PubMed Wurst KE, Poole C, Ephross SA, Olshan AF: First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010, 88: 159-170.PubMed
1118.
Zurück zum Zitat Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A: Selected pregnancy and delivery outcomes after exposure to antidepressant medication: A systematic review and meta-analysis. JAMA Psychiatry. 2013, 70: 436-443.PubMed Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A: Selected pregnancy and delivery outcomes after exposure to antidepressant medication: A systematic review and meta-analysis. JAMA Psychiatry. 2013, 70: 436-443.PubMed
1119.
Zurück zum Zitat Hemels ME, Einarson A, Koren G, Lanctot KL, Einarson TR: Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother. 2005, 39: 803-809.PubMed Hemels ME, Einarson A, Koren G, Lanctot KL, Einarson TR: Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother. 2005, 39: 803-809.PubMed
1120.
Zurück zum Zitat Rahimi R, Nikfar S, Abdollahi M: Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol. 2006, 22: 571-575.PubMed Rahimi R, Nikfar S, Abdollahi M: Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol. 2006, 22: 571-575.PubMed
1121.
Zurück zum Zitat Grigoriadis S, Vonderporten EH, Mamisashvili L, Eady A, Tomlinson G, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE: The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry. 2013, 74: e309-320.PubMed Grigoriadis S, Vonderporten EH, Mamisashvili L, Eady A, Tomlinson G, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE: The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry. 2013, 74: e309-320.PubMed
1122.
Zurück zum Zitat Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL: Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005, 293: 2372-2383.PubMed Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL: Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005, 293: 2372-2383.PubMed
1123.
Zurück zum Zitat Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM: Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol. 2005, 25: 595-604.PubMed Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM: Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol. 2005, 25: 595-604.PubMed
1124.
Zurück zum Zitat Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006, 354: 579-587.PubMed Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006, 354: 579-587.PubMed
1125.
Zurück zum Zitat Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nielsen RB, Norgaard M, Stephansson O, Valdimarsdottir U, et al: Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2012, 344: d8012-PubMed Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nielsen RB, Norgaard M, Stephansson O, Valdimarsdottir U, et al: Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2012, 344: d8012-PubMed
1126.
Zurück zum Zitat Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, Boudreau DM, Smith DH, Davis RL, Willy ME, Platt R: Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2009, 18: 246-252.PubMed Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, Boudreau DM, Smith DH, Davis RL, Willy ME, Platt R: Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2009, 18: 246-252.PubMed
1127.
Zurück zum Zitat Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG: Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol. 2011, 28: 19-24.PubMed Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG: Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol. 2011, 28: 19-24.PubMed
1128.
Zurück zum Zitat Gentile S: Neurodevelopmental effects of prenatal exposure to psychotropic medications. Depress Anxiety. 2010, 27: 675-686.PubMed Gentile S: Neurodevelopmental effects of prenatal exposure to psychotropic medications. Depress Anxiety. 2010, 27: 675-686.PubMed
1129.
Zurück zum Zitat Gentile S, Galbally M: Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord. 2011, 128: 1-9.PubMed Gentile S, Galbally M: Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord. 2011, 128: 1-9.PubMed
1130.
Zurück zum Zitat Udechuku A, Nguyen T, Hill R, Szego K: Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry. 2010, 44: 978-996.PubMed Udechuku A, Nguyen T, Hill R, Szego K: Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry. 2010, 44: 978-996.PubMed
1131.
Zurück zum Zitat Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B: Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry. 2012, 169: 1165-1174.PubMed Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B: Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry. 2012, 169: 1165-1174.PubMed
1132.
Zurück zum Zitat Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V: Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011, 68: 1104-1112.PubMed Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V: Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011, 68: 1104-1112.PubMed
1133.
Zurück zum Zitat Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C: Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ. 2013, 346: f2059-PubMedCentralPubMed Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C: Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ. 2013, 346: f2059-PubMedCentralPubMed
1134.
Zurück zum Zitat Figueroa R: Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. J Dev Behav Pediatr. 2010, 31: 641-648.PubMed Figueroa R: Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. J Dev Behav Pediatr. 2010, 31: 641-648.PubMed
1135.
Zurück zum Zitat Froehlich TE, Anixt JS, Loe IM, Chirdkiatgumchai V, Kuan L, Gilman RC: Update on environmental risk factors for attention-deficit/hyperactivity disorder. Current psychiatry reports. 2011, 13: 333-344.PubMedCentralPubMed Froehlich TE, Anixt JS, Loe IM, Chirdkiatgumchai V, Kuan L, Gilman RC: Update on environmental risk factors for attention-deficit/hyperactivity disorder. Current psychiatry reports. 2011, 13: 333-344.PubMedCentralPubMed
1136.
1137.
Zurück zum Zitat Enato E, Moretti M, Koren G: The fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can. 2011, 33: 46-48.PubMed Enato E, Moretti M, Koren G: The fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can. 2011, 33: 46-48.PubMed
1138.
Zurück zum Zitat Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J: Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry. 1996, 153: 592-606.PubMed Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J: Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry. 1996, 153: 592-606.PubMed
1139.
Zurück zum Zitat Eros E, Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J: A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2002, 101: 147-154.PubMed Eros E, Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J: A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2002, 101: 147-154.PubMed
1140.
Zurück zum Zitat Kelly LE, Poon S, Madadi P, Koren G: Neonatal benzodiazepines exposure during breastfeeding. J Pediatr. 2012, 161: 448-451.PubMed Kelly LE, Poon S, Madadi P, Koren G: Neonatal benzodiazepines exposure during breastfeeding. J Pediatr. 2012, 161: 448-451.PubMed
1141.
Zurück zum Zitat Gentile S: Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010, 36: 518-544.PubMedCentralPubMed Gentile S: Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010, 36: 518-544.PubMedCentralPubMed
1142.
Zurück zum Zitat Einarson A, Boskovic R: Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009, 15: 183-192.PubMed Einarson A, Boskovic R: Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009, 15: 183-192.PubMed
1143.
Zurück zum Zitat Oyebode F, Rastogi A, Berrisford G, Coccia F: Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther. 2012, 135: 71-77.PubMed Oyebode F, Rastogi A, Berrisford G, Coccia F: Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther. 2012, 135: 71-77.PubMed
1144.
Zurück zum Zitat Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH: Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008, 192: 333-337.PubMed Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH: Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008, 192: 333-337.PubMed
1145.
Zurück zum Zitat Diav-Citrin O, Shechtman S, Ornoy S, Arnon J, Schaefer C, Garbis H, Clementi M, Ornoy A: Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry. 2005, 66: 317-322.PubMed Diav-Citrin O, Shechtman S, Ornoy S, Arnon J, Schaefer C, Garbis H, Clementi M, Ornoy A: Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry. 2005, 66: 317-322.PubMed
1146.
Zurück zum Zitat McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson A: Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005, 66: 444-449. quiz 546PubMed McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson A: Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005, 66: 444-449. quiz 546PubMed
1147.
Zurück zum Zitat Lin HC, Chen IJ, Chen YH, Lee HC, Wu FJ: Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference?. Schizophr Res. 2010, 116: 55-60.PubMed Lin HC, Chen IJ, Chen YH, Lee HC, Wu FJ: Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference?. Schizophr Res. 2010, 116: 55-60.PubMed
1148.
Zurück zum Zitat Hironaka M, Kotani T, Sumigama S, Tsuda H, Mano Y, Hayakawa H, Tanaka S, Ozaki N, Tamakoshi K, Kikkawa F: Maternal mental disorders and pregnancy outcomes: a clinical study in a Japanese population. J Obstet Gynaecol Res. 2011, 37: 1283-1289.PubMed Hironaka M, Kotani T, Sumigama S, Tsuda H, Mano Y, Hayakawa H, Tanaka S, Ozaki N, Tamakoshi K, Kikkawa F: Maternal mental disorders and pregnancy outcomes: a clinical study in a Japanese population. J Obstet Gynaecol Res. 2011, 37: 1283-1289.PubMed
1149.
Zurück zum Zitat Wichman CL: Atypical antipsychotic use in pregnancy: a retrospective review. Arch Womens Ment Health. 2009, 12: 53-57.PubMed Wichman CL: Atypical antipsychotic use in pregnancy: a retrospective review. Arch Womens Ment Health. 2009, 12: 53-57.PubMed
1150.
Zurück zum Zitat Galbally M, Snellen M, Lewis AJ: A review of the use of psychotropic medication in pregnancy. Curr Opin Obstet Gynecol. 2011, 23: 408-414.PubMed Galbally M, Snellen M, Lewis AJ: A review of the use of psychotropic medication in pregnancy. Curr Opin Obstet Gynecol. 2011, 23: 408-414.PubMed
1154.
Zurück zum Zitat Gentile S: Infant safety with antipsychotic therapy in breast-feeding: a systematic review. J Clin Psychiatry. 2008, 69: 666-673.PubMed Gentile S: Infant safety with antipsychotic therapy in breast-feeding: a systematic review. J Clin Psychiatry. 2008, 69: 666-673.PubMed
1155.
Zurück zum Zitat Kessler RC, Avenevoli S, Costello EJ, Georgiades K, Green JG, Gruber MJ, He JP, Koretz D, McLaughlin KA, Petukhova M, et al: Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. Arch Gen Psychiatry. 2012, 69: 372-380.PubMedCentralPubMed Kessler RC, Avenevoli S, Costello EJ, Georgiades K, Green JG, Gruber MJ, He JP, Koretz D, McLaughlin KA, Petukhova M, et al: Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. Arch Gen Psychiatry. 2012, 69: 372-380.PubMedCentralPubMed
1156.
Zurück zum Zitat Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L, Benjet C, Georgiades K, Swendsen J: Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010, 49: 980-989.PubMedCentralPubMed Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L, Benjet C, Georgiades K, Swendsen J: Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010, 49: 980-989.PubMedCentralPubMed
1157.
Zurück zum Zitat Meltzer H, Vostanis P, Dogra N, Doos L, Ford T, Goodman R: Children's specific fears. Child Care Health Dev. 2009, 35: 781-789.PubMed Meltzer H, Vostanis P, Dogra N, Doos L, Ford T, Goodman R: Children's specific fears. Child Care Health Dev. 2009, 35: 781-789.PubMed
1158.
Zurück zum Zitat Heyman I, Fombonne E, Simmons H, Ford T, Meltzer H, Goodman R: Prevalence of obsessive-compulsive disorder in the British nationwide survey of child mental health. Int Rev Psychiatry. 2003, 15: 178-184.PubMed Heyman I, Fombonne E, Simmons H, Ford T, Meltzer H, Goodman R: Prevalence of obsessive-compulsive disorder in the British nationwide survey of child mental health. Int Rev Psychiatry. 2003, 15: 178-184.PubMed
1159.
Zurück zum Zitat Apter A, Fallon TJ, King RA, Ratzoni G, Zohar AH, Binder M, Weizman A, Leckman JF, Pauls DL, Kron S, Cohen DJ: Obsessive-compulsive characteristics: from symptoms to syndrome. J Am Acad Child Adolesc Psychiatry. 1996, 35: 907-912.PubMed Apter A, Fallon TJ, King RA, Ratzoni G, Zohar AH, Binder M, Weizman A, Leckman JF, Pauls DL, Kron S, Cohen DJ: Obsessive-compulsive characteristics: from symptoms to syndrome. J Am Acad Child Adolesc Psychiatry. 1996, 35: 907-912.PubMed
1160.
Zurück zum Zitat Flament MF, Whitaker A, Rapoport JL, Davies M, Berg CZ, Kalikow K, Sceery W, Shaffer D: Obsessive compulsive disorder in adolescence: an epidemiological study. J Am Acad Child Adolesc Psychiatry. 1988, 27: 764-771.PubMed Flament MF, Whitaker A, Rapoport JL, Davies M, Berg CZ, Kalikow K, Sceery W, Shaffer D: Obsessive compulsive disorder in adolescence: an epidemiological study. J Am Acad Child Adolesc Psychiatry. 1988, 27: 764-771.PubMed
1161.
Zurück zum Zitat Albano AM, Kendall PC: Cognitive behavioural therapy for children and adolescents with anxiety disorders: Clinical research advances. Int Rev Psychiatry. 2002, 14: 129-134. Albano AM, Kendall PC: Cognitive behavioural therapy for children and adolescents with anxiety disorders: Clinical research advances. Int Rev Psychiatry. 2002, 14: 129-134.
1162.
Zurück zum Zitat Kendall P, Brady E, Verduin T: Comorbidity in childhood anxiety disorders and treatment outcome. J Am Acad Child Adolesc Psychiatry. 2001, 40: 787-794.PubMed Kendall P, Brady E, Verduin T: Comorbidity in childhood anxiety disorders and treatment outcome. J Am Acad Child Adolesc Psychiatry. 2001, 40: 787-794.PubMed
1163.
Zurück zum Zitat Verduin T, Kendall P: Differential occurrence of comorbidity within childhood anxiety disorders. J Clin Child Adolesc Psychol. 2003, 32: 290-295.PubMed Verduin T, Kendall P: Differential occurrence of comorbidity within childhood anxiety disorders. J Clin Child Adolesc Psychol. 2003, 32: 290-295.PubMed
1164.
Zurück zum Zitat Bernstein GA, Bernat DH, Davis AA, Layne AE: Symptom presentation and classroom functioning in a nonclinical sample of children with social phobia. Depress Anxiety. 2008, 25: 752-760.PubMed Bernstein GA, Bernat DH, Davis AA, Layne AE: Symptom presentation and classroom functioning in a nonclinical sample of children with social phobia. Depress Anxiety. 2008, 25: 752-760.PubMed
1165.
Zurück zum Zitat Layne AE, Bernat DH, Victor AM, Bernstein GA: Generalized anxiety disorder in a nonclinical sample of children: symptom presentation and predictors of impairment. J Anxiety Disord. 2009, 23: 283-289.PubMedCentralPubMed Layne AE, Bernat DH, Victor AM, Bernstein GA: Generalized anxiety disorder in a nonclinical sample of children: symptom presentation and predictors of impairment. J Anxiety Disord. 2009, 23: 283-289.PubMedCentralPubMed
1166.
Zurück zum Zitat Frojd S, Ranta K, Kaltiala-Heino R, Marttunen M: Associations of social phobia and general anxiety with alcohol and drug use in a community sample of adolescents. Alcohol Alcohol. 2011, 46: 192-199.PubMed Frojd S, Ranta K, Kaltiala-Heino R, Marttunen M: Associations of social phobia and general anxiety with alcohol and drug use in a community sample of adolescents. Alcohol Alcohol. 2011, 46: 192-199.PubMed
1167.
Zurück zum Zitat Low NC, Lee SS, Johnson JG, Williams JB, Harris ES: The association between anxiety and alcohol versus cannabis abuse disorders among adolescents in primary care settings. Fam Pract. 2008, 25: 321-327.PubMed Low NC, Lee SS, Johnson JG, Williams JB, Harris ES: The association between anxiety and alcohol versus cannabis abuse disorders among adolescents in primary care settings. Fam Pract. 2008, 25: 321-327.PubMed
1168.
Zurück zum Zitat Reed PL, Anthony JC, Breslau N: Incidence of drug problems in young adults exposed to trauma and posttraumatic stress disorder: do early life experiences and predispositions matter?. Arch Gen Psychiatry. 2007, 64: 1435-1442.PubMed Reed PL, Anthony JC, Breslau N: Incidence of drug problems in young adults exposed to trauma and posttraumatic stress disorder: do early life experiences and predispositions matter?. Arch Gen Psychiatry. 2007, 64: 1435-1442.PubMed
1169.
Zurück zum Zitat Cornelius JR, Kirisci L, Reynolds M, Clark DB, Hayes J, Tarter R: PTSD contributes to teen and young adult cannabis use disorders. Addict Behav. 2010, 35: 91-94.PubMedCentralPubMed Cornelius JR, Kirisci L, Reynolds M, Clark DB, Hayes J, Tarter R: PTSD contributes to teen and young adult cannabis use disorders. Addict Behav. 2010, 35: 91-94.PubMedCentralPubMed
1170.
Zurück zum Zitat Forbes EE, Bertocci MA, Gregory AM, Ryan ND, Axelson DA, Birmaher B, Dahl RE: Objective sleep in pediatric anxiety disorders and major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2008, 47: 148-155.PubMedCentralPubMed Forbes EE, Bertocci MA, Gregory AM, Ryan ND, Axelson DA, Birmaher B, Dahl RE: Objective sleep in pediatric anxiety disorders and major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2008, 47: 148-155.PubMedCentralPubMed
1171.
Zurück zum Zitat Alfano CA, Ginsburg GS, Kingery JN: Sleep-related problems among children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2007, 46: 224-232.PubMed Alfano CA, Ginsburg GS, Kingery JN: Sleep-related problems among children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2007, 46: 224-232.PubMed
1172.
Zurück zum Zitat Alfano CA, Kim KL: Objective sleep patterns and severity of symptoms in pediatric obsessive compulsive disorder: a pilot investigation. J Anxiety Disord. 2011, 25: 835-839.PubMedCentralPubMed Alfano CA, Kim KL: Objective sleep patterns and severity of symptoms in pediatric obsessive compulsive disorder: a pilot investigation. J Anxiety Disord. 2011, 25: 835-839.PubMedCentralPubMed
1173.
Zurück zum Zitat Storch EA, Murphy TK, Lack CW, Geffken GR, Jacob ML, Goodman WK: Sleep-related problems in pediatric obsessive-compulsive disorder. J Anxiety Disord. 2008, 22: 877-885.PubMedCentralPubMed Storch EA, Murphy TK, Lack CW, Geffken GR, Jacob ML, Goodman WK: Sleep-related problems in pediatric obsessive-compulsive disorder. J Anxiety Disord. 2008, 22: 877-885.PubMedCentralPubMed
1174.
Zurück zum Zitat Ginsburg GS, Riddle MA, Davies M: Somatic symptoms in children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2006, 45: 1179-1187.PubMed Ginsburg GS, Riddle MA, Davies M: Somatic symptoms in children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2006, 45: 1179-1187.PubMed
1175.
Zurück zum Zitat Boden JM, Fergusson DM, Horwood LJ: Anxiety disorders and suicidal behaviours in adolescence and young adulthood: findings from a longitudinal study. Psychol Med. 2007, 37: 431-440.PubMed Boden JM, Fergusson DM, Horwood LJ: Anxiety disorders and suicidal behaviours in adolescence and young adulthood: findings from a longitudinal study. Psychol Med. 2007, 37: 431-440.PubMed
1176.
Zurück zum Zitat Andres S, Boget T, Lazaro L, Penades R, Morer A, Salamero M, Castro-Fornieles J: Neuropsychological performance in children and adolescents with obsessive-compulsive disorder and influence of clinical variables. Biol Psychiatry. 2007, 61: 946-951.PubMed Andres S, Boget T, Lazaro L, Penades R, Morer A, Salamero M, Castro-Fornieles J: Neuropsychological performance in children and adolescents with obsessive-compulsive disorder and influence of clinical variables. Biol Psychiatry. 2007, 61: 946-951.PubMed
1177.
Zurück zum Zitat Jacob ML, Morelen D, Suveg C, Brown Jacobsen AM, Whiteside SP: Emotional, behavioral, and cognitive factors that differentiate obsessive-compulsive disorder and other anxiety disorders in youth. Anxiety Stress Coping. 2012, 25: 229-237.PubMed Jacob ML, Morelen D, Suveg C, Brown Jacobsen AM, Whiteside SP: Emotional, behavioral, and cognitive factors that differentiate obsessive-compulsive disorder and other anxiety disorders in youth. Anxiety Stress Coping. 2012, 25: 229-237.PubMed
1178.
Zurück zum Zitat Hughes AA, Lourea-Waddell B, Kendall PC: Somatic complaints in children with anxiety disorders and their unique prediction of poorer academic performance. Child Psychiatry Hum Dev. 2008, 39: 211-220.PubMed Hughes AA, Lourea-Waddell B, Kendall PC: Somatic complaints in children with anxiety disorders and their unique prediction of poorer academic performance. Child Psychiatry Hum Dev. 2008, 39: 211-220.PubMed
1179.
Zurück zum Zitat Grills-Taquechel AE, Fletcher JM, Vaughn SR, Denton CA, Taylor P: Anxiety and inattention as predictors of achievement in early elementary school children. Anxiety Stress Coping. 2013, 26: 391-410.PubMedCentralPubMed Grills-Taquechel AE, Fletcher JM, Vaughn SR, Denton CA, Taylor P: Anxiety and inattention as predictors of achievement in early elementary school children. Anxiety Stress Coping. 2013, 26: 391-410.PubMedCentralPubMed
1180.
Zurück zum Zitat Tillfors M, Persson S, Willen M, Burk WJ: Prospective links between social anxiety and adolescent peer relations. J Adolesc. 2012, 35: 1255-1263.PubMed Tillfors M, Persson S, Willen M, Burk WJ: Prospective links between social anxiety and adolescent peer relations. J Adolesc. 2012, 35: 1255-1263.PubMed
1181.
Zurück zum Zitat Teubert D, Pinquart M: A meta-analytic review on the prevention of symptoms of anxiety in children and adolescents. J Anxiety Disord. 2011, 25: 1046-1059. Teubert D, Pinquart M: A meta-analytic review on the prevention of symptoms of anxiety in children and adolescents. J Anxiety Disord. 2011, 25: 1046-1059.
1182.
Zurück zum Zitat Barrett PM, Farrell LJ, Ollendick TH, Dadds M: Long-term outcomes of an Australian universal prevention trial of anxiety and depression symptoms in children and youth: an evaluation of the friends program. J Clin Child Adolesc Psychol. 2006, 35: 403-411.PubMed Barrett PM, Farrell LJ, Ollendick TH, Dadds M: Long-term outcomes of an Australian universal prevention trial of anxiety and depression symptoms in children and youth: an evaluation of the friends program. J Clin Child Adolesc Psychol. 2006, 35: 403-411.PubMed
1183.
Zurück zum Zitat Simon E, Bogels SM, Voncken JM: Efficacy of child-focused and parent-focused interventions in a child anxiety prevention study. J Clin Child Adolesc Psychol. 2011, 40: 204-219.PubMed Simon E, Bogels SM, Voncken JM: Efficacy of child-focused and parent-focused interventions in a child anxiety prevention study. J Clin Child Adolesc Psychol. 2011, 40: 204-219.PubMed
1184.
Zurück zum Zitat Manassis K, Wilansky-Traynor P, Farzan N, Kleiman V, Parker K, Sanford M: The feelings club: randomized controlled evaluation of school-based CBT for anxious or depressive symptoms. Depress Anxiety. 2010, 27: 945-952.PubMed Manassis K, Wilansky-Traynor P, Farzan N, Kleiman V, Parker K, Sanford M: The feelings club: randomized controlled evaluation of school-based CBT for anxious or depressive symptoms. Depress Anxiety. 2010, 27: 945-952.PubMed
1185.
Zurück zum Zitat Stallard P, Velleman R, Salter E, Howse I, Yule W, Taylor G: A randomised controlled trial to determine the effectiveness of an early psychological intervention with children involved in road traffic accidents. J Child Psychol Psychiatry. 2006, 47: 127-134.PubMed Stallard P, Velleman R, Salter E, Howse I, Yule W, Taylor G: A randomised controlled trial to determine the effectiveness of an early psychological intervention with children involved in road traffic accidents. J Child Psychol Psychiatry. 2006, 47: 127-134.PubMed
1186.
Zurück zum Zitat Nugent NR, Christopher NC, Crow JP, Browne L, Ostrowski S, Delahanty DL: The efficacy of early propranolol administration at reducing PTSD symptoms in pediatric injury patients: a pilot study. J Trauma Stress. 2010, 23: 282-287.PubMedCentralPubMed Nugent NR, Christopher NC, Crow JP, Browne L, Ostrowski S, Delahanty DL: The efficacy of early propranolol administration at reducing PTSD symptoms in pediatric injury patients: a pilot study. J Trauma Stress. 2010, 23: 282-287.PubMedCentralPubMed
1187.
Zurück zum Zitat Weisz JR, Jensen-Doss A, Hawley KM: Evidence-based youth psychotherapies versus usual clinical care: a meta-analysis of direct comparisons. Am Psychol. 2006, 61: 671-689.PubMed Weisz JR, Jensen-Doss A, Hawley KM: Evidence-based youth psychotherapies versus usual clinical care: a meta-analysis of direct comparisons. Am Psychol. 2006, 61: 671-689.PubMed
1188.
Zurück zum Zitat Chu BC, Harrison TL: Disorder-specific effects of CBT for anxious and depressed youth: a meta-analysis of candidate mediators of change. Clin Child Fam Psychol Rev. 2007, 10: 352-372.PubMed Chu BC, Harrison TL: Disorder-specific effects of CBT for anxious and depressed youth: a meta-analysis of candidate mediators of change. Clin Child Fam Psychol Rev. 2007, 10: 352-372.PubMed
1189.
Zurück zum Zitat In-Albon T, Schneider S: Psychotherapy of childhood anxiety disorders: a meta-analysis. Psychother Psychosom. 2007, 76: 15-24.PubMed In-Albon T, Schneider S: Psychotherapy of childhood anxiety disorders: a meta-analysis. Psychother Psychosom. 2007, 76: 15-24.PubMed
1190.
Zurück zum Zitat Silverman WK, Pina AA, Viswesvaran C: Evidence-based psychosocial treatments for phobic and anxiety disorders in children and adolescents. J Clin Child Adolesc Psychol. 2008, 37: 105-130.PubMed Silverman WK, Pina AA, Viswesvaran C: Evidence-based psychosocial treatments for phobic and anxiety disorders in children and adolescents. J Clin Child Adolesc Psychol. 2008, 37: 105-130.PubMed
1191.
Zurück zum Zitat Cartwright-Hatton S, Roberts C, Chitsabesan P, Fothergill C, Harrington R: Systematic review of the efficacy of cognitive behaviour therapies for childhood and adolescent anxiety disorders. Br J Clin Psychol. 2004, 43: 421-436.PubMed Cartwright-Hatton S, Roberts C, Chitsabesan P, Fothergill C, Harrington R: Systematic review of the efficacy of cognitive behaviour therapies for childhood and adolescent anxiety disorders. Br J Clin Psychol. 2004, 43: 421-436.PubMed
1192.
Zurück zum Zitat Baer S, Garland E: Pilot study of community-based cognitive behavioral group therapy for adolescents with social phobia. J Am Acad Child Adolesc Psychiatry. 2005, 44: 258-264.PubMed Baer S, Garland E: Pilot study of community-based cognitive behavioral group therapy for adolescents with social phobia. J Am Acad Child Adolesc Psychiatry. 2005, 44: 258-264.PubMed
1193.
Zurück zum Zitat Beidel D, Turner S, Morris T: Behavioral treatment of childhood social phobia. J Consult Clin Psychol. 2000, 68: 1072-1080.PubMed Beidel D, Turner S, Morris T: Behavioral treatment of childhood social phobia. J Consult Clin Psychol. 2000, 68: 1072-1080.PubMed
1194.
Zurück zum Zitat Herbert JD, Gaudiano BA, Rheingold AA, Moitra E, Myers VH, Dalrymple KL, Brandsma LL: Cognitive behavior therapy for generalized social anxiety disorder in adolescents: a randomized controlled trial. J Anxiety Disord. 2009, 23: 167-177.PubMedCentralPubMed Herbert JD, Gaudiano BA, Rheingold AA, Moitra E, Myers VH, Dalrymple KL, Brandsma LL: Cognitive behavior therapy for generalized social anxiety disorder in adolescents: a randomized controlled trial. J Anxiety Disord. 2009, 23: 167-177.PubMedCentralPubMed
1195.
Zurück zum Zitat Piet J, Hougaard E, Hecksher MS, Rosenberg NK: A randomized pilot study of mindfulness-based cognitive therapy and group cognitive-behavioral therapy for young adults with social phobia. Scand J Psychol. 2010, 51: 503-410. Piet J, Hougaard E, Hecksher MS, Rosenberg NK: A randomized pilot study of mindfulness-based cognitive therapy and group cognitive-behavioral therapy for young adults with social phobia. Scand J Psychol. 2010, 51: 503-410.
1196.
Zurück zum Zitat Melfsen S, Kuhnemund M, Schwieger J, Warnke A, Stadler C, Poustka F, Stangier U: Cognitive behavioral therapy of socially phobic children focusing on cognition: a randomised wait-list control study. Child Adolesc Psychiatry Ment Health. 2011, 5: 5-PubMedCentralPubMed Melfsen S, Kuhnemund M, Schwieger J, Warnke A, Stadler C, Poustka F, Stangier U: Cognitive behavioral therapy of socially phobic children focusing on cognition: a randomised wait-list control study. Child Adolesc Psychiatry Ment Health. 2011, 5: 5-PubMedCentralPubMed
1197.
Zurück zum Zitat Segool NK, Carlson JS: Efficacy of cognitive-behavioral and pharmacological treatments for children with social anxiety. Depress Anxiety. 2008, 25: 620-631.PubMed Segool NK, Carlson JS: Efficacy of cognitive-behavioral and pharmacological treatments for children with social anxiety. Depress Anxiety. 2008, 25: 620-631.PubMed
1198.
Zurück zum Zitat Pincus DB, May JE, Whitton SW, Mattis SG, Barlow DH: Cognitive-behavioral treatment of panic disorder in adolescence. J Clin Child Adolesc Psychol. 2010, 39: 638-649.PubMed Pincus DB, May JE, Whitton SW, Mattis SG, Barlow DH: Cognitive-behavioral treatment of panic disorder in adolescence. J Clin Child Adolesc Psychol. 2010, 39: 638-649.PubMed
1199.
Zurück zum Zitat Franklin ME, Sapyta J, Freeman JB, Khanna M, Compton S, Almirall D, Moore P, Choate-Summers M, Garcia A, Edson AL, et al: Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA. 2011, 306: 1224-1232.PubMedCentralPubMed Franklin ME, Sapyta J, Freeman JB, Khanna M, Compton S, Almirall D, Moore P, Choate-Summers M, Garcia A, Edson AL, et al: Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA. 2011, 306: 1224-1232.PubMedCentralPubMed
1200.
Zurück zum Zitat Williams TI, Salkovskis PM, Forrester L, Turner S, White H, Allsopp MA: A randomised controlled trial of cognitive behavioural treatment for obsessive compulsive disorder in children and adolescents. Eur Child Adolesc Psychiatry. 2010, 19: 449-456.PubMed Williams TI, Salkovskis PM, Forrester L, Turner S, White H, Allsopp MA: A randomised controlled trial of cognitive behavioural treatment for obsessive compulsive disorder in children and adolescents. Eur Child Adolesc Psychiatry. 2010, 19: 449-456.PubMed
1201.
Zurück zum Zitat Bolton D, Williams T, Perrin S, Atkinson L, Gallop C, Waite P, Salkovskis P: Randomized controlled trial of full and brief cognitive-behaviour therapy and wait-list for paediatric obsessive-compulsive disorder. J Child Psychol Psychiatry. 2011, 52: 1269-1278.PubMed Bolton D, Williams T, Perrin S, Atkinson L, Gallop C, Waite P, Salkovskis P: Randomized controlled trial of full and brief cognitive-behaviour therapy and wait-list for paediatric obsessive-compulsive disorder. J Child Psychol Psychiatry. 2011, 52: 1269-1278.PubMed
1202.
Zurück zum Zitat Turner C, Heyman I, Futh A, Lovell K: A pilot study of telephone cognitive-behavioural therapy for obsessive-compulsive disorder in young people. Behav Cogn Psychother. 2009, 37: 469-474.PubMed Turner C, Heyman I, Futh A, Lovell K: A pilot study of telephone cognitive-behavioural therapy for obsessive-compulsive disorder in young people. Behav Cogn Psychother. 2009, 37: 469-474.PubMed
1203.
Zurück zum Zitat O'Kearney RT, Anstey KJ, von Sanden C: Behavioural and cognitive behavioural therapy for obsessive compulsive disorder in children and adolescents. Cochrane Database Syst Rev. 2006, CD004856- O'Kearney RT, Anstey KJ, von Sanden C: Behavioural and cognitive behavioural therapy for obsessive compulsive disorder in children and adolescents. Cochrane Database Syst Rev. 2006, CD004856-
1204.
Zurück zum Zitat Watson HJ, Rees CS: Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder. J Child Psychol Psychiatry. 2008, 49: 489-498.PubMed Watson HJ, Rees CS: Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder. J Child Psychol Psychiatry. 2008, 49: 489-498.PubMed
1205.
Zurück zum Zitat Smith P, Yule W, Perrin S, Tranah T, Dalgleish T, Clark DM: Cognitive-behavioral therapy for PTSD in children and adolescents: a preliminary randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2007, 46: 1051-1061.PubMed Smith P, Yule W, Perrin S, Tranah T, Dalgleish T, Clark DM: Cognitive-behavioral therapy for PTSD in children and adolescents: a preliminary randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2007, 46: 1051-1061.PubMed
1206.
Zurück zum Zitat Nixon RD, Sterk J, Pearce A: A randomized trial of cognitive behaviour therapy and cognitive therapy for children with posttraumatic stress disorder following single-incident trauma. J Abnorm Child Psychol. 2012, 40: 327-337.PubMed Nixon RD, Sterk J, Pearce A: A randomized trial of cognitive behaviour therapy and cognitive therapy for children with posttraumatic stress disorder following single-incident trauma. J Abnorm Child Psychol. 2012, 40: 327-337.PubMed
1207.
Zurück zum Zitat Kowalik J, Weller J, Venter J, Drachman D: Cognitive behavioral therapy for the treatment of pediatric posttraumatic stress disorder: a review and meta-analysis. J Behav Ther Exp Psychiatry. 2011, 42: 405-413.PubMed Kowalik J, Weller J, Venter J, Drachman D: Cognitive behavioral therapy for the treatment of pediatric posttraumatic stress disorder: a review and meta-analysis. J Behav Ther Exp Psychiatry. 2011, 42: 405-413.PubMed
1208.
Zurück zum Zitat King N, Tonge B, Mullen P, Myerson N, Heyne D, Rollings S, Martin R, Ollendick T: Treating sexually abused children with posttraumatic stress symptoms: a randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2000, 39: 1347-1355.PubMed King N, Tonge B, Mullen P, Myerson N, Heyne D, Rollings S, Martin R, Ollendick T: Treating sexually abused children with posttraumatic stress symptoms: a randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2000, 39: 1347-1355.PubMed
1209.
Zurück zum Zitat Cohen J, Mannarino A: A treatment outcome study for sexually abused preschool children: initial findings. J Am Acad Child Adolesc Psychiatry. 1996, 35: 42-50.PubMed Cohen J, Mannarino A: A treatment outcome study for sexually abused preschool children: initial findings. J Am Acad Child Adolesc Psychiatry. 1996, 35: 42-50.PubMed
1210.
Zurück zum Zitat Scheeringa MS, Weems CF, Cohen JA, Amaya-Jackson L, Guthrie D: Trauma-focused cognitive-behavioral therapy for posttraumatic stress disorder in three-through six year-old children: a randomized clinical trial. J Child Psychol Psychiatry. 2011, 52: 853-860.PubMedCentralPubMed Scheeringa MS, Weems CF, Cohen JA, Amaya-Jackson L, Guthrie D: Trauma-focused cognitive-behavioral therapy for posttraumatic stress disorder in three-through six year-old children: a randomized clinical trial. J Child Psychol Psychiatry. 2011, 52: 853-860.PubMedCentralPubMed
1211.
Zurück zum Zitat Deblinger E, Mannarino AP, Cohen JA, Steer RA: A follow-up study of a multisite, randomized, controlled trial for children with sexual abuse-related PTSD symptoms. J Am Acad Child Adolesc Psychiatry. 2006, 45: 1474-1484.PubMed Deblinger E, Mannarino AP, Cohen JA, Steer RA: A follow-up study of a multisite, randomized, controlled trial for children with sexual abuse-related PTSD symptoms. J Am Acad Child Adolesc Psychiatry. 2006, 45: 1474-1484.PubMed
1212.
Zurück zum Zitat King N, Tonge B, Heyne D, Pritchard M, Rollings S, Young D, Myerson N, Ollendick T: Cognitive-behavioral treatment of school-refusing children: a controlled evaluation. J Am Acad Child Adolesc Psychiatry. 1998, 37: 395-403.PubMed King N, Tonge B, Heyne D, Pritchard M, Rollings S, Young D, Myerson N, Ollendick T: Cognitive-behavioral treatment of school-refusing children: a controlled evaluation. J Am Acad Child Adolesc Psychiatry. 1998, 37: 395-403.PubMed
1213.
Zurück zum Zitat Last C, Hansen C, Franco N: Cognitive-behavioral treatment of school phobia. J Am Acad Child Adolesc Psychiatry. 1998, 37: 404-411.PubMed Last C, Hansen C, Franco N: Cognitive-behavioral treatment of school phobia. J Am Acad Child Adolesc Psychiatry. 1998, 37: 404-411.PubMed
1214.
Zurück zum Zitat Pina AA, Zerr AA, Gonzales NA, Ortiz CD: Psychosocial interventions for school refusal behavior in children and adolescents. Child Dev Perspect. 2009, 3: 11-20.PubMedCentralPubMed Pina AA, Zerr AA, Gonzales NA, Ortiz CD: Psychosocial interventions for school refusal behavior in children and adolescents. Child Dev Perspect. 2009, 3: 11-20.PubMedCentralPubMed
1215.
Zurück zum Zitat Heyne D, King NJ, Tonge BJ, Rollings S, Young D, Pritchard M, Ollendick TH: Evaluation of child therapy and caregiver training in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry. 2002, 41: 687-695.PubMed Heyne D, King NJ, Tonge BJ, Rollings S, Young D, Pritchard M, Ollendick TH: Evaluation of child therapy and caregiver training in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry. 2002, 41: 687-695.PubMed
1216.
Zurück zum Zitat Schneider S, Blatter-Meunier J, Herren C, Adornetto C, In-Albon T, Lavallee K: Disorder-specific cognitive-behavioral therapy for separation anxiety disorder in young children: a randomized waiting-list-controlled trial. Psychother Psychosom. 2011, 80: 206-215.PubMed Schneider S, Blatter-Meunier J, Herren C, Adornetto C, In-Albon T, Lavallee K: Disorder-specific cognitive-behavioral therapy for separation anxiety disorder in young children: a randomized waiting-list-controlled trial. Psychother Psychosom. 2011, 80: 206-215.PubMed
1217.
Zurück zum Zitat Manassis K, Mendlowitz S, Scapillato D, Avery D, Fiksenbaum L, Freire M, Monga S, Owens M: Group and individual cognitive-behavioral therapy for childhood anxiety disorders: a randomized trial. J Am Acad Child Adolesc Psychiatry. 2002, 41: 1423-1430.PubMed Manassis K, Mendlowitz S, Scapillato D, Avery D, Fiksenbaum L, Freire M, Monga S, Owens M: Group and individual cognitive-behavioral therapy for childhood anxiety disorders: a randomized trial. J Am Acad Child Adolesc Psychiatry. 2002, 41: 1423-1430.PubMed
1218.
Zurück zum Zitat O'Leary EM, Barrett P, Fjermestad KW: Cognitive-behavioral family treatment for childhood obsessive-compulsive disorder: a 7-year follow-up study. J Anxiety Disord. 2009, 23: 973-978.PubMed O'Leary EM, Barrett P, Fjermestad KW: Cognitive-behavioral family treatment for childhood obsessive-compulsive disorder: a 7-year follow-up study. J Anxiety Disord. 2009, 23: 973-978.PubMed
1219.
Zurück zum Zitat Richardson T, Stallard P, Velleman S: Computerised cognitive behavioural therapy for the prevention and treatment of depression and anxiety in children and adolescents: a systematic review. Clin Child Fam Psychol Rev. 2010, 13: 275-290.PubMed Richardson T, Stallard P, Velleman S: Computerised cognitive behavioural therapy for the prevention and treatment of depression and anxiety in children and adolescents: a systematic review. Clin Child Fam Psychol Rev. 2010, 13: 275-290.PubMed
1220.
Zurück zum Zitat Storch EA, Caporino NE, Morgan JR, Lewin AB, Rojas A, Brauer L, Larson MJ, Murphy TK: Preliminary investigation of web-camera delivered cognitive-behavioral therapy for youth with obsessive-compulsive disorder. Psychiatry Res. 2011, 189: 407-412.PubMed Storch EA, Caporino NE, Morgan JR, Lewin AB, Rojas A, Brauer L, Larson MJ, Murphy TK: Preliminary investigation of web-camera delivered cognitive-behavioral therapy for youth with obsessive-compulsive disorder. Psychiatry Res. 2011, 189: 407-412.PubMed
1221.
Zurück zum Zitat Kendall P: Treating anxiety disorders in children: results of a randomized clinical trial. J Consult Clin Psychol. 1994, 62: 100-110.PubMed Kendall P: Treating anxiety disorders in children: results of a randomized clinical trial. J Consult Clin Psychol. 1994, 62: 100-110.PubMed
1222.
Zurück zum Zitat Kendall P, Flannery-Schroeder E, Panichelli-Mindel S, Southam-Gerow M, Henin A, Warman M: Therapy for youths with anxiety disorders: a second randomized clinical trial. J Consult Clin Psychol. 1997, 65: 366-380.PubMed Kendall P, Flannery-Schroeder E, Panichelli-Mindel S, Southam-Gerow M, Henin A, Warman M: Therapy for youths with anxiety disorders: a second randomized clinical trial. J Consult Clin Psychol. 1997, 65: 366-380.PubMed
1223.
Zurück zum Zitat Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, et al: Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008, 359: 2753-2766.PubMedCentralPubMed Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, et al: Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008, 359: 2753-2766.PubMedCentralPubMed
1224.
Zurück zum Zitat Ginsburg GS, Kendall PC, Sakolsky D, Compton SN, Piacentini J, Albano AM, Walkup JT, Sherrill J, Coffey KA, Rynn MA, et al: Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol. 2011, 79: 806-813.PubMedCentralPubMed Ginsburg GS, Kendall PC, Sakolsky D, Compton SN, Piacentini J, Albano AM, Walkup JT, Sherrill J, Coffey KA, Rynn MA, et al: Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol. 2011, 79: 806-813.PubMedCentralPubMed
1225.
Zurück zum Zitat Kendall P, Safford S, Flannery-Schroeder E, Webb A: Child anxiety treatment: outcomes in adolescence and impact on substance use and depression at 7.4-year follow-up. J Consult Clin Psychol. 2004, 72: 276-287.PubMed Kendall P, Safford S, Flannery-Schroeder E, Webb A: Child anxiety treatment: outcomes in adolescence and impact on substance use and depression at 7.4-year follow-up. J Consult Clin Psychol. 2004, 72: 276-287.PubMed
1226.
Zurück zum Zitat Eldar S, Apter A, Lotan D, Edgar KP, Naim R, Fox NA, Pine DS, Bar-Haim Y: Attention bias modification treatment for pediatric anxiety disorders: a randomized controlled trial. Am J Psychiatry. 2012, 169: 213-230.PubMedCentralPubMed Eldar S, Apter A, Lotan D, Edgar KP, Naim R, Fox NA, Pine DS, Bar-Haim Y: Attention bias modification treatment for pediatric anxiety disorders: a randomized controlled trial. Am J Psychiatry. 2012, 169: 213-230.PubMedCentralPubMed
1227.
Zurück zum Zitat Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S: SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2007, 46: 1622-1632.PubMed Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S: SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2007, 46: 1622-1632.PubMed
1228.
Zurück zum Zitat Beidel DC, Turner SM, Young BJ: Social effectiveness therapy for children: five years later. Behav Ther. 2006, 37: 416-425.PubMed Beidel DC, Turner SM, Young BJ: Social effectiveness therapy for children: five years later. Behav Ther. 2006, 37: 416-425.PubMed
1229.
Zurück zum Zitat Simons M, Schneider S, Herpertz-Dahlmann B: Metacognitive therapy versus exposure and response prevention for pediatric obsessive-compulsive disorder. A case series with randomized allocation. Psychother Psychosom. 2006, 75: 257-264.PubMed Simons M, Schneider S, Herpertz-Dahlmann B: Metacognitive therapy versus exposure and response prevention for pediatric obsessive-compulsive disorder. A case series with randomized allocation. Psychother Psychosom. 2006, 75: 257-264.PubMed
1230.
Zurück zum Zitat Bolton D, Perrin S: Evaluation of exposure with response-prevention for obsessive compulsive disorder in childhood and adolescence. J Behav Ther Exp Psychiatry. 2008, 39: 11-22.PubMed Bolton D, Perrin S: Evaluation of exposure with response-prevention for obsessive compulsive disorder in childhood and adolescence. J Behav Ther Exp Psychiatry. 2008, 39: 11-22.PubMed
1231.
Zurück zum Zitat Storch EA, Geffken GR, Merlo LJ, Mann G, Duke D, Munson M, Adkins J, Grabill KM, Murphy TK, Goodman WK: Family-based cognitive-behavioral therapy for pediatric obsessive-compulsive disorder: comparison of intensive and weekly approaches. J Am Acad Child Adolesc Psychiatry. 2007, 46: 469-478.PubMed Storch EA, Geffken GR, Merlo LJ, Mann G, Duke D, Munson M, Adkins J, Grabill KM, Murphy TK, Goodman WK: Family-based cognitive-behavioral therapy for pediatric obsessive-compulsive disorder: comparison of intensive and weekly approaches. J Am Acad Child Adolesc Psychiatry. 2007, 46: 469-478.PubMed
1232.
Zurück zum Zitat Barrett P, Healy-Farrell L, March J: Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trial. J Am Acad Child Adolesc Psychiatry. 2004, 43: 46-62.PubMed Barrett P, Healy-Farrell L, March J: Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trial. J Am Acad Child Adolesc Psychiatry. 2004, 43: 46-62.PubMed
1233.
Zurück zum Zitat Van der Oord S, Lucassen S, Van Emmerik AA, Emmelkamp PM: Treatment of post-traumatic stress disorder in children using cognitive behavioural writing therapy. Clin Psychol Psychother. 2010, 17: 240-249.PubMed Van der Oord S, Lucassen S, Van Emmerik AA, Emmelkamp PM: Treatment of post-traumatic stress disorder in children using cognitive behavioural writing therapy. Clin Psychol Psychother. 2010, 17: 240-249.PubMed
1234.
Zurück zum Zitat Lesmana CB, Suryani LK, Jensen GD, Tiliopoulos N: A spiritual-hypnosis assisted treatment of children with PTSD after the 2002 Bali terrorist attack. Am J Clin Hypn. 2009, 52: 23-34.PubMed Lesmana CB, Suryani LK, Jensen GD, Tiliopoulos N: A spiritual-hypnosis assisted treatment of children with PTSD after the 2002 Bali terrorist attack. Am J Clin Hypn. 2009, 52: 23-34.PubMed
1235.
Zurück zum Zitat Ford JD, Steinberg KL, Hawke J, Levine J, Zhang W: Randomized trial comparison of emotion regulation and relational psychotherapies for PTSD with girls involved in delinquency. J Clin Child Adolesc Psychol. 2012, 41: 27-37.PubMed Ford JD, Steinberg KL, Hawke J, Levine J, Zhang W: Randomized trial comparison of emotion regulation and relational psychotherapies for PTSD with girls involved in delinquency. J Clin Child Adolesc Psychol. 2012, 41: 27-37.PubMed
1236.
Zurück zum Zitat Gilboa-Schechtman E, Foa EB, Shafran N, Aderka IM, Powers MB, Rachamim L, Rosenbach L, Yadin E, Apter A: Prolonged exposure versus dynamic therapy for adolescent PTSD: a pilot randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2010, 49: 1034-1042.PubMedCentralPubMed Gilboa-Schechtman E, Foa EB, Shafran N, Aderka IM, Powers MB, Rachamim L, Rosenbach L, Yadin E, Apter A: Prolonged exposure versus dynamic therapy for adolescent PTSD: a pilot randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2010, 49: 1034-1042.PubMedCentralPubMed
1237.
Zurück zum Zitat Ahmad A, Sundelin-Wahlsten V: Applying EMDR on children with PTSD. Eur Child Adolesc Psychiatry. 2008, 17: 127-132.PubMed Ahmad A, Sundelin-Wahlsten V: Applying EMDR on children with PTSD. Eur Child Adolesc Psychiatry. 2008, 17: 127-132.PubMed
1238.
Zurück zum Zitat Ahmad A, Larsson B, Sundelin-Wahlsten V: EMDR treatment for children with PTSD: results of a randomized controlled trial. Nord J Psychiatry. 2007, 61: 349-354.PubMed Ahmad A, Larsson B, Sundelin-Wahlsten V: EMDR treatment for children with PTSD: results of a randomized controlled trial. Nord J Psychiatry. 2007, 61: 349-354.PubMed
1239.
Zurück zum Zitat Barrett P, Dadds M, Rapee R: Family treatment of childhood anxiety: a controlled trial. J Consult Clin Psychol. 1996, 64: 333-342.PubMed Barrett P, Dadds M, Rapee R: Family treatment of childhood anxiety: a controlled trial. J Consult Clin Psychol. 1996, 64: 333-342.PubMed
1240.
Zurück zum Zitat Mendlowitz S, Manassis K, Bradley S, Scapillato D, Miezitis S, Shaw B: Cognitive-behavioral group treatments in childhood anxiety disorders: the role of parental involvement. J Am Acad Child Adolesc Psychiatry. 1999, 38: 1223-1229.PubMed Mendlowitz S, Manassis K, Bradley S, Scapillato D, Miezitis S, Shaw B: Cognitive-behavioral group treatments in childhood anxiety disorders: the role of parental involvement. J Am Acad Child Adolesc Psychiatry. 1999, 38: 1223-1229.PubMed
1241.
Zurück zum Zitat Shortt A, Barrett P, Fox T: Evaluating the FRIENDS program: a cognitive-behavioral group treatment for anxious children and their parents. J Clin Child Psychol. 2001, 30: 525-535.PubMed Shortt A, Barrett P, Fox T: Evaluating the FRIENDS program: a cognitive-behavioral group treatment for anxious children and their parents. J Clin Child Psychol. 2001, 30: 525-535.PubMed
1242.
Zurück zum Zitat Nauta M, Scholing A, Emmelkamp P, Minderaa R: Cognitive-behavioral therapy for children with anxiety disorders in a clinical setting: no additional effect of a cognitive parent training. J Am Acad Child Adolesc Psychiatry. 2003, 42: 1270-1278.PubMed Nauta M, Scholing A, Emmelkamp P, Minderaa R: Cognitive-behavioral therapy for children with anxiety disorders in a clinical setting: no additional effect of a cognitive parent training. J Am Acad Child Adolesc Psychiatry. 2003, 42: 1270-1278.PubMed
1243.
Zurück zum Zitat Bogels SM, Siqueland L: Family cognitive behavioral therapy for children and adolescents with clinical anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2006, 45: 134-141.PubMed Bogels SM, Siqueland L: Family cognitive behavioral therapy for children and adolescents with clinical anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2006, 45: 134-141.PubMed
1244.
Zurück zum Zitat Wood JJ, Piacentini JC, Southam-Gerow M, Chu BC, Sigman M: Family cognitive behavioral therapy for child anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2006, 45: 314-321.PubMed Wood JJ, Piacentini JC, Southam-Gerow M, Chu BC, Sigman M: Family cognitive behavioral therapy for child anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2006, 45: 314-321.PubMed
1245.
Zurück zum Zitat Piacentini J, Bergman RL, Chang S, Langley A, Peris T, Wood JJ, McCracken J: Controlled comparison of family cognitive behavioral therapy and psychoeducation/relaxation training for child obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2011, 50: 1149-1161.PubMedCentralPubMed Piacentini J, Bergman RL, Chang S, Langley A, Peris T, Wood JJ, McCracken J: Controlled comparison of family cognitive behavioral therapy and psychoeducation/relaxation training for child obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2011, 50: 1149-1161.PubMedCentralPubMed
1246.
Zurück zum Zitat Cobham VE, Dadds MR, Spence SH: The role of parental anxiety in the treatment of childhood anxiety. J Consult Clin Psychol. 1998, 66: 893-905.PubMed Cobham VE, Dadds MR, Spence SH: The role of parental anxiety in the treatment of childhood anxiety. J Consult Clin Psychol. 1998, 66: 893-905.PubMed
1247.
Zurück zum Zitat Eisen AR, Raleigh H, Neuhoff CC: The unique impact of parent training for separation anxiety disorder in children. Behav Ther. 2008, 39: 195-206.PubMed Eisen AR, Raleigh H, Neuhoff CC: The unique impact of parent training for separation anxiety disorder in children. Behav Ther. 2008, 39: 195-206.PubMed
1248.
Zurück zum Zitat Thienemann M, Moore P, Tompkins K: A parent-only group intervention for children with anxiety disorders: pilot study. J Am Acad Child Adolesc Psychiatry. 2006, 45: 37-46.PubMed Thienemann M, Moore P, Tompkins K: A parent-only group intervention for children with anxiety disorders: pilot study. J Am Acad Child Adolesc Psychiatry. 2006, 45: 37-46.PubMed
1249.
Zurück zum Zitat Storch EA, Merlo LJ, Larson MJ, Geffken GR, Lehmkuhl HD, Jacob ML, Murphy TK, Goodman WK: Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2008, 47: 583-592.PubMed Storch EA, Merlo LJ, Larson MJ, Geffken GR, Lehmkuhl HD, Jacob ML, Murphy TK, Goodman WK: Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2008, 47: 583-592.PubMed
1250.
Zurück zum Zitat Jarrett MA, Ollendick TH: Treatment of comorbid attention-deficit/hyperactivity disorder and anxiety in children: A multiple baseline design analysis. J Consult Clin Psychol. 2012, 80: 239-244.PubMed Jarrett MA, Ollendick TH: Treatment of comorbid attention-deficit/hyperactivity disorder and anxiety in children: A multiple baseline design analysis. J Consult Clin Psychol. 2012, 80: 239-244.PubMed
1251.
Zurück zum Zitat Levy K, Hunt C, Heriot S: Treating comorbid anxiety and aggression in children. J Am Acad Child Adolesc Psychiatry. 2007, 46: 1111-1118.PubMed Levy K, Hunt C, Heriot S: Treating comorbid anxiety and aggression in children. J Am Acad Child Adolesc Psychiatry. 2007, 46: 1111-1118.PubMed
1252.
Zurück zum Zitat Najavits LM, Gallop RJ, Weiss RD: Seeking safety therapy for adolescent girls with PTSD and substance use disorder: a randomized controlled trial. J Behav Health Serv Res. 2006, 33: 453-463.PubMed Najavits LM, Gallop RJ, Weiss RD: Seeking safety therapy for adolescent girls with PTSD and substance use disorder: a randomized controlled trial. J Behav Health Serv Res. 2006, 33: 453-463.PubMed
1253.
Zurück zum Zitat Dadds MR, Holland DE, Laurens KR, Mullins M, Barrett PM, Spence SH: Early intervention and prevention of anxiety disorders in children: results at 2-year follow-up. J Consult Clin Psychol. 1999, 67: 145-150.PubMed Dadds MR, Holland DE, Laurens KR, Mullins M, Barrett PM, Spence SH: Early intervention and prevention of anxiety disorders in children: results at 2-year follow-up. J Consult Clin Psychol. 1999, 67: 145-150.PubMed
1254.
Zurück zum Zitat Barrett P, Duffy A, Dadds M, Rapee R: Cognitive-behavioral treatment of anxiety disorders in children: long-term (6-year) follow-up. J Consult Clin Psychol. 2001, 69: 135-141.PubMed Barrett P, Duffy A, Dadds M, Rapee R: Cognitive-behavioral treatment of anxiety disorders in children: long-term (6-year) follow-up. J Consult Clin Psychol. 2001, 69: 135-141.PubMed
1255.
Zurück zum Zitat Connolly SD, Bernstein GA: Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2007, 46: 267-283.PubMed Connolly SD, Bernstein GA: Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2007, 46: 267-283.PubMed
1256.
Zurück zum Zitat Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009, 48: 961-973. Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009, 48: 961-973.
1257.
Zurück zum Zitat Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2012, 51: 98-113. Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2012, 51: 98-113.
1258.
Zurück zum Zitat Cohen JA, Bukstein O, Walter H, Benson SR, Chrisman A, Farchione TR, Hamilton J, Keable H, Kinlan J, Schoettle U, et al: Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. J Am Acad Child Adolesc Psychiatry. 2010, 49: 414-430.PubMed Cohen JA, Bukstein O, Walter H, Benson SR, Chrisman A, Farchione TR, Hamilton J, Keable H, Kinlan J, Schoettle U, et al: Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. J Am Acad Child Adolesc Psychiatry. 2010, 49: 414-430.PubMed
1259.
Zurück zum Zitat Bernstein G, Borchardt C, Perwien A, Crosby R, Kushner M, Thuras P, Last C: Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry. 2000, 39: 276-283.PubMed Bernstein G, Borchardt C, Perwien A, Crosby R, Kushner M, Thuras P, Last C: Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry. 2000, 39: 276-283.PubMed
1260.
Zurück zum Zitat Reinblatt SP, Riddle MA: The pharmacological management of childhood anxiety disorders: a review. Psychopharmacology. 2007, 191: 67-86.PubMed Reinblatt SP, Riddle MA: The pharmacological management of childhood anxiety disorders: a review. Psychopharmacology. 2007, 191: 67-86.PubMed
1261.
Zurück zum Zitat Ipser JC, Stein DJ, Hawkridge S, Hoppe L: Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2009, CD005170- Ipser JC, Stein DJ, Hawkridge S, Hoppe L: Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2009, CD005170-
1262.
Zurück zum Zitat Uthman OA, Abdulmalik J: Comparative efficacy and acceptability of pharmacotherapeutic agents for anxiety disorders in children and adolescents: a mixed treatment comparison meta-analysis. Curr Med Res Opin. 2010, 26: 53-59.PubMed Uthman OA, Abdulmalik J: Comparative efficacy and acceptability of pharmacotherapeutic agents for anxiety disorders in children and adolescents: a mixed treatment comparison meta-analysis. Curr Med Res Opin. 2010, 26: 53-59.PubMed
1263.
Zurück zum Zitat Geller D, Biederman J, Stewart S, Mullin B, Martin A, Spencer T, Faraone S: Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry. 2003, 160: 1919-1928.PubMed Geller D, Biederman J, Stewart S, Mullin B, Martin A, Spencer T, Faraone S: Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry. 2003, 160: 1919-1928.PubMed
1264.
Zurück zum Zitat Alaghband-Rad J, Hakimshooshtary M: A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). Eur Child Adolesc Psychiatry. 2009, 18: 131-135.PubMed Alaghband-Rad J, Hakimshooshtary M: A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). Eur Child Adolesc Psychiatry. 2009, 18: 131-135.PubMed
1265.
Zurück zum Zitat Coskun M, Zoroglu S: Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2009, 19: 297-300.PubMed Coskun M, Zoroglu S: Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2009, 19: 297-300.PubMed
1266.
Zurück zum Zitat Ercan ES, Kandulu R, Akyol Ardic U: Preschool children with obsessive-compulsive disorder and fluoxetine treatment. Eur Child Adolesc Psychiatry. 2012, 21: 169-172.PubMed Ercan ES, Kandulu R, Akyol Ardic U: Preschool children with obsessive-compulsive disorder and fluoxetine treatment. Eur Child Adolesc Psychiatry. 2012, 21: 169-172.PubMed
1267.
Zurück zum Zitat Geller D, Hoog S, Heiligenstein J, Ricardi R, Tamura R, Kluszynski S, Jacobson J: Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 2001, 40: 773-779.PubMed Geller D, Hoog S, Heiligenstein J, Ricardi R, Tamura R, Kluszynski S, Jacobson J: Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 2001, 40: 773-779.PubMed
1268.
Zurück zum Zitat Riddle M, Scahill L, King R, Hardin M, Anderson G, Ort S, Smith J, Leckman J, Cohen D: Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1992, 31: 1062-1069.PubMed Riddle M, Scahill L, King R, Hardin M, Anderson G, Ort S, Smith J, Leckman J, Cohen D: Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1992, 31: 1062-1069.PubMed
1269.
Zurück zum Zitat Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO, Graae F, Jaffer M, Lin SH, Sallee FR, et al: Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2002, 41: 1431-1438.PubMed Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO, Graae F, Jaffer M, Lin SH, Sallee FR, et al: Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2002, 41: 1431-1438.PubMed
1270.
Zurück zum Zitat Mukaddes NM, Abali O, Kaynak N: Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary report. Psychiatry Clin Neurosci. 2003, 57: 405-408.PubMed Mukaddes NM, Abali O, Kaynak N: Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary report. Psychiatry Clin Neurosci. 2003, 57: 405-408.PubMed
1271.
Zurück zum Zitat Riddle M, Reeve E, Yaryura-Tobias J, Yang H, Claghorn J, Gaffney G, Greist J, Holland D, McConville B, Pigott T, Walkup J: Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry. 2001, 40: 222-229.PubMed Riddle M, Reeve E, Yaryura-Tobias J, Yang H, Claghorn J, Gaffney G, Greist J, Holland D, McConville B, Pigott T, Walkup J: Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry. 2001, 40: 222-229.PubMed
1272.
Zurück zum Zitat Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E, Perera P, Machin A, Gardiner C: Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2004, 43: 1387-1396.PubMed Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E, Perera P, Machin A, Gardiner C: Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2004, 43: 1387-1396.PubMed
1273.
Zurück zum Zitat March J, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook E, Cutler N, Dominguez R, Ferguson J, Muller B, et al: Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA. 1998, 280: 1752-1756.PubMed March J, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook E, Cutler N, Dominguez R, Ferguson J, Muller B, et al: Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA. 1998, 280: 1752-1756.PubMed
1274.
Zurück zum Zitat De Veaugh-Geiss J, Moroz G, Biederman J, Cantwell D, Fontaine R, Greist J, Reichler R, Katz R, Landau P: Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial. J Am Acad Child Adolesc Psychiatry. 1992, 31: 45-49. De Veaugh-Geiss J, Moroz G, Biederman J, Cantwell D, Fontaine R, Greist J, Reichler R, Katz R, Landau P: Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial. J Am Acad Child Adolesc Psychiatry. 1992, 31: 45-49.
1275.
Zurück zum Zitat Leonard HL, Swedo SE, Rapoport JL, Koby EV, Lenane MC, Cheslow DL, Hamburger SD: Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry. 1989, 46: 1088-1092.PubMed Leonard HL, Swedo SE, Rapoport JL, Koby EV, Lenane MC, Cheslow DL, Hamburger SD: Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry. 1989, 46: 1088-1092.PubMed
1276.
Zurück zum Zitat Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstrom B, Linnoila M: Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry. 1985, 42: 977-983.PubMed Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstrom B, Linnoila M: Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry. 1985, 42: 977-983.PubMed
1277.
Zurück zum Zitat Birmaher B, Axelson D, Monk K, Kalas C, Clark D, Ehmann M, Bridge J, Heo J, Brent D: Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003, 42: 415-423.PubMed Birmaher B, Axelson D, Monk K, Kalas C, Clark D, Ehmann M, Bridge J, Heo J, Brent D: Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003, 42: 415-423.PubMed
1278.
Zurück zum Zitat Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med. 2001, 344: 1279-1285. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med. 2001, 344: 1279-1285.
1279.
Zurück zum Zitat Wagner K, Berard R, Stein M, Wetherhold E, Carpenter D, Perera P, Gee M, Davy K, Machin A: A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004, 61: 1153-1162.PubMed Wagner K, Berard R, Stein M, Wetherhold E, Carpenter D, Perera P, Gee M, Davy K, Machin A: A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004, 61: 1153-1162.PubMed
1280.
Zurück zum Zitat Isolan L, Pheula G, Salum GA, Oswald S, Rohde LA, Manfro GG: An open-label trial of escitalopram in children and adolescents with social anxiety disorder. J Child Adolesc Psychopharmacol. 2007, 17: 751-760.PubMed Isolan L, Pheula G, Salum GA, Oswald S, Rohde LA, Manfro GG: An open-label trial of escitalopram in children and adolescents with social anxiety disorder. J Child Adolesc Psychopharmacol. 2007, 17: 751-760.PubMed
1281.
Zurück zum Zitat Compton S, Grant P, Chrisman A, Gammon P, Brown V, March J: Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry. 2001, 40: 564-571.PubMed Compton S, Grant P, Chrisman A, Gammon P, Brown V, March J: Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry. 2001, 40: 564-571.PubMed
1282.
Zurück zum Zitat March JS, Entusah AR, Rynn M, Albano AM, Tourian KA: A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry. 2007, 62: 1149-1154.PubMed March JS, Entusah AR, Rynn M, Albano AM, Tourian KA: A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry. 2007, 62: 1149-1154.PubMed
1283.
Zurück zum Zitat Mrakotsky C, Masek B, Biederman J, Raches D, Hsin O, Forbes P, de Moor C, DeMaso DR, Gonzalez-Heydrich J: Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia. J Anxiety Disord. 2008, 22: 88-97.PubMed Mrakotsky C, Masek B, Biederman J, Raches D, Hsin O, Forbes P, de Moor C, DeMaso DR, Gonzalez-Heydrich J: Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia. J Anxiety Disord. 2008, 22: 88-97.PubMed
1284.
Zurück zum Zitat Rynn MA, Siqueland L, Rickels K: Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry. 2001, 158: 2008-2014.PubMed Rynn MA, Siqueland L, Rickels K: Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry. 2001, 158: 2008-2014.PubMed
1285.
Zurück zum Zitat Lepola U, Leinonen E, Koponen H: Citalopram in the treatment of early-onset panic disorder and school phobia. Pharmacopsychiatry. 1996, 29: 30-32.PubMed Lepola U, Leinonen E, Koponen H: Citalopram in the treatment of early-onset panic disorder and school phobia. Pharmacopsychiatry. 1996, 29: 30-32.PubMed
1286.
Zurück zum Zitat Robb AS, Cueva JE, Sporn J, Yang R, Vanderburg DG: Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2010, 20: 463-471.PubMed Robb AS, Cueva JE, Sporn J, Yang R, Vanderburg DG: Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2010, 20: 463-471.PubMed
1287.
Zurück zum Zitat Kutcher SP, MacKenzie S: Successful clonazepam treatment of adolescents with panic disorder. J Clin Psychopharmacol. 1988, 8: 299-301.PubMed Kutcher SP, MacKenzie S: Successful clonazepam treatment of adolescents with panic disorder. J Clin Psychopharmacol. 1988, 8: 299-301.PubMed
1288.
Zurück zum Zitat Biederman J: Clonazepam in the treatment of prepubertal children with panic-like symptoms. J Clin Psychiatry. 1987, 48 (Suppl): 38-42.PubMed Biederman J: Clonazepam in the treatment of prepubertal children with panic-like symptoms. J Clin Psychiatry. 1987, 48 (Suppl): 38-42.PubMed
1289.
Zurück zum Zitat Ballenger JC, Carek DJ, Steele JJ, Cornish-McTighe D: Three cases of panic disorder with agoraphobia in children. Am J Psychiatry. 1989, 146: 922-924.PubMed Ballenger JC, Carek DJ, Steele JJ, Cornish-McTighe D: Three cases of panic disorder with agoraphobia in children. Am J Psychiatry. 1989, 146: 922-924.PubMed
1290.
Zurück zum Zitat Simeon JG, Ferguson HB, Knott V, Roberts N, Gauthier B, Dubois C, Wiggins D: Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry. 1992, 31: 29-33.PubMed Simeon JG, Ferguson HB, Knott V, Roberts N, Gauthier B, Dubois C, Wiggins D: Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry. 1992, 31: 29-33.PubMed
1291.
Zurück zum Zitat Bernstein GA, Garfinkel BD, Borchardt CM: Comparative studies of pharmacotherapy for school refusal. J Am Acad Child Adolesc Psychiatry. 1990, 29: 773-781.PubMed Bernstein GA, Garfinkel BD, Borchardt CM: Comparative studies of pharmacotherapy for school refusal. J Am Acad Child Adolesc Psychiatry. 1990, 29: 773-781.PubMed
1292.
Zurück zum Zitat Graae F, Milner J, Rizzotto L, Klein RG: Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 1994, 33: 372-376.PubMed Graae F, Milner J, Rizzotto L, Klein RG: Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 1994, 33: 372-376.PubMed
1293.
Zurück zum Zitat Masi G, Pfanner C, Millepiedi S, Berloffa S: Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2010, 30: 688-693.PubMed Masi G, Pfanner C, Millepiedi S, Berloffa S: Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2010, 30: 688-693.PubMed
1294.
Zurück zum Zitat Grant P, Lougee L, Hirschtritt M, Swedo SE: An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2007, 17: 761-767.PubMed Grant P, Lougee L, Hirschtritt M, Swedo SE: An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2007, 17: 761-767.PubMed
1295.
Zurück zum Zitat Storch EA, Murphy TK, Goodman WK, Geffken GR, Lewin AB, Henin A, Micco JA, Sprich S, Wilhelm S, Bengtson M, Geller DA: A preliminary study of d-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010, 68: 1073-1076.PubMedCentralPubMed Storch EA, Murphy TK, Goodman WK, Geffken GR, Lewin AB, Henin A, Micco JA, Sprich S, Wilhelm S, Bengtson M, Geller DA: A preliminary study of d-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010, 68: 1073-1076.PubMedCentralPubMed
1296.
Zurück zum Zitat Larun L, Nordheim LV, Ekeland E, Hagen KB, Heian F: Exercise in prevention and treatment of anxiety and depression among children and young people. Cochrane Database Syst Rev. 2006, 3: CD004691-PubMed Larun L, Nordheim LV, Ekeland E, Hagen KB, Heian F: Exercise in prevention and treatment of anxiety and depression among children and young people. Cochrane Database Syst Rev. 2006, 3: CD004691-PubMed
1297.
Zurück zum Zitat Newman CL, Motta RW: The effects of aerobic exercise on childhood PTSD, anxiety, and depression. Int J Emerg Ment Health. 2007, 9: 133-158.PubMed Newman CL, Motta RW: The effects of aerobic exercise on childhood PTSD, anxiety, and depression. Int J Emerg Ment Health. 2007, 9: 133-158.PubMed
1298.
Zurück zum Zitat Diaz AB, Motta R: The effects of an aerobic exercise program on posttraumatic stress disorder symptom severity in adolescents. Int J Emerg Ment Health. 2008, 10: 49-59.PubMed Diaz AB, Motta R: The effects of an aerobic exercise program on posttraumatic stress disorder symptom severity in adolescents. Int J Emerg Ment Health. 2008, 10: 49-59.PubMed
1299.
Zurück zum Zitat Harris E, Eng HY, Kowatch R, Delgado SV, Saldana SN: Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2010, 20: 347-353.PubMed Harris E, Eng HY, Kowatch R, Delgado SV, Saldana SN: Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2010, 20: 347-353.PubMed
1300.
Zurück zum Zitat Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D: Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004, 158: 773-780.PubMed Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D: Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004, 158: 773-780.PubMed
1301.
Zurück zum Zitat Findling RL, Nucci G, Piergies AA, Gomeni R, Bartolic EI, Fong R, Carpenter DJ, Leeder JS, Gaedigk A, Danoff TM: Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology. 2006, 31: 1274-1285.PubMed Findling RL, Nucci G, Piergies AA, Gomeni R, Bartolic EI, Fong R, Carpenter DJ, Leeder JS, Gaedigk A, Danoff TM: Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology. 2006, 31: 1274-1285.PubMed
1302.
Zurück zum Zitat Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA: Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007, 297: 1683-1696.PubMed Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA: Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007, 297: 1683-1696.PubMed
1303.
Zurück zum Zitat Safer DJ, Zito JM: Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol. 2006, 16: 159-169.PubMed Safer DJ, Zito JM: Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol. 2006, 16: 159-169.PubMed
1304.
Zurück zum Zitat Gum AM, King-Kallimanis B, Kohn R: Prevalence of mood, anxiety, and substance-abuse disorders for older Americans in the National Comorbidity Survey-Replication. Am J Geriatr Psychiatry. 2009, 17: 769-781.PubMed Gum AM, King-Kallimanis B, Kohn R: Prevalence of mood, anxiety, and substance-abuse disorders for older Americans in the National Comorbidity Survey-Replication. Am J Geriatr Psychiatry. 2009, 17: 769-781.PubMed
1305.
Zurück zum Zitat Grenier S, Preville M, Boyer R, O'Connor K, Beland SG, Potvin O, Hudon C, Brassard J: The impact of DSM-IV symptom and clinical significance criteria on the prevalence estimates of subthreshold and threshold anxiety in the older adult population. Am J Geriatr Psychiatry. 2011, 19: 316-326.PubMedCentralPubMed Grenier S, Preville M, Boyer R, O'Connor K, Beland SG, Potvin O, Hudon C, Brassard J: The impact of DSM-IV symptom and clinical significance criteria on the prevalence estimates of subthreshold and threshold anxiety in the older adult population. Am J Geriatr Psychiatry. 2011, 19: 316-326.PubMedCentralPubMed
1306.
Zurück zum Zitat Streiner DL, Cairney J, Veldhuizen S: The epidemiology of psychological problems in the elderly. Can J Psychiatry. 2006, 51: 185-191.PubMed Streiner DL, Cairney J, Veldhuizen S: The epidemiology of psychological problems in the elderly. Can J Psychiatry. 2006, 51: 185-191.PubMed
1307.
Zurück zum Zitat Hollingworth SA, Burgess PM, Whiteford HA: Affective and anxiety disorders: prevalence, treatment and antidepressant medication use. Aust N Z J Psychiatry. 2010, 44: 513-519.PubMed Hollingworth SA, Burgess PM, Whiteford HA: Affective and anxiety disorders: prevalence, treatment and antidepressant medication use. Aust N Z J Psychiatry. 2010, 44: 513-519.PubMed
1308.
Zurück zum Zitat Jorm A: Does old age reduce the risk of anxiety and depression? A review of epidemiological studies across the adult life span. Psychol Med. 2000, 30: 11-22.PubMed Jorm A: Does old age reduce the risk of anxiety and depression? A review of epidemiological studies across the adult life span. Psychol Med. 2000, 30: 11-22.PubMed
1309.
Zurück zum Zitat Calleo J, Stanley MA, Greisinger A, Wehmanen O, Johnson M, Novy D, Wilson N, Kunik M: Generalized anxiety disorder in older medical patients: diagnostic recognition, mental health management and service utilization. J Clin Psychol Med Settings. 2009, 16: 178-185.PubMedCentralPubMed Calleo J, Stanley MA, Greisinger A, Wehmanen O, Johnson M, Novy D, Wilson N, Kunik M: Generalized anxiety disorder in older medical patients: diagnostic recognition, mental health management and service utilization. J Clin Psychol Med Settings. 2009, 16: 178-185.PubMedCentralPubMed
1310.
Zurück zum Zitat Cairney J, Corna LM, Streiner DL: Mental health care use in later life: results from a national survey of Canadians. Can J Psychiatry. 2010, 55: 157-164.PubMed Cairney J, Corna LM, Streiner DL: Mental health care use in later life: results from a national survey of Canadians. Can J Psychiatry. 2010, 55: 157-164.PubMed
1311.
Zurück zum Zitat Byers AL, Arean PA, Yaffe K: Low use of mental health services among older Americans with mood and anxiety disorders. Psychiatr Serv. 2012, 63: 66-72.PubMedCentralPubMed Byers AL, Arean PA, Yaffe K: Low use of mental health services among older Americans with mood and anxiety disorders. Psychiatr Serv. 2012, 63: 66-72.PubMedCentralPubMed
1312.
Zurück zum Zitat Scott T, Mackenzie CS, Chipperfield JG, Sareen J: Mental health service use among Canadian older adults with anxiety disorders and clinically significant anxiety symptoms. Aging Ment Health. 2010, 14: 790-800.PubMed Scott T, Mackenzie CS, Chipperfield JG, Sareen J: Mental health service use among Canadian older adults with anxiety disorders and clinically significant anxiety symptoms. Aging Ment Health. 2010, 14: 790-800.PubMed
1313.
Zurück zum Zitat Brenes GA, Miller ME, Stanley MA, Williamson JD, Knudson M, McCall WV: Insomnia in older adults with generalized anxiety disorder. Am J Geriatr Psychiatry. 2009, 17: 465-472.PubMedCentralPubMed Brenes GA, Miller ME, Stanley MA, Williamson JD, Knudson M, McCall WV: Insomnia in older adults with generalized anxiety disorder. Am J Geriatr Psychiatry. 2009, 17: 465-472.PubMedCentralPubMed
1314.
Zurück zum Zitat Spira AP, Stone K, Beaudreau SA, Ancoli-Israel S, Yaffe K: Anxiety symptoms and objectively measured sleep quality in older women. Am J Geriatr Psychiatry. 2009, 17: 136-143.PubMedCentralPubMed Spira AP, Stone K, Beaudreau SA, Ancoli-Israel S, Yaffe K: Anxiety symptoms and objectively measured sleep quality in older women. Am J Geriatr Psychiatry. 2009, 17: 136-143.PubMedCentralPubMed
1315.
Zurück zum Zitat Mehta K, Simonsick E, Penninx B, Schulz R, Rubin S, Satterfield S, Yaffe K: Prevalence and correlates of anxiety symptoms in well-functioning older adults: findings from the health aging and body composition study. J Am Geriatr Soc. 2003, 51: 499-504.PubMed Mehta K, Simonsick E, Penninx B, Schulz R, Rubin S, Satterfield S, Yaffe K: Prevalence and correlates of anxiety symptoms in well-functioning older adults: findings from the health aging and body composition study. J Am Geriatr Soc. 2003, 51: 499-504.PubMed
1316.
Zurück zum Zitat Beaudreau SA, O'Hara R: The association of anxiety and depressive symptoms with cognitive performance in community-dwelling older adults. Psychol Aging. 2009, 24: 507-512.PubMedCentralPubMed Beaudreau SA, O'Hara R: The association of anxiety and depressive symptoms with cognitive performance in community-dwelling older adults. Psychol Aging. 2009, 24: 507-512.PubMedCentralPubMed
1317.
Zurück zum Zitat Butters MA, Bhalla RK, Andreescu C, Wetherell JL, Mantella R, Begley AE, Lenze EJ: Changes in neuropsychological functioning following treatment for late-life generalised anxiety disorder. Br J Psychiatry. 2011, 199: 211-218.PubMedCentralPubMed Butters MA, Bhalla RK, Andreescu C, Wetherell JL, Mantella R, Begley AE, Lenze EJ: Changes in neuropsychological functioning following treatment for late-life generalised anxiety disorder. Br J Psychiatry. 2011, 199: 211-218.PubMedCentralPubMed
1318.
Zurück zum Zitat Sinoff G, Werner P: Anxiety disorder and accompanying subjective memory loss in the elderly as a predictor of future cognitive decline. Int J Geriatr Psychiatry. 2003, 18: 951-959.PubMed Sinoff G, Werner P: Anxiety disorder and accompanying subjective memory loss in the elderly as a predictor of future cognitive decline. Int J Geriatr Psychiatry. 2003, 18: 951-959.PubMed
1319.
Zurück zum Zitat Scott Mackin R, Lesselyong JA, Yaffe K: Pattern of cognitive impairment in older veterans with posttraumatic stress disorder evaluated at a memory disorders clinic. Int J Geriatr Psychiatry. 2012, 27: 637-642.PubMedCentralPubMed Scott Mackin R, Lesselyong JA, Yaffe K: Pattern of cognitive impairment in older veterans with posttraumatic stress disorder evaluated at a memory disorders clinic. Int J Geriatr Psychiatry. 2012, 27: 637-642.PubMedCentralPubMed
1320.
Zurück zum Zitat Mehta KM, Yaffe K, Brenes GA, Newman AB, Shorr RI, Simonsick EM, Ayonayon HN, Rubin SM, Covinsky KE: Anxiety symptoms and decline in physical function over 5 years in the health, aging and body composition study. J Am Geriatr Soc. 2007, 55: 265-270.PubMedCentralPubMed Mehta KM, Yaffe K, Brenes GA, Newman AB, Shorr RI, Simonsick EM, Ayonayon HN, Rubin SM, Covinsky KE: Anxiety symptoms and decline in physical function over 5 years in the health, aging and body composition study. J Am Geriatr Soc. 2007, 55: 265-270.PubMedCentralPubMed
1321.
Zurück zum Zitat Porensky EK, Dew MA, Karp JF, Skidmore E, Rollman BL, Shear MK, Lenze EJ: The burden of late-life generalized anxiety disorder: effects on disability, health-related quality of life, and healthcare utilization. Am J Geriatr Psychiatry. 2009, 17: 473-482.PubMedCentralPubMed Porensky EK, Dew MA, Karp JF, Skidmore E, Rollman BL, Shear MK, Lenze EJ: The burden of late-life generalized anxiety disorder: effects on disability, health-related quality of life, and healthcare utilization. Am J Geriatr Psychiatry. 2009, 17: 473-482.PubMedCentralPubMed
1322.
Zurück zum Zitat Diefenbach GJ, Tolin DF, Gilliam CM: Impairments in life quality among clients in geriatric home care: associations with depressive and anxiety symptoms. Int J Geriatr Psychiatry. 2012, 27: 828-835.PubMedCentralPubMed Diefenbach GJ, Tolin DF, Gilliam CM: Impairments in life quality among clients in geriatric home care: associations with depressive and anxiety symptoms. Int J Geriatr Psychiatry. 2012, 27: 828-835.PubMedCentralPubMed
1323.
Zurück zum Zitat Cairney J, Corna LM, Veldhuizen S, Herrmann N, Streiner DL: Comorbid depression and anxiety in later life: patterns of association, subjective well-being, and impairment. Am J Geriatr Psychiatry. 2008, 16: 201-208.PubMed Cairney J, Corna LM, Veldhuizen S, Herrmann N, Streiner DL: Comorbid depression and anxiety in later life: patterns of association, subjective well-being, and impairment. Am J Geriatr Psychiatry. 2008, 16: 201-208.PubMed
1324.
Zurück zum Zitat King-Kallimanis B, Gum AM, Kohn R: Comorbidity of depressive and anxiety disorders for older Americans in the National Comorbidity Survey-Replication. Am J Geriatr Psychiatry. 2009, 17: 782-792.PubMed King-Kallimanis B, Gum AM, Kohn R: Comorbidity of depressive and anxiety disorders for older Americans in the National Comorbidity Survey-Replication. Am J Geriatr Psychiatry. 2009, 17: 782-792.PubMed
1325.
Zurück zum Zitat Wetherell JL, Ayers CR, Nuevo R, Stein MB, Ramsdell J, Patterson TL: Medical conditions and depressive, anxiety, and somatic symptoms in older adults with and without generalized anxiety disorder. Aging Ment Health. 2010, 14: 764-768.PubMedCentralPubMed Wetherell JL, Ayers CR, Nuevo R, Stein MB, Ramsdell J, Patterson TL: Medical conditions and depressive, anxiety, and somatic symptoms in older adults with and without generalized anxiety disorder. Aging Ment Health. 2010, 14: 764-768.PubMedCentralPubMed
1326.
Zurück zum Zitat Schoevers R, Deeg D, van Tilburg W, Beekman A: Depression and generalized anxiety disorder: co-occurrence and longitudinal patterns in elderly patients. Am J Geriatr Psychiatry. 2005, 13: 31-39.PubMed Schoevers R, Deeg D, van Tilburg W, Beekman A: Depression and generalized anxiety disorder: co-occurrence and longitudinal patterns in elderly patients. Am J Geriatr Psychiatry. 2005, 13: 31-39.PubMed
1327.
Zurück zum Zitat Wolitzky-Taylor KB, Castriotta N, Lenze EJ, Stanley MA, Craske MG: Anxiety disorders in older adults: a comprehensive review. Depress Anxiety. 2010, 27: 190-211.PubMed Wolitzky-Taylor KB, Castriotta N, Lenze EJ, Stanley MA, Craske MG: Anxiety disorders in older adults: a comprehensive review. Depress Anxiety. 2010, 27: 190-211.PubMed
1328.
Zurück zum Zitat Qureshi SU, Kimbrell T, Pyne JM, Magruder KM, Hudson TJ, Petersen NJ, Yu HJ, Schulz PE, Kunik ME: Greater prevalence and incidence of dementia in older veterans with posttraumatic stress disorder. J Am Geriatr Soc. 2010, 58: 1627-1633.PubMed Qureshi SU, Kimbrell T, Pyne JM, Magruder KM, Hudson TJ, Petersen NJ, Yu HJ, Schulz PE, Kunik ME: Greater prevalence and incidence of dementia in older veterans with posttraumatic stress disorder. J Am Geriatr Soc. 2010, 58: 1627-1633.PubMed
1329.
Zurück zum Zitat Vogele C, von Leupoldt A: Mental disorders in chronic obstructive pulmonary disease (COPD). Respir Med. 2008, 102: 764-773.PubMed Vogele C, von Leupoldt A: Mental disorders in chronic obstructive pulmonary disease (COPD). Respir Med. 2008, 102: 764-773.PubMed
1330.
Zurück zum Zitat Smoller JW, Pollack MH, Wassertheil-Smoller S, Jackson RD, Oberman A, Wong ND, Sheps D: Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study. Arch Gen Psychiatry. 2007, 64: 1153-1160.PubMed Smoller JW, Pollack MH, Wassertheil-Smoller S, Jackson RD, Oberman A, Wong ND, Sheps D: Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study. Arch Gen Psychiatry. 2007, 64: 1153-1160.PubMed
1331.
Zurück zum Zitat Tully PJ, Baker RA, Knight JL: Anxiety and depression as risk factors for mortality after coronary artery bypass surgery. J Psychosom Res. 2008, 64: 285-290.PubMed Tully PJ, Baker RA, Knight JL: Anxiety and depression as risk factors for mortality after coronary artery bypass surgery. J Psychosom Res. 2008, 64: 285-290.PubMed
1332.
Zurück zum Zitat Bryant C, Jackson H, Ames D: The prevalence of anxiety in older adults: methodological issues and a review of the literature. J Affect Disord. 2008, 109: 233-250.PubMed Bryant C, Jackson H, Ames D: The prevalence of anxiety in older adults: methodological issues and a review of the literature. J Affect Disord. 2008, 109: 233-250.PubMed
1333.
Zurück zum Zitat Mohlman J, Bryant C, Lenze EJ, Stanley MA, Gum A, Flint A, Beekman AT, Wetherell JL, Thorp SR, Craske MG: Improving recognition of late life anxiety disorders in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: observations and recommendations of the Advisory Committee to the Lifespan Disorders Work Group. Int J Geriatr Psychiatry. 2012, 27: 549-556.PubMedCentralPubMed Mohlman J, Bryant C, Lenze EJ, Stanley MA, Gum A, Flint A, Beekman AT, Wetherell JL, Thorp SR, Craske MG: Improving recognition of late life anxiety disorders in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: observations and recommendations of the Advisory Committee to the Lifespan Disorders Work Group. Int J Geriatr Psychiatry. 2012, 27: 549-556.PubMedCentralPubMed
1334.
Zurück zum Zitat Brenes GA, Knudson M, McCall WV, Williamson JD, Miller ME, Stanley MA: Age and racial differences in the presentation and treatment of generalized anxiety disorder in primary care. J Anxiety Disord. 2008, 22: 1128-1136.PubMedCentralPubMed Brenes GA, Knudson M, McCall WV, Williamson JD, Miller ME, Stanley MA: Age and racial differences in the presentation and treatment of generalized anxiety disorder in primary care. J Anxiety Disord. 2008, 22: 1128-1136.PubMedCentralPubMed
1335.
Zurück zum Zitat Wetherell JL, Petkus AJ, McChesney K, Stein MB, Judd PH, Rockwell E, Sewell DD, Patterson TL: Older adults are less accurate than younger adults at identifying symptoms of anxiety and depression. J Nerv Ment Dis. 2009, 197: 623-626.PubMedCentralPubMed Wetherell JL, Petkus AJ, McChesney K, Stein MB, Judd PH, Rockwell E, Sewell DD, Patterson TL: Older adults are less accurate than younger adults at identifying symptoms of anxiety and depression. J Nerv Ment Dis. 2009, 197: 623-626.PubMedCentralPubMed
1336.
Zurück zum Zitat Jeste DV, Blazer DG, First M: Aging-related diagnostic variations: need for diagnostic criteria appropriate for elderly psychiatric patients. Biol Psychiatry. 2005, 58: 265-271.PubMed Jeste DV, Blazer DG, First M: Aging-related diagnostic variations: need for diagnostic criteria appropriate for elderly psychiatric patients. Biol Psychiatry. 2005, 58: 265-271.PubMed
1337.
Zurück zum Zitat Ayers CR, Sorrell JT, Thorp SR, Wetherell JL: Evidence-based psychological treatments for late-life anxiety. Psychol Aging. 2007, 22: 8-17.PubMed Ayers CR, Sorrell JT, Thorp SR, Wetherell JL: Evidence-based psychological treatments for late-life anxiety. Psychol Aging. 2007, 22: 8-17.PubMed
1338.
Zurück zum Zitat Pinquart M, Duberstein PR: Treatment of anxiety disorders in older adults: a meta-analytic comparison of behavioral and pharmacological interventions. Am J Geriatr Psychiatry. 2007, 15: 639-651.PubMed Pinquart M, Duberstein PR: Treatment of anxiety disorders in older adults: a meta-analytic comparison of behavioral and pharmacological interventions. Am J Geriatr Psychiatry. 2007, 15: 639-651.PubMed
1339.
Zurück zum Zitat Goncalves DC, Byrne GJ: Interventions for generalized anxiety disorder in older adults: systematic review and meta-analysis. J Anxiety Disord. 2012, 26: 1-11.PubMed Goncalves DC, Byrne GJ: Interventions for generalized anxiety disorder in older adults: systematic review and meta-analysis. J Anxiety Disord. 2012, 26: 1-11.PubMed
1340.
Zurück zum Zitat Hendriks GJ, Oude Voshaar RC, Keijsers GP, Hoogduin CA, van Balkom AJ: Cognitive-behavioural therapy for late-life anxiety disorders: a systematic review and meta-analysis. Acta Psychiatr Scand. 2008, 117: 403-411.PubMed Hendriks GJ, Oude Voshaar RC, Keijsers GP, Hoogduin CA, van Balkom AJ: Cognitive-behavioural therapy for late-life anxiety disorders: a systematic review and meta-analysis. Acta Psychiatr Scand. 2008, 117: 403-411.PubMed
1341.
Zurück zum Zitat Thorp SR, Ayers CR, Nuevo R, Stoddard JA, Sorrell JT, Wetherell JL: Meta-analysis comparing different behavioral treatments for late-life anxiety. Am J Geriatr Psychiatry. 2009, 17: 105-115.PubMedCentralPubMed Thorp SR, Ayers CR, Nuevo R, Stoddard JA, Sorrell JT, Wetherell JL: Meta-analysis comparing different behavioral treatments for late-life anxiety. Am J Geriatr Psychiatry. 2009, 17: 105-115.PubMedCentralPubMed
1342.
Zurück zum Zitat Gould RL, Coulson MC, Howard RJ: Efficacy of cognitive behavioral therapy for anxiety disorders in older people: a meta-analysis and meta-regression of randomized controlled trials. J Am Geriatr Soc. 2012, 60: 218-229.PubMed Gould RL, Coulson MC, Howard RJ: Efficacy of cognitive behavioral therapy for anxiety disorders in older people: a meta-analysis and meta-regression of randomized controlled trials. J Am Geriatr Soc. 2012, 60: 218-229.PubMed
1343.
Zurück zum Zitat Mohlman J, Gorenstein E, Kleber M, de JM, Gorman J, Papp L: Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety disorder: two pilot investigations. Am J Geriatr Psychiatry. 2003, 11: 24-32.PubMed Mohlman J, Gorenstein E, Kleber M, de JM, Gorman J, Papp L: Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety disorder: two pilot investigations. Am J Geriatr Psychiatry. 2003, 11: 24-32.PubMed
1344.
Zurück zum Zitat Stanley M, Hopko D, Diefenbach G, Bourland S, Rodriguez H, Wagener P: Cognitive-behavior therapy for late-life generalized anxiety disorder in primary care: preliminary findings. Am J Geriatr Psychiatry. 2003, 11: 92-96.PubMed Stanley M, Hopko D, Diefenbach G, Bourland S, Rodriguez H, Wagener P: Cognitive-behavior therapy for late-life generalized anxiety disorder in primary care: preliminary findings. Am J Geriatr Psychiatry. 2003, 11: 92-96.PubMed
1345.
Zurück zum Zitat Bradford A, Cully J, Rhoades H, Kunik M, Kraus-Schuman C, Wilson N, Stanley M: Early response to psychotherapy and long-term change in worry symptoms in older adults with generalized anxiety disorder. Am J Geriatr Psychiatry. 2011, 19: 347-356.PubMedCentralPubMed Bradford A, Cully J, Rhoades H, Kunik M, Kraus-Schuman C, Wilson N, Stanley M: Early response to psychotherapy and long-term change in worry symptoms in older adults with generalized anxiety disorder. Am J Geriatr Psychiatry. 2011, 19: 347-356.PubMedCentralPubMed
1346.
Zurück zum Zitat Stanley MA, Wilson NL, Novy DM, Rhoades HM, Wagener PD, Greisinger AJ, Cully JA, Kunik ME: Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trial. JAMA. 2009, 301: 1460-1467.PubMedCentralPubMed Stanley MA, Wilson NL, Novy DM, Rhoades HM, Wagener PD, Greisinger AJ, Cully JA, Kunik ME: Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trial. JAMA. 2009, 301: 1460-1467.PubMedCentralPubMed
1347.
Zurück zum Zitat Wetherell J, Gatz M, Craske M: Treatment of generalized anxiety disorder in older adults. J Consult Clin Psychol. 2003, 71: 31-40.PubMed Wetherell J, Gatz M, Craske M: Treatment of generalized anxiety disorder in older adults. J Consult Clin Psychol. 2003, 71: 31-40.PubMed
1348.
Zurück zum Zitat Hendriks GJ, Keijsers GP, Kampman M, Oude Voshaar RC, Verbraak MJ, Broekman TG, Hoogduin CA: A randomized controlled study of paroxetine and cognitive-behavioural therapy for late-life panic disorder. Acta Psychiatr Scand. 2010, 122: 11-19.PubMed Hendriks GJ, Keijsers GP, Kampman M, Oude Voshaar RC, Verbraak MJ, Broekman TG, Hoogduin CA: A randomized controlled study of paroxetine and cognitive-behavioural therapy for late-life panic disorder. Acta Psychiatr Scand. 2010, 122: 11-19.PubMed
1349.
Zurück zum Zitat Schuurmans J, Comijs H, Emmelkamp PM, Gundy CM, Weijnen I, van den Hout M, van Dyck R: A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. Am J Geriatr Psychiatry. 2006, 14: 255-263.PubMed Schuurmans J, Comijs H, Emmelkamp PM, Gundy CM, Weijnen I, van den Hout M, van Dyck R: A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. Am J Geriatr Psychiatry. 2006, 14: 255-263.PubMed
1350.
Zurück zum Zitat Thorp SR, Stein MB, Jeste DV, Patterson TL, Wetherell JL: Prolonged exposure therapy for older veterans with posttraumatic stress disorder: a pilot study. Am J Geriatr Psychiatry. 2012, 20: 276-280.PubMed Thorp SR, Stein MB, Jeste DV, Patterson TL, Wetherell JL: Prolonged exposure therapy for older veterans with posttraumatic stress disorder: a pilot study. Am J Geriatr Psychiatry. 2012, 20: 276-280.PubMed
1351.
Zurück zum Zitat Pachana NA, Woodward RM, Byrne GJ: Treatment of specific phobia in older adults. Clin Interv Aging. 2007, 2: 469-476.PubMedCentralPubMed Pachana NA, Woodward RM, Byrne GJ: Treatment of specific phobia in older adults. Clin Interv Aging. 2007, 2: 469-476.PubMedCentralPubMed
1352.
Zurück zum Zitat Brenes GA, Miller ME, Williamson JD, McCall WV, Knudson M, Stanley MA: A randomized controlled trial of telephone-delivered cognitive-behavioral therapy for late-life anxiety disorders. Am J Geriatr Psychiatry. 2012, 20: 707-716.PubMedCentralPubMed Brenes GA, Miller ME, Williamson JD, McCall WV, Knudson M, Stanley MA: A randomized controlled trial of telephone-delivered cognitive-behavioral therapy for late-life anxiety disorders. Am J Geriatr Psychiatry. 2012, 20: 707-716.PubMedCentralPubMed
1353.
Zurück zum Zitat Pasco JA, Williams LJ, Jacka FN, Henry MJ, Coulson CE, Brennan SL, Leslie E, Nicholson GC, Kotowicz MA, Berk M: Habitual physical activity and the risk for depressive and anxiety disorders among older men and women. Int Psychogeriatr. 2011, 23: 292-298.PubMed Pasco JA, Williams LJ, Jacka FN, Henry MJ, Coulson CE, Brennan SL, Leslie E, Nicholson GC, Kotowicz MA, Berk M: Habitual physical activity and the risk for depressive and anxiety disorders among older men and women. Int Psychogeriatr. 2011, 23: 292-298.PubMed
1354.
Zurück zum Zitat Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F: Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry. 2008, 193: 389-394.PubMed Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F: Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry. 2008, 193: 389-394.PubMed
1355.
Zurück zum Zitat Karaiskos D, Pappa D, Tzavellas E, Siarkos K, Katirtzoglou E, Papadimitriou GN, Politis A: Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study. Int J Geriatr Psychiatry. 2013, 28: 100-105.PubMed Karaiskos D, Pappa D, Tzavellas E, Siarkos K, Katirtzoglou E, Papadimitriou GN, Politis A: Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study. Int J Geriatr Psychiatry. 2013, 28: 100-105.PubMed
1356.
Zurück zum Zitat Davidson J, Allgulander C, Pollack MH, Hartford J, Erickson JS, Russell JM, Perahia D, Wohlreich MM, Carlson J, Raskin J: Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol. 2008, 23: 519-526.PubMed Davidson J, Allgulander C, Pollack MH, Hartford J, Erickson JS, Russell JM, Perahia D, Wohlreich MM, Carlson J, Raskin J: Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol. 2008, 23: 519-526.PubMed
1357.
Zurück zum Zitat Lenze EJ, Mulsant BH, Shear MK, Dew MA, Miller MD, Pollock BG, Houck P, Tracey B, Reynolds CF: Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry. 2005, 162: 146-150.PubMed Lenze EJ, Mulsant BH, Shear MK, Dew MA, Miller MD, Pollock BG, Houck P, Tracey B, Reynolds CF: Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry. 2005, 162: 146-150.PubMed
1358.
Zurück zum Zitat Blank S, Lenze EJ, Mulsant BH, Dew MA, Karp JF, Shear MK, Houck PR, Miller MD, Pollock BG, Tracey B, Reynolds CF: Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment. J Clin Psychiatry. 2006, 67: 468-472.PubMed Blank S, Lenze EJ, Mulsant BH, Dew MA, Karp JF, Shear MK, Houck PR, Miller MD, Pollock BG, Tracey B, Reynolds CF: Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment. J Clin Psychiatry. 2006, 67: 468-472.PubMed
1359.
Zurück zum Zitat Mohamed S, Osatuke K, Aslam M, Kasckow J: Escitalopram for comorbid depression and anxiety in elderly patients: a 12-week, open-label, flexible-dose, pilot trial. Am J Geriatr Pharmacother. 2006, 4: 201-209.PubMed Mohamed S, Osatuke K, Aslam M, Kasckow J: Escitalopram for comorbid depression and anxiety in elderly patients: a 12-week, open-label, flexible-dose, pilot trial. Am J Geriatr Pharmacother. 2006, 4: 201-209.PubMed
1360.
Zurück zum Zitat Schuurmans J, Comijs H, Emmelkamp PM, Weijnen IJ, van den Hout M, van Dyck R: Long-term effectiveness and prediction of treatment outcome in cognitive behavioral therapy and sertraline for late-life anxiety disorders. Int Psychogeriatr. 2009, 21: 1148-1159.PubMed Schuurmans J, Comijs H, Emmelkamp PM, Weijnen IJ, van den Hout M, van Dyck R: Long-term effectiveness and prediction of treatment outcome in cognitive behavioral therapy and sertraline for late-life anxiety disorders. Int Psychogeriatr. 2009, 21: 1148-1159.PubMed
1361.
Zurück zum Zitat Rampello L, Alvano A, Raffaele R, Malaguarnera M, Vecchio I: New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. J Clin Psychopharmacol. 2006, 26: 67-70.PubMed Rampello L, Alvano A, Raffaele R, Malaguarnera M, Vecchio I: New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. J Clin Psychopharmacol. 2006, 26: 67-70.PubMed
1362.
Zurück zum Zitat Wylie M, Miller M, Shear M, Little J, Mulsant B, Pollock B, Reynolds C: Fluvoxamine pharmacotherapy of anxiety disorders in later life: preliminary open-trial data. J Geriatr Psychiatry Neurol. 2000, 13: 43-48.PubMed Wylie M, Miller M, Shear M, Little J, Mulsant B, Pollock B, Reynolds C: Fluvoxamine pharmacotherapy of anxiety disorders in later life: preliminary open-trial data. J Geriatr Psychiatry Neurol. 2000, 13: 43-48.PubMed
1363.
Zurück zum Zitat Gardner M, Malone D, Sey M, Babington M: Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities. J Am Med Dir Assoc. 2004, 5: 101-106.PubMed Gardner M, Malone D, Sey M, Babington M: Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities. J Am Med Dir Assoc. 2004, 5: 101-106.PubMed
1364.
Zurück zum Zitat Schatzberg A, Kremer C, Rodrigues H, Murphy G: Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 2002, 10: 541-550.PubMed Schatzberg A, Kremer C, Rodrigues H, Murphy G: Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 2002, 10: 541-550.PubMed
1365.
Zurück zum Zitat Benitez CI, Smith K, Vasile RG, Rende R, Edelen MO, Keller MB: Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study. Am J Geriatr Psychiatry. 2008, 16: 5-13.PubMed Benitez CI, Smith K, Vasile RG, Rende R, Edelen MO, Keller MB: Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study. Am J Geriatr Psychiatry. 2008, 16: 5-13.PubMed
1366.
Zurück zum Zitat Uchida H, Suzuki T, Mamo DC, Mulsant BH, Kikuchi T, Takeuchi H, Tomita M, Watanabe K, Yagi G, Kashima H: Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan. J Anxiety Disord. 2009, 23: 477-481.PubMed Uchida H, Suzuki T, Mamo DC, Mulsant BH, Kikuchi T, Takeuchi H, Tomita M, Watanabe K, Yagi G, Kashima H: Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan. J Anxiety Disord. 2009, 23: 477-481.PubMed
1367.
Zurück zum Zitat Preville M, Vasiliadis HM, Bosse C, Dionne PA, Voyer P, Brassard J: Pattern of psychotropic drug use among older adults having a depression or an anxiety disorder: results from the longitudinal ESA study. Can J Psychiatry. 2011, 56: 348-357.PubMed Preville M, Vasiliadis HM, Bosse C, Dionne PA, Voyer P, Brassard J: Pattern of psychotropic drug use among older adults having a depression or an anxiety disorder: results from the longitudinal ESA study. Can J Psychiatry. 2011, 56: 348-357.PubMed
1368.
Zurück zum Zitat Mallet L, Spinewine A, Huang A: The challenge of managing drug interactions in elderly people. Lancet. 2007, 370: 185-191.PubMed Mallet L, Spinewine A, Huang A: The challenge of managing drug interactions in elderly people. Lancet. 2007, 370: 185-191.PubMed
1369.
Zurück zum Zitat Hines LE, Murphy JE: Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011, 9: 364-377.PubMed Hines LE, Murphy JE: Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011, 9: 364-377.PubMed
1370.
Zurück zum Zitat Klotz U: Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009, 41: 67-76.PubMed Klotz U: Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009, 41: 67-76.PubMed
1371.
Zurück zum Zitat Boyce RD, Handler SM, Karp JF, Hanlon JT: Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information. Am J Geriatr Pharmacother. 2012, 10: 139-150.PubMedCentralPubMed Boyce RD, Handler SM, Karp JF, Hanlon JT: Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information. Am J Geriatr Pharmacother. 2012, 10: 139-150.PubMedCentralPubMed
1372.
Zurück zum Zitat Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST: Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008, 300: 2867-2878.PubMedCentralPubMed Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST: Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008, 300: 2867-2878.PubMedCentralPubMed
1373.
Zurück zum Zitat Takkouche B, Montes-Martinez A, Gill SS, Etminan M: Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 2007, 30: 171-184.PubMed Takkouche B, Montes-Martinez A, Gill SS, Etminan M: Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 2007, 30: 171-184.PubMed
1374.
Zurück zum Zitat Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Sturmer T: Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf. 2010, 19: 1248-1255.PubMedCentralPubMed Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Sturmer T: Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf. 2010, 19: 1248-1255.PubMedCentralPubMed
1375.
Zurück zum Zitat Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH: Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol. 2008, 28: 411-417.PubMed Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH: Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol. 2008, 28: 411-417.PubMed
1376.
Zurück zum Zitat Chatterjee S, Chen H, Johnson ML, Aparasu RR: Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study. Am J Geriatr Pharmacother. 2012, 10: 83-94.PubMed Chatterjee S, Chen H, Johnson ML, Aparasu RR: Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study. Am J Geriatr Pharmacother. 2012, 10: 83-94.PubMed
1378.
Zurück zum Zitat Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, Bell CM, Lee PE, Fischer HD, Herrmann N, et al: Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007, 146: 775-786.PubMed Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, Bell CM, Lee PE, Fischer HD, Herrmann N, et al: Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007, 146: 775-786.PubMed
1379.
Zurück zum Zitat Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC: Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012, 169: 71-79.PubMedCentralPubMed Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC: Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012, 169: 71-79.PubMedCentralPubMed
1380.
Zurück zum Zitat Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS: Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007, 176: 627-632.PubMedCentralPubMed Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS: Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007, 176: 627-632.PubMedCentralPubMed
1381.
Zurück zum Zitat Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L: Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011, 107: 972-979.PubMed Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L: Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011, 107: 972-979.PubMed
1382.
Zurück zum Zitat Meng X, D'Arcy C: Common and unique risk factors and comorbidity for 12-month mood and anxiety disorders among Canadians. Can J Psychiatry. 2012, 57: 479-487.PubMed Meng X, D'Arcy C: Common and unique risk factors and comorbidity for 12-month mood and anxiety disorders among Canadians. Can J Psychiatry. 2012, 57: 479-487.PubMed
1383.
Zurück zum Zitat Goldstein BI, Levitt AJ: The specific burden of comorbid anxiety disorders and of substance use disorders in bipolar I disorder. Bipolar Disord. 2008, 10: 67-78.PubMed Goldstein BI, Levitt AJ: The specific burden of comorbid anxiety disorders and of substance use disorders in bipolar I disorder. Bipolar Disord. 2008, 10: 67-78.PubMed
1384.
Zurück zum Zitat O'Neil KA, Podell JL, Benjamin CL, Kendall PC: Comorbid depressive disorders in anxiety-disordered youth: demographic, clinical, and family characteristics. Child Psychiatry Hum Dev. 2010, 41: 330-341.PubMed O'Neil KA, Podell JL, Benjamin CL, Kendall PC: Comorbid depressive disorders in anxiety-disordered youth: demographic, clinical, and family characteristics. Child Psychiatry Hum Dev. 2010, 41: 330-341.PubMed
1385.
Zurück zum Zitat Green BL, Krupnick JL, Chung J, Siddique J, Krause ED, Revicki D, Frank L, Miranda J: Impact of PTSD comorbidity on one-year outcomes in a depression trial. J Clin Psychol. 2006, 62: 815-835.PubMed Green BL, Krupnick JL, Chung J, Siddique J, Krause ED, Revicki D, Frank L, Miranda J: Impact of PTSD comorbidity on one-year outcomes in a depression trial. J Clin Psychol. 2006, 62: 815-835.PubMed
1386.
Zurück zum Zitat Andreescu C, Lenze EJ, Dew MA, Begley AE, Mulsant BH, Dombrovski AY, Pollock BG, Stack J, Miller MD, Reynolds CF: Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry. 2007, 190: 344-349.PubMed Andreescu C, Lenze EJ, Dew MA, Begley AE, Mulsant BH, Dombrovski AY, Pollock BG, Stack J, Miller MD, Reynolds CF: Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry. 2007, 190: 344-349.PubMed
1387.
Zurück zum Zitat Goes FS, McCusker MG, Bienvenu OJ, Mackinnon DF, Mondimore FM, Schweizer B, Depaulo JR, Potash JB: Co-morbid anxiety disorders in bipolar disorder and major depression: familial aggregation and clinical characteristics of co-morbid panic disorder, social phobia, specific phobia and obsessive-compulsive disorder. Psychol Med. 2012, 42: 1449-1459.PubMedCentralPubMed Goes FS, McCusker MG, Bienvenu OJ, Mackinnon DF, Mondimore FM, Schweizer B, Depaulo JR, Potash JB: Co-morbid anxiety disorders in bipolar disorder and major depression: familial aggregation and clinical characteristics of co-morbid panic disorder, social phobia, specific phobia and obsessive-compulsive disorder. Psychol Med. 2012, 42: 1449-1459.PubMedCentralPubMed
1388.
Zurück zum Zitat Otto MW, Simon NM, Wisniewski SR, Miklowitz DJ, Kogan JN, Reilly-Harrington NA, Frank E, Nierenberg AA, Marangell LB, Sagduyu K, et al: Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry. 2006, 189: 20-25.PubMed Otto MW, Simon NM, Wisniewski SR, Miklowitz DJ, Kogan JN, Reilly-Harrington NA, Frank E, Nierenberg AA, Marangell LB, Sagduyu K, et al: Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry. 2006, 189: 20-25.PubMed
1389.
Zurück zum Zitat Sala R, Goldstein BI, Morcillo C, Liu SM, Castellanos M, Blanco C: Course of comorbid anxiety disorders among adults with bipolar disorder in the U.S. population. J Psychiatr Res. 2012, 46: 865-872.PubMedCentralPubMed Sala R, Goldstein BI, Morcillo C, Liu SM, Castellanos M, Blanco C: Course of comorbid anxiety disorders among adults with bipolar disorder in the U.S. population. J Psychiatr Res. 2012, 46: 865-872.PubMedCentralPubMed
1390.
Zurück zum Zitat McWilliams LA, Cox BJ, Enns MW: Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain. 2003, 106: 127-133.PubMed McWilliams LA, Cox BJ, Enns MW: Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain. 2003, 106: 127-133.PubMed
1391.
Zurück zum Zitat Mittal D, Fortney JC, Pyne JM, Edlund MJ, Wetherell JL: Impact of comorbid anxiety disorders on health-related quality of life among patients with major depressive disorder. Psychiatr Serv. 2006, 57: 1731-1737.PubMed Mittal D, Fortney JC, Pyne JM, Edlund MJ, Wetherell JL: Impact of comorbid anxiety disorders on health-related quality of life among patients with major depressive disorder. Psychiatr Serv. 2006, 57: 1731-1737.PubMed
1392.
Zurück zum Zitat Katz C, Yaseen ZS, Mojtabai R, Cohen LJ, Galynker II: Panic as an independent risk factor for suicide attempt in depressive illness: findings from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Clin Psychiatry. 2011, 72: 1628-1635.PubMed Katz C, Yaseen ZS, Mojtabai R, Cohen LJ, Galynker II: Panic as an independent risk factor for suicide attempt in depressive illness: findings from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Clin Psychiatry. 2011, 72: 1628-1635.PubMed
1393.
Zurück zum Zitat Brown LA, Gaudiano BA, Miller IW: The impact of panic-agoraphobic comorbidity on suicidality in hospitalized patients with major depression. Depress Anxiety. 2010, 27: 310-315.PubMedCentralPubMed Brown LA, Gaudiano BA, Miller IW: The impact of panic-agoraphobic comorbidity on suicidality in hospitalized patients with major depression. Depress Anxiety. 2010, 27: 310-315.PubMedCentralPubMed
1394.
Zurück zum Zitat Schaffer A, McIntosh D, Goldstein BI, Rector NA, McIntyre RS, Beaulieu S, Swinson R, Yatham LN: The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012, 24: 6-22.PubMed Schaffer A, McIntosh D, Goldstein BI, Rector NA, McIntyre RS, Beaulieu S, Swinson R, Yatham LN: The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012, 24: 6-22.PubMed
1395.
Zurück zum Zitat Silverstone P, Salinas E: Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry. 2001, 62: 523-529.PubMed Silverstone P, Salinas E: Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry. 2001, 62: 523-529.PubMed
1396.
Zurück zum Zitat Maneeton N, Maneeton B, Srisurapanont M, Martin SD: Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. 2012, 12: 160-PubMedCentralPubMed Maneeton N, Maneeton B, Srisurapanont M, Martin SD: Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. 2012, 12: 160-PubMedCentralPubMed
1397.
Zurück zum Zitat Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG: Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011, 306: 1359-1369.PubMed Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG: Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011, 306: 1359-1369.PubMed
1398.
Zurück zum Zitat McIntyre A, Gendron A: Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007, 24: 487-494.PubMed McIntyre A, Gendron A: Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007, 24: 487-494.PubMed
1399.
Zurück zum Zitat Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007, 64: 543-552.PubMedCentralPubMed Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007, 64: 543-552.PubMedCentralPubMed
1400.
Zurück zum Zitat Young S, Pfaff D, Lewandowski KE, Ravichandran C, Cohen BM, Ongur D: Anxiety disorder comorbidity in bipolar disorder, schizophrenia and schizoaffective disorder. Psychopathology. 2013, 46: 176-185.PubMed Young S, Pfaff D, Lewandowski KE, Ravichandran C, Cohen BM, Ongur D: Anxiety disorder comorbidity in bipolar disorder, schizophrenia and schizoaffective disorder. Psychopathology. 2013, 46: 176-185.PubMed
1401.
Zurück zum Zitat Achim AM, Maziade M, Raymond E, Olivier D, Merette C, Roy MA: How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull. 2011, 37: 811-821.PubMedCentralPubMed Achim AM, Maziade M, Raymond E, Olivier D, Merette C, Roy MA: How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull. 2011, 37: 811-821.PubMedCentralPubMed
1402.
Zurück zum Zitat Simon NM, Zalta AK, Otto MW, Ostacher MJ, Fischmann D, Chow CW, Thompson EH, Stevens JC, Demopulos CM, Nierenberg AA, Pollack MH: The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar disorder. J Psychiatr Res. 2007, 41: 255-264.PubMed Simon NM, Zalta AK, Otto MW, Ostacher MJ, Fischmann D, Chow CW, Thompson EH, Stevens JC, Demopulos CM, Nierenberg AA, Pollack MH: The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar disorder. J Psychiatr Res. 2007, 41: 255-264.PubMed
1403.
Zurück zum Zitat Nakagawa A, Grunebaum MF, Sullivan GM, Currier D, Ellis SP, Burke AK, Brent DA, Mann JJ, Oquendo MA: Comorbid anxiety in bipolar disorder: does it have an independent effect on suicidality?. Bipolar Disord. 2008, 10: 530-538.PubMedCentralPubMed Nakagawa A, Grunebaum MF, Sullivan GM, Currier D, Ellis SP, Burke AK, Brent DA, Mann JJ, Oquendo MA: Comorbid anxiety in bipolar disorder: does it have an independent effect on suicidality?. Bipolar Disord. 2008, 10: 530-538.PubMedCentralPubMed
1404.
Zurück zum Zitat Pallanti S, Quercioli L, Hollander E: Social anxiety in outpatients with schizophrenia: a relevant cause of disability. Am J Psychiatry. 2004, 161: 53-58.PubMed Pallanti S, Quercioli L, Hollander E: Social anxiety in outpatients with schizophrenia: a relevant cause of disability. Am J Psychiatry. 2004, 161: 53-58.PubMed
1405.
Zurück zum Zitat Makara-Studzinska M, Wolyniak M, Krys K: Influence of anxiety and depression on quality of life of people with schizophrenia in the eastern region of poland. ISRN Psychiatry. 2012, 2012: 839324-PubMedCentralPubMed Makara-Studzinska M, Wolyniak M, Krys K: Influence of anxiety and depression on quality of life of people with schizophrenia in the eastern region of poland. ISRN Psychiatry. 2012, 2012: 839324-PubMedCentralPubMed
1406.
Zurück zum Zitat Barnes TR: Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011, 25: 567-620.PubMed Barnes TR: Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011, 25: 567-620.PubMed
1407.
Zurück zum Zitat Sheehan DV, McElroy SL, Harnett-Sheehan K, Keck PE, Janavs J, Rogers J, Gonzalez R, Shivakumar G, Suppes T: Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord. 2009, 115: 376-385.PubMed Sheehan DV, McElroy SL, Harnett-Sheehan K, Keck PE, Janavs J, Rogers J, Gonzalez R, Shivakumar G, Suppes T: Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord. 2009, 115: 376-385.PubMed
1408.
Zurück zum Zitat Maina G, Albert U, Rosso G, Bogetto F: Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. J Clin Psychiatry. 2008, 69: 609-616.PubMed Maina G, Albert U, Rosso G, Bogetto F: Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. J Clin Psychiatry. 2008, 69: 609-616.PubMed
1409.
Zurück zum Zitat Hirschfeld RM, Weisler RH, Raines SR, Macfadden W: Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006, 67: 355-362.PubMed Hirschfeld RM, Weisler RH, Raines SR, Macfadden W: Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006, 67: 355-362.PubMed
1410.
Zurück zum Zitat McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH: A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010, 71: 163-174.PubMed McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH: A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010, 71: 163-174.PubMed
1411.
Zurück zum Zitat Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M: A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010, 71: 150-162.PubMed Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M: A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010, 71: 150-162.PubMed
1412.
Zurück zum Zitat Sagman D, Lee B, Chandresena R, Jones B, Brunner E: A Canadian naturalistic study of a community-based cohort treated for bipolar disorder. BMC Psychiatry. 2010, 10: 24-PubMedCentralPubMed Sagman D, Lee B, Chandresena R, Jones B, Brunner E: A Canadian naturalistic study of a community-based cohort treated for bipolar disorder. BMC Psychiatry. 2010, 10: 24-PubMedCentralPubMed
1413.
Zurück zum Zitat Tohen M, Calabrese J, Vieta E, Bowden C, Gonzalez-Pinto A, Lin D, Xu W, Corya S: Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord. 2007, 104: 137-146.PubMed Tohen M, Calabrese J, Vieta E, Bowden C, Gonzalez-Pinto A, Lin D, Xu W, Corya S: Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord. 2007, 104: 137-146.PubMed
1414.
Zurück zum Zitat Perugi G, Toni C, Frare F, Ruffolo G, Moretti L, Torti C, Akiskal HS: Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?. J Clin Psychopharmacol. 2002, 22: 584-591.PubMed Perugi G, Toni C, Frare F, Ruffolo G, Moretti L, Torti C, Akiskal HS: Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?. J Clin Psychopharmacol. 2002, 22: 584-591.PubMed
1415.
Zurück zum Zitat Davis LL, Bartolucci A, Petty F: Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord. 2005, 85: 259-266.PubMed Davis LL, Bartolucci A, Petty F: Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord. 2005, 85: 259-266.PubMed
1416.
Zurück zum Zitat Vieta E, Martinez-Aran A, Nieto E, Colom F, Reinares M, Benabarre A, Gasto C: Adjunctive gabapentin treatment of bipolar disorder. Eur Psychiatry. 2000, 15: 433-437.PubMed Vieta E, Martinez-Aran A, Nieto E, Colom F, Reinares M, Benabarre A, Gasto C: Adjunctive gabapentin treatment of bipolar disorder. Eur Psychiatry. 2000, 15: 433-437.PubMed
1417.
Zurück zum Zitat Wender PH, Wolf LE, Wasserstein J: Adults with ADHD. An overview. Ann N Y Acad Sci. 2001, 931: 1-16.PubMed Wender PH, Wolf LE, Wasserstein J: Adults with ADHD. An overview. Ann N Y Acad Sci. 2001, 931: 1-16.PubMed
1418.
Zurück zum Zitat Dulcan M: Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997, 36: 85S-121S.PubMed Dulcan M: Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997, 36: 85S-121S.PubMed
1419.
Zurück zum Zitat Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M: Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993, 50: 565-576.PubMed Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M: Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993, 50: 565-576.PubMed
1420.
Zurück zum Zitat Weiss G, Hechtman L: Hyperactive children grown up: ADHD in children, adolescents, and adults. 1993, New York, NY: Guilford Press Weiss G, Hechtman L: Hyperactive children grown up: ADHD in children, adolescents, and adults. 1993, New York, NY: Guilford Press
1421.
Zurück zum Zitat Pary R, Lewis S, Matuschka PR, Rudzinskiy P, Safi M, Lippmann S: Attention deficit disorder in adults. Ann Clin Psychiatry. 2002, 14: 105-111.PubMed Pary R, Lewis S, Matuschka PR, Rudzinskiy P, Safi M, Lippmann S: Attention deficit disorder in adults. Ann Clin Psychiatry. 2002, 14: 105-111.PubMed
1422.
Zurück zum Zitat Wilens TE, Biederman J, Spencer TJ: Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med. 2002, 53: 113-131.PubMed Wilens TE, Biederman J, Spencer TJ: Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med. 2002, 53: 113-131.PubMed
1423.
Zurück zum Zitat Wilens TE, Faraone SV, Biederman J: Attention-deficit/hyperactivity disorder in adults. JAMA. 2004, 292: 619-623.PubMed Wilens TE, Faraone SV, Biederman J: Attention-deficit/hyperactivity disorder in adults. JAMA. 2004, 292: 619-623.PubMed
1424.
Zurück zum Zitat Garcia SP, Guimaraes J, Zampieri JF, Martinez AL, Polanczyk G, Rohde LA: Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?. J Neural Transm. 2009, 116: 631-636.PubMed Garcia SP, Guimaraes J, Zampieri JF, Martinez AL, Polanczyk G, Rohde LA: Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?. J Neural Transm. 2009, 116: 631-636.PubMed
1425.
Zurück zum Zitat Blouin B, Maddeaux C, Stanley Firestone J, van Stralen J: Predicting response of ADHD symptoms to methylphenidate treatment based on comorbid anxiety. J Atten Disord. 2010, 13: 414-419.PubMed Blouin B, Maddeaux C, Stanley Firestone J, van Stralen J: Predicting response of ADHD symptoms to methylphenidate treatment based on comorbid anxiety. J Atten Disord. 2010, 13: 414-419.PubMed
1426.
Zurück zum Zitat Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005, 44: 915-924.PubMed Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005, 44: 915-924.PubMed
1427.
Zurück zum Zitat Goodman DW, Thase ME: Recognizing ADHD in adults with comorbid mood disorders: implications for identification and management. Postgrad Med. 2009, 121: 20-30.PubMed Goodman DW, Thase ME: Recognizing ADHD in adults with comorbid mood disorders: implications for identification and management. Postgrad Med. 2009, 121: 20-30.PubMed
1428.
Zurück zum Zitat Gabriel A, Violato C: Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study. Atten Defic Hyperact Disord. 2011, 3: 319-326.PubMed Gabriel A, Violato C: Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study. Atten Defic Hyperact Disord. 2011, 3: 319-326.PubMed
1429.
Zurück zum Zitat Gabriel A: The mixed amphetamine salt extended release (Adderall XR, Max-XR) as an adjunctive to SSRIS or SNRIS in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety: an open-label study. Atten Defic Hyperact Disord. 2010, 2: 87-92.PubMed Gabriel A: The mixed amphetamine salt extended release (Adderall XR, Max-XR) as an adjunctive to SSRIS or SNRIS in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety: an open-label study. Atten Defic Hyperact Disord. 2010, 2: 87-92.PubMed
1430.
Zurück zum Zitat El-Gabalawy R, Mackenzie CS, Shooshtari S, Sareen J: Comorbid physical health conditions and anxiety disorders: a population-based exploration of prevalence and health outcomes among older adults. Gen Hosp Psychiatry. 2011, 33: 556-564.PubMed El-Gabalawy R, Mackenzie CS, Shooshtari S, Sareen J: Comorbid physical health conditions and anxiety disorders: a population-based exploration of prevalence and health outcomes among older adults. Gen Hosp Psychiatry. 2011, 33: 556-564.PubMed
1431.
Zurück zum Zitat Vogelzangs N, Seldenrijk A, Beekman AT, van Hout HP, de Jonge P, Penninx BW: Cardiovascular disease in persons with depressive and anxiety disorders. J Affect Disord. 2010, 125: 241-248.PubMedCentralPubMed Vogelzangs N, Seldenrijk A, Beekman AT, van Hout HP, de Jonge P, Penninx BW: Cardiovascular disease in persons with depressive and anxiety disorders. J Affect Disord. 2010, 125: 241-248.PubMedCentralPubMed
1432.
Zurück zum Zitat Huang KL, Su TP, Chen TJ, Chou YH, Bai YM: Comorbidity of cardiovascular diseases with mood and anxiety disorder: a population based 4-year study. Psychiatry Clin Neurosci. 2009, 63: 401-409.PubMed Huang KL, Su TP, Chen TJ, Chou YH, Bai YM: Comorbidity of cardiovascular diseases with mood and anxiety disorder: a population based 4-year study. Psychiatry Clin Neurosci. 2009, 63: 401-409.PubMed
1433.
Zurück zum Zitat Demyttenaere K, Bonnewyn A, Bruffaerts R, De Graaf R, Haro JM, Alonso J: Comorbid painful physical symptoms and anxiety: prevalence, work loss and help-seeking. J Affect Disord. 2008, 109: 264-272.PubMed Demyttenaere K, Bonnewyn A, Bruffaerts R, De Graaf R, Haro JM, Alonso J: Comorbid painful physical symptoms and anxiety: prevalence, work loss and help-seeking. J Affect Disord. 2008, 109: 264-272.PubMed
1434.
Zurück zum Zitat Asmundson GJ, Katz J: Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. Depress Anxiety. 2009, 26: 888-901.PubMed Asmundson GJ, Katz J: Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. Depress Anxiety. 2009, 26: 888-901.PubMed
1435.
Zurück zum Zitat Hartford JT, Endicott J, Kornstein SG, Allgulander C, Wohlreich MM, Russell JM, Perahia DG, Erickson JS: Implications of pain in generalized anxiety disorder: efficacy of duloxetine. Prim Care Companion J Clin Psychiatry. 2008, 10: 197-204.PubMedCentralPubMed Hartford JT, Endicott J, Kornstein SG, Allgulander C, Wohlreich MM, Russell JM, Perahia DG, Erickson JS: Implications of pain in generalized anxiety disorder: efficacy of duloxetine. Prim Care Companion J Clin Psychiatry. 2008, 10: 197-204.PubMedCentralPubMed
1436.
Zurück zum Zitat Beesdo K, Hartford J, Russell J, Spann M, Ball S, Wittchen HU: The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials. J Anxiety Disord. 2009, 23: 1064-1071.PubMed Beesdo K, Hartford J, Russell J, Spann M, Ball S, Wittchen HU: The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials. J Anxiety Disord. 2009, 23: 1064-1071.PubMed
1437.
Zurück zum Zitat Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS, D'Souza DN: Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety. 2008, 25: E1-11.PubMed Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS, D'Souza DN: Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety. 2008, 25: E1-11.PubMed
1438.
Zurück zum Zitat Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, Berbano E, O'Malley PG: Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010, 341: c5222-PubMedCentralPubMed Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, Berbano E, O'Malley PG: Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010, 341: c5222-PubMedCentralPubMed
1439.
Zurück zum Zitat Saarto T, Wiffen PJ: Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007, CD005454- Saarto T, Wiffen PJ: Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007, CD005454-
1440.
Zurück zum Zitat Denollet J, Maas K, Knottnerus A, Keyzer JJ, Pop VJ: Anxiety predicted premature all-cause and cardiovascular death in a 10-year follow-up of middle-aged women. J Clin Epidemiol. 2009, 62: 452-456.PubMed Denollet J, Maas K, Knottnerus A, Keyzer JJ, Pop VJ: Anxiety predicted premature all-cause and cardiovascular death in a 10-year follow-up of middle-aged women. J Clin Epidemiol. 2009, 62: 452-456.PubMed
1441.
Zurück zum Zitat Chamberlain AM, Vickers KS, Colligan RC, Weston SA, Rummans TA, Roger VL: Associations of preexisting depression and anxiety with hospitalization in patients with cardiovascular disease. Mayo Clin Proc. 2011, 86: 1056-1062.PubMedCentralPubMed Chamberlain AM, Vickers KS, Colligan RC, Weston SA, Rummans TA, Roger VL: Associations of preexisting depression and anxiety with hospitalization in patients with cardiovascular disease. Mayo Clin Proc. 2011, 86: 1056-1062.PubMedCentralPubMed
1442.
Zurück zum Zitat Doering LV, Moser DK, Riegel B, McKinley S, Davidson P, Baker H, Meischke H, Dracup K: Persistent comorbid symptoms of depression and anxiety predict mortality in heart disease. Int J Cardiol. 2010, 145: 188-192.PubMedCentralPubMed Doering LV, Moser DK, Riegel B, McKinley S, Davidson P, Baker H, Meischke H, Dracup K: Persistent comorbid symptoms of depression and anxiety predict mortality in heart disease. Int J Cardiol. 2010, 145: 188-192.PubMedCentralPubMed
1443.
Zurück zum Zitat McIntyre RS, Alsuwaidan M, Goldstein BI, Taylor VH, Schaffer A, Beaulieu S, Kemp DE: The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry. 2012, 24: 69-81.PubMed McIntyre RS, Alsuwaidan M, Goldstein BI, Taylor VH, Schaffer A, Beaulieu S, Kemp DE: The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry. 2012, 24: 69-81.PubMed
1444.
Zurück zum Zitat Ramasubbu R, Taylor VH, Saaman Z, Sockalingham S, Li M, Patten S, Rodin G, Schaffer A, Beaulieu S, McIntyre RS: The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry. 2012, 24: 91-109.PubMed Ramasubbu R, Taylor VH, Saaman Z, Sockalingham S, Li M, Patten S, Rodin G, Schaffer A, Beaulieu S, McIntyre RS: The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry. 2012, 24: 91-109.PubMed
1445.
Zurück zum Zitat Ramasubbu R, Beaulieu S, Taylor VH, Schaffer A, McIntyre RS: The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. Ann Clin Psychiatry. 2012, 24: 82-90.PubMed Ramasubbu R, Beaulieu S, Taylor VH, Schaffer A, McIntyre RS: The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. Ann Clin Psychiatry. 2012, 24: 82-90.PubMed
1446.
Zurück zum Zitat Engum A: The role of depression and anxiety in onset of diabetes in a large population-based study. J Psychosom Res. 2007, 62: 31-38.PubMed Engum A: The role of depression and anxiety in onset of diabetes in a large population-based study. J Psychosom Res. 2007, 62: 31-38.PubMed
1447.
Zurück zum Zitat Aujla N, Davies MJ, Skinner TC, Gray LJ, Webb DR, Srinivasan B, Khunti K: The association between anxiety and measures of glycaemia in a population-based diabetes screening programme. Diabet Med. 2011, 28: 785-788.PubMed Aujla N, Davies MJ, Skinner TC, Gray LJ, Webb DR, Srinivasan B, Khunti K: The association between anxiety and measures of glycaemia in a population-based diabetes screening programme. Diabet Med. 2011, 28: 785-788.PubMed
1448.
Zurück zum Zitat Serretti A, Mandelli L: Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010, 71: 1259-1272.PubMed Serretti A, Mandelli L: Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010, 71: 1259-1272.PubMed
Metadaten
Titel
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders
verfasst von
Martin A Katzman
Pierre Bleau
Pierre Blier
Pratap Chokka
Kevin Kjernisted
Michael Van Ameringen
the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University
Publikationsdatum
01.07.2014
Verlag
BioMed Central
Erschienen in
BMC Psychiatry / Ausgabe Sonderheft 1/2014
Elektronische ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-14-S1-S1